US20220152014A1 - Compounds for inhibition of alpha 4 beta 7 integrin - Google Patents
Compounds for inhibition of alpha 4 beta 7 integrin Download PDFInfo
- Publication number
- US20220152014A1 US20220152014A1 US17/508,267 US202117508267A US2022152014A1 US 20220152014 A1 US20220152014 A1 US 20220152014A1 US 202117508267 A US202117508267 A US 202117508267A US 2022152014 A1 US2022152014 A1 US 2022152014A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- independently selected
- membered heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 421
- 230000005764 inhibitory process Effects 0.000 title description 7
- 108010021315 integrin beta7 Proteins 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 123
- 150000003839 salts Chemical class 0.000 claims abstract description 82
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- -1 cyano, hydroxyl Chemical group 0.000 claims description 265
- 125000000623 heterocyclic group Chemical group 0.000 claims description 166
- 239000003112 inhibitor Substances 0.000 claims description 127
- 125000005843 halogen group Chemical group 0.000 claims description 112
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 89
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 80
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 74
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 61
- 239000003814 drug Substances 0.000 claims description 61
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 56
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 51
- 102000006495 integrins Human genes 0.000 claims description 49
- 108010044426 integrins Proteins 0.000 claims description 49
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 46
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 38
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 35
- 229940124597 therapeutic agent Drugs 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 125000004429 atom Chemical group 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 16
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 16
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 15
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 14
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 12
- 229910020008 S(O) Inorganic materials 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 7
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 claims description 7
- 208000024908 graft versus host disease Diseases 0.000 claims description 7
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 5
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 5
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 claims description 4
- 229940127590 IRAK4 inhibitor Drugs 0.000 claims description 2
- 102000008208 Toll-Like Receptor 8 Human genes 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 160
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 103
- 239000000203 mixture Substances 0.000 description 101
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 74
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 68
- 235000019439 ethyl acetate Nutrition 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 65
- 239000005557 antagonist Substances 0.000 description 63
- 201000010099 disease Diseases 0.000 description 62
- 201000006417 multiple sclerosis Diseases 0.000 description 62
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 59
- 239000000243 solution Substances 0.000 description 57
- 238000011282 treatment Methods 0.000 description 56
- 238000005160 1H NMR spectroscopy Methods 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 53
- 238000003786 synthesis reaction Methods 0.000 description 46
- 239000003446 ligand Substances 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 42
- 229910001868 water Inorganic materials 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- 125000003118 aryl group Chemical group 0.000 description 34
- 229910052739 hydrogen Inorganic materials 0.000 description 34
- 239000000556 agonist Substances 0.000 description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 33
- 230000002829 reductive effect Effects 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 30
- 125000000217 alkyl group Chemical group 0.000 description 29
- 125000001072 heteroaryl group Chemical group 0.000 description 29
- 238000003756 stirring Methods 0.000 description 29
- 230000001404 mediated effect Effects 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 25
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 229910052938 sodium sulfate Inorganic materials 0.000 description 21
- 239000002904 solvent Substances 0.000 description 20
- 125000001424 substituent group Chemical group 0.000 description 20
- 238000005859 coupling reaction Methods 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 239000002585 base Substances 0.000 description 17
- 239000012442 inert solvent Substances 0.000 description 17
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 17
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 16
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 16
- 238000001990 intravenous administration Methods 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 229940044551 receptor antagonist Drugs 0.000 description 16
- 239000002464 receptor antagonist Substances 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 229910052805 deuterium Inorganic materials 0.000 description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 14
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 14
- 229910052801 chlorine Inorganic materials 0.000 description 14
- 229910052731 fluorine Inorganic materials 0.000 description 14
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 13
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 125000001188 haloalkyl group Chemical group 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- 230000008878 coupling Effects 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 11
- 239000007832 Na2SO4 Substances 0.000 description 10
- 125000004404 heteroalkyl group Chemical group 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 102100038495 Bile acid receptor Human genes 0.000 description 9
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 230000009266 disease activity Effects 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 229940044601 receptor agonist Drugs 0.000 description 9
- 239000000018 receptor agonist Substances 0.000 description 9
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 9
- FXHVOJAGFJQLBV-UHFFFAOYSA-N 3-bromo-6-fluoro-1,4-dimethylquinolin-2-one Chemical compound BrC=1C(N(C2=CC=C(C=C2C=1C)F)C)=O FXHVOJAGFJQLBV-UHFFFAOYSA-N 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 235000011056 potassium acetate Nutrition 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000003107 substituted aryl group Chemical group 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000007821 HATU Substances 0.000 description 7
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 7
- 208000003456 Juvenile Arthritis Diseases 0.000 description 7
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 7
- 208000002353 alcoholic hepatitis Diseases 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 7
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002431 hydrogen Chemical group 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108010029697 CD40 Ligand Proteins 0.000 description 6
- 102100032937 CD40 ligand Human genes 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- 201000005569 Gout Diseases 0.000 description 6
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 102100032818 Integrin alpha-4 Human genes 0.000 description 6
- 108010041012 Integrin alpha4 Proteins 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 6
- 239000002260 anti-inflammatory agent Substances 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 125000003636 chemical group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- UEGRUVQHWVSSBY-INIZCTEOSA-N methyl (2S)-2-amino-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]propanoate Chemical compound N[C@H](C(=O)OC)CC=1C=CC(=C2C=CC=NC=12)C1=C(C=C(C=C1Cl)F)Cl UEGRUVQHWVSSBY-INIZCTEOSA-N 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- HYGUBIDSNACYAS-QHCPKHFHSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(6-fluoro-1,4-dimethyl-2-oxoquinolin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC2=CC=C(C=3C=CC=NC2=3)C=2C(N(C3=CC=C(C=C3C=2C)F)C)=O)C(=CC=C1)Cl HYGUBIDSNACYAS-QHCPKHFHSA-N 0.000 description 5
- DJSFBRDWKGBYPM-UHFFFAOYSA-N 3-bromo-6-cyclopropyl-1,4-dimethylquinolin-2-one Chemical compound BrC=1C(N(C2=CC=C(C=C2C=1C)C1CC1)C)=O DJSFBRDWKGBYPM-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 5
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 5
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 229940121649 protein inhibitor Drugs 0.000 description 5
- 239000012268 protein inhibitor Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000013456 study Methods 0.000 description 5
- 238000004808 supercritical fluid chromatography Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 4
- VKRNWUOWRJTGNJ-CYBMUJFWSA-N 2,6-difluoro-4-[[(1R)-2,2,2-trifluoro-1-phenylethyl]amino]benzoic acid Chemical compound FC1=C(C(=O)O)C(=CC(=C1)N[C@@H](C(F)(F)F)C1=CC=CC=C1)F VKRNWUOWRJTGNJ-CYBMUJFWSA-N 0.000 description 4
- RALKUKNQUWLENV-UHFFFAOYSA-N 3-bromo-4-(trifluoromethyl)isoquinoline Chemical compound BrC=1N=CC2=CC=CC=C2C=1C(F)(F)F RALKUKNQUWLENV-UHFFFAOYSA-N 0.000 description 4
- WXGDCGUQLSLAQT-UHFFFAOYSA-N 3-iodo-1,4-dimethyl-6-(trifluoromethyl)quinolin-2-one Chemical compound IC=1C(N(C2=CC=C(C=C2C=1C)C(F)(F)F)C)=O WXGDCGUQLSLAQT-UHFFFAOYSA-N 0.000 description 4
- MCKNXKKOUBTJRA-UHFFFAOYSA-N 3-iodo-1-methyl-1,6-naphthyridin-2-one Chemical compound IC=1C(N(C2=CC=NC=C2C=1)C)=O MCKNXKKOUBTJRA-UHFFFAOYSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- 201000009273 Endometriosis Diseases 0.000 description 4
- 102100033016 Integrin beta-7 Human genes 0.000 description 4
- 108010022222 Integrin beta1 Proteins 0.000 description 4
- 102000012355 Integrin beta1 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065637 Interleukin-23 Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 4
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 201000002481 Myositis Diseases 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 4
- 102400000055 Neuregulin-4 Human genes 0.000 description 4
- 101800002641 Neuregulin-4 Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010034277 Pemphigoid Diseases 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000000594 bullous pemphigoid Diseases 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 4
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000036267 drug metabolism Effects 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 201000006747 infectious mononucleosis Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- XCIGZBVOUQVIPI-UHFFFAOYSA-N lanraplenib Chemical compound NC1=CN=CC(=N1)C=1N=C(C=2N(C1)C=CN2)NC2=CC=C(C=C2)N2CCN(CC2)C2COC2 XCIGZBVOUQVIPI-UHFFFAOYSA-N 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- CHBAQMBUKHSYLG-QHCPKHFHSA-N methyl (2S)-2-(benzhydrylideneamino)-3-(5-bromoquinolin-8-yl)propanoate Chemical compound BrC1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)OC)N=C(C1=CC=CC=C1)C1=CC=CC=C1 CHBAQMBUKHSYLG-QHCPKHFHSA-N 0.000 description 4
- OAEWAPNIJYMXCM-QFIPXVFZSA-N methyl (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl]propanoate Chemical compound FC1=C(C(=O)N[C@H](C(=O)OC)CC2=CC=C(C3=CC=CC=C23)B2OC(C(O2)(C)C)(C)C)C(=CC=C1)F OAEWAPNIJYMXCM-QFIPXVFZSA-N 0.000 description 4
- OZDBGHSJDZLBRN-LOSJGSFVSA-N methyl (2S)-2-[[2,6-difluoro-4-[[(2R)-1,1,1-trifluorobutan-2-yl]amino]benzoyl]amino]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl]propanoate Chemical compound FC1=C(C(=O)N[C@H](C(=O)OC)CC2=CC=C(C3=CC=CC=C23)B2OC(C(O2)(C)C)(C)C)C(=CC(=C1)N[C@@H](C(F)(F)F)CC)F OZDBGHSJDZLBRN-LOSJGSFVSA-N 0.000 description 4
- GHMHLMNFKPCJOH-XZOQPEGZSA-N methyl (2S)-2-[[2,6-difluoro-4-[[(2R)-1,1,1-trifluorobutan-2-yl]amino]benzoyl]amino]-3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl]propanoate Chemical compound FC1=C(C(=O)N[C@H](C(=O)OC)CC=2C=CC(=C3C=CC=NC=23)B2OC(C(O2)(C)C)(C)C)C(=CC(=C1)N[C@@H](C(F)(F)F)CC)F GHMHLMNFKPCJOH-XZOQPEGZSA-N 0.000 description 4
- YEZZYSMYWKYNMD-SFHVURJKSA-N methyl (2S)-3-(4-bromonaphthalen-1-yl)-2-[(2,6-difluorobenzoyl)amino]propanoate Chemical compound BrC1=CC=C(C2=CC=CC=C12)C[C@@H](C(=O)OC)NC(C1=C(C=CC=C1F)F)=O YEZZYSMYWKYNMD-SFHVURJKSA-N 0.000 description 4
- BXGHXEXBABKUPJ-DHUJRADRSA-N methyl (2S)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl]-2-(tritylamino)propanoate Chemical compound CC1(OB(OC1(C)C)C1=CC=C(C2=CC=CC=C12)C[C@@H](C(=O)OC)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C BXGHXEXBABKUPJ-DHUJRADRSA-N 0.000 description 4
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 4
- 229940121308 nidufexor Drugs 0.000 description 4
- JYTIXGYXBIBOMN-UHFFFAOYSA-N nidufexor Chemical compound Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(O)=O)c2COc3ccc(Cl)cc3-c12 JYTIXGYXBIBOMN-UHFFFAOYSA-N 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 229960001350 tofacitinib Drugs 0.000 description 4
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 4
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 4
- VCPGBTIHFTZWTG-QHCPKHFHSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(1,4-dimethyl-2-oxoquinolin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC2=CC=C(C=3C=CC=NC2=3)C=2C(N(C3=CC=CC=C3C=2C)C)=O)C(=CC=C1)Cl VCPGBTIHFTZWTG-QHCPKHFHSA-N 0.000 description 3
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 3
- NVSMLSKXNOHPFW-UHFFFAOYSA-N 1-bromo-5-chloro-4-fluoro-2-methoxybenzene Chemical compound COC1=CC(F)=C(Cl)C=C1Br NVSMLSKXNOHPFW-UHFFFAOYSA-N 0.000 description 3
- VHQBLGDZCBRMMA-UHFFFAOYSA-N 1-methyl-4-(trifluoromethyl)quinolin-2-one Chemical compound C1=CC=C2C(C(F)(F)F)=CC(=O)N(C)C2=C1 VHQBLGDZCBRMMA-UHFFFAOYSA-N 0.000 description 3
- JBLIDPPHFGWTKU-UHFFFAOYSA-N 2,6-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=CC=C1Cl JBLIDPPHFGWTKU-UHFFFAOYSA-N 0.000 description 3
- QRHUZEVERIHEPT-UHFFFAOYSA-N 2,6-difluorobenzoyl chloride Chemical compound FC1=CC=CC(F)=C1C(Cl)=O QRHUZEVERIHEPT-UHFFFAOYSA-N 0.000 description 3
- RVLCUCVJZVRNDC-IMJSIDKUSA-N 2-[(2s,5s)-5-methyl-3,6-dioxopiperazin-2-yl]acetic acid Chemical compound C[C@@H]1NC(=O)[C@H](CC(O)=O)NC1=O RVLCUCVJZVRNDC-IMJSIDKUSA-N 0.000 description 3
- ZTFXTKVRXFCONP-UHFFFAOYSA-N 3-bromo-1,4-dimethylquinolin-2-one Chemical compound C1=CC=C2C(C)=C(Br)C(=O)N(C)C2=C1 ZTFXTKVRXFCONP-UHFFFAOYSA-N 0.000 description 3
- VWDWUUMFDYKANC-UHFFFAOYSA-N 3-bromo-7-chloro-1,4-dimethylquinolin-2-one Chemical compound BrC=1C(N(C2=CC(=CC=C2C=1C)Cl)C)=O VWDWUUMFDYKANC-UHFFFAOYSA-N 0.000 description 3
- OFZXIFDQGUIYRM-UHFFFAOYSA-N 3-bromo-7-fluoro-1,4-dimethylquinolin-2-one Chemical compound BrC=1C(N(C2=CC(=CC=C2C=1C)F)C)=O OFZXIFDQGUIYRM-UHFFFAOYSA-N 0.000 description 3
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 description 3
- IHYGNSKKRJWYPR-UHFFFAOYSA-N 6-bromo-3-iodo-1-methyl-4-(trifluoromethyl)quinolin-2-one Chemical compound BrC=1C=C2C(=C(C(N(C2=CC=1)C)=O)I)C(F)(F)F IHYGNSKKRJWYPR-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 102000004379 Adrenomedullin Human genes 0.000 description 3
- 101800004616 Adrenomedullin Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 229940124291 BTK inhibitor Drugs 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010006811 Bursitis Diseases 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- 101150063947 CHST15 gene Proteins 0.000 description 3
- 229940122805 Cathepsin S inhibitor Drugs 0.000 description 3
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- 102100023688 Eotaxin Human genes 0.000 description 3
- 101710139422 Eotaxin Proteins 0.000 description 3
- 102000013818 Fractalkine Human genes 0.000 description 3
- 229940121703 Free fatty acid receptor 2 antagonist Drugs 0.000 description 3
- 102000004610 GATA3 Transcription Factor Human genes 0.000 description 3
- 108010003338 GATA3 Transcription Factor Proteins 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 3
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 3
- 108010078321 Guanylate Cyclase Proteins 0.000 description 3
- 102000014469 Guanylate cyclase Human genes 0.000 description 3
- 102100025255 Haptoglobin Human genes 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 3
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 102100030703 Interleukin-22 Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 3
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 3
- 102000042838 JAK family Human genes 0.000 description 3
- 108091082332 JAK family Proteins 0.000 description 3
- 101150069380 JAK3 gene Proteins 0.000 description 3
- 102100034723 LanC-like protein 2 Human genes 0.000 description 3
- 101710195374 LanC-like protein 2 Proteins 0.000 description 3
- 208000005777 Lupus Nephritis Diseases 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108010008364 Melanocortins Proteins 0.000 description 3
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 3
- 101001065566 Mus musculus Lymphocyte antigen 6A-2/6E-1 Proteins 0.000 description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 3
- 101710106341 NKG2-D type II integral membrane protein Proteins 0.000 description 3
- 102000002452 NPR3 Human genes 0.000 description 3
- 108010042215 OX40 Ligand Proteins 0.000 description 3
- 102000004473 OX40 Ligand Human genes 0.000 description 3
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 3
- 108010054395 P-selectin ligand protein Proteins 0.000 description 3
- 108010028924 PPAR alpha Proteins 0.000 description 3
- 102000023984 PPAR alpha Human genes 0.000 description 3
- 108010015181 PPAR delta Proteins 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102000000536 PPAR gamma Human genes 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 description 3
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 239000004012 Tofacitinib Substances 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 3
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 3
- 229940046731 calcineurin inhibitors Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 208000019069 chronic childhood arthritis Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 3
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 3
- LGIBDQRYOFBMTC-UHFFFAOYSA-N dnc010031 Chemical compound C1=CC(O)=CC=C1C1C(=O)NC2=CC=CC=C2C2=C3C1=CNC3=NC=C2 LGIBDQRYOFBMTC-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 101150015947 fimH gene Proteins 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229960000598 infliximab Drugs 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 102000002467 interleukin receptors Human genes 0.000 description 3
- 108010093036 interleukin receptors Proteins 0.000 description 3
- 108010074109 interleukin-22 Proteins 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000002865 melanocortin Substances 0.000 description 3
- ZYRKMPNRGSRTJQ-FQEVSTJZSA-N methyl (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl]propanoate Chemical compound FC1=C(C(=O)N[C@H](C(=O)OC)CC=2C=CC(=C3C=CC=NC=23)B2OC(C(O2)(C)C)(C)C)C(=CC=C1)F ZYRKMPNRGSRTJQ-FQEVSTJZSA-N 0.000 description 3
- HLRRMWNATCMJQU-IZZNHLLZSA-N methyl (2S)-2-[[2,6-difluoro-4-[(3R)-3-(trifluoromethyl)morpholin-4-yl]benzoyl]amino]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl]propanoate Chemical compound FC1=C(C(=O)N[C@H](C(=O)OC)CC2=CC=C(C3=CC=CC=C23)B2OC(C(O2)(C)C)(C)C)C(=CC(=C1)N1[C@H](COCC1)C(F)(F)F)F HLRRMWNATCMJQU-IZZNHLLZSA-N 0.000 description 3
- HLQNJCVZCYBNNB-ZDUSSCGKSA-N methyl (2S)-2-amino-3-(4-bromonaphthalen-1-yl)propanoate Chemical compound N[C@H](C(=O)OC)CC1=CC=C(C2=CC=CC=C12)Br HLQNJCVZCYBNNB-ZDUSSCGKSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002457 oxidoreductase inhibitor Substances 0.000 description 3
- 229950008141 ozanimod Drugs 0.000 description 3
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 3
- 229950005157 peficitinib Drugs 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 208000002574 reactive arthritis Diseases 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229950007943 risankizumab Drugs 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108010027843 zonulin Proteins 0.000 description 3
- LURZYZNDESYBTE-FCHUYYIVSA-N (2S)-2-[[2,6-difluoro-4-[[(2R)-1,1,1-trifluorobutan-2-yl]amino]benzoyl]amino]-3-[5-(1,3,4-trimethyl-2,6-dioxopyrimidin-5-yl)quinolin-8-yl]propanoic acid Chemical compound FC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C(N(C=2C)C)=O)C)=O)C(=CC(=C1)N[C@@H](C(F)(F)F)CC)F LURZYZNDESYBTE-FCHUYYIVSA-N 0.000 description 2
- NSPHQWLKCGGCQR-DLJDZFDSSA-N (2s)-2-[[(1r,4s,7s,10s,13s,16r,21r,27s,34r,37s,40s)-10-(2-amino-2-oxoethyl)-34-[[(2s)-4-carboxy-2-[[(2s)-3-carboxy-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-37-(2-carboxyethyl)-27-[(1r)-1-hydroxyethyl]-4-methyl-40-(2-methylp Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)CSSC[C@@H]2NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC2=O NSPHQWLKCGGCQR-DLJDZFDSSA-N 0.000 description 2
- QLJYLJGYIDIJPT-VIFPVBQESA-N (2s)-3-(4-aminophenyl)-2-methoxypropanoic acid Chemical compound CO[C@H](C(O)=O)CC1=CC=C(N)C=C1 QLJYLJGYIDIJPT-VIFPVBQESA-N 0.000 description 2
- KSELABKNBIUMGG-YGBAREPYSA-N (2z,3ar,4r,5r,6as)-3,3-difluoro-4-[(e,3r,4r)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2h-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3ah-cyclopenta[b]furan-5-ol Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@H]1C1(F)F)/C=C/[C@@H](O)[C@H](C)C=2C=C(C)C=CC=2)\C1=C/CCCC=1N=NNN=1 KSELABKNBIUMGG-YGBAREPYSA-N 0.000 description 2
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 2
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 2
- 125000004815 1,2-dimethylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([*:2])C([H])([H])[H] 0.000 description 2
- SJKLCUGQVVYDCX-HRNVLBFRSA-N 1-(4-tert-butylphenyl)sulfonyl-3-[(3R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl]urea Chemical compound CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 SJKLCUGQVVYDCX-HRNVLBFRSA-N 0.000 description 2
- XSIZCQPLWUYIIV-UHFFFAOYSA-N 1-bromo-2-cyclopropyloxy-4,5-difluorobenzene Chemical compound BrC1=C(C=C(C(=C1)F)F)OC1CC1 XSIZCQPLWUYIIV-UHFFFAOYSA-N 0.000 description 2
- DKARISQFDBAJEZ-FIBGUPNXSA-N 1-bromo-4,5-difluoro-2-(trideuteriomethoxy)benzene Chemical compound BrC1=C(C=C(C(=C1)F)F)OC([2H])([2H])[2H] DKARISQFDBAJEZ-FIBGUPNXSA-N 0.000 description 2
- JHHKWHVDJFQNNG-UHFFFAOYSA-N 1-bromo-4-fluoro-2-methoxy-5-methylbenzene Chemical compound COC1=CC(F)=C(C)C=C1Br JHHKWHVDJFQNNG-UHFFFAOYSA-N 0.000 description 2
- QICOGXIPXYXZOH-UHFFFAOYSA-N 1-methyl-4-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-2-one Chemical compound CN1C2=C(C(=CC1=O)C(F)(F)F)CCC2 QICOGXIPXYXZOH-UHFFFAOYSA-N 0.000 description 2
- XFRBXZCBOYNMJP-UHFFFAOYSA-N 2,2,6-trimethyl-1,3-dioxin-4-one Chemical compound CC1=CC(=O)OC(C)(C)O1 XFRBXZCBOYNMJP-UHFFFAOYSA-N 0.000 description 2
- CAACPXVQUJYVPS-SECBINFHSA-N 2,6-difluoro-4-[(3R)-3-(trifluoromethyl)morpholin-4-yl]benzoic acid Chemical compound FC1=C(C(=O)O)C(=CC(=C1)N1[C@H](COCC1)C(F)(F)F)F CAACPXVQUJYVPS-SECBINFHSA-N 0.000 description 2
- FPGXLSWGSKSVNJ-MRVPVSSYSA-N 2,6-difluoro-4-[[(2R)-1,1,1-trifluorobutan-2-yl]amino]benzoic acid Chemical compound FC1=C(C(=O)O)C(=CC(=C1)N[C@@H](C(F)(F)F)CC)F FPGXLSWGSKSVNJ-MRVPVSSYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 2
- MYIFLDFUXIHOCJ-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 MYIFLDFUXIHOCJ-UHFFFAOYSA-N 0.000 description 2
- JVCPIJKPAKAIIP-UHFFFAOYSA-N 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol Chemical compound CCCCCCCOC1=CC=C(CCC(N)(CO)CO)C=C1C(F)(F)F JVCPIJKPAKAIIP-UHFFFAOYSA-N 0.000 description 2
- GWJCDDNGNBDDGM-UHFFFAOYSA-N 2-bromo-1-chloro-5-fluoro-3-methoxybenzene Chemical compound COc1cc(F)cc(Cl)c1Br GWJCDDNGNBDDGM-UHFFFAOYSA-N 0.000 description 2
- FCYZOOHWUOEAOX-UHFFFAOYSA-N 2-bromo-4,5-difluorophenol Chemical compound OC1=CC(F)=C(F)C=C1Br FCYZOOHWUOEAOX-UHFFFAOYSA-N 0.000 description 2
- SSFDEFHSCRESFF-UHFFFAOYSA-N 2-bromo-5-fluoro-1-methoxy-3-(trifluoromethyl)benzene Chemical compound COc1cc(F)cc(c1Br)C(F)(F)F SSFDEFHSCRESFF-UHFFFAOYSA-N 0.000 description 2
- MMGLVQRGMPQKLH-UHFFFAOYSA-N 2-fluoro-6-methylbenzoyl chloride Chemical compound CC1=CC=CC(F)=C1C(Cl)=O MMGLVQRGMPQKLH-UHFFFAOYSA-N 0.000 description 2
- FWXVGKSWZJEPQI-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-ethynyl-n-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]benzamide Chemical compound C#CC1=CC(C(=O)NCCOCCOCCOC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4C(=C(NS(C)(=O)=O)C=C(C=4)C(C)(C)C)OC)=CC=3)C=CN=2)=C1 FWXVGKSWZJEPQI-UHFFFAOYSA-N 0.000 description 2
- XCGRDAKKNLETIA-UHFFFAOYSA-N 3-bromo-6-chloro-1,4-dimethylquinolin-2-one Chemical compound ClC=1C=C2C(=C(C(N(C2=CC=1)C)=O)Br)C XCGRDAKKNLETIA-UHFFFAOYSA-N 0.000 description 2
- MPBAYVIIKBYPKD-UHFFFAOYSA-N 3-chloro-1,4,6-trimethylpyridin-2-one Chemical compound ClC=1C(N(C(=CC=1C)C)C)=O MPBAYVIIKBYPKD-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- CNFUCIZHCSFYLA-UHFFFAOYSA-N 3-iodo-1,6-dimethyl-4-(trifluoromethyl)pyridin-2-one Chemical compound CC1=CC(C(F)(F)F)=C(I)C(=O)N1C CNFUCIZHCSFYLA-UHFFFAOYSA-N 0.000 description 2
- QYTVGUUCBTUUSX-UHFFFAOYSA-N 3-iodo-1-methyl-4-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-2-one Chemical compound IC1=C(C2=C(N(C1=O)C)CCC2)C(F)(F)F QYTVGUUCBTUUSX-UHFFFAOYSA-N 0.000 description 2
- AZMVBUPAMSZHPH-UHFFFAOYSA-N 3-iodo-1-methyl-4-(trifluoromethyl)quinolin-2-one Chemical compound IC=1C(N(C2=CC=CC=C2C=1C(F)(F)F)C)=O AZMVBUPAMSZHPH-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 2
- DGMZYNTVOVTLLH-UHFFFAOYSA-N 5-bromo-8-(bromomethyl)quinoline Chemical compound C1=CN=C2C(CBr)=CC=C(Br)C2=C1 DGMZYNTVOVTLLH-UHFFFAOYSA-N 0.000 description 2
- BNVPFDRNGHMRJS-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 BNVPFDRNGHMRJS-UHFFFAOYSA-N 0.000 description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
- RPVDFHPBGBMWID-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid Chemical compound C1=C2N(C)C=C(C(O)=O)C2=CC=C1N(CC1)CCC1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl RPVDFHPBGBMWID-UHFFFAOYSA-N 0.000 description 2
- CDBDDNIKKBMWOU-UHFFFAOYSA-N 6-bromo-1-methyl-4-(trifluoromethyl)quinolin-2-one Chemical compound BrC=1C=C2C(=CC(N(C2=CC=1)C)=O)C(F)(F)F CDBDDNIKKBMWOU-UHFFFAOYSA-N 0.000 description 2
- IUJGGMVMMSHOBM-UHFFFAOYSA-N 6-bromo-3-iodo-1,4-dimethylquinolin-2-one Chemical compound BrC=1C=C2C(=C(C(N(C2=CC=1)C)=O)I)C IUJGGMVMMSHOBM-UHFFFAOYSA-N 0.000 description 2
- BOLWPPDABDAOEN-UHFFFAOYSA-N 6-fluoro-1,4-dimethylquinolin-2-one Chemical compound C1=C(F)C=C2C(C)=CC(=O)N(C)C2=C1 BOLWPPDABDAOEN-UHFFFAOYSA-N 0.000 description 2
- NHSZLLLHEGMZID-UHFFFAOYSA-N 7-chloro-1,4-dimethylquinolin-2-one Chemical compound CN1C(=O)C=C(C)C2=C1C=C(Cl)C=C2 NHSZLLLHEGMZID-UHFFFAOYSA-N 0.000 description 2
- QOAGHYQNKUCXRP-UHFFFAOYSA-N 7-fluoro-1,4-dimethylquinolin-2-one Chemical compound FC1=CC=C2C(=CC(N(C2=C1)C)=O)C QOAGHYQNKUCXRP-UHFFFAOYSA-N 0.000 description 2
- 230000035502 ADME Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010067717 AT-1001 Proteins 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 229940123786 Adenosine A3 receptor antagonist Drugs 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 2
- 206010003267 Arthritis reactive Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- 102220607926 C-reactive protein_H20Y_mutation Human genes 0.000 description 2
- WGEWYYPHYMGJNT-HLHYUOOASA-N CC(C)C[C@@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(=O)N)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](N)CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)C(=O)O Chemical compound CC(C)C[C@@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(=O)N)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](N)CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)C(=O)O WGEWYYPHYMGJNT-HLHYUOOASA-N 0.000 description 2
- 201000003274 CINCA syndrome Diseases 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- 108010078546 Complement C5a Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010072224 Deficiency of the interleukin-1 receptor antagonist Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 231100000491 EC50 Toxicity 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 2
- 239000008961 HMPL-004 Substances 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 description 2
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 2
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 2
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 2
- 101150050263 ICAM1 gene Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 102100032241 Lactotransferrin Human genes 0.000 description 2
- ORFLZNAGUTZRLQ-ZMBVWFSWSA-N Larazotide Chemical compound NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O ORFLZNAGUTZRLQ-ZMBVWFSWSA-N 0.000 description 2
- 206010024434 Lichen sclerosus Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 208000001826 Marfan syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 102100034681 Myeloblastin Human genes 0.000 description 2
- 108090000973 Myeloblastin Proteins 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 2
- 125000000815 N-oxide group Chemical group 0.000 description 2
- CUWTTWVBVUZPAP-UHFFFAOYSA-N NC(CO)(CO)CO.OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl Chemical compound NC(CO)(CO)CO.OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl CUWTTWVBVUZPAP-UHFFFAOYSA-N 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- VYLOOGHLKSNNEK-PIIMJCKOSA-N OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 VYLOOGHLKSNNEK-PIIMJCKOSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 2
- 102000047198 P2X7 purinoceptor Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000002389 Pouchitis Diseases 0.000 description 2
- 206010036774 Proctitis Diseases 0.000 description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 2
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 2
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102220577960 RPA-interacting protein_H21A_mutation Human genes 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 2
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 102220509333 Small integral membrane protein 10_H22A_mutation Human genes 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 229940098113 Transglutaminase inhibitor Drugs 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- IXYNFLOLUBKHQU-FZCWJHTDSA-N [(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl] hydrogen phosphate Chemical compound Cc1cn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)[C@@H](COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)O2)c(=O)[nH]c1=O IXYNFLOLUBKHQU-FZCWJHTDSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 239000002580 adenosine A3 receptor antagonist Substances 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- ZMJWRJKGPUDEOX-LMXUULCNSA-A alicaforsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 ZMJWRJKGPUDEOX-LMXUULCNSA-A 0.000 description 2
- 229950011466 alicaforsen Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000005466 alkylenyl group Chemical group 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 229950004817 amiselimod Drugs 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 229960004238 anakinra Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229960001164 apremilast Drugs 0.000 description 2
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 108010038239 aspartyl-alanyl-diketopiperazine Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 229950010015 bertilimumab Drugs 0.000 description 2
- 229960003735 brodalumab Drugs 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000002559 chemokine receptor antagonist Substances 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229950001404 cobitolimod Drugs 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
- IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 108010022410 dolcanatide Proteins 0.000 description 2
- 229950008818 dolcanatide Drugs 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 229950001279 elafibranor Drugs 0.000 description 2
- 208000010227 enterocolitis Diseases 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 229950004912 etrolizumab Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229950006663 filgotinib Drugs 0.000 description 2
- 235000019000 fluorine Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 2
- 229950010415 givinostat Drugs 0.000 description 2
- 150000002344 gold compounds Chemical class 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 208000002557 hidradenitis Diseases 0.000 description 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 2
- 239000003084 hiv integrase inhibitor Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 108010038415 interleukin-8 receptors Proteins 0.000 description 2
- 102000010681 interleukin-8 receptors Human genes 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 201000004614 iritis Diseases 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 230000005445 isotope effect Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229940121292 leronlimab Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- JHBZAAACZVPPRQ-UHFFFAOYSA-L lithium;magnesium;2,2,6,6-tetramethylpiperidin-1-ide;dichloride Chemical compound [Li+].[Cl-].[Cl-].CC1(C)CCCC(C)(C)N1[Mg+] JHBZAAACZVPPRQ-UHFFFAOYSA-L 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- GQMYPXFJFQXDIZ-QFIPXVFZSA-N methyl (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl]propanoate Chemical compound ClC1=C(C(=O)N[C@H](C(=O)OC)CC2=CC=C(C3=CC=CC=C23)B2OC(C(O2)(C)C)(C)C)C(=CC=C1)Cl GQMYPXFJFQXDIZ-QFIPXVFZSA-N 0.000 description 2
- DLDHEVVWFZYOBT-FQEVSTJZSA-N methyl (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl]propanoate Chemical compound ClC1=C(C(=O)N[C@H](C(=O)OC)CC=2C=CC(=C3C=CC=NC=23)B2OC(C(O2)(C)C)(C)C)C(=CC=C1)Cl DLDHEVVWFZYOBT-FQEVSTJZSA-N 0.000 description 2
- WOLBPMFTJZZCRW-BJKOFHAPSA-N methyl (2S)-2-[[2,6-difluoro-4-[(3R)-3-(trifluoromethyl)morpholin-4-yl]benzoyl]amino]-3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl]propanoate Chemical compound FC1=C(C(=O)N[C@H](C(=O)OC)CC=2C=CC(=C3C=CC=NC=23)B2OC(C(O2)(C)C)(C)C)C(=CC(=C1)N1[C@H](COCC1)C(F)(F)F)F WOLBPMFTJZZCRW-BJKOFHAPSA-N 0.000 description 2
- IZLFLJOIVRBXHR-XZOQPEGZSA-N methyl (2S)-2-[[2,6-difluoro-4-[[(2R)-1,1,1-trifluorobutan-2-yl]amino]benzoyl]amino]-3-[5-(1,3,4-trimethyl-2,6-dioxopyrimidin-5-yl)quinolin-8-yl]propanoate Chemical compound FC1=C(C(=O)N[C@H](C(=O)OC)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C(N(C=2C)C)=O)C)=O)C(=CC(=C1)N[C@@H](C(F)(F)F)CC)F IZLFLJOIVRBXHR-XZOQPEGZSA-N 0.000 description 2
- LKOFUMOBAOWCNB-NSHDSACASA-N methyl (2S)-2-amino-3-(5-bromoquinolin-8-yl)propanoate Chemical compound N[C@H](C(=O)OC)CC=1C=CC(=C2C=CC=NC=12)Br LKOFUMOBAOWCNB-NSHDSACASA-N 0.000 description 2
- VPYAVKBEXFGANH-MERQFXBCSA-N methyl (2S)-2-amino-3-(5-bromoquinolin-8-yl)propanoate hydrochloride Chemical compound COC(=O)[C@H](CC1=C2C(=C(C=C1)Br)C=CC=N2)N.Cl VPYAVKBEXFGANH-MERQFXBCSA-N 0.000 description 2
- OGLZXCPJKKWHDH-SFHVURJKSA-N methyl (2S)-3-(4-bromonaphthalen-1-yl)-2-[(2,6-dichlorobenzoyl)amino]propanoate Chemical compound BrC1=CC=C(C2=CC=CC=C12)C[C@@H](C(=O)OC)NC(C1=C(C=CC=C1Cl)Cl)=O OGLZXCPJKKWHDH-SFHVURJKSA-N 0.000 description 2
- NCXSFNOZBJSOCT-INIZCTEOSA-N methyl (2S)-3-(5-bromoquinolin-8-yl)-2-[(2,6-dichlorobenzoyl)amino]propanoate Chemical compound BrC1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)OC)NC(C1=C(C=CC=C1Cl)Cl)=O NCXSFNOZBJSOCT-INIZCTEOSA-N 0.000 description 2
- GSLAAZXOEHFHQD-RBUKOAKNSA-N methyl (2S)-3-(5-bromoquinolin-8-yl)-2-[[2,6-difluoro-4-[[(2R)-1,1,1-trifluorobutan-2-yl]amino]benzoyl]amino]propanoate Chemical compound BrC1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)OC)NC(C1=C(C=C(C=C1F)N[C@@H](C(F)(F)F)CC)F)=O GSLAAZXOEHFHQD-RBUKOAKNSA-N 0.000 description 2
- YQUNOPYERFMMDJ-SANMLTNESA-N methyl (2S)-3-(8-bromoquinolin-5-yl)-2-[[2,6-difluoro-4-[[4-(2-fluoropyridin-4-yl)phenyl]sulfonylamino]benzoyl]amino]propanoate Chemical compound BrC=1C=CC(=C2C=CC=NC=12)C[C@@H](C(=O)OC)NC(C1=C(C=C(C=C1F)NS(=O)(=O)C1=CC=C(C=C1)C1=CC(=NC=C1)F)F)=O YQUNOPYERFMMDJ-SANMLTNESA-N 0.000 description 2
- WATJUAAKSYDGQV-NRFANRHFSA-N methyl (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[(2,6-difluorobenzoyl)amino]propanoate Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)OC)NC(C1=C(C=CC=C1F)F)=O WATJUAAKSYDGQV-NRFANRHFSA-N 0.000 description 2
- PNGLPAORBZPORI-JTSJOTPCSA-N methyl (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[[2,6-difluoro-4-[[(1R)-2,2,2-trifluoro-1-phenylethyl]amino]benzoyl]amino]propanoate Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)OC)NC(C1=C(C=C(C=C1F)N[C@@H](C(F)(F)F)C1=CC=CC=C1)F)=O PNGLPAORBZPORI-JTSJOTPCSA-N 0.000 description 2
- ADFVPYCTHYRSCG-SNVBAGLBSA-N methyl 2,6-difluoro-4-[(3R)-3-(trifluoromethyl)morpholin-4-yl]benzoate Chemical compound FC1=C(C(=O)OC)C(=CC(=C1)N1[C@H](COCC1)C(F)(F)F)F ADFVPYCTHYRSCG-SNVBAGLBSA-N 0.000 description 2
- PQTOLHHWLUCKSB-UHFFFAOYSA-N methyl 2-(benzhydrylideneamino)acetate Chemical compound C=1C=CC=CC=1C(=NCC(=O)OC)C1=CC=CC=C1 PQTOLHHWLUCKSB-UHFFFAOYSA-N 0.000 description 2
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 2
- 108010041596 mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 2
- 229960001601 obeticholic acid Drugs 0.000 description 2
- 229950010006 olokizumab Drugs 0.000 description 2
- 229960004110 olsalazine Drugs 0.000 description 2
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 108010018859 plecanatide Proteins 0.000 description 2
- 229950008515 plecanatide Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 208000017502 proteosome-associated autoinflammatory syndrome Diseases 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 229940121599 quetmolimab Drugs 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 2
- 229960003040 rifaximin Drugs 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 150000003873 salicylate salts Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- SFHMWDMKUYVSQJ-VECBPBMLSA-N sibofimloc Chemical compound C1CN(C(=O)C)CCC21C1=CC(C#C[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C1C1=CC=C(C#C[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=C12 SFHMWDMKUYVSQJ-VECBPBMLSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 229940121331 sutimlimab Drugs 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 108010073046 teduglutide Proteins 0.000 description 2
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 description 2
- 229960002444 teduglutide Drugs 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- DZHZULZJBHXPGY-MRXNPFEDSA-N tert-butyl 2,6-difluoro-4-[[(1R)-2,2,2-trifluoro-1-phenylethyl]amino]benzoate Chemical compound FC1=C(C(=O)OC(C)(C)C)C(=CC(=C1)N[C@@H](C(F)(F)F)C1=CC=CC=C1)F DZHZULZJBHXPGY-MRXNPFEDSA-N 0.000 description 2
- ATDIJGHJRMFYNX-LLVKDONJSA-N tert-butyl 2,6-difluoro-4-[[(2R)-1,1,1-trifluorobutan-2-yl]amino]benzoate Chemical compound FC1=C(C(=O)OC(C)(C)C)C(=CC(=C1)N[C@@H](C(F)(F)F)CC)F ATDIJGHJRMFYNX-LLVKDONJSA-N 0.000 description 2
- KKTKGKORENKLNV-UHFFFAOYSA-N tert-butyl 4-bromo-2,6-difluorobenzoate Chemical compound CC(C)(C)OC(=O)C1=C(F)C=C(Br)C=C1F KKTKGKORENKLNV-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 229950005515 tildrakizumab Drugs 0.000 description 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229950000835 tralokinumab Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229940070126 tropifexor Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229960003824 ustekinumab Drugs 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 229960004914 vedolizumab Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLGQSYUNOIJBNR-UHFFFAOYSA-N vonafexor Chemical compound C=1C=C2OC(C(=O)O)=CC2=C(Cl)C=1N(CC1)CCN1S(=O)(=O)C1=C(Cl)C=CC=C1Cl XLGQSYUNOIJBNR-UHFFFAOYSA-N 0.000 description 2
- 208000013013 vulvar carcinoma Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- DZCAUMADOBDJJH-SSDOTTSWSA-N (1r)-2,2,2-trifluoro-1-phenylethanamine Chemical compound FC(F)(F)[C@H](N)C1=CC=CC=C1 DZCAUMADOBDJJH-SSDOTTSWSA-N 0.000 description 1
- XNWCIDBPLDKKAG-UHFFFAOYSA-N (2-chloro-6-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(Cl)=C1B(O)O XNWCIDBPLDKKAG-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JPVGWAJBPPLMAW-NRFANRHFSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(1,5-dimethyl-2-oxopyridin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C=C(C=2)C)C)=O)C(=CC=C1)Cl JPVGWAJBPPLMAW-NRFANRHFSA-N 0.000 description 1
- ZODMJMMQETUDDZ-NRFANRHFSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(1,6-dimethyl-2-oxopyridin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C(=CC=2)C)C)=O)C(=CC=C1)Cl ZODMJMMQETUDDZ-NRFANRHFSA-N 0.000 description 1
- SWSFQWGOAPROHT-NRFANRHFSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(1-ethyl-2-oxopyridin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C=CC=2)CC)=O)C(=CC=C1)Cl SWSFQWGOAPROHT-NRFANRHFSA-N 0.000 description 1
- PHBQZOGYVZSOGP-FQEVSTJZSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(1-methyl-2-oxopyridin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C=CC=2)C)=O)C(=CC=C1)Cl PHBQZOGYVZSOGP-FQEVSTJZSA-N 0.000 description 1
- YWDLIRWKKWTKNM-QHCPKHFHSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(1-methyl-2-oxoquinolin-3-yl)quinolin-8-yl]propanoic acid Chemical compound C1=2C=CC=NC=2C(=CC=C1C=1C(=O)N(C2=C(C=1)C=CC=C2)C)C[C@@H](C(=O)O)NC(=O)C1=C(Cl)C=CC=C1Cl YWDLIRWKKWTKNM-QHCPKHFHSA-N 0.000 description 1
- XPCRDQPLGVCIHE-IBGZPJMESA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(1-oxidopyridin-1-ium-2-yl)quinolin-8-yl]propanoic acid Chemical compound C(=O)(O)[C@H](CC=1C=CC(=C2C=CC=NC=12)C1=[N+](C=CC=C1)[O-])NC(C1=C(C=CC=C1Cl)Cl)=O XPCRDQPLGVCIHE-IBGZPJMESA-N 0.000 description 1
- XOKGMNOPXZDGBG-SFHVURJKSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(2,5-dimethyltriazol-4-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=NN(N=C2C)C)C(=CC=C1)Cl XOKGMNOPXZDGBG-SFHVURJKSA-N 0.000 description 1
- WUTYMLPMYOFVKA-FQEVSTJZSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]propanoic acid Chemical compound C=1(C2=C(C(=CC=1)C[C@@H](C(=O)O)NC(=O)C1=C(Cl)C=CC=C1Cl)N=CC=C2)C1=C(Cl)C=C(F)C=C1Cl WUTYMLPMYOFVKA-FQEVSTJZSA-N 0.000 description 1
- YSKYHVVNSZKNNZ-FQEVSTJZSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(3,4-difluoro-2-methoxyphenyl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=C(C(=C(C=C2)F)F)OC)C(=CC=C1)Cl YSKYHVVNSZKNNZ-FQEVSTJZSA-N 0.000 description 1
- KWRLSTMAYBMROK-DEOSSOPVSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(3,4-dihydro-1H-isochromen-8-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C=CC=C3CCOCC=23)C(=CC=C1)Cl KWRLSTMAYBMROK-DEOSSOPVSA-N 0.000 description 1
- YPAZPRULWFICJK-QHCPKHFHSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(3,4-dihydro-2H-chromen-8-yl)quinolin-8-yl]propanoic acid Chemical compound O1CCCC2=CC=CC(=C12)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1Cl)Cl)=O YPAZPRULWFICJK-QHCPKHFHSA-N 0.000 description 1
- UANMGUGRCHNKME-NRFANRHFSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(3,5-difluoro-2-methoxyphenyl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=C(C(=CC(=C2)F)F)OC)C(=CC=C1)Cl UANMGUGRCHNKME-NRFANRHFSA-N 0.000 description 1
- YXBKVKBCFBIPQF-NRFANRHFSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(3-fluoro-2-methoxyphenyl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=C(C(=CC=C2)F)OC)C(=CC=C1)Cl YXBKVKBCFBIPQF-NRFANRHFSA-N 0.000 description 1
- IFUBUEVJSLPHTM-NRFANRHFSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(4,5-difluoro-2-methoxyphenyl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=C(C=C(C(=C2)F)F)OC)C(=CC=C1)Cl IFUBUEVJSLPHTM-NRFANRHFSA-N 0.000 description 1
- ACHZYDUBVDHHTM-SFHVURJKSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(4-methyl-3-oxopyrazin-2-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=NC=CN(C2=O)C)C(=CC=C1)Cl ACHZYDUBVDHHTM-SFHVURJKSA-N 0.000 description 1
- QVZAALCFNRTLJC-DEOSSOPVSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(4-methylisoquinolin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2N=CC3=CC=CC=C3C=2C)C(=CC=C1)Cl QVZAALCFNRTLJC-DEOSSOPVSA-N 0.000 description 1
- LWOFLYWUWWKJNS-FQEVSTJZSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(5-fluoro-1-methyl-2-oxopyridin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C=C(C=2)F)C)=O)C(=CC=C1)Cl LWOFLYWUWWKJNS-FQEVSTJZSA-N 0.000 description 1
- HSIQFPVVWPNVRF-FQEVSTJZSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(5-fluoro-2-methoxypyridin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(=NC=C(C=2)F)OC)C(=CC=C1)Cl HSIQFPVVWPNVRF-FQEVSTJZSA-N 0.000 description 1
- TYPKTXYZZLJNLZ-IBGZPJMESA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(5-fluoro-3-methoxypyridin-2-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=NC=C(C=C2OC)F)C(=CC=C1)Cl TYPKTXYZZLJNLZ-IBGZPJMESA-N 0.000 description 1
- INJRUEGFUBDEQD-QHCPKHFHSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-(7-fluoro-1,4-dimethyl-2-oxoquinolin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC2=CC=C(C=3C=CC=NC2=3)C=2C(N(C3=CC(=CC=C3C=2C)F)C)=O)C(=CC=C1)Cl INJRUEGFUBDEQD-QHCPKHFHSA-N 0.000 description 1
- LYWATRDCEHXYHP-SFHVURJKSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-[1,5-dimethyl-3-(trifluoromethyl)pyrazol-4-yl]quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(=NN(C=2C)C)C(F)(F)F)C(=CC=C1)Cl LYWATRDCEHXYHP-SFHVURJKSA-N 0.000 description 1
- LIAFIVFQEFENMN-FQEVSTJZSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-[1-methyl-2-oxo-5-(trifluoromethyl)pyridin-3-yl]quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C=C(C=2)C(F)(F)F)C)=O)C(=CC=C1)Cl LIAFIVFQEFENMN-FQEVSTJZSA-N 0.000 description 1
- RMVFRJGMSLZCLS-SFHVURJKSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(=NN(C=2)C)C(F)(F)F)C(=CC=C1)Cl RMVFRJGMSLZCLS-SFHVURJKSA-N 0.000 description 1
- XVSXPRUEVLMRMU-KRWDZBQOSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-[3-(trifluoromethyl)pyrazin-2-yl]quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=NC=CN=C2C(F)(F)F)C(=CC=C1)Cl XVSXPRUEVLMRMU-KRWDZBQOSA-N 0.000 description 1
- XYNJUVYXCDHKLC-FQEVSTJZSA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-[4-fluoro-2-methoxy-6-(trifluoromethyl)phenyl]quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C2=C(C=C(C=C2C(F)(F)F)F)OC)C(=CC=C1)Cl XYNJUVYXCDHKLC-FQEVSTJZSA-N 0.000 description 1
- QVRZPROSFWZGJQ-IBGZPJMESA-N (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[5-[6-methyl-4-(trifluoromethyl)pyridazin-3-yl]quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)N[C@H](C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2N=NC(=CC=2C(F)(F)F)C)C(=CC=C1)Cl QVRZPROSFWZGJQ-IBGZPJMESA-N 0.000 description 1
- ONSRUWIPFTYMHW-LOSJGSFVSA-N (2S)-2-[[2,6-difluoro-4-[(3R)-3-(trifluoromethyl)morpholin-4-yl]benzoyl]amino]-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl]propanoic acid Chemical compound B1(OC(C(O1)(C)C)(C)C)C2=CC=C(C3=CC=CC=C23)C[C@@H](C(=O)O)NC(=O)C4=C(C=C(C=C4F)N5CCOC[C@@H]5C(F)(F)F)F ONSRUWIPFTYMHW-LOSJGSFVSA-N 0.000 description 1
- YCENNTKURLHLPV-FQEVSTJZSA-N (2S)-3-[5-(1,3-benzothiazol-4-yl)quinolin-8-yl]-2-[(2,6-dichlorobenzoyl)amino]propanoic acid Chemical compound S1C=NC2=C1C=CC=C2C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1Cl)Cl)=O YCENNTKURLHLPV-FQEVSTJZSA-N 0.000 description 1
- CUVRZMAUPURJSD-FQEVSTJZSA-N (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[(2,6-difluorobenzoyl)amino]propanoic acid Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1F)F)=O CUVRZMAUPURJSD-FQEVSTJZSA-N 0.000 description 1
- SSBRVGSVZSVZLJ-FQEVSTJZSA-N (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[(2-fluoro-6-methoxybenzoyl)amino]propanoic acid Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1OC)F)=O SSBRVGSVZSVZLJ-FQEVSTJZSA-N 0.000 description 1
- JPNVOHWQUXIWJA-NRFANRHFSA-N (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[[2,6-difluoro-4-(methanesulfonamido)benzoyl]amino]propanoic acid Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=C(C=C1F)NS(=O)(=O)C)F)=O JPNVOHWQUXIWJA-NRFANRHFSA-N 0.000 description 1
- WMLFTNZAOJJULX-BJKOFHAPSA-N (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[[2,6-difluoro-4-[(3R)-3-(trifluoromethyl)morpholin-4-yl]benzoyl]amino]propanoic acid Chemical compound C=1(C2=C(C(=CC=1)C[C@@H](C(=O)O)NC(=O)C1=C(F)C=C(N3[C@@H](C(F)(F)F)COCC3)C=C1F)N=CC=C2)C1=C(Cl)C=C(F)C=C1Cl WMLFTNZAOJJULX-BJKOFHAPSA-N 0.000 description 1
- WMLFTNZAOJJULX-ZEQRLZLVSA-N (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[[2,6-difluoro-4-[(3S)-3-(trifluoromethyl)morpholin-4-yl]benzoyl]amino]propanoic acid Chemical compound C1=2C=CC=NC=2C(=CC=C1C1=C(Cl)C=C(F)C=C1Cl)C[C@@H](C(=O)O)NC(=O)C1=C(F)C=C(N2[C@H](C(F)(F)F)COCC2)C=C1F WMLFTNZAOJJULX-ZEQRLZLVSA-N 0.000 description 1
- WMLFTNZAOJJULX-UXMRNZNESA-N (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[[2,6-difluoro-4-[3-(trifluoromethyl)morpholin-4-yl]benzoyl]amino]propanoic acid Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=C(C=C1F)N1C(COCC1)C(F)(F)F)F)=O WMLFTNZAOJJULX-UXMRNZNESA-N 0.000 description 1
- QYVXAHMWTMQDFI-FREGXXQWSA-N (2S)-3-[5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl]-2-[[2,6-difluoro-4-[[(1R)-2,2,2-trifluoro-1-phenylethyl]amino]benzoyl]amino]propanoic acid Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=C(C=C1F)N[C@@H](C(F)(F)F)C1=CC=CC=C1)F)=O QYVXAHMWTMQDFI-FREGXXQWSA-N 0.000 description 1
- FUSUPYXVUOPNHZ-FQEVSTJZSA-N (2S)-3-[5-(2-chloro-4-fluoro-6-methoxyphenyl)quinolin-8-yl]-2-[(2,6-dichlorobenzoyl)amino]propanoic acid Chemical compound ClC1=C(C(=CC(=C1)F)OC)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1Cl)Cl)=O FUSUPYXVUOPNHZ-FQEVSTJZSA-N 0.000 description 1
- HYTMOTKXGSPFBW-FQEVSTJZSA-N (2S)-3-[5-(2-chloro-6-methoxyphenyl)quinolin-8-yl]-2-[(2,6-dichlorobenzoyl)amino]propanoic acid Chemical compound ClC1=C(C(=CC=C1)OC)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1Cl)Cl)=O HYTMOTKXGSPFBW-FQEVSTJZSA-N 0.000 description 1
- GCYCTXZLCUIOGA-QFIPXVFZSA-N (2S)-3-[5-(4-bromoisoquinolin-3-yl)quinolin-8-yl]-2-[(2,6-dichlorobenzoyl)amino]propanoic acid Chemical compound C1=C2C(C3=NC=C4C(=C3Br)C=CC=C4)=CC=C(C[C@@H](C(=O)O)NC(=O)C3=C(Cl)C=CC=C3Cl)C2=NC=C1 GCYCTXZLCUIOGA-QFIPXVFZSA-N 0.000 description 1
- HVKNZTOHVYKGOJ-FQEVSTJZSA-N (2S)-3-[5-(5-chloro-1-methyl-2-oxopyridin-3-yl)quinolin-8-yl]-2-[(2,6-dichlorobenzoyl)amino]propanoic acid Chemical compound ClC=1C=C(C(N(C=1)C)=O)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1Cl)Cl)=O HVKNZTOHVYKGOJ-FQEVSTJZSA-N 0.000 description 1
- LVOIWUQLRSQOAY-NRFANRHFSA-N (2S)-3-[5-(5-chloro-4-fluoro-2-methoxyphenyl)quinolin-8-yl]-2-[(2,6-dichlorobenzoyl)amino]propanoic acid Chemical compound ClC=1C(=CC(=C(C=1)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1Cl)Cl)=O)OC)F LVOIWUQLRSQOAY-NRFANRHFSA-N 0.000 description 1
- ZHBDQOFAHUFEGM-FQEVSTJZSA-N (2S)-3-[5-[2-chloro-6-(trifluoromethyl)phenyl]quinolin-8-yl]-2-[(2,6-dichlorobenzoyl)amino]propanoic acid Chemical compound ClC1=C(C(=CC=C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1Cl)Cl)=O ZHBDQOFAHUFEGM-FQEVSTJZSA-N 0.000 description 1
- SVJPHEJGHIBNQQ-SFHVURJKSA-N (2S)-3-[5-[3-chloro-4-(trifluoromethyl)pyridin-2-yl]quinolin-8-yl]-2-[(2,6-dichlorobenzoyl)amino]propanoic acid Chemical compound ClC=1C(=NC=CC=1C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C[C@@H](C(=O)O)NC(C1=C(C=CC=C1Cl)Cl)=O SVJPHEJGHIBNQQ-SFHVURJKSA-N 0.000 description 1
- CWOFQJBATWQSHL-DEOSSOPVSA-N (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound COCCN(CCCCc1ccc2CCCNc2n1)CC[C@H](Nc1ncnc2ccccc12)C(O)=O CWOFQJBATWQSHL-DEOSSOPVSA-N 0.000 description 1
- BOOOLEGQBVUTKC-NVQSDHBMSA-N (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BOOOLEGQBVUTKC-NVQSDHBMSA-N 0.000 description 1
- PKAILYMPWXXBJS-GSVOUGTGSA-N (2r)-1,1,1-trifluorobutan-2-amine Chemical compound CC[C@@H](N)C(F)(F)F PKAILYMPWXXBJS-GSVOUGTGSA-N 0.000 description 1
- FCFWEOGTZZPCTO-MRVPVSSYSA-N (2r)-3,6-dimethoxy-2-propan-2-yl-2,5-dihydropyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=NC1 FCFWEOGTZZPCTO-MRVPVSSYSA-N 0.000 description 1
- WTKSWPYGZDCUNQ-JZXFCXSPSA-N (2s)-2,6-diaminohexanoic acid;2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid;dihydrate Chemical compound O.O.NCCCC[C@H](N)C(O)=O.C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 WTKSWPYGZDCUNQ-JZXFCXSPSA-N 0.000 description 1
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 description 1
- ISOCDPQFIXDIMS-QHCPKHFHSA-N (2s)-n-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NCCC1)NC(C=C1)=CC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 ISOCDPQFIXDIMS-QHCPKHFHSA-N 0.000 description 1
- DNBCBAXDWNDRNO-FOSCPWQOSA-N (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide Chemical compound COC1=NSC(NC(=O)N2C[C@H]3CC(C[C@H]3C2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 DNBCBAXDWNDRNO-FOSCPWQOSA-N 0.000 description 1
- QYYDXDSPYPOWRO-JHMCBHKWSA-N (3r)-3-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]butanoic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CC(O)=O)C)[C@@]2(C)CC1 QYYDXDSPYPOWRO-JHMCBHKWSA-N 0.000 description 1
- VMPUKWSLCRUGSR-SDBXPKJASA-N (3s)-3-[[(2s)-2-[[2-(2,6-difluoroanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=C(F)C=CC=C1F VMPUKWSLCRUGSR-SDBXPKJASA-N 0.000 description 1
- WZTIQQBMSJTRBR-WYKNNRPVSA-N (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCC(=O)N1 WZTIQQBMSJTRBR-WYKNNRPVSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- OXDSKEQSEGDAFN-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenylmethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1 OXDSKEQSEGDAFN-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DPGQSDLGKGLNHC-UHFFFAOYSA-N 1,1-diethylcyclopentane Chemical compound CCC1(CC)CCCC1 DPGQSDLGKGLNHC-UHFFFAOYSA-N 0.000 description 1
- YAXWOADCWUUUNX-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidine Chemical compound CC1CCCN(C)C1(C)C YAXWOADCWUUUNX-UHFFFAOYSA-N 0.000 description 1
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 description 1
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
- HUUSXLKCTQDPGL-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea Chemical compound CC(C)(O)C1=COC(S(=O)(=O)NC(=O)NC=2C=3CCCC=3C=C3CCCC3=2)=C1 HUUSXLKCTQDPGL-UHFFFAOYSA-N 0.000 description 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 1
- DNXSLLIDTGLIHX-UHFFFAOYSA-N 1-bromo-3,4-difluoro-2-methoxybenzene Chemical compound COC1=C(F)C(F)=CC=C1Br DNXSLLIDTGLIHX-UHFFFAOYSA-N 0.000 description 1
- MFXWQGHKLXJIIP-UHFFFAOYSA-N 1-bromo-3,5-difluoro-2-methoxybenzene Chemical compound COC1=C(F)C=C(F)C=C1Br MFXWQGHKLXJIIP-UHFFFAOYSA-N 0.000 description 1
- RLSQPLJXDTXSCL-UHFFFAOYSA-N 1-bromo-3-fluoro-2-methoxybenzene Chemical compound COC1=C(F)C=CC=C1Br RLSQPLJXDTXSCL-UHFFFAOYSA-N 0.000 description 1
- DKARISQFDBAJEZ-UHFFFAOYSA-N 1-bromo-4,5-difluoro-2-methoxybenzene Chemical compound COC1=CC(F)=C(F)C=C1Br DKARISQFDBAJEZ-UHFFFAOYSA-N 0.000 description 1
- FHXASJKBBLIBAQ-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)naphthalene Chemical compound C1=CC=C2C(CBr)=CC=C(Br)C2=C1 FHXASJKBBLIBAQ-UHFFFAOYSA-N 0.000 description 1
- IDRVLLRKAAHOBP-UHFFFAOYSA-N 1-bromo-4-methylnaphthalene Chemical compound C1=CC=C2C(C)=CC=C(Br)C2=C1 IDRVLLRKAAHOBP-UHFFFAOYSA-N 0.000 description 1
- WPDRTZQNLRNDMG-UHFFFAOYSA-N 1-bromopyrrolidine Chemical compound BrN1CCCC1 WPDRTZQNLRNDMG-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- CIQJWKNJDQKPPO-UHFFFAOYSA-N 1-chloropiperidine Chemical compound ClN1CCCCC1 CIQJWKNJDQKPPO-UHFFFAOYSA-N 0.000 description 1
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical group OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical group O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- RNGDOGDJOKGWSH-UHFFFAOYSA-N 2,6-difluoro-4-(methanesulfonamido)benzoic acid Chemical compound FC1=C(C(=O)O)C(=CC(=C1)NS(=O)(=O)C)F RNGDOGDJOKGWSH-UHFFFAOYSA-N 0.000 description 1
- CAACPXVQUJYVPS-UHFFFAOYSA-N 2,6-difluoro-4-[3-(trifluoromethyl)morpholin-4-yl]benzoic acid Chemical compound FC1=C(C(=O)O)C(=CC(=C1)N1C(COCC1)C(F)(F)F)F CAACPXVQUJYVPS-UHFFFAOYSA-N 0.000 description 1
- SETZIOFQYRYVBG-UHFFFAOYSA-N 2-[(2,6-dichlorobenzoyl)amino]-3-[5-(1,4-dimethyl-2-oxopyridin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)NC(C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C=CC=2C)C)=O)C(=CC=C1)Cl SETZIOFQYRYVBG-UHFFFAOYSA-N 0.000 description 1
- ODGBMELPASELRA-UHFFFAOYSA-N 2-[(2,6-dichlorobenzoyl)amino]-3-[5-(4-methoxy-1-methyl-2-oxopyridin-3-yl)quinolin-8-yl]propanoic acid Chemical compound ClC1=C(C(=O)NC(C(=O)O)CC=2C=CC(=C3C=CC=NC=23)C=2C(N(C=CC=2OC)C)=O)C(=CC=C1)Cl ODGBMELPASELRA-UHFFFAOYSA-N 0.000 description 1
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 description 1
- IDXKJSSOUXWLDB-UHFFFAOYSA-N 2-[4-(4-ethoxy-6-oxo-1h-pyridin-3-yl)-2-fluorophenyl]-n-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]acetamide Chemical compound CCOC1=CC(=O)NC=C1C(C=C1F)=CC=C1CC(=O)NC1=NOC(C(C)(C)C(F)(F)F)=C1 IDXKJSSOUXWLDB-UHFFFAOYSA-N 0.000 description 1
- XPRDUGXOWVXZLL-UHFFFAOYSA-N 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3CCCC=3C(O)=O)=CC=2)=C1 XPRDUGXOWVXZLL-UHFFFAOYSA-N 0.000 description 1
- IINUNQPYJGJCJI-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol Chemical compound C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 IINUNQPYJGJCJI-UHFFFAOYSA-N 0.000 description 1
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 description 1
- OSXAPJFZNJFFJS-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-fluorobenzene Chemical compound FC1=CC(Cl)=C(Br)C(Cl)=C1 OSXAPJFZNJFFJS-UHFFFAOYSA-N 0.000 description 1
- GMUWNTUONIQRFP-UHFFFAOYSA-N 2-bromo-1-chloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(Cl)=C1Br GMUWNTUONIQRFP-UHFFFAOYSA-N 0.000 description 1
- NJCMNBWUKHLGIC-UHFFFAOYSA-N 2-bromo-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=CC=C1Br NJCMNBWUKHLGIC-UHFFFAOYSA-N 0.000 description 1
- WILQWGAMYJUHPE-UHFFFAOYSA-N 2-bromo-3-chloro-4-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=NC(Br)=C1Cl WILQWGAMYJUHPE-UHFFFAOYSA-N 0.000 description 1
- MLRPPBYKVCYWRY-UHFFFAOYSA-N 2-bromo-3-chloro-5-fluorophenol Chemical compound Oc1cc(F)cc(Cl)c1Br MLRPPBYKVCYWRY-UHFFFAOYSA-N 0.000 description 1
- KQAXEKRONYMMKG-UHFFFAOYSA-N 2-bromo-4-chloro-5-fluorophenol Chemical compound OC1=CC(F)=C(Cl)C=C1Br KQAXEKRONYMMKG-UHFFFAOYSA-N 0.000 description 1
- DVYSUHZUJSNGJF-UHFFFAOYSA-N 2-bromo-5-fluoro-3-(trifluoromethyl)phenol Chemical compound Oc1cc(F)cc(c1Br)C(F)(F)F DVYSUHZUJSNGJF-UHFFFAOYSA-N 0.000 description 1
- DXKMFZFNZFYYSM-UHFFFAOYSA-N 2-bromo-5-fluoro-4-methylphenol Chemical compound CC1=CC(Br)=C(O)C=C1F DXKMFZFNZFYYSM-UHFFFAOYSA-N 0.000 description 1
- FXNHOYJCHUHVNX-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)pyrazine Chemical compound FC(F)(F)C1=NC=CN=C1Cl FXNHOYJCHUHVNX-UHFFFAOYSA-N 0.000 description 1
- YLLPKZZZTACMIO-UHFFFAOYSA-N 2-chloro-5-fluoro-3-methoxypyridine Chemical compound COC1=CC(F)=CN=C1Cl YLLPKZZZTACMIO-UHFFFAOYSA-N 0.000 description 1
- YZWKSOYWTHKNLX-UHFFFAOYSA-N 2-fluoro-6-methoxybenzoyl chloride Chemical compound COC1=CC=CC(F)=C1C(Cl)=O YZWKSOYWTHKNLX-UHFFFAOYSA-N 0.000 description 1
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 description 1
- KPFCPYVACMZIEF-UHFFFAOYSA-N 2-oxo-1h-1,6-naphthyridine-3-carboxylic acid Chemical compound N1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 KPFCPYVACMZIEF-UHFFFAOYSA-N 0.000 description 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- HVAPLSNCVYXFDQ-UHFFFAOYSA-N 3,3-dimethyl-1-(trifluoromethyl)-1$l^{3},2-benziodoxole Chemical compound C1=CC=C2C(C)(C)OI(C(F)(F)F)C2=C1 HVAPLSNCVYXFDQ-UHFFFAOYSA-N 0.000 description 1
- QEYCAHPFXWCHRT-UHFFFAOYSA-N 3,4-dibromoisoquinoline Chemical compound C1=CC=CC2=C(Br)C(Br)=NC=C21 QEYCAHPFXWCHRT-UHFFFAOYSA-N 0.000 description 1
- DNNVRTZJRKIUFK-UHFFFAOYSA-N 3,4-dihydroquinoline Chemical compound C1=CC=C2N=CCCC2=C1 DNNVRTZJRKIUFK-UHFFFAOYSA-N 0.000 description 1
- OHFRHIUJBMHGLQ-UHFFFAOYSA-N 3-(trifluoromethyl)morpholine;hydrochloride Chemical compound Cl.FC(F)(F)C1COCCN1 OHFRHIUJBMHGLQ-UHFFFAOYSA-N 0.000 description 1
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WNODRNXZNFSPED-UHFFFAOYSA-N 3-bromo-1-ethylpyridin-2-one Chemical compound CCN1C=CC=C(Br)C1=O WNODRNXZNFSPED-UHFFFAOYSA-N 0.000 description 1
- FTCGYBIUAXXLHH-UHFFFAOYSA-N 3-bromo-1-methyl-5-(trifluoromethyl)pyridin-2-one Chemical compound CN1C=C(C(F)(F)F)C=C(Br)C1=O FTCGYBIUAXXLHH-UHFFFAOYSA-N 0.000 description 1
- HKLQWLOMEUJSOR-UHFFFAOYSA-N 3-bromo-1-methylpyridin-2-one Chemical compound CN1C=CC=C(Br)C1=O HKLQWLOMEUJSOR-UHFFFAOYSA-N 0.000 description 1
- FSLMLEUYCWVPBN-UHFFFAOYSA-N 3-bromo-1-methylquinolin-2-one Chemical compound C1=CC=C2C=C(Br)C(=O)N(C)C2=C1 FSLMLEUYCWVPBN-UHFFFAOYSA-N 0.000 description 1
- KYQGLGASZBTTFW-UHFFFAOYSA-N 3-bromo-5-chloro-1-methylpyridin-2-one Chemical compound CN1C=C(Cl)C=C(Br)C1=O KYQGLGASZBTTFW-UHFFFAOYSA-N 0.000 description 1
- LTCXKECJVVTOOH-UHFFFAOYSA-N 3-bromo-5-fluoro-1-methylpyridin-2-one Chemical compound Cn1cc(F)cc(Br)c1=O LTCXKECJVVTOOH-UHFFFAOYSA-N 0.000 description 1
- HSWCOAGQYSBFAK-UHFFFAOYSA-N 3-bromo-5-fluoro-2-methoxypyridine Chemical compound COC1=NC=C(F)C=C1Br HSWCOAGQYSBFAK-UHFFFAOYSA-N 0.000 description 1
- NYGAATAVOPYQRE-UHFFFAOYSA-N 3-bromo-6-methyl-4-(trifluoromethyl)pyridazine Chemical compound Cc1cc(c(Br)nn1)C(F)(F)F NYGAATAVOPYQRE-UHFFFAOYSA-N 0.000 description 1
- GJELDSCPTNJBFL-UHFFFAOYSA-N 3-chloro-1,4-dimethylpyridin-2-one Chemical compound Cc1ccn(C)c(=O)c1Cl GJELDSCPTNJBFL-UHFFFAOYSA-N 0.000 description 1
- KVFSRNYIQCJEIG-UHFFFAOYSA-N 3-chloro-1,5-dimethylpyridin-2-one Chemical compound CC=1C=C(Cl)C(=O)N(C)C=1 KVFSRNYIQCJEIG-UHFFFAOYSA-N 0.000 description 1
- LTEQLOSHUQBDSC-UHFFFAOYSA-N 3-chloro-1,6-dimethylpyridin-2-one Chemical compound Cc1ccc(Cl)c(=O)n1C LTEQLOSHUQBDSC-UHFFFAOYSA-N 0.000 description 1
- DKRZOECINQAWFK-UHFFFAOYSA-N 3-chloro-1-methylpyrazin-2-one Chemical compound CN1C=CN=C(Cl)C1=O DKRZOECINQAWFK-UHFFFAOYSA-N 0.000 description 1
- VVOLQHWZWJMPAJ-UHFFFAOYSA-N 3-chloro-4,6-dimethyl-1h-pyridin-2-one Chemical compound CC1=CC(C)=C(Cl)C(O)=N1 VVOLQHWZWJMPAJ-UHFFFAOYSA-N 0.000 description 1
- QYLCTMSOYURFHD-UHFFFAOYSA-N 3-chloro-4-methoxy-1-methylpyridin-2-one Chemical compound COC=1C=CN(C)C(=O)C=1Cl QYLCTMSOYURFHD-UHFFFAOYSA-N 0.000 description 1
- WXDJNUIWNJLXEC-UHFFFAOYSA-N 3-chloro-4-methylisoquinoline Chemical compound C1=CC=C2C(C)=C(Cl)N=CC2=C1 WXDJNUIWNJLXEC-UHFFFAOYSA-N 0.000 description 1
- UXJOCUBEPDXIKR-UHFFFAOYSA-N 3-iodo-1H-1,6-naphthyridin-2-one Chemical compound IC=1C(NC2=CC=NC=C2C=1)=O UXJOCUBEPDXIKR-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- LQFRYKBDZNPJSW-UHFFFAOYSA-N 3-methylsulfonylpropanenitrile Chemical compound CS(=O)(=O)CCC#N LQFRYKBDZNPJSW-UHFFFAOYSA-N 0.000 description 1
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- GSJGKNLMGQIWJH-UHFFFAOYSA-N 4-(trifluoromethyl)-1,5,6,7-tetrahydrocyclopenta[b]pyridin-2-one Chemical compound FC(F)(F)C1=CC(=O)NC2=C1CCC2 GSJGKNLMGQIWJH-UHFFFAOYSA-N 0.000 description 1
- UUROBWTVZZNDFD-UHFFFAOYSA-N 4-(trifluoromethyl)-1h-quinolin-2-one Chemical compound C1=CC=C2C(C(F)(F)F)=CC(=O)NC2=C1 UUROBWTVZZNDFD-UHFFFAOYSA-N 0.000 description 1
- LZYBKJQEODVFGY-UHFFFAOYSA-N 4-(trifluoromethyl)isoquinolin-3-amine Chemical compound C1=CC=CC2=C(C(F)(F)F)C(N)=NC=C21 LZYBKJQEODVFGY-UHFFFAOYSA-N 0.000 description 1
- GTPZHMGXKZIHKW-UHFFFAOYSA-N 4-aminopyridine-3-carbaldehyde Chemical compound NC1=CC=NC=C1C=O GTPZHMGXKZIHKW-UHFFFAOYSA-N 0.000 description 1
- FZMQHKLFUMGAAO-UHFFFAOYSA-N 4-benzyl-4-methylpiperidine Chemical compound C=1C=CC=CC=1CC1(C)CCNCC1 FZMQHKLFUMGAAO-UHFFFAOYSA-N 0.000 description 1
- SXZKODVCLOIJGX-UHFFFAOYSA-N 4-bromo-1,3-benzothiazole Chemical compound BrC1=CC=CC2=C1N=CS2 SXZKODVCLOIJGX-UHFFFAOYSA-N 0.000 description 1
- IFCNTZRBBLIUMD-UHFFFAOYSA-N 4-bromo-1,5-dimethyl-3-(trifluoromethyl)pyrazole Chemical compound CC1=C(Br)C(C(F)(F)F)=NN1C IFCNTZRBBLIUMD-UHFFFAOYSA-N 0.000 description 1
- TZAYNGPUOOUEAP-UHFFFAOYSA-N 4-bromo-1-methyl-3-(trifluoromethyl)pyrazole Chemical compound CN1C=C(Br)C(C(F)(F)F)=N1 TZAYNGPUOOUEAP-UHFFFAOYSA-N 0.000 description 1
- FFQGJCDYFLYVPU-UHFFFAOYSA-N 4-bromo-2,5-dimethyltriazole Chemical compound CC1=NN(C)N=C1Br FFQGJCDYFLYVPU-UHFFFAOYSA-N 0.000 description 1
- AYVPVDWQZAAZCM-UHFFFAOYSA-N 4-bromo-n-methylaniline Chemical compound CNC1=CC=C(Br)C=C1 AYVPVDWQZAAZCM-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 1
- ICKFLVCCDBOBIN-SIKLNZKXSA-N 5-(2,6-dichloro-4-fluorophenyl)-8-[[(2S,5R)-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazin-2-yl]methyl]-1H-quinolin-2-one Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC(NC2=C(C=C1)C[C@@H]1N=C([C@H](N=C1OC)C(C)C)OC)=O ICKFLVCCDBOBIN-SIKLNZKXSA-N 0.000 description 1
- JBOLJSIYUGAPDS-RBBKRZOGSA-N 5-(2,6-dichloro-4-fluorophenyl)-8-[[(2S,5R)-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazin-2-yl]methyl]quinoline Chemical compound ClC1=C(C(=CC(=C1)F)Cl)C1=C2C=CC=NC2=C(C=C1)C[C@@H]1N=C([C@H](N=C1OC)C(C)C)OC JBOLJSIYUGAPDS-RBBKRZOGSA-N 0.000 description 1
- FNRNBCNUWGWVFO-UHFFFAOYSA-N 5-[[4-(carboxymethyl)phenyl]diazenyl]-2-hydroxybenzoic acid Chemical compound C1=CC(CC(=O)O)=CC=C1N=NC1=CC=C(O)C(C(O)=O)=C1 FNRNBCNUWGWVFO-UHFFFAOYSA-N 0.000 description 1
- LYPAFUINURXJSG-AWEZNQCLSA-N 5-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1h-1,2,4-triazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)C(N=1)=NNC=1CC1=CC=CC=C1 LYPAFUINURXJSG-AWEZNQCLSA-N 0.000 description 1
- RJNYZLOAGXCCHJ-UHFFFAOYSA-N 5-bromo-1,3,6-trimethylpyrimidine-2,4-dione Chemical compound CC1=C(Br)C(=O)N(C)C(=O)N1C RJNYZLOAGXCCHJ-UHFFFAOYSA-N 0.000 description 1
- DYEWCBDCJFPCCV-GOEBONIOSA-N 5-bromo-8-[[(2S,5R)-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazin-2-yl]methyl]-1H-quinolin-2-one Chemical compound BrC1=C2C=CC(NC2=C(C=C1)C[C@@H]1N=C([C@H](N=C1OC)C(C)C)OC)=O DYEWCBDCJFPCCV-GOEBONIOSA-N 0.000 description 1
- NAMTYXMHPZZWLO-JKSUJKDBSA-N 5-bromo-8-[[(2S,5R)-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazin-2-yl]methyl]quinoline Chemical compound BrC1=C2C=CC=NC2=C(C=C1)C[C@@H]1N=C([C@H](N=C1OC)C(C)C)OC NAMTYXMHPZZWLO-JKSUJKDBSA-N 0.000 description 1
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
- BZZKEPGENYLQSC-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NN(C=N1)C)OC BZZKEPGENYLQSC-FIBGUPNXSA-N 0.000 description 1
- QUYKGALHTFIKTR-UHFFFAOYSA-N 6-bromo-1,4-dimethylquinolin-2-one Chemical compound Cc1cc(=O)n(C)c2ccc(Br)cc12 QUYKGALHTFIKTR-UHFFFAOYSA-N 0.000 description 1
- LIKVSFMECXRHSH-UHFFFAOYSA-N 6-chloro-1,4-dimethylquinolin-2-one Chemical compound CN1C(=O)C=C(C)C2=C1C=CC(Cl)=C2 LIKVSFMECXRHSH-UHFFFAOYSA-N 0.000 description 1
- CDRMKCNOGIBXOG-UHFFFAOYSA-N 6-methyl-4-(trifluoromethyl)-1h-pyridin-2-one Chemical compound CC1=CC(C(F)(F)F)=CC(=O)N1 CDRMKCNOGIBXOG-UHFFFAOYSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- JRGDIVGVVLHVJX-UHFFFAOYSA-N 7-fluoro-4-methyl-1h-quinolin-2-one Chemical compound FC1=CC=C2C(C)=CC(=O)NC2=C1 JRGDIVGVVLHVJX-UHFFFAOYSA-N 0.000 description 1
- BGFVEDQBPUGBOO-AZUAARDMSA-N 8-[[(2S,5R)-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazin-2-yl]methyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-quinolin-2-one Chemical compound C(C)(C)[C@H]1N=C([C@@H](N=C1OC)CC=1C=CC(=C2C=CC(NC=12)=O)B1OC(C(O1)(C)C)(C)C)OC BGFVEDQBPUGBOO-AZUAARDMSA-N 0.000 description 1
- JXYPEUTWKHGSMA-VQTJNVASSA-N 8-[[(2S,5R)-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazin-2-yl]methyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline Chemical compound C(C)(C)[C@H]1N=C([C@@H](N=C1OC)CC=1C=CC(=C2C=CC=NC=12)B1OC(C(O1)(C)C)(C)C)OC JXYPEUTWKHGSMA-VQTJNVASSA-N 0.000 description 1
- AGVNTWBJYBSROH-UHFFFAOYSA-N 8-bromo-3,4-dihydro-1h-isochromene Chemical compound C1COCC2=C1C=CC=C2Br AGVNTWBJYBSROH-UHFFFAOYSA-N 0.000 description 1
- YJOORJDFGHETSS-UHFFFAOYSA-N 8-bromo-3,4-dihydro-2h-chromene Chemical compound C1CCOC2=C1C=CC=C2Br YJOORJDFGHETSS-UHFFFAOYSA-N 0.000 description 1
- OZOGDCZJYVSUBR-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 OZOGDCZJYVSUBR-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 102100033391 ATP-dependent RNA helicase DDX3X Human genes 0.000 description 1
- 101710156069 ATP-dependent RNA helicase DDX3X Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000026326 Adult-onset Still disease Diseases 0.000 description 1
- 229910016455 AlBN Inorganic materials 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940122065 Alpha4beta7 integrin antagonist Drugs 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical group NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010002965 Aplasia pure red cell Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108050001413 B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229940124282 BMS-986165 Drugs 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000009144 Bartter disease type 3 Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004485 Berylliosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000010183 Bradykinin receptor Human genes 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- DADAEARVGOQWHV-OSYLJGHBSA-N CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1 Chemical compound CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1 DADAEARVGOQWHV-OSYLJGHBSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 229940117952 CD3 antagonist Drugs 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 1
- 102100024310 COMM domain-containing protein 1 Human genes 0.000 description 1
- 101710155310 COMM domain-containing protein 1 Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 101100383153 Caenorhabditis elegans cdk-9 gene Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
- 102000052603 Chaperonins Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 208000023355 Chronic beryllium disease Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108010003422 Circulating Thymic Factor Proteins 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100025406 Complement C1s subcomponent Human genes 0.000 description 1
- 108050005572 Complement C1s subcomponent Proteins 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102100035432 Complement factor H Human genes 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 229940127366 Cytochrome P450 3A4 Inhibitors Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 1
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 1
- 101710111663 Egl nine homolog 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010058838 Enterocolitis infectious Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 208000030644 Esophageal Motility disease Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- BUWBRTXGQRBBHG-MJBXVCDLSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BUWBRTXGQRBBHG-MJBXVCDLSA-N 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 108700025685 HIV Enhancer Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101150046249 Havcr2 gene Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010023925 Histone Deacetylase 6 Proteins 0.000 description 1
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101100382566 Homo sapiens CASP9 gene Proteins 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 108010064899 Human Immunodeficiency Virus Ribonuclease H Proteins 0.000 description 1
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 101710122982 Integrin alpha-E Proteins 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 101710123022 Integrin alpha-V Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023439 Kidney transplant rejection Diseases 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 229940127567 LY-3041658 Drugs 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
- 229910013594 LiOAc Inorganic materials 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940122430 Liver X receptor antagonist Drugs 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 201000009324 Loeffler syndrome Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical class [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010072219 Mevalonic aciduria Diseases 0.000 description 1
- 229940122591 Microbiome modulator Drugs 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 101000798092 Mus musculus tRNA (cytosine(38)-C(5))-methyltransferase Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- VBWMQORRQLWNOT-UHFFFAOYSA-N N-(3-chlorophenyl)-N-methyl-3-oxobutanamide Chemical compound ClC=1C=C(C=CC=1)N(C(CC(C)=O)=O)C VBWMQORRQLWNOT-UHFFFAOYSA-N 0.000 description 1
- VQUHRMAYPOBOKQ-UHFFFAOYSA-N N-(4-bromophenyl)-N-methyl-3-oxobutanamide Chemical compound CC(=O)CC(=O)N(C)C1=CC=C(Br)C=C1 VQUHRMAYPOBOKQ-UHFFFAOYSA-N 0.000 description 1
- AAANIJTWLTVSDG-UHFFFAOYSA-N N-(4-fluorophenyl)-N-methyl-3-oxobutanamide Chemical compound CC(=O)CC(=O)N(C)C1=CC=C(F)C=C1 AAANIJTWLTVSDG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- RJIVFLGKRHRALC-UHFFFAOYSA-N N-methyl-N-[4-(trifluoromethyl)phenyl]but-2-ynamide Chemical compound CN(C(C#CC)=O)C1=CC=C(C=C1)C(F)(F)F RJIVFLGKRHRALC-UHFFFAOYSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- 108010007843 NADH oxidase Proteins 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- FMCICKIIHMYIFX-UHFFFAOYSA-N OC(=O)c1c(F)cc(NS(=O)(=O)c2ccc(cc2)-c2ccnc(F)c2)cc1F Chemical compound OC(=O)c1c(F)cc(NS(=O)(=O)c2ccc(cc2)-c2ccnc(F)c2)cc1F FMCICKIIHMYIFX-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 229940124281 PF-06826647 Drugs 0.000 description 1
- 206010070594 PFAPA syndrome Diseases 0.000 description 1
- 229940126021 PLN-74809 Drugs 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 208000001052 Pachyonychia Congenita Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 108700028865 Pam2CSK4 acetate and ODN M362 combination Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 101710177686 Phagocytosis-stimulating peptide Proteins 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035660 Pneumocystis Infections Diseases 0.000 description 1
- 208000025598 Pneumocystis infectious disease Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010037649 Pyogenic granuloma Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102000015097 RNA Splicing Factors Human genes 0.000 description 1
- 108010039259 RNA Splicing Factors Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 208000005688 Salter-Harris Fractures Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 101710181102 Signal transducer CD24 Proteins 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229940123051 Somatostatin receptor agonist Drugs 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
- 229940127507 Ubiquitin Ligase Inhibitors Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 101710201961 Virion infectivity factor Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000013058 Weber syndrome Diseases 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 description 1
- DSODRWWHAUGSGD-UHFFFAOYSA-N [5-(carbamimidoylsulfanylmethyl)thiophen-2-yl]methyl carbamimidothioate;dihydrochloride Chemical compound Cl.Cl.NC(=N)SCC1=CC=C(CSC(N)=N)S1 DSODRWWHAUGSGD-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 101150045355 akt1 gene Proteins 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000037769 antenatal Bartter syndrome Diseases 0.000 description 1
- 208000022338 anthrax infection Diseases 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108700023633 apraglutide Proteins 0.000 description 1
- 229940007438 apraglutide Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010927 atrophic thyroiditis Diseases 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 201000003308 autosomal dominant familial periodic fever Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- HDRGJRSISASRAJ-WKPMUQCKSA-N bazlitoran Chemical compound CO[C@@H]1[C@H](O)[C@@H](COP(=O)(S)O[C@@H]2[C@@H](COP(=O)(S)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(S)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(S)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(S)O[C@H]6C[C@@H](O[C@@H]6COP(=O)(S)O[C@H]7C[C@@H](O[C@@H]7COP(=O)(S)O[C@H]8C[C@@H](O[C@@H]8COP(=O)(S)O[C@H]9C[C@@H](O[C@@H]9COP(=O)(S)O[C@H]%10C[C@@H](O[C@@H]%10COP(=O)(S)O[C@@H]%11[C@@H](COP(=O)(S)O[C@@H]%12[C@@H](COP(=O)(S)O[C@H]%13C[C@@H](O[C@@H]%13COP(=O)(S)O[C@H]%14C[C@@H](O[C@@H]%14COP(=O)(S)O[C@H]%15C[C@@H](O[C@@H]%15COP(=O)(S)O[C@H]%16C[C@@H](O[C@@H]%16COP(=O)(S)O[C@H]%17C[C@@H](O[C@@H]%17COP(=O)(S)O[C@H]%18C[C@@H](O[C@@H]%18CO)N%19C=CC(=NC%19=O)N)N%20C=C(C)C(=O)NC%20=O)n%21cnc%22c(N)ncnc%21%22)N%23C=C(C)C(=O)NC%23=O)N%24C=CC(=NC%24=O)N)N%25C=C(C)C(=O)NC%25=O)O[C@H]([C@@H]%12OC)n%26cnc%27C(=O)NC(=Nc%26%27)N)O[C@H]([C@@H]%11OC)N%28C=CC(=O)NC%28=O)N%29C=C(C)C(=NC%29=O)N)n%30ccc%31C(=O)NC(=Nc%30%31)N)N%32C=C(C)C(=O)NC%32=O)N%33C=C(C)C(=O)NC%33=O)N%34C=CC(=NC%34=O)N)N%35C=C(C)C(=O)NC%35=O)N%36C=CC(=NC%36=O)N)N%37C=C(C)C(=O)NC%37=O)O[C@H]([C@@H]2OC)n%38cnc%39C(=O)NC(=Nc%38%39)N)O[C@H]1N%40C=CC(=O)NC%40=O HDRGJRSISASRAJ-WKPMUQCKSA-N 0.000 description 1
- 229960004965 begelomab Drugs 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 229950002853 bimekizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- HTJWUNNIRKDDIV-UHFFFAOYSA-N bis(1-adamantyl)-butylphosphane Chemical compound C1C(C2)CC(C3)CC2CC13P(CCCC)C1(C2)CC(C3)CC2CC3C1 HTJWUNNIRKDDIV-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- JCINBYQJBYJGDM-UHFFFAOYSA-N bms-911543 Chemical compound CCN1C(C(=O)N(C2CC2)C2CC2)=CC(C=2N(C)C=NC=22)=C1N=C2NC=1C=C(C)N(C)N=1 JCINBYQJBYJGDM-UHFFFAOYSA-N 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 201000007293 brain stem infarction Diseases 0.000 description 1
- 229950009342 brazikumab Drugs 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229940010849 brepocitinib Drugs 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 229960001724 brimonidine tartrate Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 description 1
- 229950011033 cenicriviroc Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 description 1
- 201000008240 chemical colitis Diseases 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- HCOROOJWVHFMRJ-UHFFFAOYSA-N chloro-tris(trimethylsilyl)silane Chemical compound C[Si](C)(C)[Si](Cl)([Si](C)(C)C)[Si](C)(C)C HCOROOJWVHFMRJ-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 108010088797 cibinetide Proteins 0.000 description 1
- 229950001629 cibinetide Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940088949 cinryze Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 229950001565 clazakizumab Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940039116 combination diclofenac Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229950002291 dapansutrile Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000004427 diamine group Chemical group 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- LMRGIWYBLKXQGS-UHFFFAOYSA-M dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane methanesulfonate palladium(2+) 2-phenylaniline Chemical compound [Pd+2].CS([O-])(=O)=O.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 LMRGIWYBLKXQGS-UHFFFAOYSA-M 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 239000003363 dihydroorotate dehydrogenase inhibitor Substances 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 229940121430 dilanubicel Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- REWLCYPYZCHYSS-UHFFFAOYSA-N ditert-butyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C(C)(C)C)C(C)(C)C REWLCYPYZCHYSS-UHFFFAOYSA-N 0.000 description 1
- 201000008243 diversion colitis Diseases 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 201000011191 dyskinesia of esophagus Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 208000002169 ectodermal dysplasia Diseases 0.000 description 1
- 229940088128 efavaleukin alfa Drugs 0.000 description 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229940069604 etrasimod Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229950003487 fedratinib Drugs 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 229950004356 foralumab Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 229940124784 gp41 inhibitor Drugs 0.000 description 1
- 201000007192 granulomatous hepatitis Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000031209 hemophilic arthropathy Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 239000002835 hiv fusion inhibitor Substances 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 102000044507 human SERPING1 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960001396 hymecromone Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 201000003535 hypohidrotic ectodermal dysplasia Diseases 0.000 description 1
- 208000035128 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 10B Diseases 0.000 description 1
- 208000032771 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 11B Diseases 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 239000009458 iberogast Substances 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 201000008254 ileocolitis Diseases 0.000 description 1
- UQTPDWDAYHAZNT-AWEZNQCLSA-N ilginatinib Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=CC(C2=CN(C)N=C2)=CC=1NC1=CN=CC=N1 UQTPDWDAYHAZNT-AWEZNQCLSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 208000027138 indeterminate colitis Diseases 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000027139 infectious colitis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229950007937 inolimomab Drugs 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940125798 integrin inhibitor Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229940121288 iscalimab Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003394 isomerase inhibitor Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- VYCKDIRCVDCQAE-UHFFFAOYSA-N isoquinolin-3-amine Chemical compound C1=CC=C2C=NC(N)=CC2=C1 VYCKDIRCVDCQAE-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229950001890 itacitinib Drugs 0.000 description 1
- 229950003818 itolizumab Drugs 0.000 description 1
- 229940126397 ivarmacitinib Drugs 0.000 description 1
- 201000008242 jejunoileitis Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 229960004577 laquinimod Drugs 0.000 description 1
- 229950000822 lefitolimod Drugs 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- 229940058170 letolizumab Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
- CJZRVARTODENJN-UHFFFAOYSA-N litenimod Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC(C(O1)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)CC1N1C=CC(N)=NC1=O CJZRVARTODENJN-UHFFFAOYSA-N 0.000 description 1
- 229950011554 litenimod Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- ULKSWZAXQDJMJT-UHFFFAOYSA-M magnesium;2,2,6,6-tetramethylpiperidin-1-ide;chloride Chemical compound [Cl-].CC1(C)CCCC(C)(C)N1[Mg+] ULKSWZAXQDJMJT-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000029081 mast cell activation syndrome Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WAQXYIBIKOCQAB-VWLOTQADSA-N methyl (2S)-2-(benzhydrylideneamino)-3-(4-bromonaphthalen-1-yl)propanoate Chemical compound BrC1=CC=C(C2=CC=CC=C12)C[C@@H](C(=O)OC)N=C(C1=CC=CC=C1)C1=CC=CC=C1 WAQXYIBIKOCQAB-VWLOTQADSA-N 0.000 description 1
- WVYUXJVJJVNXAC-HKBQPEDESA-N methyl (2S)-3-(4-bromonaphthalen-1-yl)-2-(tritylamino)propanoate Chemical compound BrC1=CC=C(C2=CC=CC=C12)C[C@@H](C(=O)OC)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 WVYUXJVJJVNXAC-HKBQPEDESA-N 0.000 description 1
- IVZKIIUHGBTGEC-FCHUYYIVSA-N methyl (2S)-3-(4-bromonaphthalen-1-yl)-2-[[2,6-difluoro-4-[(3R)-3-(trifluoromethyl)morpholin-4-yl]benzoyl]amino]propanoate Chemical compound BrC1=CC=C(C2=CC=CC=C12)C[C@@H](C(=O)OC)NC(C1=C(C=C(C=C1F)N1[C@H](COCC1)C(F)(F)F)F)=O IVZKIIUHGBTGEC-FCHUYYIVSA-N 0.000 description 1
- KCIUWIUAERXBKU-LEWJYISDSA-N methyl (2S)-3-(4-bromonaphthalen-1-yl)-2-[[2,6-difluoro-4-[[(2R)-1,1,1-trifluorobutan-2-yl]amino]benzoyl]amino]propanoate Chemical compound BrC1=CC=C(C2=CC=CC=C12)C[C@@H](C(=O)OC)NC(C1=C(C=C(C=C1F)N[C@@H](C(F)(F)F)CC)F)=O KCIUWIUAERXBKU-LEWJYISDSA-N 0.000 description 1
- JBXJLZRTTCGLNR-UHFFFAOYSA-N methyl 4-bromo-2,6-difluorobenzoate Chemical compound COC(=O)C1=C(F)C=C(Br)C=C1F JBXJLZRTTCGLNR-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 206010072221 mevalonate kinase deficiency Diseases 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 229950003734 milatuzumab Drugs 0.000 description 1
- 229950009792 mirikizumab Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 229940069679 mocravimod Drugs 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229950007627 motolimod Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- RRTPWQXEERTRRK-UHFFFAOYSA-N n-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide Chemical compound C1=CC=CC2=C3N(OCCCCNC(=O)CCCCCCCCCCCCCCCCC)C(CCCC)=NC3=C(N)N=C21 RRTPWQXEERTRRK-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229940121304 nalotimagene carmaleucel Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229940015638 narsoplimab Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229940059237 olamkicept Drugs 0.000 description 1
- 229940059427 olendalizumab Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229950009275 ponesimod Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 229940076155 protein modulator Drugs 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000010346 psychosocial stress Effects 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000002595 purinergic P2X receptor agonist Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940059472 ribaxamase Drugs 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950007178 rivogenlecleucel Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 108010011655 saratin Proteins 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229940121616 sibofimloc Drugs 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 108010066791 sphingosine-1-phosphate phosphatase Proteins 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- OCWBJZCKQBCSPB-UHFFFAOYSA-N spiro[2h-isoindole-3,1'-cyclopropane]-1-one Chemical compound C12=CC=CC=C2C(=O)NC21CC2 OCWBJZCKQBCSPB-UHFFFAOYSA-N 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- DTXLBRAVKYTGFE-UHFFFAOYSA-J tetrasodium;2-(1,2-dicarboxylatoethylamino)-3-hydroxybutanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)C(O)C(C([O-])=O)NC(C([O-])=O)CC([O-])=O DTXLBRAVKYTGFE-UHFFFAOYSA-J 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 108010034266 theta-defensin Proteins 0.000 description 1
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940107955 thymoglobulin Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229950010029 tiprelestat Drugs 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 102000015533 trkA Receptor Human genes 0.000 description 1
- 108010064884 trkA Receptor Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940060746 tulinercept Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229950010644 vidofludimus Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 101150059019 vif gene Proteins 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960005289 voclosporin Drugs 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 108010057559 voclosporin Proteins 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229940121517 zampilimab Drugs 0.000 description 1
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 description 1
- 229960002860 zucapsaicin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/44—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3
- C07D311/54—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 substituted in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present disclosure relates generally to novel compounds that have ⁇ 4 ⁇ 7 integrin inhibitory action, prodrugs of compounds having ⁇ 4 ⁇ 7 integrin inhibitory action, and methods of use and manufacture thereof.
- Integrins are heterodimeric cell surface proteins involved in numerous cellular processes including cell-cell and cell-extracellular matrix interactions. Upon binding of an extracellular ligand, integrins mediate signal transduction to the cell interior resulting in lymphocyte cell capture, adhesion, and infiltration into the tissue.
- Integrins are heterodimeric proteins consisting of an alpha and a beta subunit. There are 18 known alpha subunits and 8 known beta subunits.
- the ⁇ 4 ⁇ 7 integrin is expressed on the surface of lymphocytes and recognizes the extracellular ligand mucosal addressing cell adhesion molecule-1 (MAdCAM-1).
- MAdCAM-1 extracellular ligand mucosal addressing cell adhesion molecule-1
- ⁇ 4 ⁇ 7 integrin governs lymphocyte trafficking to and retention in gut tissues through its interaction with MAdCAM-1, which is expressed on venules in the intestinal mucosa and high endothelial venules (HEV) in the gut-associated lymphoid tissues (GALT).
- ⁇ 4 ⁇ 7 integrin antagonist molecules for the treatment of autoimmune and inflammatory diseases, including, but not limited to, inflammatory bowel disease.
- the present disclosure provides compounds that are inhibitors for ⁇ 4 ⁇ 7 integrin.
- the disclosure also provides compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds.
- the compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated, at least in part, by ⁇ 4 ⁇ 7 integrin.
- the disclosure also provides compounds for use in therapy.
- the disclosure further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by ⁇ 4 ⁇ 7 integrin.
- the disclosure provides uses of the compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated, at least in part, by ⁇ 4 ⁇ 7 integrin.
- composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and at least one pharmaceutically acceptable carrier.
- composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and further comprising a second therapeutic agent.
- a method for treating a disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and at least one pharmaceutically acceptable carrier.
- a method for treating a disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and further comprising a second therapeutic agent.
- composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and at least one pharmaceutically acceptable carrier.
- composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and further comprising a second therapeutic agent.
- a method for treating a disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and at least one pharmaceutically acceptable carrier.
- a method for treating a disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and further comprising a second therapeutic agent.
- a method for treating an inflammatory disease comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof.
- a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —CONH 2 is attached through the carbon atom.
- a dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning.
- a wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.
- C u-v indicates that the following group has from u to v carbon atoms.
- C 1-8 alkyl indicates that the alkyl group has from 1 to 8 carbon atoms.
- references to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
- the term “about” includes the indicated amount ⁇ 10%.
- the term “about” includes the indicated amount ⁇ 5%.
- the term “about” includes the indicated amount ⁇ 1%.
- to the term “about X” includes description of “X”.
- the singular forms “a” and “the” include plural references unless the context clearly dictates otherwise.
- reference to “the compound” includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art.
- Alkyl refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C 1-20 alkyl), 1 to 8 carbon atoms (i.e., C 1-8 alkyl), 1 to 6 carbon atoms (i.e., C 1-6 alkyl), or 1 to 4 carbon atoms (i.e., C 1-4 alkyl).
- alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl.
- butyl includes n-butyl (i.e., —(CH 2 ) 3 CH 3 ), sec-butyl (i.e., —CH(CH 3 )CH 2 CH 3 ), isobutyl (i.e., —CH 2 CH(CH 3 ) 2 ) and tert-butyl (i.e., —C(CH 3 ) 3 ); and “propyl” includes n-propyl (i.e., —(CH 2 ) 2 CH 3 ) and isopropyl (i.e., —CH(CH 3 ) 2 ).
- Alkenyl refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C 2-4 alkenyl).
- alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).
- Alkynyl refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C 2-4 alkynyl).
- alkynyl also includes those groups having one triple bond and one double bond.
- Alkoxy refers to the group “alkyl-O—”. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.
- alkylene refers to branched and unbranched divalent “alkyl” groups. As used herein, alkylene has 1 to 20 carbon atoms (i.e., C 1-20 alkylene), 1 to 8 carbon atoms (i.e., C 1-8 alkylene), 1 to 6 carbon atoms (i.e., C 1-6 alkylene), or 1 to 4 carbon atoms (i.e., C 1-4 alkylene). Examples include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene or 1,2-dimethylethylene.
- propylene and butylene include all the possible isomeric forms of the groups in question with the same number of carbons.
- propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1,1-dimethylethylene, and 1,2-dimethylethylene.
- acyl refers to a group refers to a group —C(O)RY, wherein RY is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein.
- acyl include, e.g., formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl and benzoyl.
- “Amido” refers to both a “C-amido” group which refers to the group —C(O)NR y R z and an “N-amido” group which refers to the group —NR y C(O)R z , wherein R y and R z are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
- Amino refers to the group —NR y R z wherein R y and R z are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, or heteroaryl; each of which may be optionally substituted.
- “Amidino” refers to —C(NH)(NH 2 ).
- Carbamoyl refers to both an “0-carbamoyl” group which refers to the group —O—C(O)NR y R z and an “N-carbamoyl” group which refers to the group —NR y C(O)OR z , wherein R y and R z are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
- Carboxyl refers to —C(O)OH.
- Carboxyl ester refers to both —OC(O)R and —C(O)OR, wherein R is alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
- Heteroalkyl refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group.
- the term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group.
- Heteroatomic groups include, but are not limited to, —NR—, —O—, —S—, —S(O)—, —S(O) 2 —, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted.
- heteroalkyl groups include —OCH 3 , —CH 2 OCH 3 , —SCH 3 , —CH 2 SCH 3 , —NRCH 3 , and —CH 2 NRCH 3 , where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted.
- heteroalkyl include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
- Alkylsulfonyl refers to the group —S(O) 2 R, where R is alkyl.
- Alkylsulfinyl refers to the group —S(O)R, where R is alkyl.
- Aryl refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused systems.
- aryl has 6 to 20 ring carbon atoms (i.e., C 6-20 aryl), 6 to 12 carbon ring atoms (i.e., C 6-12 aryl), or 6 to 10 carbon ring atoms (i.e., C 6-10 aryl).
- Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl.
- Aryl does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl.
- Cycloalkyl refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems.
- the term “cycloalkyl” includes cycloalkenyl groups (e.g., the cyclic group having at least one double bond).
- cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 cycloalkyl).
- Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems with one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems.
- Bridged refers to a ring fusion wherein non-adjacent atoms on a ring are joined by a divalent substituent, such as an alkylenyl or heteroalkylenyl group or a single heteroatom. Quinuclidinyl and admantanyl are examples of bridged ring systems.
- fused refers to a ring which is bound to an adjacent ring.
- “Spiro” refers to a ring substituent which is joined by two bonds at the same carbon atom.
- Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents.
- Halogen or “halo” includes fluoro, chloro, bromo, and iodo.
- Haloalkyl refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms, up to the total number of possible hydrogen atoms in a group, are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (—CHF 2 ) and trifluoromethyl (—CF 3 ).
- Haloalkoxyl or “haloalkoxy” refers to an alkoxy group as defined above, wherein one or more hydrogen atoms, up to the total number of possible hydrogen atoms in a group, are replaced by a halogen.
- haloalkoxyl include, but are not limited to, difluoromethoxyl (—OCHF 2 ), and trifluoromethoxyl (—OCF 3 ).
- heterocyclyl or “heterocycle” as used herein refers to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple ring system that has at least one heteroatom in the ring, i.e., at least one annular heteroatom selected from oxygen, nitrogen, and sulfur, wherein the nitrogen or sulfur may be oxidized.
- the term includes rings having one or more annular O, N, S, S(O), S(O) 2 , and N-oxide groups.
- the term includes rings having one or more annular C(O) groups.
- a heterocyclyl group has from 5 to about 20 annular atoms, for example from 3 to 12 annular atoms, for example from 3 to 10 annular atoms, for example from 5 to 10 annular atoms or for example from 5 to 6 annular atoms.
- the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings) having from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur in the ring.
- the rings of the multiple condensed ring (e.g., bicyclic heterocyclyl) system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
- Heterocycles include, but are not limited to, groups derived from azetidine, aziridine, imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, pyrrolidine, pyrrolidinone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, tetrahydro-2H-thiopyran 1,1-dioxide, quinuclidine, N-bromopyrrolidine, N-chloropiperidine, and the like.
- Heterocycles include spirocycles, such as, for example, aza or oxo-spiroheptanes.
- Heterocyclyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems with one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems.
- Examples include dihydroquinolines, e.g., 3,4-dihydroquinoline, dihydroisoquinolines, e.g., 1,2-dihydroisoquinoline, dihydroimidazole, tetrahydroimidazole, etc., indoline, isoindoline, isoindolones (e.g., isoindolin-1-one), isatin, dihydrophthalazine, quinolinone, spiro[cyclopropane-1,1′-isoindolin]-3′-one, and the like.
- dihydroquinolines e.g., 3,4-dihydroquinoline
- dihydroisoquinolines e.g., 1,2-dihydroisoquinoline, dihydroimidazole, tetrahydroimidazole, etc.
- indoline isoindoline
- isoindolones e.g., isoind
- heterocycles include 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-oxa-7,9-diazabicyclo[3.3.1]nonanyl, and hexahydropyrazino[2,1-c][1,4]oxazinyl, for example.
- Oxo refers to the group ( ⁇ O) or (O). Where tautomeric forms of the compound exist, hydroxyl and oxo groups may be interchangeable.
- Heteroaryl refers to an aromatic group, including groups having an aromatic tautomer or resonance structure, having a single ring, multiple rings, or multiple fused rings, with at least one heteroatom in the ring, i.e., one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the nitrogen or sulfur may be oxidized.
- the term includes rings having one or more annular O, N, S, S(O), S(O) 2 , and N-oxide groups.
- the term includes rings having one or more annular C(O) groups.
- heteroaryl include 5 to 20 ring atoms (i.e., 5-20 membered heteroaryl), 5 to 12 ring atoms (i.e., 5-12 membered heteroaryl), or 5 to 10 ring atoms (i.e., 5-10 membered heteroaryl), and 1 to 5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and oxidized forms of the heteroatoms.
- heteroaryl groups include pyridin-2(1H)-one, pyridazin-3(2H)-one, pyrimidin-4(3H)-one, quinolin-2(1H)-one, pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl.
- Heteroaryl does not encompass or overlap with aryl as defined above.
- “Sulfonyl” refers to the group —S(O) 2 R, where R is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
- a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc.
- a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc.
- combinations of groups are referred to herein as one moiety, e.g., arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
- substituted means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded.
- the one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof.
- impermissible substitution patterns e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms.
- impermissible substitution patterns are well known to the skilled artisan.
- substituted may describe other chemical groups defined herein. Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.
- substituted alkyl refers to an alkyl group having one or more substituents including hydroxyl, halo, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
- substituted cycloalkyl refers to a cycloalkyl group having one or more substituents including alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl
- substituted heterocyclyl refers to a heterocyclyl group having one or more substituents including alkyl, haloalkyl, heterocyclyl, cycloalkyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl
- substituted aryl refers to an aryl group having one or more substituents including halo, alkyl, haloalkyl, cycloalkyl, heterocyclyl, heteroaryl, alkoxy, and cyano
- substituted heteroaryl refers to an heteroaryl group having one or more substituents including alkyl, haloalkyl, cycloalkyl, hetero
- the one or more substituents may be further substituted with halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted.
- the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.
- Tautomeric isomers are in equilibrium with one another.
- amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.
- any formula or structure given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
- Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 36 S, 36 Cl and 126 I.
- isotopically labeled compounds of the present disclosure for example those into which radioactive isotopes such as 3 H, 13 C and 14 C are incorporated.
- isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPELT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
- PET positron emission tomography
- SPELT single-photon emission computed tomography
- the disclosure also includes compounds in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule.
- Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound provided herein when administered to a mammal, particularly a human. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984).
- Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
- Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index.
- An 18 F labeled compound may be useful for PET or SPECT studies.
- Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compound.
- the concentration of such a heavier isotope, specifically deuterium may be defined by an isotopic enrichment factor.
- any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
- a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition.
- any atom specifically designated as a deuterium (D) is meant to represent deuterium.
- the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- pharmaceutically acceptable salt of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable.
- Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, mono, di or tri cycloalkyl amines, mono, di or tri arylamines or mixed amines, etc.
- primary, secondary and tertiary amines such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri
- Suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
- Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
- “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- n is the number of hydrogen atoms in the molecule.
- the deuterium atom is a non-radioactive isotope of the hydrogen atom.
- Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism”, Trends Pharmacol. Sci., 5(12):524-527 (1984).
- Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
- “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
- “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid.
- the free base can be obtained by basifying a solution of the acid salt.
- an addition salt particularly a pharmaceutically acceptable addition salt
- a suitable organic solvent may be used to prepare nontoxic pharmaceutically acceptable addition salts.
- a “solvate” is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
- a “prodrug” is a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
- optical isomers, racemates, or other mixtures thereof of the compounds described herein or pharmaceutically acceptable salts or a mixture thereof can be obtained by asymmetric synthesis or by resolution of the racemate. Resolution of racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column.
- Z- and E-forms or cis- and trans-forms of the hydroxyamidine compounds described herein. Specifically, Z- and E-forms are included even if only one designation is named for both carbon-carbon double bonds as well as the hydroxyamidine bond.
- Enantiomers are a pair of stereoisomers that are non-superimposable mirror images of each other.
- a 1:1 mixture of a pair of enantiomers is a “racemic” mixture.
- a mixture of enantiomers at a ratio other than 1:1 is a “scalemic” mixture.
- “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
- “Atropisomers” are stereoisomers arising due to hindered rotation about a single bond, where the barrier to rotation about the bond is high enough to allow for isolation of individual stereoisomers.
- compositions provided herein that include a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof may include racemic mixtures, or mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein the same as if each and every isomeric form were specifically and individually listed.
- chelates are also chelates, non-covalent complexes, and mixtures thereof, of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof.
- a “chelate” is formed by the coordination of a compound to a metal ion at two (or more) points.
- a “non-covalent complex” is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
- Treatment is an approach for obtaining beneficial or desired results including clinical results.
- beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, “unit and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival).
- a) inhibiting the disease or condition e.g., decreasing one or more symptoms resulting from the disease
- Prevention means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop.
- Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
- Subject refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications.
- the subject is a mammal.
- the subject is a human.
- terapéuticaally effective amount or “effective amount” of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression.
- a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of ⁇ 4 ⁇ 7 integrin activity.
- the therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.
- inhibitors indicates a decrease in the baseline activity of a biological activity or process.
- “Inhibition of activity of ⁇ 4 ⁇ 7 integrin” or variants thereof refers to a decrease in activity of ⁇ 4 ⁇ 7 integrin as a direct or indirect response to the presence of a compound of the present application relative to the activity of ⁇ 4 ⁇ 7 integrin in the absence of the compound of the present application.
- “Inhibition of ⁇ 4 ⁇ 7 integrin” refers to a decrease in ⁇ 4 ⁇ 7 integrin activity as a direct or indirect response to the presence of a compound described herein relative to the activity of ⁇ 4 ⁇ 7 integrin in the absence of the compound described herein.
- the inhibition of ⁇ 4 ⁇ 7 integrin activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment.
- a compound of formula (I), or a pharmaceutically acceptable salt thereof wherein:
- R 4 is selected from H, —NR b1 R b2 , —NR b 'S(O) v R b4 , and 4-10 membered heterocyclyl containing one to two heteroatoms independently selected from N and O;
- the ring formed by Y and Z does not form
- ring Y is aromatic.
- the ring formed by Y and Z is selected from:
- each group is optionally substituted with 1 to 4 R 10 ; and wherein each R 10 is independently selected from halo, cyano, hydroxyl, C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-10 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, 5-6 membered heteroaryl, and —NR a1 R a2 ; wherein each C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-10 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, 5-6 membered heteroaryl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl
- u is selected from 0, 1, 2, 3, 4, and 5.
- Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- each R 22 is independently selected from H and R a .
- Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- each R 22 is independently selected from H and R a .
- Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- each R 22 is independently selected from H and R a .
- Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- each R 22 is independently selected from H and R a ; and wherein r is selected from 0, 1, 2, 3, 4 and 5.
- Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- each Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 is independently selected from CR 22 and N, provided that at least one of Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 is CR 22 ; and wherein R 22 is selected from H and R a .
- Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- each V 1 , V 2 , and V 3 is independently selected from CR 22 and N, provided that at least one of V 1 , V 2 , and V 3 is CR 22 ; and wherein R 22 is selected from H and Ra.
- Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- R b1 , R b2 , Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- R b , Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- R b4 , Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- Y, Z, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , p, R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined above.
- X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- each X 3 and X 4 is independently CR 10 . In some embodiments, X 3 is CR 10 and X 4 is N. In some embodiments, X 3 is N and X 4 is CR 10 . In some embodiments, each X 3 and X 4 is independently CR 10 and each R 10 is independently selected from H, halo, hydroxyl, C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, and C 1-4 haloalkoxyl, wherein each the C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, and C 3-6 cycloalkyl.
- each X 3 and X 4 is independently CR 10 and each R 10 is independently selected from H, F, Cl, cyano, hydroxyl, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , and —OCF 3 .
- each X 3 and X 4 is CH.
- L is a bond
- R 1 is selected from -L-A 1 , -L-A 2 , and -L-A 3 .
- a 1 , A 2 , or A 3 is selected from phenyl, naphthyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, isoxazolyl, triazolyl, pyrazolyl, benzothiazolyl, pyridinonyl, quinolinonyl, isoquinolinonyl, quinazolindionyl, pyrazinonyl, pyrimidinonyl, pyrimidinedionyl, pyridazinonyl, quinazolinonyl, benzofuranyl, tetrahydrocyclopenta[b]pyridinonyl, naphthyridinonyl, chromanyl, isochromanyl, and chromenonyl, and wherein each of which is independently optionally substituted with one to four R a .
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- each V 1 , V 2 , and V 3 is independently selected from CR 22 and N, provided that at least one of V 1 , V 2 , and V 3 is CR 22 ; and wherein R 22 is selected from H and R a .
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R 22 is selected from H, and R a .
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R 22 is selected from H, and R a .
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- each Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 is independently selected from CR 22 and N, provided that at least one of Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 is CR 22 ; and wherein R 22 is selected from H and R a .
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- u is selected from 0, 1, 2, 3, 4, and 5.
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R 22 is selected from H and R a .
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R 22 is selected from H and R a .
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R 22 is selected from H and R a .
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- r is selected from 0, 1, 2, 3, 4 and 5, and R 22 is selected from H and R a .
- R 1 is selected from
- r is selected from 0, 1, 2, 3, 4 and 5, and R 22 is selected from H, and R a .
- R 1 is selected from
- each R 1 is optionally substituted with one to four R a .
- R 1 is selected from
- each R 1 is optionally substituted with one to four R a .
- R 1 is substituted with one to four R a , and each R a is independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-6 cycloalkyl, phenyl, and —O—C 3-6 cycloalkyl.
- R 1 is substituted with one to three Ra, and each R a is independently selected from F, Cl, Br, cyano, hydroxyl, —NH 2 , —N(CH 3 ) 2 , —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 CN, —CH 2 CH 2 CN, —CH 2 OH, —CH 2 CH 2 OH, —OCH 3 , —OCD 3 , —OCH 2 CH 3 , —OCH(CH 3 ) 2 , —OC(CH 3 ) 3 , —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , —CH 3 OCH(CH 3 ) 2 , —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CH 2 F, —CH 2 CHF 2 , —CH 2 CF 3 , —OCH 2 F
- R 1 is selected from
- R 1 is selected from
- R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- each R a is independently selected from halo, C 1-6 alkyl, C 1-6 alkoxyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, and —O—C 3-8 cycloalkyl.
- each R a is independently selected from F, Cl, Br, —CH 3 , —CH 2 CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , —OCD 3 , —OCH 2 CH 3 , —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , cyclopropyl, and —O-cyclopropyl.
- each R 2 and R 6 is independently selected from H, halo, cyano, hydroxyl, —NR b1 R b2 , C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, and C 1-4 haloalkoxyl.
- each R 2 and R 6 is independently selected from F, Cl, cyano, hydroxyl, —NH 2 , —N(CH 3 ) 2 , —CH 3 , —CD 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , and —OCF 3 .
- each R 2 and R 6 is independently F or Cl. In some embodiments, each R 2 and R 6 is F.
- each R 3 and R 5 is independently selected from H, C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, and C 1-4 haloalkoxyl. In some embodiments, each R 3 and R 5 is H.
- R 4 is selected from H, —NR b1 R b2 , —NR b1 S(O) v R b4 , and 4-6 membered heterocyclyl containing one to two heteroatoms or groups independently selected from N, O, S, and S(O) 2 .
- R 4 is —NR b1 R b2 . In some embodiments, R 4 is —NHR b2 , wherein R b2 is selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, and 4-6 membered heterocyclyl.
- each R b1 and R b2 is independently selected from H, C 1-8 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, and 4-6 membered heterocyclyl containing one to two atoms selected from N and O.
- R b1 is selected from H, and C 1-4 alkyl.
- R b1 is selected from H, and CH 3 .
- R b2 is selected from C 1-6 alkyl, C 1-6 haloalkyl, and 4-6 membered heterocyclyl.
- R b1 is H, and R b2 is selected from C 1-6 alkyl, C 1-6 haloalkyl, and 5-6 membered heterocyclyl. In some embodiments, R b1 is H, and R b2 is C 1-6 haloalkyl. In some embodiments, R b2 is —C 1-5 alkylene-CF 3 . In some embodiments, R b2 is selected from -methylene-CF 3 , -ethylene-CF 3 , -propylene-CF 3 , -butylene-CF 3 , and -pentylene-CF 3 .
- R b2 is —C 1-5 alkylene-CF 3 substituted with one or two R b5 .
- each R b5 is independently selected from hydroxyl, C 1-4 alkoxyl, C 3-6 cycloalkyl, phenyl, and 4-6 membered heterocyclyl.
- each R b5 is independently selected from C 3-6 cycloalkyl, 4-6 membered heterocyclyl, and phenyl.
- Each C 3-6 cycloalkyl, 4-6 membered heterocyclyl, and phenyl of R b5 is independently optionally substituted with one or three groups independently selected from halo, hydroxyl, cyano, —NR b1 , R b2 , C 1-4 alkyl, C 1-4 alkoxyl, and C 1-4 haloalkyl.
- R b5 is selected from phenyl, cyclobutyl, cylcopentyl, tetrahydropyanyl, and tetrahydrofuranyl; and each R b5 is optionally substituted with one group selected from F, Cl, CN, —CH 3 , —CH 2 F, —CHF 2 , and —CF 3 .
- R b5 is phenyl.
- R b5 is phenyl substituted with one or two groups independently selected from F, Cl, CN, —CH 3 , —CH 2 F, —CHF 2 , and —CF 3 .
- R b5 is phenyl substituted with one or two groups independently selected from F, Cl, CN, and —CF 3 .
- R b5 is unsubstituted phenyl.
- R 4 is H.
- R a is selected from
- R 4 is selected from
- R 4 is selected from
- R 4 is 5-6 membered heterocyclyl optionally substituted with one to three R b ; and each R b is independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 alkoxyl, and C 1-4 haloalkyl.
- R 4 is 4-6 membered heterocyclyl containing one to two heteroatoms or groups independently selected from N, O, S, and S(O) 2 . In some embodiments, R 4 is a 4-10 membered saturated ring
- R 4 is selected from morpholinyl, piperidinyl, tetrahydropyranyl, and pyrrolidinyl. In some embodiments, R 4 is 5-6 membered heterocyclyl optionally substituted with one to two groups independently selected from F, Cl, CN, —OH, —CH 3 , —CH(CH 3 ) 2 , and —CF 3 .
- R 4 is selected from
- each R 4 is optionally substituted with one to two R b independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 alkoxyl, and C 1-4 haloalkyl.
- R 4 is selected from
- each R 4 is optionally substituted with one to two groups independently selected from F, Cl, hydroxyl, cyano, —CH 3 , —CH(CH 3 ) 2 , and —CF 3 .
- R 4 is selected from
- R 4 is selected from
- R 4 is
- R 4 is —NR b1 S(O) v R b4 .
- R 4 is —NHS(O) 2 R b4
- R b4 is selected from C 1-4 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, and phenyl.
- R b4 is selected from —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , and phenyl.
- the phenyl is optionally substituted with pyridinyl that is optionally substituted with one or two groups independently selected from halo, and C 1-4 alkyl.
- the pyridinyl is optionally substituted with one or two groups independently selected from F, and —CH 3 .
- R 4 is —NHS(O) 2 R b4 , R b4 is selected from —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , and phenyl; and wherein the phenyl is optionally substituted with pyridinyl or triazolyl that is optionally substituted with one or two groups independently selected from halo, and C 1-4 alkyl.
- R 4 is selected from
- R 4 is selected from
- R 4 is selected from
- each R 7 and R 8 is H. In some embodiments, each R 7 , R 8 , R 10 and R 11 is H.
- R 9 is selected from H, methyl, ethyl, propyl, butyl, —CH 2 C(O)N(CH 3 ) 2 , CH 2 ) 2 N(CH 2 CH 3 ) 2 , —CH 2 —O—C(O)CH 3 , —(CH 2 ) 2 —O—C(O)CH 3 , —CH 2 —O—C(O)C(CH) 3 , —(CH 2 ) 2 —O—C(O)C(CH) 3 , —CH 2 —O—C(O)C(CH) 3 , —CH 2 —O—C(O)—O—CH 3 , —CH(CH 3 )—O—C(O)—O—CH 3 , —CH 2 —O—C(O)—O—CH 2 CH 3 , —CH 2 —O—C(O)—O—CH(CH 3 ) 2 , —CH 2 —O—C(O)—O
- R 9 is selected from H, —CH 2 —O—C(O)C(CH) 3 , —CH(CH 3 )—O—C(O)—O—CH 3 ,
- R 9 is H.
- R 9 is methyl. In some embodiments, R 9 is ethyl. In some embodiments, R 9 is propyl.
- R 9 is H. In some embodiments, R 9 is selected from C 1-6 alkyl, C 3-8 cycloalkyl, and 4-6 membered heterocyclyl, wherein the C 1-6 alkyl of R 9 is optionally substituted with one to three groups independently selected from halo, —NR a1 R a2 , —C(O)NR a1 R a2 , —O—C(O)—C 1-4 alkyl, —O—C(O)—O—C 1-4 alkyl, —O—C(O)—C 1-4 alkylene-NR a1 R a2 , —O—C 1-4 alkyl, O 3-8 cycloalkyl, 4-6 membered heterocyclyl, and 4-6 membered heterocyclyl containing at least one heteroatom selected from N and O, and wherein the C 3-8 cycloalkyl, and 4-6 membered heterocyclyl of R 9 is optionally substituted with one to three groups independently selected from
- an R 9 ester when administered to a patient, an R 9 ester generates a compound wherein R 9 is H, as a result of chemical reaction(s), enzyme catalyzed chemical reaction(s), and/or metabolic chemical reaction(s).
- a compound in which R 9 is not H may be a prodrug.
- R 9 together with the N that attaches to R 8 forms a 5 membered heterocyclyl.
- the 5 membered heterocyclyl is substituted with one to two groups independently selected from C 1-6 alkyl, C 1-6 alkoxyl, C 1-6 haloalkyl, and C 6-10 aryl.
- the 5 membered heterocyclyl is substituted with one to two groups independently selected from CH 3 , CH 2 CH 3 , —OCH 3 , —OCH 2 CH 3 , and phenyl.
- the 5 membered heterocyclyl is substituted with phenyl, and phenyl is optionally substituted with one to three groups independently selected from halo, C 1-6 alkyl, C 1-6 alkoxyl, and C 1-6 haloalkyl.
- each R 10 is independently selected from H, halo, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 alkoxyl. In some embodiments, each R 10 is independently selected from H, F, Cl, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , and —OCF 3 . In some embodiments, each R 10 is H.
- each R 11 is independently selected from H, —CH 3 , —CH 2 F, —CHF 2 , and —CF 3 . In some embodiments, each R 11 is independently H or —CH 3 .
- q is 1. In some embodiments, q is 2.
- r is selected from 1, 2, and 3. In some embodiments, r is 3.
- t is 0. In some embodiments, t is 1.
- u is selected from 1, 2, and 3. In some embodiments, u is 3.
- v is 2.
- each V 1 , V 2 and V 3 is independently CR 22 or N, wherein R 22 is independently selected from H, halo, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 alkoxyl.
- each V 1 , V 2 and V 3 is independently CR 22 or N, wherein each R 22 is independently selected from H, F, Cl, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , and —OCF 3 .
- V 1 is N
- each V 2 and V 3 is independently CR 22 .
- V 1 is N, and each V 2 and V 3 is independently CR 22 , wherein each R 22 is independently selected from H, halo, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 alkoxyl.
- V 1 is N, and each V 2 and V 3 is independently CR 22 , wherein each R 22 is independently selected from H, F, Cl, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCH 3 , and —OCF 3 .
- W 1 is N, and W 2 is O. In some embodiments, W 1 is N, and W 2 is CH 2 . In some embodiments, W 1 is N, and W 2 is S(O) 2 . In some embodiments, each R b is independently selected from F, OH, —CH 3 , —CH(CH 3 ) 2 , —CH 2 F, —CHF 2 , and —CF 3 .
- At least one of Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 is N.
- Y 1 is N; and each Y 2 , Y 3 , Y 4 , and Y 5 is independently CR 22 .
- Y 2 is N; and each Y 1 , Y 3 , Y 4 , and Y 5 is independently CR 22 .
- Y 3 is N; and each Y 1 , Y 2 , Y 4 , and Y 5 is independently CR 22 .
- Y 4 is N; and each Y 1 , Y 2 , Y 3 , and Y 5 is independently CR 22 .
- Y 1 and Y 5 are N; and each Y 1 , Y 2 , and Y 3 is independently CR 22 .
- the compound of the present disclosure is selected from examples 1-176.
- the compound of the present disclosure is selected from examples 177-180.
- ex vivo means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual.
- Ex vivo means outside of a living individual.
- ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the compounds may be used for a variety of purposes, including therapeutic and experimental purposes.
- the compounds may be used ex vivo to determine the optimal schedule and/or dosing of administration of an ⁇ 4 ⁇ 7 integrin inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the compounds may be suited are described below or will become apparent to those skilled in the art.
- the selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.
- the compounds described herein may be used to inhibit the activity of ⁇ 4 ⁇ 7 integrin. In some embodiments, the compounds described herein may be used to inhibit excessive or destructive immune reactions or growth or a proliferation of a cell, such as a cancer cell, or inhibit immunosuppression.
- the present disclosure provides a compound described herein useful as an inhibitor of ⁇ 4 ⁇ 7 integrin. In some embodiments, the present disclosure provides a method of treating an inflammatory disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin, comprising administering a compound described herein.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound described herein and at least one additional therapeutic agent and at least one pharmaceutically acceptable excipient.
- the present disclosure provides a compound described herein for use in therapy.
- the present disclosure provides a compound described herein for use in the manufacture of a medicament for treating a disease or condition provided herein.
- a compound described herein useful for the treatment of a disease or condition in a patient that is amenable to treatment by inhibiting ⁇ 4 ⁇ 7 integrin.
- Diseases or conditions that may be treated with the compounds described herein include a solid tumor, diabetes, an inflammatory disease, graft versus host disease, primary sclerosing cholangitis, HIV, an autoimmune disease, inflammatory bowel disease (IBD), alcoholic hepatitis, systemic lupus erythematosus (SLE), and lupus nephritis.
- a compound described herein useful for the treatment of an inflammatory disease or condition in a patient that is mediated, at least in part, by ⁇ 4 ⁇ 7 integrin.
- administering refers to the delivery of one or more therapeutic agents to a patient.
- the administration is a monotherapy wherein a compound described herein is the only active ingredient administered to the patient in need of therapy.
- the administration is co-administration such that two or more therapeutic agents are delivered together during the course of the treatment.
- two or more therapeutic agents may be co-formulated into a single dosage form or “combined dosage unit”, or formulated separately and subsequently combined into a combined dosage unit, as is typically for intravenous administration or oral administration as a mono or bilayer tablet or capsule.
- the compound described herein is administered to a human patient in need thereof in an effective amount, such as, from about 0.1 mg to about 1000 mg per dose of said compound. In some embodiments, the effective amount is from about 0.1 mg to about 200 mg per dose. In some embodiments, the effective amount is from about 1 mg to about 100 mg per dose. In other embodiments, the effective amount is about 1 mg, about 3 mg, about 5 mg, about 10 mg, about 15 mg, about 18 mg, about 20 mg, about 30 mg, about 40 mg, about 60 mg, about 80 mg, or about 100 mg per dose.
- the compound described herein and at least one additional therapeutic agent is administered to a human patient in need thereof in an effective amount of each agent, independently from about 0.1 mg to about 1000 mg per dose of a compound or formulation per dose per compound. In some embodiments, the effective amount of the combination treatment of a compound described herein and an additional compound is independently from about 0.1 mg to about 200 mg per compound per dose. In some embodiments, the effective amount of the combination treatment of a compound described herein and an additional compound is independently from about 1 mg to about 100 mg per compound per dose.
- the effective amount of the combination treatment of a compound described herein and an additional compound is for each component, about 1 mg, about 3 mg, about 5 mg, about 10 mg, about 15 mg, about 18 mg, about 20 mg, about 30 mg, about 40 mg, about 60 mg, about 80 mg, about 100 mg, about 200 mg, or about 500 mg each per dose.
- the dose of a compound described herein and/or a combination of the dose of the compound described herein and/or the dose of an additional therapeutic agent is administered once per day, twice per day, or thrice per day.
- the dose of a compound described herein and/or the dose of an additional therapeutic agent is administered as a loading dose of from about 0.1 mg to about 1000 mg per compound on the first day and each day or on alternate days or weekly for up to a month followed by a regular regimen of a compound described herein and/or one or more additional therapeutic agents or therapies.
- the maintenance dose may be about 0.1 mg to about 1000 mg once per day, twice per day, thrice per day, or weekly, for each component of a multi component drug regimen.
- a qualified care giver or treating physician is aware of what dose regimen is best for a particular patient or particular presenting conditions and will make appropriate treating regimen decisions for that patient.
- the qualified caregiver is able to tailor a dose regimen of the compound described herein and/or an additional therapeutic agent(s) as disclosed herein to fit with the particular needs of the patient.
- the amount of the dose of a compound described herein and the amount of the dose of an additional therapeutic agent actually administered will usually be determined by a physician, in light of the relevant circumstances, including the condition(s) to be treated, the chosen route of administration, the actual compound (e.g., salt or free base) administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
- the actual compound e.g., salt or free base
- Co-administration may also include administering a dose of component drugs, e.g., a dose of one or more compounds described herein and a dose of one or more additional (e.g., a second, third, fourth or fifth) therapeutic agent(s).
- a dose of component drugs e.g., a dose of one or more compounds described herein and a dose of one or more additional (e.g., a second, third, fourth or fifth) therapeutic agent(s).
- Such combination of a dose of one on more compounds described herein and a dose of one or more additional therapeutic agent(s) may be administered simultaneously or in sequence (one after the other) within a reasonable period of time of each administration (e.g., about 1 minute to 24 hours) depending on the pharmacokinetic and/or pharmacodynamics properties of each agent or the combination.
- Co-administration may also involve treatment with a fixed combination wherein agents of the treatment regimen are combinable in a fixed dosage or combined dosage medium, e.g., solid, liquid or aerosol.
- a kit may be used to prepare and/or administer the drug or drug components.
- some embodiments of the present disclosure is a method of treating a disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin, comprising administering therapeutically effective amounts of formulations of one on more compounds described herein and one or more additional therapeutic agents, including for example, via a kit to a patient in need thereof. It will be understood that a qualified care giver will administer or direct the administration of a therapeutically effective amount of any of the compound(s) or combinations of compounds of the present disclosure.
- Intravenous administration is the administration of substances directly into a vein, or “intravenously.” Compared with other routes of administration, the intravenous (IV) route is a faster way to deliver fluids and medications throughout the body.
- An infusion pump can allow precise control over the flow rate and total amount of medication delivered. However, in cases where a change in the flow rate would not have serious consequences, or if pumps are not available, the drip is often left to flow simply by placing the bag above the level of the patient and using the clamp to regulate the rate. Alternatively, a rapid infuser can be used if the patient requires a high flow rate and the IV access device is of a large enough diameter to accommodate it.
- intermittent infusion is used which does not require additional fluid. It can use the same techniques as an intravenous drip (pump or gravity drip), but after the complete dose of medication has been given, the tubing is disconnected from the IV access device.
- Some medications are also given by IV push or bolus, meaning that a syringe is connected to the IV access device and the medication is injected directly (slowly, if it might irritate the vein or cause a too-rapid effect).
- compound(s) or combination of compounds described herein may be administered by IV administration alone or in combination with administration of certain components of the treatment regimen by oral or parenteral routes.
- Oral administration is a route of administration where a substance is taken through the mouth, and includes buccal, sub labial, and sublingual administration, as well as enteral administration and that through the respiratory tract, unless made through, e.g., tubing so the medication is not in direct contact with any of the oral mucosa.
- Typical form for the oral administration of therapeutic agents includes the use of tablets or capsules.
- compound(s) or combination of compounds described herein may be administered by oral route alone or in combination with administration of certain components of the treatment regimen by IV or parenteral routes.
- Non-limiting examples of diseases or conditions mediated, at least in part, by ⁇ 4 ⁇ 7 integrin include, without limitation, acne, acid-induced lung injury, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, adult-onset Still's disease, adult respiratory distress syndrome (ARDS), age-related macular degeneration, aging, alcoholic hepatitis, alcoholic liver disease, allergen-induced asthma, allergic bronchopulmonary, allergic conjunctivitis, allergic contact dermatitis, allergies, allergic encephalomyelitis, allergic neuritis, allograft rejection, alopecia, alopecia areata, Alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, angina pectoris, angioedema, angiofibroma, anhidrotic ectodermal dysplasia-ill
- the methods are provided for alleviating a symptom of a disease or disorder mediated, at least in part, by ⁇ 4 ⁇ 7 integrin.
- the methods include identifying a mammal having a symptom of a disease or disorder mediated, at least in part, by ⁇ 4 ⁇ 7 integrin, and providing to the mammal an amount of a compound as described herein effective to ameliorate (i.e., lessen the severity of) the symptom.
- the disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin is an inflammatory disease or LPS induced endotoxin shock.
- the disease is an autoimmune disease.
- the autoimmune disease is systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), inflammatory bowel disease (IBD), sepsis, psoriasis, Sjoegren's syndrome, autoimmune hemolytic anemia, asthma, or chronic obstructive pulmonary disease (COPD), ankylosing spondylitis, acute gout and ankylosing spondylitis, reactive arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, juvenile arthritis, juvenile onset rheumatoid arthritis, juvenile rheum
- COPD chronic obstructive
- the disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin is inflammatory bowel disease (IBD).
- IBD inflammatory bowel disease
- the term “inflammatory bowel disease” or “IBD” as used herein is a collective term describing inflammatory disorders of the gastrointestinal tract, the most common forms of which are ulcerative colitis and Crohn's disease.
- IBD forms of IBD that can be treated with the presently disclosed compounds, compositions and methods include diversion colitis, ischemic colitis, infectious colitis, chemical colitis, microscopic colitis (including collagenous colitis and lymphocytic colitis), atypical colitis, pseudomembranous colitis, fulminant colitis, autistic enterocolitis, indeterminate colitis, Behcet's disease, gastroduodenal CD, jejunoileitis, ileitis, ileocolitis, Crohn's (granulomatous) colitis, irritable bowel syndrome, mucositis, radiation induced enteritis, short bowel syndrome, celiac disease, stomach ulcers, diverticulitis, pouchitis, proctitis, and chronic diarrhea.
- diversion colitis ischemic colitis, infectious colitis, chemical colitis, microscopic colitis (including collagenous colitis and lymphocytic colitis), atypical colitis, pseudomembranous colitis, fulminant colitis
- Treating or preventing IBD also includes ameliorating or reducing one or more symptoms of IBD.
- symptoms of IBD refers to detected symptoms such as abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite, and other more serious complications, such as dehydration, anemia and malnutrition. A number of such symptoms are subject to quantitative analysis (e.g., weight loss, fever, anemia, etc.). Some symptoms are readily determined from a blood test (e.g., anemia) or a test that detects the presence of blood (e.g., rectal bleeding).
- the term “wherein said symptoms are reduced” refers to a qualitative or quantitative reduction in detectable symptoms, including but not limited to a detectable impact on the rate of recovery from disease (e.g., rate of weight gain).
- the diagnosis is typically determined by way of an endoscopic observation of the mucosa, and pathologic examination of endoscopic biopsy specimens.
- IBD interleukin deficiency .
- Various methods have been described for characterizing disease activity and severity of IBD as well as response to treatment in subjects having IBD. Treatment according to the present methods is generally applicable to a subject having IBD of any level or degree of disease activity.
- the disease or condition treated by the administration of a compound of composition described herein includes acute gout and ankylosing spondylitis, allergic disorders, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis and multiple sclerosis, atherosclerosis, bacterial infections, bone cancer pain and pain due to endometriosis, BRAF resistant melanoma, brain stem glioma or pituitary adenomas, burns, bursitis, cancer of the anal region, cancer of the endocrine system, cancer of the kidney or ureter (e.g., renal cell carcinoma, and carcinoma of the renal pelvis), cancer of the penis, cancer of the small intestine, cancer of the thyroid, cancer of the urethra, cancers of the blood such as acute myeloid leukemia, cancers of the tongue, carcinoma of the cervix, carcinoma of the endometrium, carcinoma of the fallopian tubes, carcinoma of the renal pelvis, carcinoma of
- Criteria useful for assessment of disease activity in subjects with ulcerative colitis can be found in, e.g., Truelove et al. (1955) Br Med J 2:1041-1048.) Using these criteria, disease activity can be characterized in a subject having IBD as mild disease activity or severe disease activity. Subjects who do not meet all the criteria for severe disease activity, and who exceed the criteria for mild disease activity are classified as having moderate disease activity.
- the presently disclosed treatment methods can also be applied at any point in the course of the disease.
- the methods are applied to a subject having IBD during a time period of remission (i.e., inactive disease).
- the present methods provide benefit by extending the time period of remission (e.g., extending the period of inactive disease) or by preventing, reducing, or delaying the onset of active disease.
- methods may be applied to a subject having IBD during a period of active disease. Such methods provide benefit by reducing the duration of the period of active disease, reducing or ameliorating one or more symptoms of IBD, or treating IBD.
- Measures for determining efficacy of treatment of IBD in clinical practice have been described and include, for example, the following: symptom control; fistula closure; extent of corticosteroid therapy required; and, improvement in quality of life.
- Heath-related quality of life can be assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), which is extensively used in clinical practice to assess quality of life in a subject with IBD.
- IBDQ Inflammatory Bowel Disease Questionnaire
- the disease or condition is immune-mediated liver injury, disease or condition.
- the disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin is alcoholic hepatitis.
- Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver failure that develops in subjects with chronic and active alcohol abuse. (See Akriviadis E. et. al, Ann Gastroenterol. 2016 April-June; 29(2): 236-237). Alcoholic hepatitis can cause cirrhosis and fibrosis of the liver cells.
- Glucocorticoids, (e.g., prednisolone) and phosophodiesterase inhibitors (e.g., pentoxifylline) can be used to treat alcoholic hepatitis.
- the compounds herein can be used as stand-alone treatments or in combination with the current treatments for alcoholic hepatitis.
- the present disclosure provides methods of treating or preventing a human immunodeficiency virus (HIV) infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.
- HIV human immunodeficiency virus
- the disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin is systemic lupus erythematosus (SLE), lupus nephritis, lupus-related, or other autoimmune disorders or a symptom of SLE.
- SLE systemic lupus erythematosus
- lupus nephritis lupus-related, or other autoimmune disorders or a symptom of SLE.
- Symptoms of systemic lupus erythematosus include joint pain, joint swelling, arthritis, fatigue, hair loss, mouth sores, swollen lymph nodes, sensitivity to sunlight, skin rash, headaches, numbness, tingling, seizures, vision problems, personality changes, abdominal pain, nausea, vomiting, abnormal heart rhythms, coughing up blood and difficulty breathing, patchy skin color and Raynaud's phenomenon.
- a method of treating diseases or conditions mediated, at least in part, by ⁇ 4 ⁇ 7 integrin and/or diseases or symptoms that co-present or are exacerbated or triggered by the diseases or conditions mediated, at least in part, by ⁇ 4 ⁇ 7 integrin, e.g., an allergic disorder and/or an autoimmune and/or inflammatory disease, and/or an acute inflammatory reaction comprises administering to a patient in need thereof an effective amount of a compound described herein optionally in combination with an additional agent (e.g., a second, third, fourth or fifth active agent) which can be useful for treating diseases or conditions mediated, at least in part, by ⁇ 4 ⁇ 7, an allergic disorder and/or an autoimmune and/or inflammatory disease, and/or an acute inflammatory reaction incident to or co-presenting with diseases or conditions mediated, at least in part, by ⁇ 4 ⁇ 7 integrin.
- an additional agent e.g., a second, third, fourth or fifth active agent
- Treatment with the second, third, fourth or fifth active agent may be prior to, concomitant with, or following treatment with a compound described herein.
- a compound described herein is combined with another active agent in a single dosage form.
- Suitable therapeutics that may be used in combination with a compound described herein include, but are not limited to, therapeutic agents provided herein, or a combination comprising at least one therapeutic agent provided herein.
- agents for treatment of an inflammatory disease or condition include alpha-fetoprotein modulators; adenosine A3 receptor antagonist; adrenomedullin ligands; AKT1 gene inhibitors; antibiotics; antifungals; ASK1 inhibitors; ATPase inhibitors; beta adrenoceptor antagonists; BTK inhibitors; calcineurin inhibitors; carbohydrate metabolism modulators; cathepsin S inhibitors; CCR9 chemokine antagonists; CD233 modulators; CD29 modulators; CD3 antagonists; CD40 ligand inhibitors; CD40 ligand receptor antagonists; chemokine CXC ligand inhibitors; CHST15 gene inhibitors; collagen modulators; CSF-1 antagonists; CX3CR1 chemokine modulators; ecobiotics; eotaxin lig
- Adenosine A3 receptor antagonists include PBF-677.
- Adrenomedullin ligands include adrenomedullin.
- Antibiotics include ciprofloxacin, clarithromycin, metronidazole, vancomycin, rifamycin, rifaximin, and tosufloxacin.
- ASK1 inhibitors include GS-4997.
- Alpha-fetoprotein modulators include ACT-101.
- Anti-CD28 inhibitors include JNJ-3133 and abatacept.
- Beta adrenoceptor antagonists include NM-001.
- BTK inhibitors include GS-4059.
- Calcineurin inhibitors include tacrolimus, and ciclosporin.
- Carbohydrate metabolism modulators include ASD-003.
- Cathepsin S inhibitors include VBY-129.
- CCR9 chemokine antagonists include CCX-507.
- CD233 modulators include GSK-2831781.
- CD29 modulators include PF-06687234.
- CD3 antagonists include NI-0401.
- CD4 antagonists include IT-1208.
- CD40 ligand inhibitors include SAR-441344, and letolizumab.
- CD40 gene inhibitors include NJA-730.
- CD40 ligand receptor antagonists include FFP-104, BI-655064.
- Chaperonin binding immunoglobulin protein includes IRL-201805.
- Chemokine CXC ligand inhibitors include LY-3041658.
- CHST15 gene inhibitors include STNM-01.
- Collagen modulators include ECCS-50 (DCCT-10).
- COT protein kinase inhibitors include GS-4875.
- CSF-1 antagonists include JNJ-40346527 (PRV-6527), and SNDX-6352.
- CX3CR1 chemokine modulators include E-6130.
- Ecobiotics include SER-287.
- Eotaxin ligand inhibitors include bertilimumab.
- EP4 prostanoid receptor agonists include KAG-308.
- FIFO ATP synthase modulators include LYC-30937 EC.
- Fractalkine ligand inhibitors include quetmolimab (E-6011).
- Free fatty acid receptor 2 antagonists include GLPG-0974.
- GATA 3 transcription factor inhibitors include SB-012.
- Glucagon-like peptide 2 agonists include teduglutide, and apraglutide.
- Glucocorticoid receptor agonists include budesonide, beclomethasone dipropionate, and dexamethasone sodium phosphate.
- Glucocorticoid receptor modulators/TNF ligand inhibitors include ABBV-3373.
- Guanylate cyclase receptor agonists include dolcanatide.
- HIF prolyl hydroxylase inhibitors include DS-1093, and AKB-4924.
- HIF prolyl hydroxylase-2 inhibitors/hypoxia inducible factor-1 stimulators include GB-004.
- Histone deacetylase inhibitors include givinostat.
- Histone deacetylase-6 inhibitors include CKD-506.
- HLA class II antigen modulators include HLA class II protein modulators.
- ICAM1 gene inhibitors include alicaforsen.
- IL-12 antagonists include ustekinumab (IL12/IL23).
- IL-13 antagonists include tralokinumab.
- IL-18 antagonists include GSK-1070806.
- IL-22 agonists include RG-7880.
- IL-23 antagonists include tildrakizumab, risankizumab (BI-655066), mirikizumab (LY-3074828), brazikumab (AMG-139), and PTG-200.
- IL-23A inhibitors include guselkumab.
- IL-6 antagonists include olokizumab.
- IL-7 receptor antagonists include OSE-127.
- IL-8 receptor antagonists include clotrimazole.
- Integrin alpha-4/beta-1 antagonists include natalizumab.
- Integrin alpha-4/beta-7 antagonists include etrolizumab (a4b7/aEb7), vedolizumab, carotegast methyl, TRK-170 (a4b7/a4b1), PN-10943, and PTG-100.
- Integrin antagonists include E-6007.
- Interleukin ligand inhibitors include bimekizumab (IL-17A/IL-17F).
- Interleukin receptor 17A antagonists include brodalumab.
- Interleukin-1 beta ligands include K(D)PT.
- Interleukin 1 like receptor 2 inhibitors include BI-655130.
- IL-6 receptor modulators include olamkicept.
- JAK tyrosine kinase inhibitors include tofacitinib (1 ⁇ 3), peficitinib (1 ⁇ 3), TD-3504, an TD-1473.
- Jak1 tyrosine kinase inhibitors include a compound disclosed in WO2008/109943.
- JAK inhibitors include, but are not limited to, AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110, lestaurtinib, momelotinib (CYT0387), NS-018, pacritinib (SB1518), peficitinib (ASP015K), ruxolitinib, tofacitinib (formerly tasocitinib), XL019, upadacitinib (ABT-494), filgotinib, GLPG-0555, SHR-0302, and brepocitinib (PF-06700841) (JAK1/Tyk2).
- Jak3 tyrosine kinase inhibitors include PF-06651600.
- Lactoferrin stimulators include recombinant human lactoferrin (VEN-100).
- LanC like protein 2 modulators include BT-11.
- Leukocyte elastase inhibitors/Leukocyte proteinase-3 inhibitors include tiprelestat.
- MAdCAM inhibitors include SHP-647 (PF-547659).
- MCH-1 antagonists include CSTI-100.
- Melanocortin MC1 receptor agonists include ASP-3291, and PL-8177.
- Metalloprotease-9 inhibitors include GS-5745.
- Microbiome modulator include ABI-M201.
- Natriuretic peptide receptor C agonists include plecanatide.
- Neuregulin-4 ligands include NRG-4.
- NKG2 D activating NK receptor antagonists include JNJ-4500.
- NLPR3 inhibitors include dapansutrile, BMS-986299, SB-414, MCC-950, IFM-514, JT-194, PELA-167, and NBC-6.
- Farnesoid X receptor (FXR and NR1H4) agonists or modulators include AGN-242266, cilofexor tromethamine (GS-9674), EDP-305, EYP-001, GNF-5120, MET-409, nidufexor (LMB-763), obeticholic acid, TERN-101, and tropifexor.
- Nuclear factor kappa B inhibitors include Thetanix.
- Opioid receptor antagonists include naltrexone, and IRT-103.
- OX40 ligand inhibitors include KHK-4083.
- Oxidoreductase inhibitors include olsalazine.
- Pellino homolog 1 inhibitors include BBT-401.
- P2X7 purinoceptor modulators include SGM-1019.
- PDE 4 inhibitors include apremilast.
- PPAR alpha/delta agonists include elafibranor (GFT-1007).
- PPAR gamma agonists include GED-0507-34-Levo.
- Protein fimH inhibitors include sibofimloc (EB-8018).
- P-selectin glycoprotein ligand-1 inhibitors include SEL-K2, AbGn-168H, and neihulizumab.
- Ret tyrosine kinase receptor inhibitors include GSK-3179106.
- RIP-1 kinase inhibitors include GSK-2982772.
- RIP-2 kinase inhibitors include GSK-2983559.
- Sphingosine 1 phosphate phosphatase 1 stimulators include etrasimod.
- Sphingosine-1-phosphate receptor-1 agonists include ozanimod, mocravimod (KRP-203), and BMS-986166.
- Sphingosine-1-phosphate receptor-1 agonists/Sphingosine-1-phosphate receptor-5 agonists include ozanimod.
- Sphingosine-1-phosphate receptor-1 antagonists include amiselimod (MT-1303).
- Sphingosine-1-phosphate receptor-1 modulators include OPL-002.
- Stem cell antigen-1 inhibitors include Ampion (DMI-9523).
- Superoxide dismutase modulators include midismase.
- Syk inhibitors include GS-9876.
- Tissue transglutaminase inhibitor includes zampilimab.
- TLR-3 antagonists include PRV-300.
- TLR-4 antagonists include JKB-122.
- Toll-like receptor 8 (TLR8) inhibitors include E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, VTX-1463, and VTX-763.
- TLR-9 agonists include cobitolimod, IMO-2055, IMO-2125, lefitolimod, litenimod, MGN-1601, and PUL-042.
- TNF alpha ligand inhibitors include adalimumab, certolizumab pegol, infliximab, golimumab, DLX-105, Debio-0512, HMPL-004, CYT-020-TNFQb, Hemay-007, and V-565.
- TNF antagonists include AVX-470, tulinercept, and etanercept.
- TPL-2 inhibitors include GS-4875.
- Tumor necrosis factor 14 ligand modulators include AEVI-002.
- Tumor necrosis factor 15 ligand inhibitors include PF-06480605.
- Tyk2 tyrosine kinase inhibitors include PF-06826647, and BMS-986165.
- TrkA receptor antagonist includes SNA-125.
- Type I IL-1 receptor antagonists include anakinra.
- Zonulin inhibitors include larazotide acetate.
- Anti-inflammatory agents include but are not limited to NSAIDs, non-specific and COX-2 specific cyclooxgenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptors antagonists, immunosuppressants and methotrexate.
- NSAIDs include, but are not limited to ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmetin sodium, and hydroxychloroquine.
- NSAIDs also include COX-2 specific inhibitors (i.e., a compound that inhibits COX-2 with an IC 50 that is at least 50-fold lower than the IC 50 for COX-1) such as celecoxib, valdecoxib, lumiracoxib, etoricoxib and/or rofecoxib.
- COX-2 specific inhibitors i.e., a compound that inhibits COX-2 with an IC 50 that is at least 50-fold lower than the IC 50 for COX-1
- celecoxib valdecoxib
- lumiracoxib etoricoxib
- etoricoxib etoricoxib
- rofecoxib rofecoxib
- the anti-inflammatory agent is a salicylate.
- Salicylates include but are not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.
- the anti-inflammatory agent may also be a corticosteroid.
- the corticosteroid may be chosen from cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, and prednisone.
- the anti-inflammatory therapeutic agent is a gold compound such as gold sodium thiomalate or auranofin.
- the anti-inflammatory agent is a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
- a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
- the anti-inflammatory compound is an anti-C5 monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist, such as entanercept, or infliximab, which is an anti-TNF alpha monoclonal antibody.
- an anti-C5 monoclonal antibody such as eculizumab or pexelizumab
- TNF antagonist such as entanercept, or infliximab
- the immunosuppressant is methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, or mycophenolate mofetil.
- agents for treatment of IBD include ASK1 inhibitors, beta adrenoceptor antagonists, BTK inhibitors, beta-glucuronidase inhibitors, bradykinin receptor modulators, calcineurin inhibitors, calcium channel inhibitors, cathepsin S inhibitors, CCR3 chemokine antagonists, CD40 ligand receptor antagonists, chemokine CXC ligand inhibitors, CHST15 gene inhibitors, collagen modulators, CSF-1 antagonists, cyclooxygenase inhibitors, cytochrome P450 3A4 inhibitors, eotaxin ligand inhibitors, EP4 prostanoid receptor agonists, erythropoietin receptor agonists, fractalkine ligand inhibitors, free fatty acid receptor 2 antagonists, GATA 3 transcription factor inhibitors,
- agents for treatment of IBD include those provided herein for the treatment of an inflammatory disease or condition, and ABX-464, adalimumab; alicaforsen, ALLO-ASC-CD, AMG-966, anakinra, apremilast; Alequel; AMG-139; amiselimod, ASD-003, ASP-3291, AX-1505, BBT-401, balsalazide; beclomethasone dipropionate; BI-655130, BMS-986184; budesonide; CEQ-508; certolizumab; ChAdOx2-HAV, dexamethasone sodium phosphate, DNVX-078,
- agents for treatment of graft versus host disease include those provided herein for the treatment of an inflammatory disease or condition, and [18F]F-AraG, AM-01, Alpha 1 antitrypsin stimulator: AAT-IV and CSL-964; Allocetra, efavaleukin alfa (AMG-592), arsenic trioxide, ATIR-101, belatacept, belimumab, beta lactamase modulator: ribaxamase, bortezomib, brentuximab vedotin, brimonidine, brimonidine tartrate, cannabidiol, ciclosporin, CYP-001, um, dilanubicel, dornase alfa, DSM-9843, eculizumab
- agents for treatment of primary sclerosing cholangitis include those provided herein for the treatment of an inflammatory disease or condition, and BTT-1023, CM-101, Doconexent, GRI-0124, HTD-1801, HTD-2802, hymecromone, IDN-7314, NGM-282, norursodeoxycholic acid, ORBCEL-C, integrin alpha-V/beta-1 and beta-6 antagonist: PLN-74809; PPAR delta agonist: seladelpar lysine; SCT-5-27, PTGS2 gene and TGF beta 1 gene inhibitor: SCT-5-27, and STP-705; Farnesoid X receptor (FXR, NR1H4) agonists or modulators: AGN-242266, cilofexor
- the one or more additional therapeutic agents is selected from the group consisting of: combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV
- the one or more additional therapeutic agents is selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, or a pharmaceutically acceptable salt of any of the foregoing, or any combinations thereof.
- the one or more additional therapeutic agent is an immune modulating agent, e.g., an immunostimulant or an immunosuppressant.
- an immune modulating agent is an agent capable of altering the function of immune checkpoints, including the CTLA-4, LAG-3, B7-H3, B7-H4, Tim3, BTLA, KIR, A2aR, CD200 and/or PD-1 pathways.
- the immune modulating agent is immune checkpoint modulating agents.
- Exemplary immune checkpoint modulating agents include anti-CTLA-4 antibody (e.g., ipilimumab), anti-LAG-3 antibody, anti-B7-H3 antibody, anti-B7-H4 antibody, anti-Tim3 antibody, anti-BTLA antibody, anti-KIR antibody, anti-A2aR antibody, anti CD200 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-CD28 antibody, anti-CD80 or -CD86 antibody, anti-B7RP1 antibody, anti-B7-H3 antibody, anti-HVEM antibody, anti-CD137 or -CD137L antibody, anti-OX40 or -OX40L antibody, anti-CD40 or -CD40L antibody, anti-GAL9 antibody, anti-IL-10 antibody and A2aR drug.
- CTLA-4 antibody e.g., ipilimumab
- anti-LAG-3 antibody e.g., anti-B7-H3 antibody, anti-B7-H4 antibody, anti-T
- immune modulating agents include those agents capable of altering the function of mediators in cytokine mediated signaling pathways.
- a compound as disclosed herein may be combined with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents in any dosage amount of the compound described herein (e.g., from 10 mg to 1000 mg of compound).
- one or more e.g., one, two, three, four, one or two, one to three, or one to four
- additional therapeutic agents in any dosage amount of the compound described herein (e.g., from 10 mg to 1000 mg of compound).
- a compound described herein may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.
- kits comprising a pharmaceutical composition comprising a compound described herein or a compound described herein and at least one additional therapeutic agent, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents are provided.
- Any pharmaceutical composition provided in the present disclosure may be used in the kits, the same as if each and every composition were specifically and individually listed for use in a kit.
- the kit comprises instructions for use in the treatment of an inflammatory disease or condition.
- the instructions in the kit are directed to use of the pharmaceutical composition for the treatment of IBD.
- Articles of manufacture comprising a container in which a compound described herein and at least one pharmaceutically acceptable carrier are contained are provided.
- the article of manufacture may be a bottle, vial, ampoule, single-use disposable applicator, or the like, containing the pharmaceutical composition provided in the present disclosure.
- the container may be formed from a variety of materials, such as glass or plastic and in one aspect also contains a label on, or associated with, the container which indicates directions for use in the treatment of cancer or inflammatory conditions.
- the active ingredient may be packaged in any material capable of providing reasonable chemical and physical stability, such as an aluminum foil bag.
- Unit dosage forms of the pharmaceutical composition comprising a compound described herein and at least one pharmaceutically acceptable carrier are also provided.
- Any pharmaceutical composition provided in the present disclosure may be used in the articles of manufacture, the same as if each and every composition were specifically and individually listed for use an article of manufacture.
- kits that includes a compound described herein; a label, and/or instructions for use of the compound in the treatment of a disease or condition mediated, at least in part, by ⁇ 4 ⁇ 7 integrin.
- an article of manufacture which includes a compound described herein; and a container.
- the container may be a vial, jar, ampoule, preloaded syringe, or an intravenous bag.
- Formulations of compound(s) of the present disclosure i.e., a compound described herein or the combination of a compound described herein and an additional agent may be accomplished by admixing said compounds or salt thereof with one or more non-toxic, pharmaceutically acceptable vehicles, carriers and/or diluents and/or adjuvants collectively referred to herein as excipients or carrier materials.
- the compounds of the disclosure may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such route, and in a therapeutically effective dose.
- the compounds or the combination of compounds for the disclosure may be delivered orally, mucosally, parenterally, including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intranasally in dosage formulations containing conventional pharmaceutical excipients.
- the combination of a compound described herein, and an additional therapeutic agent may be formulated in a fixed dose or combined dose formulation in a tablet, capsule or premixed IV solution.
- the fixed dose combination preferably comprises of a compound described herein, and an additional anti-inflammatory agent.
- Other fixed dose formulations may include premixed liquids, suspensions, elixirs, aerosolized sprays or patch presentations.
- fixed dose or combined dose formulations are synonymous with simultaneous co-administration of the active ingredients of the compound described herein and at least one additional therapeutic agent.
- Also provided herein are methods for treating a subject who is undergoing one or more standard therapies for treatment of an inflammatory disease or condition comprising administering or co-administering a compound described herein to said subject. Accordingly, one or more compounds described herein may be administered before, during, or after administration of another therapeutic agent for treatment of an inflammatory disease or condition, or combination thereof.
- the subject may be a human who is (i) substantially refractory to at least one treatment of an inflammatory disease or condition, or (ii) in relapse after treatment with treatment of an inflammatory disease or condition, or both (i) and (ii). In some of embodiments, the subject is refractory to at least two, at least three, or at least four treatment of an inflammatory disease or condition (including standard or experimental treatments of an inflammatory disease or condition).
- therapeutic agents when employed in combination with a compound(s) disclosed herein, may be used, for example, in those amounts indicated in the referenced manuals, e.g., Physicians' Desk Reference or in amounts generally known to a qualified care giver, i.e., one of ordinary skill in the art.
- such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the compound described herein.
- Certain other therapeutic agents may be combined into a single formulation or kit when amenable to such.
- tablet, capsule or liquid formulations may be combined with other tablet, capsule or liquid formulations into one fixed or combined dose formulation or regimen. Other combinations may be given separately, contemporaneously or otherwise.
- the compounds of the disclosure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein.
- the synthesis of typical compounds of formula (I), e.g., compounds having structures described by one or more of formula (I), or other formulas or compounds disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, may be accomplished as described in the following examples.
- Typical embodiments of compounds in accordance with the present disclosure may be synthesized using the general reaction schemes and/or examples described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Starting materials are typically obtained from commercial sources or synthesized using published methods for synthesizing compounds which are embodiments of the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein.
- Group labels e.g., R 1 , R a ) used in the reaction schemes herein are for illustrative purposes only and unless otherwise specified do not necessarily match by name or function the labels used elsewhere to describe compounds of formula (I), or any formula described herein, or aspects or fragments thereof.
- the compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
- protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
- Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein.
- the compounds of this disclosure may contain one or more asymmetric (“chiral”) centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
- the starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof.
- many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis., USA).
- Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989) organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5 th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- solvent refers to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like).
- solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
- q.s. means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
- Scheme 1 shows an exemplary synthetic route for the synthesis of compounds provided herein (e.g., compounds of Formula I).
- the compounds of Formula I, or other formulas or compounds disclosed herein are typically prepared by first providing the molecular core 503 and then attaching the desired R 1 substituents using suitable coupling conditions (e.g., Suzuki coupling) and the desired phenylamide substituents (substituted at the phenyl by R 2 -R 6 ) using suitable amide coupling conditions.
- suitable coupling conditions e.g., Suzuki coupling
- suitable phenylamide substituents substituted at the phenyl by R 2 -R 6
- R 51 is a leaving group (e.g., halo);
- R 52 is C 1-6 alkyl;
- R 53 is hydroxy or a leaving group (e.g., halo);
- R 54 is a moiety suitable for undergoing a coupling reaction (e.g., a boronic acid or halo);
- R 55 is O (i.e., oxo) or N, where if R 55 is N then R 55 is a constituent of optional ring to E 1 ;
- E 1 is a double bonded N-auxiliary that is optionally cyclized at R 55 , or E 1 may be a single bonded N-protecting group and R 8 ;
- R 56 is a moiety suitable
- compound 501 is reacted with compound 502 under standard nucleophilic displacement conditions (e.g., using a base) in a suitable solvent (e.g., THF etc.), optionally under an inert atmosphere, to provide compound 503.
- a strong base such as potassium hydroxide or butyllithium
- the reaction is carried out in an inert solvent, for example dichloromethane or THF.
- the reaction is typically conducted at a temperature of about ⁇ 78 to 0° C., for about 5 minutes to about 1 hour, or at a temperature of about 0 to 50° C., for about 1 hour to about 12 hours.
- the product compound 503 is isolated by conventional means.
- Compound 508 is reacted under acidic conditions sufficient to remove E 1 .
- compound 508 may be contacted with an acid in the presence of water or an alcohol, if E 1 is double bonded to N, such as when E 1 is a diphenylmethine.
- compound 508 may be contacted with HCl in a suitable solvent, such as methanol/dioxane.
- compound 508 may be contacted with an acid (e.g., HCl or trifluoroacetic acid) in an inert solvent (e.g., dioxane or dichloromethane), if E 1 is single bonded to N, such as when E 1 is a tert-butoxycarbonyl.
- N—H derivative of compound 508 is reacted with compound 505 under standard amide coupling conditions in a suitable solvent (e.g., THE etc.), optionally under an inert atmosphere, to provide compound 510.
- a suitable solvent e.g., THE etc.
- R 53 may be leaving group (e.g., halo), or —OH.
- R 53 is —OH
- compound 505 is activated using a suitable agent, such as HATU, and contacted with compound 508 in the presence of a base (e.g., an organic base such as triethylamine or diisopropylethylamine).
- a base e.g., an organic base such as triethylamine or diisopropylethylamine.
- the reaction is carried out in an inert solvent, for example dichloromethane, DMF or THF.
- R 53 is a leaving group
- compound 505 is contacted with compound 508 in the presence of a base (e.g., an organic base such as triethylamine or diisopropylethylamine) in an inert solvent, for example dichloromethane or THF.
- a base e.g., an organic base such as triethylamine or diisopropylethylamine
- an inert solvent for example dichloromethane or THF.
- the reaction is typically conducted at a temperature of about 0 to 30° C., for about 5 minutes to about 12 hours.
- the product compound 510 is isolated by conventional means.
- compound 503 is reacted under acidic conditions sufficient to remove E 1 .
- compound 503 may be contacted with an acid in the presence of water or an alcohol, if E 1 is double bonded to N, such as when E 1 is a diphenylmethine.
- compound 503 may be contacted with HCl in a suitable solvent, such as methanol/dioxane.
- compound 503 may be contacted with an acid (e.g., HCl or trifluoroacetic acid) in an inert solvent (e.g., dioxane or dichloromethane), if E 1 is single bonded to N, such as when E 1 is a tert-butoxycarbonyl.
- an acid e.g., HCl or trifluoroacetic acid
- an inert solvent e.g., dioxane or dichloromethane
- N—H derivative of compound 503 is reacted with compound 505 under standard amide coupling conditions in a suitable solvent (e.g., THF etc.), optionally under an inert atmosphere, to provide compound 506.
- R 53 may be a leaving group (e.g., halo), or —OH.
- compound 505 is activated using a suitable agent, such as HATU, and contacted with compound 503 in the presence of a base (e.g., an organic base such as triethylamine or diisopropylethylamine).
- a base e.g., an organic base such as triethylamine or diisopropylethylamine.
- the reaction is carried out in an inert solvent, for example dichloromethane, DMF or THF.
- compound 505 is contacted with compound 503 in the presence of a base (e.g., an organic base such as triethylamine or diisopropylethylamine) in an inert solvent, for example dichloromethane or THF.
- a base e.g., an organic base such as triethylamine or diisopropylethylamine
- an inert solvent for example dichloromethane or THF.
- the reaction is typically conducted at a temperature of about 0 to 30° C., for about 5 minutes to about 24 hours.
- the product compound 506 is isolated by conventional means.
- Compound 506 is coupled with compound 507 under standard metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., dioxane, water, etc.), optionally under an inert atmosphere, to provide compound 510.
- a suitable solvent e.g., dioxane, water, etc.
- Compound 507 is an appropriate derivative of formula R 1 -R 54 . If R 54 is a boronic acid —B(OH) 2 , or an ester thereof, compound 507 is coupled to compound 506 where R 56 is a halogen (e.g., Br).
- compound 506 may first be coupled with a suitable source of boron, e.g., bis(pinacolato)diboron, to provide a boronic acid, or an ester thereof, at R 56 .
- a suitable source of boron e.g., bis(pinacolato)diboron
- the coupling reaction is carried out in an inert solvent, for example aqueous N,N-dimethylformamide, in the presence of a mild base, for example potassium acetate, potassium carbonate, or sodium bicarbonate.
- the reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(II) or dichloro 1,1′-bis(diphenylphosphino)ferrocene palladium(II), at a temperature of about 60 to 150° C., for about 10 minutes to about 12 hours.
- a metal catalyst for example dichlorobis(triphenylphosphine) palladium(II) or dichloro 1,1′-bis(diphenylphosphino)ferrocene palladium(II)
- compound 510 is hydrolyzed at R 52 under standard aqueous hydrolysis conditions (e.g., using a base or acid) in a suitable aqueous medium (e.g., THE and water, ethanol and water, etc.), optionally under an inert atmosphere, to provide compound 511.
- a suitable aqueous medium e.g., THE and water, ethanol and water, etc.
- the reaction is typically conducted at a temperature of about 0 to 30° C., for about 10 minutes to about 1 hour or at a higher temperature, i.e., 30 to 100° C. for about 10 minutes to about 1 hour.
- the product of Formula I is isolated by conventional means.
- the R 1 substituent can be added either before (as shown in Scheme 1) or after the removal of the E 1 moiety.
- the R 1 moiety may be coupled to the core-E 1 compound 503 under coupling reaction conditions with an appropriate reagent of formula R 1 -R 54 as shown in Scheme 1.
- the R 1 moiety may be coupled to the core compound 506 with an appropriate reagent of formula R 1 -R 54 , following reaction with compound 505 as shown in Scheme 1.
- compound 508 may be synthesized by routes illustrated in Scheme 2.
- routes illustrated in Scheme 2 For example, an alternative route for the synthesis of compound 508-1 is shown in Scheme 2, wherein the ring Y—Z forms an indazolyl or an isoquinolinyl.
- R 55 is O
- E 1 is a protecting group (e.g., tert-butoxycarbonyl)
- R 52 is as defined above.
- Compound 516 is an appropriate acrylate derivative.
- Compound 515 is coupled with compound 516 under Heck metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., dioxane, water, etc.), optionally under an inert atmosphere, to provide compound 517.
- a suitable solvent e.g., dioxane, water, etc.
- the coupling reaction is carried out in an inert solvent, for example aqueous N,N-dimethylformamide, in the presence of a mild base, for example triethylamine, potassium phosphate or sodium carbonate.
- the reaction is typically conducted in the presence of a metal catalyst, for example palladium(II) acetate, at a temperature of about 60 to 150° C., for about 10 minutes to about 12 hours.
- Compound 517 is reduced under suitable conditions including a reducing agent (e.g., sodium borohydride or hydrogen), and a metal catalyst, optionally in an inert solvent.
- a reducing agent e.g., sodium borohydride or hydrogen
- a metal catalyst optionally in an inert solvent.
- compound 517 is contacted with the reducing agent sodium borohydride and nickel(II) chloride in methanol.
- compound 517 is contacted with pressurized hydrogen gas (e.g., 20 to 5000 psi) and palladium on carbon (e.g., 10% Pd/C) in an inert solvent (e.g., ethanol).
- pressurized hydrogen gas e.g., 20 to 5000 psi
- palladium on carbon e.g., 10% Pd/C
- an inert solvent e.g., ethanol
- compound 503 may be synthesized by routes illustrated in Scheme 3.
- routes illustrated in Scheme 3 For example, an alternative route for the synthesis of compound 503-1 is shown in Scheme 3, wherein the ring Y—Z forms a 1,6-naphthyridine.
- R 55 is O
- E 1 is tert-butoxycarbonyl
- the optional ring between E 1 and R 55 is absent.
- the reaction of compound 520 with compound 521 is conducted under Negishi metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., DMF, etc.), optionally under an inert atmosphere, to provide compound 503-1.
- a suitable solvent e.g., DMF, etc.
- the coupling reaction is carried out in an inert solvent, for example N,N-dimethylformamide in which compound 520 is contacted with zinc dust, e.g., in the presence of a catalytic activator (e.g., I 2 ).
- a catalytic activator e.g., I 2
- the reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(II), at a temperature of about 20 to 100° C., for about 10 minutes to about 24 hours.
- a metal catalyst with an appropriate ligand for example dichlorobis(triphenylphosphine) palladium(II
- compound 503 may be synthesized by routes illustrated in Scheme 4.
- routes illustrated in Scheme 4 an alternative route for the synthesis of compound 503-2 is shown in Scheme 4, wherein the ring Y—Z forms a naphthyl.
- E 2 is a double bonded N-auxiliary such as diphenylmethine.
- R 51 , R 52 , and R 56 are as described above.
- the reaction of compound 501 with compound 525 is carried out under standard nucleophilic displacement conditions (e.g., using a base) in a suitable solvent (e.g., THF etc.), optionally under an inert atmosphere, to provide compound 526.
- suitable solvent e.g., THF etc.
- Compound 525 is deprotonated using a strong base, such as potassium hydroxide or butyllithium, and then contacted with compound 501.
- the reaction is carried out in an inert solvent, for example dichloromethane or THF.
- the reaction is typically conducted at a temperature of about ⁇ 78 to 0° C., for about 5 minutes to about 1 hour, or at a temperature of about 0 to 50° C., for about 1 hour to about 12 hours.
- the product compound 526 is isolated by conventional means.
- Compound 526 is converted to compound 503-2 by standard deprotection and protection steps, where E 1 is trityl or tert-butoxycarbonyl, R 55 is O, and the optional ring between E 1 and R 55 is absent.
- the product compound 503-2 is isolated by conventional means.
- compound 515 may be synthesized by routes illustrated in Scheme 5.
- an alternative route for the synthesis of compounds 515-1 and 515-2 is shown in Scheme 5, wherein the ring Y—Z forms an indazolyl.
- R 1 and R 54 are as described above.
- the reaction of compound 530 to form compound 531 is carried out by contacting compound 530 with a strong base (e.g., sodium hydride) in an inert solvent (e.g., DMF) and then adding an electrophilic source of an alkylating agent (e.g., methyl iodide).
- a strong base e.g., sodium hydride
- an inert solvent e.g., DMF
- an electrophilic source of an alkylating agent e.g., methyl iodide
- the product compound 531 is isolated by conventional means.
- Compound 531 is then coupled with compound 507 under standard metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., DMF, water, etc.), optionally under an inert atmosphere, to provide a mixture of compound 515-1 and compound 515-2.
- a suitable solvent e.g., DMF, water, etc.
- Compound 507 is an appropriate derivative of formula R 1 -R 54 in which R 54 is a boronic acid —B(OH) 2 , or an ester thereof.
- the coupling reaction is carried out in an inert solvent, for example aqueous N,N-dimethylformamide, in the presence of a mild base, for example sodium carbonate.
- the reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example tetrakis(triphenylphosphine) palladium(O), at a temperature of about 60 to 150° C., for about 10 minutes to about 12 hours.
- a metal catalyst with an appropriate ligand for example tetrakis(triphenylphosphine) palladium(O)
- an appropriate ligand for example tetrakis(triphenylphosphine) palladium(O)
- an alternative route for the synthesis of compound 515 is illustrated in Scheme 6, wherein the ring Y—Z forms an isoquinoline.
- R 1 and R 54 are as described above.
- the reaction of compound 535 to form compound 515-3 and compound 515-4 is carried out by coupling with compound 507 under standard metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., dioxane, water, etc.), optionally under an inert atmosphere, to provide a mixture of compound 515-3 and compound 515-4.
- Compound 507 is an appropriate derivative of formula R 1 -R 54 in which R 54 is a boronic acid —B(OH) 2 , or an ester thereof.
- the coupling reaction is carried out in an inert solvent, for example aqueous dioxane, in the presence of a mild base, for example sodium carbonate.
- a mild base for example sodium carbonate.
- the reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(II), at a temperature of about 60 to 150° C., for about 10 minutes to about 12 hours.
- a metal catalyst with an appropriate ligand for example dichlorobis(triphenylphosphine) palladium(II)
- Suitably substituted compounds for use in the methods provided herein can be purchased from commercial sources or synthesized by known methods. Resolution of the isomers of compound 511 can be performed as needed using standard chiral separation/resolution conditions (e.g., chromatography, crystallization, etc.).
- reaction mixture was concentrated under reduced pressure, dissolved in water and washed with ethyl acetate.
- the aqueous layer was separated and basified (pH-8) using Sat. NaHCO 3 and extracted with 10% methanol/DCM.
- the combined organic layers were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure and purified by column chromatography by silica gel (100-200 mesh size) at 2% McOH/DCM to obtain methyl (S)-2-amino-3-(5-bromoquinolin-8-yl)propanoate as a mixture of two isomers. (ii).
- reaction vessel was flushed with nitrogen then heated to 100° C. overnight. It was cooled to RT and filtered. The reaction was concentrated and purified on silica gel eluting with EtOAc in hexanes (5-100%) to give the title compound.
- Methyl (R)-2,6-difluoro-4-(3-(trifluoromethyl)morpholino)benzoate To methyl 4-bromo-2,6-difluorobenzoate (120 g, 478 mmol), 3-(trifluoromethyl)morpholine hydrochloride (109 g, 573 mmol), cesium carbonate (779 g, 2.39 mol), RuPhos (8.92 g, 19.1 mmol), and tBuBrettPhos-Pd-G3 (8.17 g, 9.56 mmol) was added 840 mL Toluene. The mixture was de gassed by bubbling with N 2 for 10 min then heated to 120° C. for 16 h.
- tert-Butyl (R)-2,6-difluoro-4-((1,1,1-trifluorobutan-2-yl)amino)benzoate To a stirred suspension of tert-butyl 4-bromo-2,6-difluorobenzoate (250 mg, 0.55 mmol), (R)-1,1,1-trifluorobutan-2-amine (85 mg, 0.67 mmol), cesium carbonate (904 mg, 2.8 mmol) and toluene (5 mL) was added XPhos Pd G3 (42 mg, 0.06 mmol). The reaction mixture was sparged with nitrogen and then heated to 90° C. for 12 h.
- tert-Butyl (R)-2,6-difluoro-4-((2,2,2-trifluoro-1-phenylethyl)amino)benzoate To a 500 mL pressure vessel was added tert-butyl 4-bromo-2,6-difluorobenzoate (3 g, 6.65 mmol), (R)-2,2,2-trifluoro-1-phenylethan-1-amine (1.39 g, 7.98 mmol), cesium carbonate, (10.84 g, 33.26 mmol), XPhos Pd G3 (0.5 g, 0.67 mmol), toluene (37 mL) and the mixture was sparged with N 2 for 15 min, sealed and stirred at 90° C. overnight. The mixture was cooled, filtered through celite, concentrated under vacuum to afford the title compound which was used without further purification.
- NIA 1-bromo-4-(bromomethyl)naphthalene
- N2 Methyl (S)-3-(4-bromonaphthalen-1-yl)-2-(2,6-difluorobenzamido)propanoate (N2): To a stirred solution of N1 (172 mg, 0.5 mmol)) in DCM (5 mL) was added 2-fluoro-6-methylbenzoyl chloride (0.07 mL, 0.55 mmol) and TEA (0.35 mL, 2.5 mmol). The reaction mixture was allowed to stir for 1 h, then diluted with DCM and concentrated. The material was purified on silica gel eluting with EtOAc in hexanes (0-80%) to give the title compound.
- (2S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluoro-4-(3-(trifluoromethyl)morpholino)benzamido)propanoic acid The title compound was prepared according to the method presented for the synthesis of Example 3 replacing T3 with 2,6-difluoro-4-(3-(trifluoromethyl)morpholino)benzoic acid. Enantiomers were arbitrarily assigned after separation by supercritical fluid chromatography eluting with 20% McOH/DEA co-solvent on an IC SFC column.
- Example 8 (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(5-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)quinolin-8-yl)propanoic Acid (Atropisomer 1)
- Example 8 was the first eluting isomer. MS (m/z) 634.72 [M+H]+.
- Example 10 (S)-2-(2,6-dichlorobenzamido)-3-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid was chromatographed on an SFC-ADH column eluting with 30% methanol to afford example 11 as the first eluting isomer. MS (m/z) 578.1 [M+H]+.
- Example 10 (S)-2-(2,6-dichlorobenzamido)-3-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid was chromatographed on an SFC-ADH column eluting with 30% methanol to afford example 12 as the second eluting isomer. MS (m/z) 578.10 [M+H]+.
- (2S)-3-(5-(2-chloro-4-fluoro-6-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichloro benzamido)propanoic acid Prepared according to the procedure described for example 10 employing H15 in place of H2. MS (m/z) 547.061 [M+H]+.
- (2S)-3-(5-(2-chloro-6-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichloro benzamido) propanoic acid Prepared according to the procedure described for example 10 employing (2-chloro-6-methoxyphenyl)boronic acid in place of EQ6 and EQ5 in place of H2. MS (m/z) 530.0 [M+H]+.
- (2S)-3-(5-(2-chloro-6-(trifluoromethyl)phenyl)quinolin-8-yl)-2-(2,6-dichloro benzamido)propanoic acid Prepared according to the procedure described for example 10 employing 2-bromo-1-chloro-3-(trifluoromethyl)benzene in place of H2. MS (m/z) 536.957 [M+H]+.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure provides a compound of Formula (I):or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
Description
- This application claims priority to U.S. Provisional Application No. 62/752,854, filed Oct. 30, 2018, which is incorporated herein in its entirety for all purposes.
- The present disclosure relates generally to novel compounds that have α4β7 integrin inhibitory action, prodrugs of compounds having α4β7 integrin inhibitory action, and methods of use and manufacture thereof.
- Integrins are heterodimeric cell surface proteins involved in numerous cellular processes including cell-cell and cell-extracellular matrix interactions. Upon binding of an extracellular ligand, integrins mediate signal transduction to the cell interior resulting in lymphocyte cell capture, adhesion, and infiltration into the tissue.
- Integrins are heterodimeric proteins consisting of an alpha and a beta subunit. There are 18 known alpha subunits and 8 known beta subunits. The α4β7 integrin is expressed on the surface of lymphocytes and recognizes the extracellular ligand mucosal addressing cell adhesion molecule-1 (MAdCAM-1). α4β7 integrin governs lymphocyte trafficking to and retention in gut tissues through its interaction with MAdCAM-1, which is expressed on venules in the intestinal mucosa and high endothelial venules (HEV) in the gut-associated lymphoid tissues (GALT). Inhibiting the interactions of integrins with their respective ligands has been proposed as an effective method of treating a variety of autoimmune and inflammatory diseases, and blocking the α4β7-MAdCAM-1 interaction has shown therapeutic benefit in inflammatory bowel disease (Crohn's disease and ulcerative colitis).
- There is a need to for improved α4β7 integrin antagonist molecules for the treatment of autoimmune and inflammatory diseases, including, but not limited to, inflammatory bowel disease.
- The present disclosure provides compounds that are inhibitors for α4β7 integrin. The disclosure also provides compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated, at least in part, by α4β7 integrin. The disclosure also provides compounds for use in therapy. The disclosure further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by α4β7 integrin. Moreover, the disclosure provides uses of the compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated, at least in part, by α4β7 integrin.
- The present disclosure provides a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
-
- X1 and X2 are each independently selected from C, and N; wherein the bond between X1 and X2 is a single or a double bond;
- X3 and X4 are each independently selected from CR10, and N;
- X5 and X7 are each independently selected from CR10R10, CR10, S, S(O), S(O)2, N, NR11, C(O), and O;
- each X6 is independently selected from CR10R10, CR10, S, S(O), S(O)2, N, NR11, C(O), and O; wherein the bond between X5 and X6, X6 and X6, or X6 and X7 is a single or a double, provided that at least one is a double bond;
- R1 is selected from -L-A1, -L-A2, -L-A3, and -L-A4;
- L is selected from a bond, —O—, —O—C(O)—*, —NH—, —C(O)—N(H)—*, and —N(H)—C(O)—*;
- wherein * indicates a point of attachment of L to A1, A2, A3, or A4;
- A1 is C6-10aryl optionally substituted with one to six Ra;
- A2 is 5-10 membered heteroaryl containing one to five heteroatoms independently selected from S, N, and O, and optionally one or two C(O); wherein A2 is optionally substituted with one to six Ra;
- A3 is 5-10 membered cycloalkyl or 5-14 membered heterocyclyl; wherein A3 is optionally substituted with one to six Ra; and
- A4 is —NRa1Ra2;
- wherein each Ra is independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, —S(O)m—C1-6alkyl, C3-5cycloalkyl, 3-6 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C1-4alkylene-C3-8cycloalkyl, —O-phenyl, and —O—C3-8cycloalkyl;
- each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, and —S(O)m—C1-6alkyl of Ra are optionally substituted with one to three Ra3; wherein each Ra3 is independently selected from hydroxyl, cyano, —NRa1Ra2, C1-6alkoxyl, C3-5cycloalkyl, phenyl, and 3-6 membered heterocyclyl; wherein each C3-5cycloalkyl, phenyl, and 3-6 membered heterocyclyl of Ra3 is independently optionally substituted with one to three Ra4; wherein each Ra4 is independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, C1-6haloalkoxyl, C3-5cycloalkyl, and 3-6 membered heterocyclyl; and
- each C3-5cycloalkyl, 3-6 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C1-4alkylene-C3-8cycloalkyl, —O-phenyl, and —O—C3-8cycloalkyl of Ra is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, and C1-6haloalkoxyl;
- each R2, R3, R4, R5, and R6 is independently selected from H, halo, cyano, hydroxyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, —NRb1Rb2, —Rb3S(O)mRb4, —S(O)mRb4, —NRb1S(O)vRb4, —COORb1, —CONRb1Rb2, —NRb1COORb2, —NRb1CORb4, —Rb3NRb1Rb2, —S(O)vNRb1Rb2, C3-12cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 3-12 membered heterocyclyl;
- each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-8haloalkyl, and C1-6haloalkoxyl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to two Rc; wherein each Rc is independently selected from azido, oxo, cyano, halo, hydroxyl, —NRa1Ra2, C1-4alkoxyl, C3-8cycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C3-5cycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rc is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-6haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
- each C6-10aryl and 5-6 membered heteroaryl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to five Rb; and
- each C3-12cycloalkyl and 3-12 membered heterocyclyl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to six groups independently selected from ═CRb1Rb2, and Rb;
- wherein each Rb is independently selected from azido, cyano, halo, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-8haloalkyl, C1-6alkoxyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocycly; wherein each C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rb is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl;
- each Rb1 and Rb2 is independently selected from H, C1-8alkyl, C1-8haloalkyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl;
- each C1-8alkyl and C1-6haloalkyl of Rb1 and Rb2 is optionally substituted with one to two Rb5; and
- each C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl of Rb1 and Rb2 is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-8alkyl, C1-8haloalkyl, C1-6alkoxyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl;
- Rb3 is C1-4alkylene;
- Rb4 is selected from C1-4alkyl, C1-6haloalkyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C1-4alkyl, C1-4haloalkyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and the 4-6 membered heterocyclyl of Rb4 is optionally substituted with one to three Rb6;
- each Rb5 is independently selected from cyano, hydroxyl, C1-4alkoxyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rb5 is optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and phenyl; and
- each Rb6 is independently selected from halo, cyano, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, C3-6cycloalkyl, phenyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl; wherein each C3-6cycloalkyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl of Rb6 is independently optionally substituted with one to three groups independently selected from halo, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl;
- or R2 and R3, R3 and R4, or R5 and R6 together with the atoms to which they are attached may form a C6-10 aryl, 5-6 membered heteroaryl, C3-6cycloalkyl, or 5-6 membered heterocyclyl; wherein each C6-10 aryl, 5-6 membered heteroaryl, C3-6cycloalkyl, or 5-6 membered heterocyclyl is optionally substituted with one to three groups independently selected from halo, cyano, —NRa1Ra2, C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, C3-8cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl, 5-6 membered heteroaryl, C1-4alkylene-C3-8cycloalkyl, C1-4alkylene-C6-10 aryl, and C1-4alkylene-(5-6 membered heteroaryl);
- R7 is selected from H, C1-4alkyl, and C1-4haloalkyl;
- R8 is selected from H, C1-4alkyl, and C1-4haloalkyl;
- R9 is selected from H, C1-6alkyl, —C1-4alkylene-NRa1Ra2, —C1-4alkylene-C(O)NRa1Ra2, —C1-4 alkylene-O—C(O)—C1-4alkyl, —C1-4alkylene-O—C(O)—O—C1-4alkyl, —C1-4alkylene-O—C(O)—C1-4alkylene-NRa1Ra2, —C1-4alkylene-O—C1-4alkyl, C3-8cycloalkyl, —C1-4alkylene-C3-8cycloalkyl, 4-6 membered heterocyclyl, and —C1-4alkylene-(4-6 membered heterocyclyl);
- wherein each C3-8cycloalkyl, —C1-4alkylene-C3-8cycloalkyl, and 4-6 membered heterocyclyl of R9 is optionally substituted with one to three groups independently selected from halo, C1-4alkyl, C1-4alkoxyl, and C1-4haloalkyl; or
- R9 together with the N that attaches to R8 forms a 5 membered heterocyclyl; wherein the 5 membered heterocyclyl is optionally substituted with one to two groups independently selected from halo, C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, and C6-10aryl; wherein C6-10aryl is optionally substituted with one to three groups independently selected from halo, C1-6alkyl, C1-6alkoxyl, and C1-6haloalkyl;
- each R10 is independently selected from H, halo, cyano, hydroxyl, —C(O)Rb1, —NRa1Ra2, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-10cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, and 5-6 membered heteroaryl; wherein each C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-10cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, and 5-6 membered heteroaryl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
- or two R10 either attached to the same or adjacent atoms form C3-12cycloalkyl or 3-10 membered heterocyclyl; wherein each C3-12cycloalkyl and 3-10 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl;
- wherein each C3-8cycloalkyl, —C1-4alkylene-C3-8cycloalkyl, and 4-6 membered heterocyclyl of R9 is optionally substituted with one to three groups independently selected from halo, C1-4alkyl, C1-4alkoxyl, and C1-4haloalkyl; or
- each R11 is independently selected from H, C1-4alkyl, and C1-4haloalkyl; wherein each C1-4alkyl, —C(O)Rb1, and C1-4haloalkyl of R11 is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
- or R10 and R11, or two R11 together with the atoms to which they are attached to form 3-12 membered heterocyclyl; wherein 3-12 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl;
- each Ra1 and Ra2 is independently selected from H, C1-6alkyl, and C1-6haloalkyl;
- p is selected from 1, 2, and 3;
- m is selected from 0, 1, and 2; and
- v is selected from 1 and 2.
- Also provided herein is a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and at least one pharmaceutically acceptable carrier.
- Also provided herein is a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and further comprising a second therapeutic agent.
- In some embodiments, provided is a method for treating a disease or condition mediated, at least in part, by α4β7 integrin comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and at least one pharmaceutically acceptable carrier.
- In some embodiments, provided is a method for treating a disease or condition mediated, at least in part, by α4β7 integrin comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and further comprising a second therapeutic agent.
- Also provided herein is a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and at least one pharmaceutically acceptable carrier.
- Also provided herein is a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and further comprising a second therapeutic agent.
- In some embodiments, provided is a method for treating a disease or condition mediated, at least in part, by α4β7 integrin comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and at least one pharmaceutically acceptable carrier.
- In some embodiments, provided is a method for treating a disease or condition mediated, at least in part, by α4β7 integrin comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, and further comprising a second therapeutic agent.
- In some embodiments, provided is a method for treating an inflammatory disease comprising administrating to a subject an effective amount of a pharmaceutical composition comprising a compound of formula (I), or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof.
- The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.
- As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
- A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —CONH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.
- A squiggly line on a chemical group as shown below, for example,
- indicates a point of attachment, i.e., it shows the broken bond by which the group is connected to another described group.
- The prefix “Cu-v” indicates that the following group has from u to v carbon atoms. For example, “C1-8 alkyl” indicates that the alkyl group has from 1 to 8 carbon atoms.
- Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In some embodiments, the term “about” includes the indicated amount ±10%. In other embodiments, the term “about” includes the indicated amount ±5%. In certain other embodiments, the term “about” includes the indicated amount ±1%. Also, to the term “about X” includes description of “X”. Also, the singular forms “a” and “the” include plural references unless the context clearly dictates otherwise. Thus, e.g., reference to “the compound” includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art.
- “Alkyl” refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C1-20 alkyl), 1 to 8 carbon atoms (i.e., C1-8 alkyl), 1 to 6 carbon atoms (i.e., C1-6 alkyl), or 1 to 4 carbon atoms (i.e., C1-4 alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e., —(CH2)3CH3), sec-butyl (i.e., —CH(CH3)CH2CH3), isobutyl (i.e., —CH2CH(CH3)2) and tert-butyl (i.e., —C(CH3)3); and “propyl” includes n-propyl (i.e., —(CH2)2CH3) and isopropyl (i.e., —CH(CH3)2).
- “Alkenyl” refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkenyl), 2 to 8 carbon atoms (i.e., C2-8 alkenyl), 2 to 6 carbon atoms (i.e., C2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-4 alkenyl). Examples of alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).
- “Alkynyl” refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkynyl), 2 to 8 carbon atoms (i.e., C2-8 alkynyl), 2 to 6 carbon atoms (i.e., C2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C2-4 alkynyl). The term “alkynyl” also includes those groups having one triple bond and one double bond.
- “Alkoxy” refers to the group “alkyl-O—”. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.
- “Alkylene” (including those which are part of other groups) refers to branched and unbranched divalent “alkyl” groups. As used herein, alkylene has 1 to 20 carbon atoms (i.e., C1-20alkylene), 1 to 8 carbon atoms (i.e., C1-8 alkylene), 1 to 6 carbon atoms (i.e., C1-6 alkylene), or 1 to 4 carbon atoms (i.e., C1-4 alkylene). Examples include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene or 1,2-dimethylethylene. Unless stated otherwise, the definitions propylene and butylene include all the possible isomeric forms of the groups in question with the same number of carbons. Thus, for example, propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1,1-dimethylethylene, and 1,2-dimethylethylene.
- “Acyl” refers to a group refers to a group —C(O)RY, wherein RY is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include, e.g., formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl and benzoyl.
- “Amido” refers to both a “C-amido” group which refers to the group —C(O)NRyRz and an “N-amido” group which refers to the group —NRyC(O)Rz, wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
- “Amino” refers to the group —NRyRz wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, or heteroaryl; each of which may be optionally substituted.
- “Amidino” refers to —C(NH)(NH2).
- “Carbamoyl” refers to both an “0-carbamoyl” group which refers to the group —O—C(O)NRyRz and an “N-carbamoyl” group which refers to the group —NRyC(O)ORz, wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.
- “Carboxyl” refers to —C(O)OH.
- “Carboxyl ester” refers to both —OC(O)R and —C(O)OR, wherein R is alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
- “Guanidino” refers to —NHC(NH)(NH2).
- “Heteroalkyl” refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. The term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, —NR—, —O—, —S—, —S(O)—, —S(O)2—, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted. Examples of heteroalkyl groups include —OCH3, —CH2OCH3, —SCH3, —CH2SCH3, —NRCH3, and —CH2NRCH3, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. As used herein, heteroalkyl include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
- “Alkylsulfonyl” refers to the group —S(O)2R, where R is alkyl.
- “Alkylsulfinyl” refers to the group —S(O)R, where R is alkyl.
- “Aryl” refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., C6-20 aryl), 6 to 12 carbon ring atoms (i.e., C6-12 aryl), or 6 to 10 carbon ring atoms (i.e., C6-10 aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl.
- “Azido” refers to the group —N3.
- “Cyano” or “carbonitrile” refers to the group —CN.
- “Cycloalkyl” refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term “cycloalkyl” includes cycloalkenyl groups (e.g., the cyclic group having at least one double bond). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-6 cycloalkyl). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems with one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems.
- “Bridged” refers to a ring fusion wherein non-adjacent atoms on a ring are joined by a divalent substituent, such as an alkylenyl or heteroalkylenyl group or a single heteroatom. Quinuclidinyl and admantanyl are examples of bridged ring systems.
- The term “fused” refers to a ring which is bound to an adjacent ring.
- “Spiro” refers to a ring substituent which is joined by two bonds at the same carbon atom. Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents.
- “Halogen” or “halo” includes fluoro, chloro, bromo, and iodo.
- “Haloalkyl” refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms, up to the total number of possible hydrogen atoms in a group, are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (—CHF2) and trifluoromethyl (—CF3).
- “Haloalkoxyl” or “haloalkoxy” refers to an alkoxy group as defined above, wherein one or more hydrogen atoms, up to the total number of possible hydrogen atoms in a group, are replaced by a halogen. Examples of haloalkoxyl include, but are not limited to, difluoromethoxyl (—OCHF2), and trifluoromethoxyl (—OCF3).
- The term “heterocyclyl” or “heterocycle” as used herein refers to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple ring system that has at least one heteroatom in the ring, i.e., at least one annular heteroatom selected from oxygen, nitrogen, and sulfur, wherein the nitrogen or sulfur may be oxidized. Thus, the term includes rings having one or more annular O, N, S, S(O), S(O)2, and N-oxide groups. The term includes rings having one or more annular C(O) groups. Unless otherwise specified, a heterocyclyl group has from 5 to about 20 annular atoms, for example from 3 to 12 annular atoms, for example from 3 to 10 annular atoms, for example from 5 to 10 annular atoms or for example from 5 to 6 annular atoms. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings) having from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The rings of the multiple condensed ring (e.g., bicyclic heterocyclyl) system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. Heterocycles include, but are not limited to, groups derived from azetidine, aziridine, imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, pyrrolidine, pyrrolidinone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, tetrahydro-2H-thiopyran 1,1-dioxide, quinuclidine, N-bromopyrrolidine, N-chloropiperidine, and the like. Heterocycles include spirocycles, such as, for example, aza or oxo-spiroheptanes. Heterocyclyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems with one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems. Examples include dihydroquinolines, e.g., 3,4-dihydroquinoline, dihydroisoquinolines, e.g., 1,2-dihydroisoquinoline, dihydroimidazole, tetrahydroimidazole, etc., indoline, isoindoline, isoindolones (e.g., isoindolin-1-one), isatin, dihydrophthalazine, quinolinone, spiro[cyclopropane-1,1′-isoindolin]-3′-one, and the like. Additional examples of heterocycles include 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-oxa-7,9-diazabicyclo[3.3.1]nonanyl, and hexahydropyrazino[2,1-c][1,4]oxazinyl, for example.
- “Hydroxyl” and “hydroxy” are used interchangeably and refer to —OH.
- “Oxo” refers to the group (═O) or (O). Where tautomeric forms of the compound exist, hydroxyl and oxo groups may be interchangeable.
- “Heteroaryl” refers to an aromatic group, including groups having an aromatic tautomer or resonance structure, having a single ring, multiple rings, or multiple fused rings, with at least one heteroatom in the ring, i.e., one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the nitrogen or sulfur may be oxidized. Thus, the term includes rings having one or more annular O, N, S, S(O), S(O)2, and N-oxide groups. The term includes rings having one or more annular C(O) groups. As used herein, heteroaryl include 5 to 20 ring atoms (i.e., 5-20 membered heteroaryl), 5 to 12 ring atoms (i.e., 5-12 membered heteroaryl), or 5 to 10 ring atoms (i.e., 5-10 membered heteroaryl), and 1 to 5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and oxidized forms of the heteroatoms. Examples of heteroaryl groups include pyridin-2(1H)-one, pyridazin-3(2H)-one, pyrimidin-4(3H)-one, quinolin-2(1H)-one, pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass or overlap with aryl as defined above.
- “Sulfonyl” refers to the group —S(O)2R, where R is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
- Whenever the graphical representation of a group terminates in a singly bonded nitrogen atom, that group represents an —NH group unless otherwise indicated. Similarly, unless otherwise expressed, hydrogen atom(s) are implied and deemed present where necessary in view of the knowledge of one of skill in the art to complete valency or provide stability.
- Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group, an “arylene” group or an “arylenyl” group, respectively. Also, unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, e.g., arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
- The terms “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term “optionally substituted” refers to any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.
- The term “substituted” means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof. Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term “substituted” may describe other chemical groups defined herein. Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.
- In some embodiments, the term “substituted alkyl” refers to an alkyl group having one or more substituents including hydroxyl, halo, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl. In additional embodiments, “substituted cycloalkyl” refers to a cycloalkyl group having one or more substituents including alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl; “substituted heterocyclyl” refers to a heterocyclyl group having one or more substituents including alkyl, haloalkyl, heterocyclyl, cycloalkyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl; “substituted aryl” refers to an aryl group having one or more substituents including halo, alkyl, haloalkyl, cycloalkyl, heterocyclyl, heteroaryl, alkoxy, and cyano; “substituted heteroaryl” refers to an heteroaryl group having one or more substituents including halo, alkyl, haloalkyl, heterocyclyl, heteroaryl, alkoxy, and cyano and “substituted sulfonyl” refers to a group —S(O)2R, in which R is substituted with one or more substituents including alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl. In other embodiments, the one or more substituents may be further substituted with halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted. In other embodiments, the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.
- Some of the compounds exist as tautomeric isomers. Tautomeric isomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.
- Any formula or structure given herein, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 36S, 36Cl and 126I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as 3H, 13C and 14C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPELT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
- The disclosure also includes compounds in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound provided herein when administered to a mammal, particularly a human. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
- Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index. An 18F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compound.
- The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.
- In many cases, the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- The term “pharmaceutically acceptable salt” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, mono, di or tri cycloalkyl amines, mono, di or tri arylamines or mixed amines, etc. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
- Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
- As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- Provided are also compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. As known in the art, the deuterium atom is a non-radioactive isotope of the hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism”, Trends Pharmacol. Sci., 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
- Provided are also pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein. “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use. “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts.
- A “solvate” is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
- A “prodrug” is a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
- In some embodiments, provided are optical isomers, racemates, or other mixtures thereof of the compounds described herein or pharmaceutically acceptable salts or a mixture thereof. In those situations, the single enantiomer or diastereomer, i.e., optically active form, can be obtained by asymmetric synthesis or by resolution of the racemate. Resolution of racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column. In addition, provided are also Z- and E-forms (or cis- and trans-forms) of the hydroxyamidine compounds described herein. Specifically, Z- and E-forms are included even if only one designation is named for both carbon-carbon double bonds as well as the hydroxyamidine bond.
- Where chirality is not specified but is present, it is understood that the embodiment is directed to either the specific diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of such compound(s).
- “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. A mixture of enantiomers at a ratio other than 1:1 is a “scalemic” mixture.
- “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
- “Atropisomers” are stereoisomers arising due to hindered rotation about a single bond, where the barrier to rotation about the bond is high enough to allow for isolation of individual stereoisomers.
- Compositions provided herein that include a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof may include racemic mixtures, or mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein the same as if each and every isomeric form were specifically and individually listed.
- In some embodiments, provided are also chelates, non-covalent complexes, and mixtures thereof, of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof. A “chelate” is formed by the coordination of a compound to a metal ion at two (or more) points. A “non-covalent complex” is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
- “Treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, “unit and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival).
- “Prevention” or “preventing” means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
- “Subject” refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.
- The term “therapeutically effective amount” or “effective amount” of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of α4β7 integrin activity. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.
- The term “inhibition” indicates a decrease in the baseline activity of a biological activity or process. “Inhibition of activity of α4β7 integrin” or variants thereof refers to a decrease in activity of α4β7 integrin as a direct or indirect response to the presence of a compound of the present application relative to the activity of α4β7 integrin in the absence of the compound of the present application. “Inhibition of α4β7 integrin” refers to a decrease in α4β7 integrin activity as a direct or indirect response to the presence of a compound described herein relative to the activity of α4β7 integrin in the absence of the compound described herein. In some embodiments, the inhibition of α4β7 integrin activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment.
- Provided herein are compounds that function as inhibitors of α4β7 integrin. In some embodiments, provided is a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
-
- X1 and X2 are each independently selected from C, and N; wherein the bond between X1 and X2 is a single or a double bond;
- X3 and X4 are each independently selected from CR10, and N;
- X5 and X7 are each independently selected from CR10R10, CR10, S, S(O), S(O)2, N, NR11, C(O), and O;
- each X6 is independently selected from CR10R10, CR10, S, S(O), S(O)2, N, NR11, C(O), and O; wherein the bond between X5 and X6, X6 and X6, or X6 and X7 is a single or a double, provided that at least one is a double bond;
- R1 is selected from -L-A1, -L-A2, -L-A3, and -L-A4;
- L is selected from a bond, —O—, —O—C(O)—*, —NH—, —C(O)—N(H)—*, and —N(H)—C(O)—*;
- wherein * indicates a point of attachment of L to A1, A2, A3, or A4;
- A1 is C6-10aryl optionally substituted with one to six Ra;
- A2 is 5-10 membered heteroaryl containing one to five heteroatoms independently selected from S, N, and O, and optionally one or two C(O); wherein A2 is optionally substituted with one to six Ra;
- A3 is 5-10 membered cycloalkyl or 5-14 membered heterocyclyl; wherein A3 is optionally substituted with one to six Ra; and
- A4 is —NRa1Ra2;
- wherein each Ra is independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, —S(O)m—C1-6alkyl, C3-5cycloalkyl, 3-6 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C1-4alkylene-C3-8cycloalkyl, —O-phenyl, and —O—C3-8cycloalkyl;
- each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, and —S(O)m—C1-6alkyl of Ra are optionally substituted with one to three Ra3; wherein each Ra3 is independently selected from hydroxyl, cyano, —NRa1Ra2, C1-6alkoxyl, C3-5cycloalkyl, phenyl, and 3-6 membered heterocyclyl; wherein each C3-5cycloalkyl, phenyl, and 3-6 membered heterocyclyl of Ra3 is independently optionally substituted with one to three Ra4; wherein each Ra4 is independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, C1-6haloalkoxyl, C3-5cycloalkyl, and 3-6 membered heterocyclyl; and
- each C3-5cycloalkyl, 3-6 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C1-4alkylene-C3-8cycloalkyl, —O-phenyl, and —O—C3-8cycloalkyl of Ra is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, and C1-6haloalkoxyl;
- each R2, R3, R4, R5, and R6 is independently selected from H, halo, cyano, hydroxyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-8haloalkoxyl, —NRb1Rb2, —Rb3S(O)mRb4, —S(O)mRb4, —NRb1S(O)vRb4, —COORb1, —CONRb1Rb2, —NRb1COORb2, —NRb1CORb4, —Rb3NRb1Rb2, —S(O)vNRb1Rb2, C3-12cycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, and 3-12 membered heterocyclyl;
- each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-8haloalkyl, and C1-8haloalkoxyl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to two Rc; wherein each Rc is independently selected from azido, oxo, cyano, halo, hydroxyl, —NRa1Ra2, C1-4alkoxyl, C3-5cycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C3-5cycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rc is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-6haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
- each C6-10aryl and 5-6 membered heteroaryl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to five Rb; and
- each C3-12cycloalkyl and 3-12 membered heterocyclyl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to six groups independently selected from ═CRb1Rb2, and Rb;
- wherein each Rb is independently selected from azido, cyano, halo, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-8haloalkyl, C1-6alkoxyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocycly; wherein each C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rb is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl;
- each Rb1 and Rb2 is independently selected from H, C1-8alkyl, C1-8haloalkyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl;
- each C1-8alkyl and C1-6haloalkyl of Rb1 and Rb2 is optionally substituted with one to two Rb5; and
- each C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl of Rb1 and Rb2 is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-8alkyl, C1-8haloalkyl, C1-6alkoxyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl;
- Rba is C1-4alkylene;
- Rb4 is selected from C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C1-4alkyl, C1-4haloalkyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and the 4-6 membered heterocyclyl of Rb4 is optionally substituted with one to three Rb6;
- each Rb5 is independently selected from cyano, hydroxyl, C1-4alkoxyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rb5 is optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and phenyl; and
- each Rb6 is independently selected from halo, cyano, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, C3-6cycloalkyl, phenyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl; wherein each C3-6cycloalkyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl of Rb6 is independently optionally substituted with one to three groups independently selected from halo, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl;
- or R2 and R3, R3 and R4, or R5 and R6 together with the atoms to which they are attached may form a C6-10 aryl, 5-6 membered heteroaryl, C3-6cycloalkyl, or 5-6 membered heterocyclyl; wherein each C6-10 aryl, 5-6 membered heteroaryl, C3-6cycloalkyl, or 5-6 membered heterocyclyl is optionally substituted with one to three groups independently selected from halo, cyano, —NRa1Ra2, C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, C3-8cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl, 5-6 membered heteroaryl, C1-4alkylene-C3-8cycloalkyl, C1-4alkylene-C6-10 aryl, and C1-4alkylene-(5-6 membered heteroaryl);
- R7 is selected from H, C1-4alkyl, and C1-4haloalkyl;
- R8 is selected from H, C1-4alkyl, and C1-4haloalkyl;
- R9 is selected from H, C1-6alkyl, —C1-4alkylene-NRa1Ra2, —C1-4alkylene-C(O)NRa1Ra2, —C1-4 alkylene-O—C(O)—C1-4alkyl, —C1-4alkylene-O—C(O)—O—C1-4alkyl, —C1-4alkylene-O—C(O)—C1-4alkylene-NRa1Ra2, —C1-4alkylene-O—C1-4alkyl, C3-8cycloalkyl, —C1-4alkylene-C3-8cycloalkyl, 4-6 membered heterocyclyl, and —C1-4alkylene-(4-6 membered heterocyclyl);
- wherein each C3-8cycloalkyl, —C1-4alkylene-C3-8cycloalkyl, and 4-6 membered heterocyclyl of R9 is optionally substituted with one to three groups independently selected from halo, C1-4alkyl, C1-4alkoxyl, and C1-4haloalkyl; or
- R9 together with the N that attaches to R8 forms a 5 membered heterocyclyl; wherein the 5 membered heterocyclyl is optionally substituted with one to two groups independently selected from halo, C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, and C6-10aryl; wherein C6-10aryl is optionally substituted with one to three groups independently selected from halo, C1-6alkyl, C1-6alkoxyl, and C1-6haloalkyl;
- each R10 is independently selected from H, halo, cyano, hydroxyl, —C(O)Rb1—NRa1Ra2, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-10cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, and 5-6 membered heteroaryl; wherein each C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-10cycloalkyl, 3-8-membered heterocyclyl, C6-10 aryl, and 5-6 membered heteroaryl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
- or two R10 either attached to the same or adjacent atoms form C3-12cycloalkyl or 3-10 membered heterocyclyl; wherein each C3-12cycloalkyl and 3-10 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl;
- each R11 is independently selected from H, C1-4alkyl, and C1-4haloalkyl; wherein each C1-4alkyl, —C(O)Rb1, and C1-4haloalkyl of R11 is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
- or R10 and R11, or two R11 together with the atoms to which they are attached to form 3-12 membered heterocyclyl; wherein 3-12 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl;
- each Ra1 and Ra2 is independently selected from H, C1-6alkyl, and C1-6haloalkyl;
- wherein each C3-8cycloalkyl, —C1-4alkylene-C3-8cycloalkyl, and 4-6 membered heterocyclyl of R9 is optionally substituted with one to three groups independently selected from halo, C1-4alkyl, C1-4alkoxyl, and C1-4haloalkyl; or
- p is selected from 1, 2, and 3;
- m is selected from 0, 1, and 2; and
- v is selected from 1 and 2.
- In some embodiments, provided is a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein:
-
- X1 and X2 are each independently selected from C, and N; wherein the bond between X1 and X2 is a single or a double bond;
- X3 and X4 are each independently selected from CR10, and N;
- X5 and X7 are each independently selected from CR10R10, CR10, S, S(O), S(O)2, N, NR11, C(O), and O;
- each X6 is independently selected from CR10R10, CR10, S, S(O), S(O)2, N, NR11, C(O), and O; wherein the bond between X5 and X6, X6 and X6, or X6 and X7 is a single or a double, provided that at least one is a double bond;
- R1 is selected from A1, A2, and A3;
- A1 is C6-10aryl optionally substituted with one to six Ra;
- A2 is 5-10 membered heteroaryl containing one to five heteroatoms independently selected from S, N, and O, and optionally one or two C(O); wherein A2 is optionally substituted with one to six Ra; and
- A3 is 5-10 membered cycloalkyl or 5-14 membered heterocyclyl; wherein A3 is optionally substituted with one to four Ra;
- wherein each Ra is independently selected from halo, cyano, hydroxyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, C3-8cycloalkyl, and —O—C3-8cycloalkyl;
- each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, C3-8cycloalkyl, and —O—C3-8cycloalkyl of Ra is optionally substituted with one to three Ra3; wherein each Ra3 is independently selected from hydroxyl, C1-6alkoxyl, C1-6haloalkyl, and C1-6haloalkoxyl;
- wherein each Ra is independently selected from halo, cyano, hydroxyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, C3-8cycloalkyl, and —O—C3-8cycloalkyl;
- each R2 and R6 is independently selected from H, halo, C1-6alkyl, and C1-6haloalkyl;
- each R3 and R5 is H;
- R4 is selected from H, halo, C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, —NRb1Rb2, —Rb3S(O)mRb4, —S(O)mRb4, —NRb1S(O)vRb4, —COORb1, —CONRb1Rb2, —NRb1COORb2, —NRb1CORb2, —Rb3NRb1Rb2, —S(O)vNRb1Rb2, C6-10aryl, C3-10cycloalkyl, 5-6 membered heteroaryl, and 4-10 membered heterocyclyl;
- each C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, and C1-6haloalkoxyl of R4 is independently optionally substituted with one to two Rc; wherein each Rc is independently selected from cyano, azido, oxo, hydroxyl, —NRa1Ra2, C1-4alkoxyl, C3-6cycloalkyl, and 4-6 membered heterocyclyl; and wherein each C3-6cycloalkyl, and 4-6 membered heterocyclyl of Rc is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
- each C6-10aryl, C3-10cycloalkyl, 5-6 membered heteroaryl, and 4-10 membered heterocyclyl of R4 is independently optionally substituted with one to three Rb; wherein each Rb is independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl; wherein each C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl of Rb is optionally substituted with one to two groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl;
- each Rb1 and Rb2 is independently selected from H, C1-8alkyl, C1-5haloalkyl, C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl;
- each C1-6alkyl and C1-6haloalkyl of Rb1 and Rb2 is independently optionally substituted with one to two Rb5; wherein each Rb5 is independently selected from hydroxyl, C1-4alkoxyl, C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl; wherein each C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl of Rb5 is optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and phenyl; and
- each C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl of Rb1 and Rb2 is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl;
- Rba is C1-4alkylene;
- Rb4 is selected from C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl; wherein each C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl of Rb4 is optionally substituted with one to three Rb6; wherein each Rb6 is independently 4-6 membered heterocyclyl, and 5-6 membered heteroaryl; and wherein each C3-6cycloalkyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl of Rb6 is independently optionally substituted with one to three groups independently selected from halo, cyano, —NRa1Ra2, C1-4alkyl, C1-5haloalkyl, and C1-4alkoxyl;
- each Ra1 and Ra2 is independently selected from H, C1-6alkyl, and C1-6haloalkyl;
- R7 is H;
- R8 is H;
- R9 is H;
- each R19 is independently selected from H, halo, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl;
- or two R19 either attached to the same or adjacent atoms form a C3-10cycloalkyl; and
- each R11 is independently selected from H, —C(O)Rb1, C1-4alkyl, and C1-4haloalkyl, wherein each C1-4alkyl and C1-4haloalkyl, is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
- p is selected from 1 and 2;
- m is selected from 0, 1, and 2;
- v is selected from 1 and 2.
- In some embodiments, provided is a compound of formula (I), or a pharmaceutically acceptable salt, R4 is selected from H, —NRb1Rb2, —NRb'S(O)vRb4, and 4-10 membered heterocyclyl containing one to two heteroatoms independently selected from N and O;
-
- the 4-10 membered heterocyclyl of R4 is independently optionally substituted with one to three Rb; each Rb is independently selected from halo, C1-6alkyl, and C1-6haloalkyl;
- each of Rb1 and Rb2 is independently selected from H, C1-8alkyl, and C1-8haloalkyl;
- each of the C1-8alkyl and C1-6haloalkyl of Rb1 and Rb2 is optionally substituted with one to two Rb5; each Rb5 is independently selected from C1-4 alkoxyl, C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl; and each the C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl of Rb5 is optionally substituted with one to three groups independently selected from halo, C1-4alkyl, and C1-4haloalkyl;
- Rb4 is selected from C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, and phenyl; each the C3-6cycloalkyl and phenyl of Rb4 is optionally substituted with one to three Rb6; each Rb6 is independently selected from halo, C1-4alkyl, C1-4haloalkyl, and 5-6 membered heteroaryl; and the 5-6 membered heteroaryl of Rb6 is independently optionally substituted with one to three groups independently selected from halo, C1-4alkyl, and C1-4haloalkyl.
- In some embodiments, the ring formed by Y and Z does not form
- wherein * indicates a point of attachment to R1.
- In some embodiments, ring Y is aromatic.
- In some embodiments, the ring formed by Y and Z is selected from:
- wherein * indicates a point of attachment to R1; wherein each group is optionally substituted with 1 to 4 R10; and wherein each R10 is independently selected from halo, cyano, hydroxyl, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-10cycloalkyl, 3-8 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl, and —NRa1Ra2; wherein each C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-10cycloalkyl, 3-8 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl.
- Also provided are compounds of formula (Ia):
- or a pharmaceutically acceptable salt thereof; wherein u is selected from 0, 1, 2, 3, 4, and 5. Y, Z, X1, X2, X3, X4, X5, X6, X7, p, Ra, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Ib):
- or a pharmaceutically acceptable salt; thereof; wherein each R22 is independently selected from H and Ra. Y, Z, X1, X2, X3, X4, X5, X6, X7, p, Ra, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Ic):
- or a pharmaceutically acceptable salt thereof; wherein each R22 is independently selected from H and Ra. Y, Z, X1, X2, X3, X4, X5, X6, X7, p, Ra, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Id):
- or a pharmaceutically acceptable salt thereof; wherein each R22 is independently selected from H and Ra. Y, Z, X1, X2, X3, X4, X5, X6, X7, p, Ra, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Ie):
- or a pharmaceutically acceptable salt thereof; wherein each R22 is independently selected from H and Ra; and wherein r is selected from 0, 1, 2, 3, 4 and 5. Y, Z, X1, X2, X3, X4, X5, X6, X7, p, Ra, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (If):
- or a pharmaceutically acceptable salt thereof; wherein each Y1, Y2, Y3, Y4, and Y5 is independently selected from CR22 and N, provided that at least one of Y1, Y2, Y3, Y4, and Y5 is CR22; and wherein R22 is selected from H and Ra. Y, Z, X1, X2, X3, X4, X5, X6, X7, p, Ra, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Ig):
- or a pharmaceutically acceptable salt thereof; each V1, V2, and V3 is independently selected from CR22 and N, provided that at least one of V1, V2, and V3 is CR22; and wherein R22 is selected from H and Ra. Y, Z, X1, X2, X3, X4, X5, X6, X7, p, Ra, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Ih):
- or a pharmaceutically acceptable salt thereof. Rb1, Rb2, Y, Z, X1, X2, X3, X4, X5, X6, X7, p, R1, R2, R3, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Ii):
- or a pharmaceutically acceptable salt thereof, wherein W1 is selected from CR31 and N; W2 is selected from CR31R31, NR32, O, and S(O)2; each R31 is independently selected from H and Rb; and R32 is selected from H, C1-4alkyl, and C1-4haloalkyl; q is selected from 0, 1, 2, and 3; and t is 0 or 1. Rb, Y, Z, X1, X2, X3, X4, X5, X6, X7, p, R1, R2, R3, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Ik):
- or a pharmaceutically acceptable salt thereof. Rb4, Y, Z, X1, X2, X3, X4, X5, X6, X7, p, R1, R2, R3, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (Im):
- or a pharmaceutically acceptable salt thereof. Y, Z, X1, X2, X3, X4, X5, X6, X7, p, R1, R2, R3, R5, R6, R7, R8, and R9 are as defined above.
- Also provided are compounds of formula (II):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (III):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (IV):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are as defined above.
- Also provided are compounds of formula (V):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (VI):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (VII):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (VIII):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are as defined above.
- Also provided are compounds of formula (IX):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (X):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (XI):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (XII):
- or a pharmaceutically acceptable salt thereof; wherein X3, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (XIII):
- or a pharmaceutically acceptable salt thereof; wherein X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (XIV):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are as defined above.
- Also provided are compounds of formula (XV):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined above.
- Also provided are compounds of formula (XVI):
- or a pharmaceutically acceptable salt thereof; wherein X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
- In some embodiments, each X3 and X4 is independently CR10. In some embodiments, X3 is CR10 and X4 is N. In some embodiments, X3 is N and X4 is CR10. In some embodiments, each X3 and X4 is independently CR10 and each R10 is independently selected from H, halo, hydroxyl, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl, wherein each the C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl. In some embodiments, each X3 and X4 is independently CR10 and each R10 is independently selected from H, F, Cl, cyano, hydroxyl, —CH3, —CH2F, —CHF2, —CF3, —OCH3, and —OCF3.
- In some embodiments, each X3 and X4 is CH.
- In some embodiments, L is a bond, and R1 is selected from -L-A1, -L-A2, and -L-A3.
- In some embodiments, A1, A2, or A3 is selected from phenyl, naphthyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, isoxazolyl, triazolyl, pyrazolyl, benzothiazolyl, pyridinonyl, quinolinonyl, isoquinolinonyl, quinazolindionyl, pyrazinonyl, pyrimidinonyl, pyrimidinedionyl, pyridazinonyl, quinazolinonyl, benzofuranyl, tetrahydrocyclopenta[b]pyridinonyl, naphthyridinonyl, chromanyl, isochromanyl, and chromenonyl, and wherein each of which is independently optionally substituted with one to four Ra.
- In some embodiments, R1 is
- wherein each V1, V2, and V3 is independently selected from CR22 and N, provided that at least one of V1, V2, and V3 is CR22; and wherein R22 is selected from H and Ra.
- In some embodiments, R1 is
- wherein R22 is selected from H, and Ra.
- In some embodiments, R1 is
- wherein R22 is selected from H, and Ra.
- In some embodiments, R1 is
- wherein each Y1, Y2, Y3, Y4, and Y5 is independently selected from CR22 and N, provided that at least one of Y1, Y2, Y3, Y4, and Y5 is CR22; and wherein R22 is selected from H and Ra.
- In some embodiments, R1 is
- wherein u is selected from 0, 1, 2, 3, 4, and 5.
- In some embodiments, R1 is
- wherein R22 is selected from H and Ra.
- In some embodiments, R1 is
- wherein R22 is selected from H and Ra.
- In some embodiments, R1 is
- wherein R22 is selected from H and Ra.
- In some embodiments, R1 is
- wherein r is selected from 0, 1, 2, 3, 4 and 5, and R22 is selected from H and Ra.
- In some embodiments, R1 is selected from
- wherein r is selected from 0, 1, 2, 3, 4 and 5, and R22 is selected from H, and Ra.
- In some embodiments, R1 is selected from
- wherein each R1 is optionally substituted with one to four Ra.
- In some embodiments, R1 is selected from
- wherein each R1 is optionally substituted with one to four Ra.
- In some embodiments, R1 is substituted with one to four Ra, and each Ra is independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-6cycloalkyl, phenyl, and —O—C3-6cycloalkyl.
- In some embodiments, R1 is substituted with one to three Ra, and each Ra is independently selected from F, Cl, Br, cyano, hydroxyl, —NH2, —N(CH3)2, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2CN, —CH2CH2CN, —CH2OH, —CH2CH2OH, —OCH3, —OCD3, —OCH2CH3, —OCH(CH3)2, —OC(CH3)3, —CH2OCH3, —CH2OCH2CH3, —CH3OCH(CH3)2, —CH2F, —CHF2, —CF3, —CH2CH2F, —CH2CHF2, —CH2CF3, —OCH2F, —OCHF2, —OCF3, —OCH2CH2F, —OCH2CHF2, —OCH2CF3, —SO2CH3, —SO2CH2CH3,
- cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, —O-cyclopropyl, —O—CH2-cyclopropyl, —O-cyclobutyl, —O—CH2cyclobutyl, —O-cyclopentyl, —O—CH2cyclopentyl, —O-cyclohexyl, —O—CH2cyclohexyl, and —O-phenyl.
- In some embodiments, R1 is selected from
- In some embodiments, R1 is selected from
- In some embodiments, R1 is
- In some embodiments, each Ra is independently selected from halo, C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, C3-8cycloalkyl, and —O—C3-8cycloalkyl. In some embodiments, each Ra is independently selected from F, Cl, Br, —CH3, —CH2CH3, —CH2F, —CHF2, —CF3, —OCH3, —OCD3, —OCH2CH3, —CH2OCH3, —CH2OCH2CH3, cyclopropyl, and —O-cyclopropyl.
- In some embodiments, each R2 and R6 is independently selected from H, halo, cyano, hydroxyl, —NRb1Rb2, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl. In some embodiments, each R2 and R6 is independently selected from F, Cl, cyano, hydroxyl, —NH2, —N(CH3)2, —CH3, —CD3, —CH2F, —CHF2, —CF3, —OCH3, and —OCF3.
- In some embodiments, each R2 and R6 is independently F or Cl. In some embodiments, each R2 and R6 is F.
- In some embodiments, each R3 and R5 is independently selected from H, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl. In some embodiments, each R3 and R5 is H.
- In some embodiments, R4 is selected from H, —NRb1Rb2, —NRb1S(O)vRb4, and 4-6 membered heterocyclyl containing one to two heteroatoms or groups independently selected from N, O, S, and S(O)2.
- In some embodiments, R4 is —NRb1Rb2. In some embodiments, R4 is —NHRb2, wherein Rb2 is selected from C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, and 4-6 membered heterocyclyl.
- In some embodiments, each Rb1 and Rb2 is independently selected from H, C1-8alkyl, C1-6haloalkyl, C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl containing one to two atoms selected from N and O. In some embodiments, Rb1 is selected from H, and C1-4alkyl. In some embodiments, Rb1 is selected from H, and CH3. In some embodiments, Rb2 is selected from C1-6alkyl, C1-6haloalkyl, and 4-6 membered heterocyclyl. In some embodiments, Rb1 is H, and Rb2 is selected from C1-6alkyl, C1-6haloalkyl, and 5-6 membered heterocyclyl. In some embodiments, Rb1 is H, and Rb2 is C1-6haloalkyl. In some embodiments, Rb2 is —C1-5alkylene-CF3. In some embodiments, Rb2 is selected from -methylene-CF3, -ethylene-CF3, -propylene-CF3, -butylene-CF3, and -pentylene-CF3. In some embodiments, Rb2 is —C1-5alkylene-CF3 substituted with one or two Rb5. In some embodiments, each Rb5 is independently selected from hydroxyl, C1-4alkoxyl, C3-6cycloalkyl, phenyl, and 4-6 membered heterocyclyl. In some embodiments, each Rb5 is independently selected from C3-6cycloalkyl, 4-6 membered heterocyclyl, and phenyl. Each C3-6cycloalkyl, 4-6 membered heterocyclyl, and phenyl of Rb5 is independently optionally substituted with one or three groups independently selected from halo, hydroxyl, cyano, —NRb1, Rb2, C1-4alkyl, C1-4alkoxyl, and C1-4haloalkyl. In some embodiments, Rb5 is selected from phenyl, cyclobutyl, cylcopentyl, tetrahydropyanyl, and tetrahydrofuranyl; and each Rb5 is optionally substituted with one group selected from F, Cl, CN, —CH3, —CH2F, —CHF2, and —CF3. In some embodiments, Rb5 is phenyl. In some embodiments, Rb5 is phenyl substituted with one or two groups independently selected from F, Cl, CN, —CH3, —CH2F, —CHF2, and —CF3. In some embodiments, Rb5 is phenyl substituted with one or two groups independently selected from F, Cl, CN, and —CF3. In some embodiments, Rb5 is unsubstituted phenyl.
- In some embodiments, R4 is H.
- In some embodiments, Ra is selected from
- In some embodiments, R4 is selected from
- some embodiments, R4 is selected from
- In some embodiments, R4 is 5-6 membered heterocyclyl optionally substituted with one to three Rb; and each Rb is independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4alkoxyl, and C1-4haloalkyl.
- In some embodiments, R4 is 4-6 membered heterocyclyl containing one to two heteroatoms or groups independently selected from N, O, S, and S(O)2. In some embodiments, R4 is a 4-10 membered saturated ring
- containing zero to two heteroatoms or groups independently selected from N, O, S, and S(O)2.
- In some embodiments, R4 is selected from morpholinyl, piperidinyl, tetrahydropyranyl, and pyrrolidinyl. In some embodiments, R4 is 5-6 membered heterocyclyl optionally substituted with one to two groups independently selected from F, Cl, CN, —OH, —CH3, —CH(CH3)2, and —CF3.
- In some embodiments, R4 is selected from
- and each R4 is optionally substituted with one to two Rb independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4alkoxyl, and C1-4haloalkyl.
- In some embodiments, R4 is selected from
- wherein each R4 is optionally substituted with one to two groups independently selected from F, Cl, hydroxyl, cyano, —CH3, —CH(CH3)2, and —CF3.
In some embodiments, R4 is selected from - In some embodiments, R4 is selected from
- In some embodiments, R4 is
- In some embodiments, R4 is —NRb1S(O)vRb4. In some embodiments R4 is —NHS(O)2Rb4, and Rb4 is selected from C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, and phenyl. In some embodiments, Rb4 is selected from —CH3, —CH2F, —CHF2, —CF3, and phenyl. The phenyl is optionally substituted with pyridinyl that is optionally substituted with one or two groups independently selected from halo, and C1-4alkyl. In some embodiments, the pyridinyl is optionally substituted with one or two groups independently selected from F, and —CH3. In some embodiments, R4 is —NHS(O)2Rb4, Rb4 is selected from —CH3, —CH2F, —CHF2, —CF3, and phenyl; and wherein the phenyl is optionally substituted with pyridinyl or triazolyl that is optionally substituted with one or two groups independently selected from halo, and C1-4alkyl.
- In some embodiments, R4 is selected from
- In some embodiments, R4 is selected from
- In some embodiments, R4 is selected from
- In some embodiments, each R7 and R8 is H. In some embodiments, each R7, R8, R10 and R11 is H.
- In some embodiments, R9 is selected from H, methyl, ethyl, propyl, butyl, —CH2C(O)N(CH3)2, CH2)2N(CH2CH3)2, —CH2—O—C(O)CH3, —(CH2)2—O—C(O)CH3, —CH2—O—C(O)C(CH)3, —(CH2)2—O—C(O)C(CH)3, —CH2—O—C(O)—O—CH3, —CH(CH3)—O—C(O)—O—CH3, —CH2—O—C(O)—O—CH2CH3, —CH2—O—C(O)—O—CH(CH3)2, —CH2—O—C(O)—O—C(CH3)3, —(CH2)2C(O)CH3,
- In some embodiments, R9 is selected from H, —CH2—O—C(O)C(CH)3, —CH(CH3)—O—C(O)—O—CH3,
- In some embodiments, R9 is H.
- In some embodiments, R9 is methyl. In some embodiments, R9 is ethyl. In some embodiments, R9 is propyl.
- In some embodiments, R9 is H. In some embodiments, R9 is selected from C1-6alkyl, C3-8cycloalkyl, and 4-6 membered heterocyclyl, wherein the C1-6alkyl of R9 is optionally substituted with one to three groups independently selected from halo, —NRa1Ra2, —C(O)NRa1Ra2, —O—C(O)—C1-4alkyl, —O—C(O)—O—C1-4alkyl, —O—C(O)—C1-4alkylene-NRa1Ra2, —O—C1-4alkyl, O3-8cycloalkyl, 4-6 membered heterocyclyl, and 4-6 membered heterocyclyl containing at least one heteroatom selected from N and O, and wherein the C3-8cycloalkyl, and 4-6 membered heterocyclyl of R9 is optionally substituted with one to three groups independently selected from halo, C1-4alkyl, and C1-4haloalkyl. In some embodiments, when administered to a patient, an R9 ester generates a compound wherein R9 is H, as a result of chemical reaction(s), enzyme catalyzed chemical reaction(s), and/or metabolic chemical reaction(s). In some embodiments, a compound in which R9 is not H may be a prodrug.
- In some embodiments, R9 together with the N that attaches to R8 forms a 5 membered heterocyclyl. In some embodiments, the 5 membered heterocyclyl is substituted with one to two groups independently selected from C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, and C6-10aryl. In some embodiments, the 5 membered heterocyclyl is substituted with one to two groups independently selected from CH3, CH2CH3, —OCH3, —OCH2CH3, and phenyl. In some embodiments, the 5 membered heterocyclyl is substituted with phenyl, and phenyl is optionally substituted with one to three groups independently selected from halo, C1-6alkyl, C1-6alkoxyl, and C1-6haloalkyl.
- In some embodiments, each R10 is independently selected from H, halo, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl. In some embodiments, each R10 is independently selected from H, F, Cl, —CH3, —CH2F, —CHF2, —CF3, —OCH3, and —OCF3. In some embodiments, each R10 is H.
- In some embodiments, each R11 is independently selected from H, —CH3, —CH2F, —CHF2, and —CF3. In some embodiments, each R11 is independently H or —CH3.
- In some embodiments, q is 1. In some embodiments, q is 2.
- In some embodiments, r is selected from 1, 2, and 3. In some embodiments, r is 3.
- In some embodiments, t is 0. In some embodiments, t is 1.
- In some embodiments, u is selected from 1, 2, and 3. In some embodiments, u is 3.
- In some embodiments, v is 2.
- In some embodiments, each V1, V2 and V3 is independently CR22 or N, wherein R22 is independently selected from H, halo, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl. In some embodiments, each V1, V2 and V3 is independently CR22 or N, wherein each R22 is independently selected from H, F, Cl, —CH3, —CH2F, —CHF2, —CF3, —OCH3, and —OCF3. In some embodiments, V1 is N, and each V2 and V3 is independently CR22. In some embodiments, V1 is N, and each V2 and V3 is independently CR22, wherein each R22 is independently selected from H, halo, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl. In some embodiments, V1 is N, and each V2 and V3 is independently CR22, wherein each R22 is independently selected from H, F, Cl, —CH3, —CH2F, —CHF2, —CF3, —OCH3, and —OCF3.
- In some embodiments, W1 is N, and W2 is O. In some embodiments, W1 is N, and W2 is CH2. In some embodiments, W1 is N, and W2 is S(O)2. In some embodiments, each Rb is independently selected from F, OH, —CH3, —CH(CH3)2, —CH2F, —CHF2, and —CF3.
- In some embodiments, at least one of Y1, Y2, Y3, Y4, and Y5 is N. In some embodiments, Y1 is N; and each Y2, Y3, Y4, and Y5 is independently CR22. In some embodiments, Y2 is N; and each Y1, Y3, Y4, and Y5 is independently CR22. In some embodiments, Y3 is N; and each Y1, Y2, Y4, and Y5 is independently CR22. In some embodiments, Y4 is N; and each Y1, Y2, Y3, and Y5 is independently CR22. In some embodiments, Y1 and Y5 are N; and each Y1, Y2, and Y3 is independently CR22.
- In some embodiments, the compound of the present disclosure is selected from examples 1-176.
- In some embodiments, the compound of the present disclosure is selected from examples 177-180.
- In some embodiments, provided is a compound of the present disclosure, or a pharmaceutically acceptable salt thereof.
- One of skill in the art is aware that each and every embodiment of a group (e.g., R1) disclosed herein may be combined with any other embodiment of each of the remaining groups (e.g., R4, R9, X3, etc.) to generate a complete compound of formula (I), or any formula described herein or a pharmaceutically acceptable salt thereof, each of which is deemed within the ambit of the present disclosure.
-
List of Abbreviations and Acronyms Abbreviation Meaning % Percent ° C. Degree Celsius Ac Acetyl AcOH Acetic acid ACN/CH3CN/ Acetonitrile MeCN ADME Absorption, distribution, metabolism and excretion AlBN 2,2′-Azobis(2-methylpropionitrile) Aq. Aqueous ASK Apoptosis signal-regulating kinase Bicarb Bicarbonate Bn Benzyl BOC/Boc Tert-butyloxycarbonyl Bpin Pinacolborane br Broad CAS Chemical Abstract Service cataCXium A Di(1-adamantyl)-n-butylphosphine CNS Central nervous system COPD Chronic obstructive pulmonary disease CREST Calcinosis, Raynaud′s syndrome, esophageal dysmotility, sclerodactyly and telangiectasia CVP Cyclophosphamide, vincristine, prednisone d Doublet D/d Deuterium DAST Diethylaminosulfur trifluoride DABCO ® 1,4-Diazabicyclo[2.2.2]octane DCC N,N′-Dicyclohexylcarbodiimide DCE Dichloroethane DCM Dichloromethane/methylene chloride dd Doublet of doublets DIEA N,N-Diisopropylethylamine DIPEA N,N-Diisopropylethylamine DMA N,N-Dimethylacetamide DMAP 4-Dimethylaminopyridine DME Dimethoxy ethane DMF Dimethylformamide DMPK Drug metabolism and pharmacokinetics DMSO Dimethylsulfoxide dppf 1,1′-Bis(diphenylphosphino)ferrocene dppp 1,3-Bis(diphenylphosphino)propane EC50 The half maximal effective concentration equiv/eq Equivalents EA Ethyl acetate Et Ethyl Et2O Diethyl ether EtOAc/ Ethyl acetate AcOEt EtOH Ethanol F Fahrenheit FBS Fetal bovine serum g Grams Gp Glycoprotein h/hr Hours HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium 3-oxid hexafluorophosphate) hex Hexanes HPLC High pressure liquid chromatography Hz Hertz IL Interleukin IUPAC International Union of Pure and Applied Chemistry J Coupling constant (MHz) JAK Janus kinase Kg/kg Kilogram KOAc Potassium acetate L Liter LCMS/ Liquid chromatography-mass spectrometry LC-MS LHMDS Lithium hexamethyl disilazide LiMg-TMP 2,2,6,6-Tetramethylpiperidinylmagnesium chloride lithium chloride complex M Molar m multiplet M+ Mass peak M + H Mass peak plus hydrogen m-CPBA Meta-Chloroperbenzoic acid Me Methyl Me2N Dimethylamine MeI Methyl Iodide MeOH Methanol MeOTs Methyl Tosylate mg Milligram MHz Megahertz min/m Minute ml/mL Milliliter mM Millimolar mmol Millimole mol Mole MS Mass spectroscopy MS Multiple sclerosis MsCl Methanesulfonyl chloride MTBE Methyl tert-Butyl ether M/Z Mass/Charge N Normal NADH Nicotinamide adenine dinucleotide in reduced form NaOH Sodium hydroxide NBS N-Bromosuccinimide ng Nanograms NIS N-Iodosuccinimide nM Nanomolar NMR Nuclear magnetic resonance ON Overnight PEG Polyethylene glycol PET Positron emission tomography Ph Phenyl PhMe Toluene PhNO2 Nitrobenzene PhNTf2 N-Phenyl triflamide pH Expressing the acidity or alkalinity of a solution prep Preparative RA Rheumatoid arthritis Rf Retention factor RPM Revolutions per minute RT/r Room temperature RuPhos 2-Dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl s Second s Singlet sat. Saturated SFC Super-critical fluid chromatography SLE Systemic lupus erythematosus SPECT Single-photon emission computed tomography SPhos Pd G3 (2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl) [2- (2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate SYK Spleen tyrosine kinase t Triplet TBACl Tetrabutylammonium chloride TBS/TBDMS Tert-butyldimethylsilyl tBuOH Tert-Butanol tBuBrettPhos [(2-Di-tert-butylphosphino-3,6-dimethoxy-2′,4′,6′- Pd G3 triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′- biphenyl)]palladium(II) methanesulfonate TCA Trichloroacetic acid TEA/NEt3 Triethylamine temp. Temperature TES Triethylsilane TFA Trifluoroacetic acid TFAA Trifluoroacetic acid anhydride THF Tetrahydrofuran TLC Thin-layer chromatography TMP Tetramethyl piperidine TMS Trimethylsilyl Tol Toluene TPL2 Tumor Progression Locus 2 Kinase Trityl Triphenylmethyl Vac Vacuum w/v Weight/volume w/w Weight/weight XPhos Pd G3 (2-Dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′- biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate δ Chemical shift (ppm) μg Microgram μL/μl Microliter μM Micromolar μm Micrometer μmol Micromole - The methods described herein may be applied to cell populations in vivo or ex vivo. “In vivo” means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual. “Ex vivo” means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the compounds may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the compounds may be used ex vivo to determine the optimal schedule and/or dosing of administration of an α4β7 integrin inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the compounds may be suited are described below or will become apparent to those skilled in the art. The selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.
- In some embodiments, compounds described herein, for example, compounds of formula (I), formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie), formula (If), formula (Ig), formula (Ih), formula (Ii), formula (Ik), formula (Im), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (XI), formula (XII), formula (XIII), formula (XIV), formula (XV), or formula (XVI), or a pharmaceutically acceptable salt thereof, may be used to treat subjects who have or are suspected of having disease states, disorders, and conditions (also collectively referred to as “indications”) responsive or believed to be responsive to the inhibition of α4β7 integrin activity. In some embodiments, the compounds described herein may be used to inhibit the activity of α4β7 integrin. In some embodiments, the compounds described herein may be used to inhibit excessive or destructive immune reactions or growth or a proliferation of a cell, such as a cancer cell, or inhibit immunosuppression.
- In some embodiments, the present disclosure provides a compound described herein useful as an inhibitor of α4β7 integrin. In some embodiments, the present disclosure provides a method of treating an inflammatory disease or condition mediated, at least in part, by α4β7 integrin, comprising administering a compound described herein.
- In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier.
- In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound described herein and at least one additional therapeutic agent and at least one pharmaceutically acceptable excipient.
- The present disclosure provides a compound described herein for use in therapy.
- In another embodiment, the present disclosure provides a compound described herein for use in the manufacture of a medicament for treating a disease or condition provided herein.
- In some embodiments, provided is a compound described herein useful for the treatment of a disease or condition in a patient that is amenable to treatment by inhibiting α4β7 integrin. Diseases or conditions that may be treated with the compounds described herein include a solid tumor, diabetes, an inflammatory disease, graft versus host disease, primary sclerosing cholangitis, HIV, an autoimmune disease, inflammatory bowel disease (IBD), alcoholic hepatitis, systemic lupus erythematosus (SLE), and lupus nephritis.
- In some embodiments, provided is a compound described herein useful for the treatment of an inflammatory disease or condition in a patient that is mediated, at least in part, by α4β7 integrin.
- “Administering” or “administration” refers to the delivery of one or more therapeutic agents to a patient. In some embodiments, the administration is a monotherapy wherein a compound described herein is the only active ingredient administered to the patient in need of therapy. In another embodiment, the administration is co-administration such that two or more therapeutic agents are delivered together during the course of the treatment. In some embodiments, two or more therapeutic agents may be co-formulated into a single dosage form or “combined dosage unit”, or formulated separately and subsequently combined into a combined dosage unit, as is typically for intravenous administration or oral administration as a mono or bilayer tablet or capsule.
- In some embodiments, the compound described herein is administered to a human patient in need thereof in an effective amount, such as, from about 0.1 mg to about 1000 mg per dose of said compound. In some embodiments, the effective amount is from about 0.1 mg to about 200 mg per dose. In some embodiments, the effective amount is from about 1 mg to about 100 mg per dose. In other embodiments, the effective amount is about 1 mg, about 3 mg, about 5 mg, about 10 mg, about 15 mg, about 18 mg, about 20 mg, about 30 mg, about 40 mg, about 60 mg, about 80 mg, or about 100 mg per dose.
- In some embodiments, the compound described herein and at least one additional therapeutic agent is administered to a human patient in need thereof in an effective amount of each agent, independently from about 0.1 mg to about 1000 mg per dose of a compound or formulation per dose per compound. In some embodiments, the effective amount of the combination treatment of a compound described herein and an additional compound is independently from about 0.1 mg to about 200 mg per compound per dose. In some embodiments, the effective amount of the combination treatment of a compound described herein and an additional compound is independently from about 1 mg to about 100 mg per compound per dose. In other embodiments, the effective amount of the combination treatment of a compound described herein and an additional compound is for each component, about 1 mg, about 3 mg, about 5 mg, about 10 mg, about 15 mg, about 18 mg, about 20 mg, about 30 mg, about 40 mg, about 60 mg, about 80 mg, about 100 mg, about 200 mg, or about 500 mg each per dose.
- In some embodiments, the dose of a compound described herein and/or a combination of the dose of the compound described herein and/or the dose of an additional therapeutic agent is administered once per day, twice per day, or thrice per day. In yet another embodiment, the dose of a compound described herein and/or the dose of an additional therapeutic agent is administered as a loading dose of from about 0.1 mg to about 1000 mg per compound on the first day and each day or on alternate days or weekly for up to a month followed by a regular regimen of a compound described herein and/or one or more additional therapeutic agents or therapies. The maintenance dose may be about 0.1 mg to about 1000 mg once per day, twice per day, thrice per day, or weekly, for each component of a multi component drug regimen. A qualified care giver or treating physician is aware of what dose regimen is best for a particular patient or particular presenting conditions and will make appropriate treating regimen decisions for that patient. Thus, in another embodiment, the qualified caregiver is able to tailor a dose regimen of the compound described herein and/or an additional therapeutic agent(s) as disclosed herein to fit with the particular needs of the patient. Thus, it will be understood that the amount of the dose of a compound described herein and the amount of the dose of an additional therapeutic agent actually administered will usually be determined by a physician, in light of the relevant circumstances, including the condition(s) to be treated, the chosen route of administration, the actual compound (e.g., salt or free base) administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
- Co-administration may also include administering a dose of component drugs, e.g., a dose of one or more compounds described herein and a dose of one or more additional (e.g., a second, third, fourth or fifth) therapeutic agent(s). Such combination of a dose of one on more compounds described herein and a dose of one or more additional therapeutic agent(s) may be administered simultaneously or in sequence (one after the other) within a reasonable period of time of each administration (e.g., about 1 minute to 24 hours) depending on the pharmacokinetic and/or pharmacodynamics properties of each agent or the combination. Co-administration may also involve treatment with a fixed combination wherein agents of the treatment regimen are combinable in a fixed dosage or combined dosage medium, e.g., solid, liquid or aerosol. In some embodiments, a kit may be used to prepare and/or administer the drug or drug components.
- Thus, some embodiments of the present disclosure is a method of treating a disease or condition mediated, at least in part, by α4β7 integrin, comprising administering therapeutically effective amounts of formulations of one on more compounds described herein and one or more additional therapeutic agents, including for example, via a kit to a patient in need thereof. It will be understood that a qualified care giver will administer or direct the administration of a therapeutically effective amount of any of the compound(s) or combinations of compounds of the present disclosure.
- “Intravenous administration” is the administration of substances directly into a vein, or “intravenously.” Compared with other routes of administration, the intravenous (IV) route is a faster way to deliver fluids and medications throughout the body. An infusion pump can allow precise control over the flow rate and total amount of medication delivered. However, in cases where a change in the flow rate would not have serious consequences, or if pumps are not available, the drip is often left to flow simply by placing the bag above the level of the patient and using the clamp to regulate the rate. Alternatively, a rapid infuser can be used if the patient requires a high flow rate and the IV access device is of a large enough diameter to accommodate it. This is either an inflatable cuff placed around the fluid bag to force the fluid into the patient or a similar electrical device that may also heat the fluid being infused. When a patient requires medications only at certain times, intermittent infusion is used which does not require additional fluid. It can use the same techniques as an intravenous drip (pump or gravity drip), but after the complete dose of medication has been given, the tubing is disconnected from the IV access device. Some medications are also given by IV push or bolus, meaning that a syringe is connected to the IV access device and the medication is injected directly (slowly, if it might irritate the vein or cause a too-rapid effect). Once a medicine has been injected into the fluid stream of the IV tubing there must be some means of ensuring that it gets from the tubing to the patient. Usually this is accomplished by allowing the fluid stream to flow normally and thereby carry the medicine into the bloodstream; however, a second fluid injection is sometimes used, as a “flush”, following the injection to push the medicine into the bloodstream more quickly. Thus in some embodiments, compound(s) or combination of compounds described herein may be administered by IV administration alone or in combination with administration of certain components of the treatment regimen by oral or parenteral routes.
- “Oral administration” is a route of administration where a substance is taken through the mouth, and includes buccal, sub labial, and sublingual administration, as well as enteral administration and that through the respiratory tract, unless made through, e.g., tubing so the medication is not in direct contact with any of the oral mucosa. Typical form for the oral administration of therapeutic agents includes the use of tablets or capsules. Thus in some embodiments, compound(s) or combination of compounds described herein may be administered by oral route alone or in combination with administration of certain components of the treatment regimen by IV or parenteral routes.
- The compounds disclosed herein are useful for the treatment of diseases or conditions mediated, at least in part, by α4β7 integrin. Non-limiting examples of diseases or conditions mediated, at least in part, by α4β7 integrin include, without limitation, acne, acid-induced lung injury, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, adult-onset Still's disease, adult respiratory distress syndrome (ARDS), age-related macular degeneration, aging, alcoholic hepatitis, alcoholic liver disease, allergen-induced asthma, allergic bronchopulmonary, allergic conjunctivitis, allergic contact dermatitis, allergies, allergic encephalomyelitis, allergic neuritis, allograft rejection, alopecia, alopecia areata, Alzheimer's disease, amyloidosis, amyotrophic lateral sclerosis, angina pectoris, angioedema, angiofibroma, anhidrotic ectodermal dysplasia-ill, anti-glomerular basement membrane disease, antigen-antibody complex mediated diseases, ankylosing spondylitis, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, ascites, aspergillosis, asthma, atherosclerosis, atherosclerotic plaques, atopic dermatitis, atrophic thyroiditis, autoimmune diseases, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune polyendocrinopathies, autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), autoimmune hepatitis, autoimmune thyroid disorders, autoinflammatory diseases, back pain, Bacillus anthracis infection, Bechet's disease, bee sting-induced inflammation, Behcet's syndrome, Bell's palsy, berylliosis, Blau syndrome, bone pain, bronchiolitis, bullous pemphigoid (BP) asthma, burns, bursitis, cardiac hypertrophy, carpal tunnel syndrome, Castleman's disease, catabolic disorders, cataracts, Celiac disease, cerebral aneurysm, chemical irritant-induced inflammation, chorioretinitis, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, chronic heart failure, chronic lung disease of prematurity, chronic obstructive pulmonary disease (COPD), chronic pancreatitis, chronic prostatitis, chronic recurrent multifocal osteomyelitis, cicatricial alopecia, colitis, complex regional pain syndrome, complications of organ transplantation, conjunctivitis, connective tissue disease, contact dermatitis, corneal graft neovascularization, corneal ulcer, Crohn's disease, cryopyrin-associated periodic syndromes, cutaneous lupus erythematosus (CLE), cryptococcosis, cystic fibrosis, deficiency of the interleukin-1 receptor antagonist (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis, diabetic macular edema, diverticulitis, eczema, encephalitis, endometriosis, endotoxemia, eosinophilic pneumonias, epicondylitis, epidermolysis bullosa, erythema multiforme, erythroblastopenia, esophagitis, familial amyloidotic polyneuropathy, familial cold urticarial, familial Mediterranean fever, fetal growth retardation, fibromyalgia, fistulizing Crohn's disease, food allergies, giant cell arteritis, glaucoma, glioblastoma, glomerular disease, glomerular nephritis, glomerulonephritis, gluten-sensitive enteropathy, gout, gouty arthritis, graft-versus-host disease (GVHD), granulomatous hepatitis, Graves' disease, growth plate injuries, Guillain-Barre syndrome, gut diseases, hair loss, Hashimoto's thyroiditis, head injury, headache, hearing loss, heart disease, hemangioma, hemolytic anemia, hemophilic joints, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, heritable disorders of connective tissue, herpes zoster and simplex, hidradenitis suppurativa (HS), hip replacement, Hodgkin's disease, Huntington's disease, hyaline membrane disease, hyperactive inflammatory response, hyperammonemia, hypercalcemia, hypercholesterolemia, hypereosinophilic syndrome (HES), hyperimmunoglobulinemia D with recurrent fever (HIDS), hypersensitivity pneumonitis, hypertropic bone formation, hypoplastic and other anemias, hypoplastic anemia, ichthyosis, idiopathic demyelinating polyneuropathy, Idiopathic inflammatory myopathies (dermatomyositis, polymyositis), idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura, immunoglobulin nephropathies, immune complex nephritis, immune thrombocytopenic purpura (ITP), incontinentia pigmenti (IP, Bloch-Siemens syndrome), infectious mononucleosis, infectious diseases including viral diseases such as AIDS (HIV infection), hepatitis A, B, C, D, and E, herpes; inflammation, inflammation of the CNS, inflammatory bowel disease (IBD), inflammatory disease of the lower respiratory tract including bronchitis or chronic obstructive pulmonary diseases, inflammatory disease of the upper respiratory tract including the nose and sinuses such as rhinitis or sinusitis, inflammatory diseases of the respiratory tract, inflammatory ischemic event such as stroke or cardiac arrest, inflammatory lung disease, inflammatory myopathy such as myocarditis, inflammatory liver disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, interstitial cystitis, interstitial lung disease, iritis, irritant-induced inflammation, ischemia/reperfusion, joint replacement, juvenile arthritis, juvenile rheumatoid arthritis, keratitis, kidney injury caused by parasitic infections, kidney transplant rejection, leptospirosis, leukocyte adhesion deficiency, lichen sclerosus (LS), Lambert-Eaton myasthenic syndrome, Loeffler's syndrome, lupus, lupus nephritis, Lyme disease, Marfan syndrome (MFS), mast cell activation syndrome, mastocytosis, meningitis, meningioma, mesothelioma, mixed connective tissue disease, Muckle-Wells syndrome (urticaria deafness amyloidosis), mucositis, multiple organ injury syndrome, multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis (MG), myelodysplastic syndrome, myocarditis, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID), neovascular glaucoma, nephrotic syndrome, neuritis, neuropathological diseases, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant rejection, Osier-Weber syndrome, osteoarthritis, osteogenesis imperfecta, osteonecrosis, osteoporosis, osterarthritis, otitis, pachyonychia congenita, Paget's disease, Paget's disease of bone, pancreatitis, Parkinson's disease, pediatric rheumatology, pelvic inflammatory disease, pemphigus, pemphigus vulgaris (PV), bullous pemphigoid (BP), pericarditis, periodic fever, periodontitis, peritoneal endometriosis, pernicious anemia (Addison's disease), pertussis, PFAPA (periodic fever aphthous pharyngitis and cervical adenopathy), pharyngitis and adenitis (PFAPA syndrome), plant irritant-induced inflammation, pneumocystis infection, pneumonia, pneumonitis, poison ivy/urushiol oil-induced inflammation, polyarthritis nodosa, polychondritis, polycystic kidney disease, polymyalgia rheumatic, giant cell arteritis, polymyositis, pouchitis, reperfusion injury and transplant rejection, primary biliary cirrhosis, primary pulmonary hypertension, primary sclerosing cholangitis (PSC), proctitis, psoriasis, psoriasis vulgaris, psoriatic arthritis, psoriatic epidermis, psychosocial stress diseases, pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pyoderma gangrenosum, pyogenic granuloma retrolental fibroplasias, pyogenic sterile arthritis, Raynaud's syndrome, Reiter's disease, reactive arthritis, renal disease, renal graft rejection, reperfusion injury, respiratory distress syndrome, retinal disease, retrolental fibroplasia, Reynaud's syndrome, rheumatic carditis, rheumatic diseases, rheumatic fever, rheumatoid arthritis, rhinitis, rhinitis psoriasis, rosacea, sarcoidosis, Schnitzler syndrome, scleritis, sclerosis, scleroderma, scoliosis, seborrhea, sepsis, septic shock, severe pain, Sezary syndrome, sickle cell anemia, silica-induced disease (Silicosis), Sjogren's syndrome, skin diseases, skin irritation, skin rash, skin sensitization (contact dermatitis or allergic contact dermatitis), sleep apnea, spinal cord injury, spinal stenosis, spondyloarthropathies, sports injuries, sprains and strains, Stevens-Johnson syndrome (SJS), stroke, subarachnoid hemorrhage, sunburn, synovial inflammation, systemic inflammatory response syndrome (SIRS), systemic lupus erythematosus, systemic mast cell disease (SMCD), systemic vasculitis, systemic-onset juvenile idiopathic arthritis, temporal arteritis, tendinitis, tenosynovitis, thrombocytopenia, thyroditis, thyroiditis, tissue transplant, toxoplasmosis, trachoma, transplantation rejection, traumatic brain injury, tuberculosis, tubulointerstitial nephritis, tumor necrosis factor (TN F) receptor associated periodic syndrome (TRAPS), type 1 diabetes, type 2 diabetes, complications from type 1 or type 2 diabetes, ulcerative colitis, urticaria, uterine fibroids, uveitis, uveoretinitis, vascular restenosis, vasculitis, vasculitis (NHLBI), vitiligo, Wegener's granulomatosis, and Whipple's disease.
- In further embodiments, the methods are provided for alleviating a symptom of a disease or disorder mediated, at least in part, by α4β7 integrin. In some embodiments, the methods include identifying a mammal having a symptom of a disease or disorder mediated, at least in part, by α4β7 integrin, and providing to the mammal an amount of a compound as described herein effective to ameliorate (i.e., lessen the severity of) the symptom.
- In some embodiments, the disease or condition mediated, at least in part, by α4β7 integrin is an inflammatory disease or LPS induced endotoxin shock. In some embodiments, the disease is an autoimmune disease. In particular embodiments, the autoimmune disease is systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), inflammatory bowel disease (IBD), sepsis, psoriasis, Sjoegren's syndrome, autoimmune hemolytic anemia, asthma, or chronic obstructive pulmonary disease (COPD), ankylosing spondylitis, acute gout and ankylosing spondylitis, reactive arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, juvenile arthritis, juvenile onset rheumatoid arthritis, juvenile rheumatoid arthritis or psoriatic arthritis. In other embodiments, the disease is inflammation. In yet other embodiments, the disease is excessive or destructive immune reactions, such as asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), and lupus.
- In some embodiments, the disease or condition mediated, at least in part, by α4β7 integrin is inflammatory bowel disease (IBD). The term “inflammatory bowel disease” or “IBD” as used herein is a collective term describing inflammatory disorders of the gastrointestinal tract, the most common forms of which are ulcerative colitis and Crohn's disease. Other forms of IBD that can be treated with the presently disclosed compounds, compositions and methods include diversion colitis, ischemic colitis, infectious colitis, chemical colitis, microscopic colitis (including collagenous colitis and lymphocytic colitis), atypical colitis, pseudomembranous colitis, fulminant colitis, autistic enterocolitis, indeterminate colitis, Behcet's disease, gastroduodenal CD, jejunoileitis, ileitis, ileocolitis, Crohn's (granulomatous) colitis, irritable bowel syndrome, mucositis, radiation induced enteritis, short bowel syndrome, celiac disease, stomach ulcers, diverticulitis, pouchitis, proctitis, and chronic diarrhea.
- Treating or preventing IBD also includes ameliorating or reducing one or more symptoms of IBD. As used herein, the term “symptoms of IBD” refers to detected symptoms such as abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite, and other more serious complications, such as dehydration, anemia and malnutrition. A number of such symptoms are subject to quantitative analysis (e.g., weight loss, fever, anemia, etc.). Some symptoms are readily determined from a blood test (e.g., anemia) or a test that detects the presence of blood (e.g., rectal bleeding). The term “wherein said symptoms are reduced” refers to a qualitative or quantitative reduction in detectable symptoms, including but not limited to a detectable impact on the rate of recovery from disease (e.g., rate of weight gain). The diagnosis is typically determined by way of an endoscopic observation of the mucosa, and pathologic examination of endoscopic biopsy specimens.
- The course of IBD varies, and is often associated with intermittent periods of disease remission and disease exacerbation. Various methods have been described for characterizing disease activity and severity of IBD as well as response to treatment in subjects having IBD. Treatment according to the present methods is generally applicable to a subject having IBD of any level or degree of disease activity.
- In some embodiments, the disease or condition treated by the administration of a compound of composition described herein includes acute gout and ankylosing spondylitis, allergic disorders, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis and multiple sclerosis, atherosclerosis, bacterial infections, bone cancer pain and pain due to endometriosis, BRAF resistant melanoma, brain stem glioma or pituitary adenomas, burns, bursitis, cancer of the anal region, cancer of the endocrine system, cancer of the kidney or ureter (e.g., renal cell carcinoma, and carcinoma of the renal pelvis), cancer of the penis, cancer of the small intestine, cancer of the thyroid, cancer of the urethra, cancers of the blood such as acute myeloid leukemia, cancers of the tongue, carcinoma of the cervix, carcinoma of the endometrium, carcinoma of the fallopian tubes, carcinoma of the renal pelvis, carcinoma of the vagina or carcinoma of the vulva, chronic myeloid leukemia, chronic or acute leukemia, chronic pain, classic Bartter syndrome, common cold conjunctivitis, coronary heart disease, cutaneous or intraocular melanoma, dermatitis, dysmenorrhea, eczema, endometriosis, familial adenomatous polyposis, fibromyalgia, fungal infections, gout, gynecologic tumors, uterine sarcomas, carcinoma of the fallopian tubes, headache, hemophilic arthropathy, Parkinson's disease, AIDS, herpes zoster, Hodgkin's disease, Huntington's, hyperprostaglandin E syndrome, influenza, iritis, juvenile arthritis, juvenile onset rheumatoid arthritis, juvenile rheumatoid arthritis, low back and neck pain, lymphocytic lymphomas, myofascial disorders, myositis, neuralgia, neurodegenerative disorders such as Alzheimer's disease, neuroinflammatory disorders, neuropathic pain, carcinoma of the vulva, Parkinson's disease, pediatric malignancy, pulmonary fibrosis rectal cancer, rhinitis, sarcoidosis, sarcomas of soft tissues, scleritis, skin cancer, solid tumors of childhood, spinal axis tumors, sprains and strains, stomach cancer, stroke, subacute and chronic musculoskeletal pain syndromes such as bursitis, surgical or dental procedures, symptoms associated with influenza or other viral infections, synovitis, toothache, ulcers, uterine cancer, uterine sarcomas, uveitis, vasculitis, viral infections, viral infections (e.g., influenza) and wound healing.
- Criteria useful for assessment of disease activity in subjects with ulcerative colitis can be found in, e.g., Truelove et al. (1955) Br Med J 2:1041-1048.) Using these criteria, disease activity can be characterized in a subject having IBD as mild disease activity or severe disease activity. Subjects who do not meet all the criteria for severe disease activity, and who exceed the criteria for mild disease activity are classified as having moderate disease activity.
- The presently disclosed treatment methods can also be applied at any point in the course of the disease. In some embodiments, the methods are applied to a subject having IBD during a time period of remission (i.e., inactive disease). In such embodiments, the present methods provide benefit by extending the time period of remission (e.g., extending the period of inactive disease) or by preventing, reducing, or delaying the onset of active disease. In other embodiments, methods may be applied to a subject having IBD during a period of active disease. Such methods provide benefit by reducing the duration of the period of active disease, reducing or ameliorating one or more symptoms of IBD, or treating IBD.
- Measures for determining efficacy of treatment of IBD in clinical practice have been described and include, for example, the following: symptom control; fistula closure; extent of corticosteroid therapy required; and, improvement in quality of life. Heath-related quality of life (HRQL) can be assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), which is extensively used in clinical practice to assess quality of life in a subject with IBD. (See Guyatt et al. (1989) Gastroenterology 96:804-810.) In some embodiments, the disease or condition is immune-mediated liver injury, disease or condition.
- In some embodiments, the disease or condition mediated, at least in part, by α4β7 integrin is alcoholic hepatitis. Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver failure that develops in subjects with chronic and active alcohol abuse. (See Akriviadis E. et. al, Ann Gastroenterol. 2016 April-June; 29(2): 236-237). Alcoholic hepatitis can cause cirrhosis and fibrosis of the liver cells. Glucocorticoids, (e.g., prednisolone) and phosophodiesterase inhibitors (e.g., pentoxifylline) can be used to treat alcoholic hepatitis. The compounds herein can be used as stand-alone treatments or in combination with the current treatments for alcoholic hepatitis.
- In one aspect, the present disclosure provides methods of treating or preventing a human immunodeficiency virus (HIV) infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.
- In some embodiments, the disease or condition mediated, at least in part, by α4β7 integrin is systemic lupus erythematosus (SLE), lupus nephritis, lupus-related, or other autoimmune disorders or a symptom of SLE. Symptoms of systemic lupus erythematosus include joint pain, joint swelling, arthritis, fatigue, hair loss, mouth sores, swollen lymph nodes, sensitivity to sunlight, skin rash, headaches, numbness, tingling, seizures, vision problems, personality changes, abdominal pain, nausea, vomiting, abnormal heart rhythms, coughing up blood and difficulty breathing, patchy skin color and Raynaud's phenomenon.
- Also provided are methods of treatment in which a compound described herein is given to a patient in combination with one or more additional active agents or therapy.
- Thus in some embodiments, a method of treating diseases or conditions mediated, at least in part, by α4β7 integrin and/or diseases or symptoms that co-present or are exacerbated or triggered by the diseases or conditions mediated, at least in part, by α4β7 integrin, e.g., an allergic disorder and/or an autoimmune and/or inflammatory disease, and/or an acute inflammatory reaction, comprises administering to a patient in need thereof an effective amount of a compound described herein optionally in combination with an additional agent (e.g., a second, third, fourth or fifth active agent) which can be useful for treating diseases or conditions mediated, at least in part, by α4β7, an allergic disorder and/or an autoimmune and/or inflammatory disease, and/or an acute inflammatory reaction incident to or co-presenting with diseases or conditions mediated, at least in part, by α4β7 integrin. Treatment with the second, third, fourth or fifth active agent may be prior to, concomitant with, or following treatment with a compound described herein. In some embodiments, a compound described herein is combined with another active agent in a single dosage form. Suitable therapeutics that may be used in combination with a compound described herein include, but are not limited to, therapeutic agents provided herein, or a combination comprising at least one therapeutic agent provided herein.
- Included herein are methods of treatment in which a compound described herein is administered in combination with an agent for treatment of an inflammatory disease or condition. Examples of agents for treatment of an inflammatory disease or condition that can be used in combination with compounds described herein, include alpha-fetoprotein modulators; adenosine A3 receptor antagonist; adrenomedullin ligands; AKT1 gene inhibitors; antibiotics; antifungals; ASK1 inhibitors; ATPase inhibitors; beta adrenoceptor antagonists; BTK inhibitors; calcineurin inhibitors; carbohydrate metabolism modulators; cathepsin S inhibitors; CCR9 chemokine antagonists; CD233 modulators; CD29 modulators; CD3 antagonists; CD40 ligand inhibitors; CD40 ligand receptor antagonists; chemokine CXC ligand inhibitors; CHST15 gene inhibitors; collagen modulators; CSF-1 antagonists; CX3CR1 chemokine modulators; ecobiotics; eotaxin ligand inhibitors; EP4 prostanoid receptor agonists; FIFO ATP synthase modulators; farnesoid X receptor (FXR and NR1H4) agonists or modulators; fecal microbiota transplantation (FMT); fractalkine ligand inhibitors; free fatty acid receptor 2 antagonists; GATA 3 transcription factor inhibitors; glucagon-like peptide 2 agonists; glucocorticoid agonists; Glucocorticoid receptor modulators; guanylate cyclase receptor agonists; HIF prolyl hydroxylase inhibitors; histone deacetylase inhibitors; HLA class II antigen modulators; hypoxia inducible factor-1 stimulator; ICAM1 gene inhibitors; IL-1 beta ligand modulators; IL-12 antagonists; IL-13 antagonists; IL-18 antagonists; IL-22 agonists; IL-23 antagonists; IL-23A inhibitors; IL-6 antagonists; IL-7 receptor antagonists; IL-8 receptor antagonists; integrin alpha-4/beta-1 antagonists; integrin alpha-4/beta-7 antagonists; integrin antagonists; interleukin ligand inhibitors; interleukin receptor 17A antagonists; interleukin-1 beta ligands; interleukin 1 like receptor 2 inhibitors; IL-6 receptor modulators; JAK tyrosine kinase inhibitors; Jak1 tyrosine kinase inhibitors; Jak3 tyrosine kinase inhibitors; lactoferrin stimulators; LanC like protein 2 modulators; leukocyte elastate inhibitors; leukocyte proteinase-3 inhibitors; MAdCAM inhibitors; melanin concentrating hormone (MCH-1) antagonist; melanocortin agonists; metalloprotease-9 inhibitors; microbiome-targeting therapeutics; natriuretic peptide receptor C agonists; neuregulin-4 ligands; NLPR3 inhibitors; NKG2 D activating NK receptor antagonists; nuclear factor kappa B inhibitors; opioid receptor antagonists; OX40 ligand inhibitors; oxidoreductase inhibitors; P2X7 purinoceptor modulators; PDE 4 inhibitors; Pellino homolog 1 inhibitors; PPAR alpha/delta agonists; PPAR gamma agonists; protein fimH inhibitors; P-selectin glycoprotein ligand-1 inhibitors; Ret tyrosine kinase receptor inhibitors; RIP-1 kinase inhibitors; RIP-2 kinase inhibitors; RNA polymerase inhibitors; sphingosine 1 phosphate phosphatase 1 stimulators; sphingosine-1-phosphate receptor-1 agonists; sphingosine-1-phosphate receptor-5 agonists; sphingosine-1-phosphate receptor-1 antagonists; sphingosine-1-phosphate receptor-1 modulators; stem cell antigen-1 inhibitors; superoxide dismutase modulators; SYK inhibitors; tissue transglutaminase inhibitor; TLR-3 antagonists; TLR-4 antagonists; Toll-like receptor 8 (TLR8) inhibitors; TLR-9 agonists; TNF alpha ligand inhibitors; TNF ligand inhibitors; TNF alpha ligand modulators; TNF antagonists; TPL-2 inhibitors; tumor necrosis factor 14 ligand modulators; tumor necrosis factor 15 ligand inhibitors; Tyk2 tyrosine kinase inhibitors; type 1IL-1 receptor antagonists; vanilloid VR1 agonists; and zonulin inhibitors, and combinations thereof.
- Adenosine A3 receptor antagonists include PBF-677.
- Adrenomedullin ligands include adrenomedullin.
- Antibiotics include ciprofloxacin, clarithromycin, metronidazole, vancomycin, rifamycin, rifaximin, and tosufloxacin.
- ASK1 inhibitors include GS-4997.
- Alpha-fetoprotein modulators include ACT-101.
- Anti-CD28 inhibitors include JNJ-3133 and abatacept.
- Beta adrenoceptor antagonists include NM-001.
- BTK inhibitors include GS-4059.
- Calcineurin inhibitors: include tacrolimus, and ciclosporin.
- Carbohydrate metabolism modulators include ASD-003.
- Cathepsin S inhibitors include VBY-129.
- CCR9 chemokine antagonists include CCX-507.
- CD233 modulators include GSK-2831781.
- CD29 modulators include PF-06687234.
- CD3 antagonists include NI-0401.
- CD4 antagonists include IT-1208.
- CD40 ligand inhibitors include SAR-441344, and letolizumab.
- CD40 gene inhibitors include NJA-730.
- CD40 ligand receptor antagonists include FFP-104, BI-655064.
- Chaperonin binding immunoglobulin protein includes IRL-201805.
- Chemokine CXC ligand inhibitors include LY-3041658.
- CHST15 gene inhibitors include STNM-01.
- Collagen modulators include ECCS-50 (DCCT-10).
- COT protein kinase inhibitors include GS-4875.
- CSF-1 antagonists include JNJ-40346527 (PRV-6527), and SNDX-6352.
- CX3CR1 chemokine modulators include E-6130.
- Ecobiotics include SER-287.
- Eotaxin ligand inhibitors include bertilimumab.
- EP4 prostanoid receptor agonists include KAG-308.
- FIFO ATP synthase modulators include LYC-30937 EC.
- Fractalkine ligand inhibitors include quetmolimab (E-6011).
- Free fatty acid receptor 2 antagonists include GLPG-0974.
- GATA 3 transcription factor inhibitors include SB-012.
- Glucagon-like peptide 2 agonists include teduglutide, and apraglutide.
- Glucocorticoid receptor agonists include budesonide, beclomethasone dipropionate, and dexamethasone sodium phosphate.
- Glucocorticoid receptor modulators/TNF ligand inhibitors include ABBV-3373.
- Guanylate cyclase receptor agonists include dolcanatide.
- HIF prolyl hydroxylase inhibitors include DS-1093, and AKB-4924.
- HIF prolyl hydroxylase-2 inhibitors/hypoxia inducible factor-1 stimulators include GB-004.
- Histone deacetylase inhibitors include givinostat.
- Histone deacetylase-6 inhibitors include CKD-506.
- HLA class II antigen modulators include HLA class II protein modulators.
- ICAM1 gene inhibitors include alicaforsen.
- IL-12 antagonists include ustekinumab (IL12/IL23).
- IL-13 antagonists include tralokinumab.
- IL-18 antagonists include GSK-1070806.
- IL-22 agonists include RG-7880.
- IL-23 antagonists include tildrakizumab, risankizumab (BI-655066), mirikizumab (LY-3074828), brazikumab (AMG-139), and PTG-200.
- IL-23A inhibitors include guselkumab.
- IL-6 antagonists include olokizumab.
- IL-7 receptor antagonists include OSE-127.
- IL-8 receptor antagonists include clotrimazole.
- Integrin alpha-4/beta-1 antagonists include natalizumab.
- Integrin alpha-4/beta-7 antagonists include etrolizumab (a4b7/aEb7), vedolizumab, carotegast methyl, TRK-170 (a4b7/a4b1), PN-10943, and PTG-100.
- Integrin antagonists include E-6007.
- Interleukin ligand inhibitors include bimekizumab (IL-17A/IL-17F).
- Interleukin receptor 17A antagonists include brodalumab.
- Interleukin-1 beta ligands include K(D)PT.
- Interleukin 1 like receptor 2 inhibitors include BI-655130.
- IL-6 receptor modulators include olamkicept.
- JAK tyrosine kinase inhibitors include tofacitinib (⅓), peficitinib (⅓), TD-3504, an TD-1473. Jak1 tyrosine kinase inhibitors include a compound disclosed in WO2008/109943. Examples of other JAK inhibitors include, but are not limited to, AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110, lestaurtinib, momelotinib (CYT0387), NS-018, pacritinib (SB1518), peficitinib (ASP015K), ruxolitinib, tofacitinib (formerly tasocitinib), XL019, upadacitinib (ABT-494), filgotinib, GLPG-0555, SHR-0302, and brepocitinib (PF-06700841) (JAK1/Tyk2).
- Jak3 tyrosine kinase inhibitors include PF-06651600.
- Lactoferrin stimulators include recombinant human lactoferrin (VEN-100).
- LanC like protein 2 modulators include BT-11.
- Leukocyte elastase inhibitors/Leukocyte proteinase-3 inhibitors include tiprelestat.
- MAdCAM inhibitors include SHP-647 (PF-547659).
- Melanin concentrating hormone (MCH-1) antagonists include CSTI-100.
- Melanocortin MC1 receptor agonists include ASP-3291, and PL-8177.
- Metalloprotease-9 inhibitors include GS-5745.
- Microbiome modulator include ABI-M201.
- Natriuretic peptide receptor C agonists include plecanatide.
- Neuregulin-4 ligands include NRG-4.
- NKG2 D activating NK receptor antagonists include JNJ-4500.
- NLPR3 inhibitors include dapansutrile, BMS-986299, SB-414, MCC-950, IFM-514, JT-194, PELA-167, and NBC-6.
- Farnesoid X receptor (FXR and NR1H4) agonists or modulators include AGN-242266, cilofexor tromethamine (GS-9674), EDP-305, EYP-001, GNF-5120, MET-409, nidufexor (LMB-763), obeticholic acid, TERN-101, and tropifexor.
- Nuclear factor kappa B inhibitors include Thetanix.
- Opioid receptor antagonists include naltrexone, and IRT-103.
- OX40 ligand inhibitors include KHK-4083.
- Oxidoreductase inhibitors include olsalazine.
- Pellino homolog 1 inhibitors include BBT-401.
- P2X7 purinoceptor modulators include SGM-1019.
- PDE 4 inhibitors include apremilast.
- PPAR alpha/delta agonists include elafibranor (GFT-1007).
- PPAR gamma agonists include GED-0507-34-Levo.
- Protein fimH inhibitors include sibofimloc (EB-8018).
- P-selectin glycoprotein ligand-1 inhibitors include SEL-K2, AbGn-168H, and neihulizumab.
- Ret tyrosine kinase receptor inhibitors include GSK-3179106.
- RIP-1 kinase inhibitors include GSK-2982772.
- RIP-2 kinase inhibitors include GSK-2983559.
- Sphingosine 1 phosphate phosphatase 1 stimulators include etrasimod.
- Sphingosine-1-phosphate receptor-1 agonists include ozanimod, mocravimod (KRP-203), and BMS-986166.
- Sphingosine-1-phosphate receptor-1 agonists/Sphingosine-1-phosphate receptor-5 agonists include ozanimod.
- Sphingosine-1-phosphate receptor-1 antagonists include amiselimod (MT-1303).
- Sphingosine-1-phosphate receptor-1 modulators include OPL-002.
- Stem cell antigen-1 inhibitors include Ampion (DMI-9523).
- Superoxide dismutase modulators include midismase.
- Syk inhibitors include GS-9876.
- Tissue transglutaminase inhibitor includes zampilimab.
- TLR-3 antagonists include PRV-300.
- TLR-4 antagonists include JKB-122.
- Toll-like receptor 8 (TLR8) inhibitors include E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, VTX-1463, and VTX-763.
- TLR-9 agonists include cobitolimod, IMO-2055, IMO-2125, lefitolimod, litenimod, MGN-1601, and PUL-042.
- TNF alpha ligand inhibitors include adalimumab, certolizumab pegol, infliximab, golimumab, DLX-105, Debio-0512, HMPL-004, CYT-020-TNFQb, Hemay-007, and V-565.
- TNF antagonists include AVX-470, tulinercept, and etanercept.
- TPL-2 inhibitors include GS-4875.
- Tumor necrosis factor 14 ligand modulators include AEVI-002.
- Tumor necrosis factor 15 ligand inhibitors include PF-06480605.
- Tyk2 tyrosine kinase inhibitors include PF-06826647, and BMS-986165.
- TrkA receptor antagonist includes SNA-125.
- Type I IL-1 receptor antagonists include anakinra.
- Zonulin inhibitors include larazotide acetate.
- Included herein are methods of treatment in which a compound described herein is administered in combination with an anti-inflammatory agent. Anti-inflammatory agents include but are not limited to NSAIDs, non-specific and COX-2 specific cyclooxgenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptors antagonists, immunosuppressants and methotrexate.
- Examples of NSAIDs include, but are not limited to ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmetin sodium, and hydroxychloroquine. Examples of NSAIDs also include COX-2 specific inhibitors (i.e., a compound that inhibits COX-2 with an IC50 that is at least 50-fold lower than the IC50 for COX-1) such as celecoxib, valdecoxib, lumiracoxib, etoricoxib and/or rofecoxib.
- In a further embodiment, the anti-inflammatory agent is a salicylate. Salicylates include but are not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.
- The anti-inflammatory agent may also be a corticosteroid. For example, the corticosteroid may be chosen from cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, and prednisone.
- In some embodiments, the anti-inflammatory therapeutic agent is a gold compound such as gold sodium thiomalate or auranofin.
- In some embodiments, the anti-inflammatory agent is a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
- In some embodiments, the anti-inflammatory compound is an anti-C5 monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist, such as entanercept, or infliximab, which is an anti-TNF alpha monoclonal antibody.
- Included herein are methods of treatment in which a compound described herein, is administered in combination with an immunosuppressant. In some embodiments, the immunosuppressant is methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, or mycophenolate mofetil.
- Included herein are methods of treatment in which a compound described herein, is administered in combination with a class of agent for treatment of IBD. Examples of classes of agents for treatment of IBD that can be used in combination with a compound described herein include ASK1 inhibitors, beta adrenoceptor antagonists, BTK inhibitors, beta-glucuronidase inhibitors, bradykinin receptor modulators, calcineurin inhibitors, calcium channel inhibitors, cathepsin S inhibitors, CCR3 chemokine antagonists, CD40 ligand receptor antagonists, chemokine CXC ligand inhibitors, CHST15 gene inhibitors, collagen modulators, CSF-1 antagonists, cyclooxygenase inhibitors, cytochrome P450 3A4 inhibitors, eotaxin ligand inhibitors, EP4 prostanoid receptor agonists, erythropoietin receptor agonists, fractalkine ligand inhibitors, free fatty acid receptor 2 antagonists, GATA 3 transcription factor inhibitors, glucagon-like peptide 2 agonists, glucocorticoid agonists, guanylate cyclase receptor agonists, histone deacetylase inhibitors, HLA class II antigen modulators, IL-12 antagonists, IL-13 antagonists, IL-23 antagonists, IL-6 antagonists, IL-6 receptor modulators, interleukin-7 receptor modulators, IL-7 antagonists, IL-8 antagonists, integrin alpha-4/beta-1 antagonists, integrin alpha-4/beta-7 antagonists, integrin alpha-E antagonists, integrin antagonists, integrin beta-7 antagonists, interleukin ligand inhibitors, interleukin-2 ligand, interleukin receptor 17A antagonists, interleukin-1 beta ligands, interleukin-1 beta ligand modulators, IRAK4 inhibitors, JAK tyrosine kinase inhibitors, Jak1 tyrosine kinase inhibitors, Jak3 tyrosine kinase inhibitors, LanC like protein 2 modulators, lipoxygenase modulators, MAdCAM inhibitors, matrix metalloprotease inhibitors, melanocortin agonists, metalloprotease-9 inhibitors, natriuretic peptide receptor C agonists, neuregulin-4 ligands, NKG2 D activating NK receptor antagonists, opioid receptor antagonists, opioid receptor delta antagonists, oxidoreductase inhibitors, P2X7 purinoceptor agonists, PDE 4 inhibitors, phagocytosis stimulating peptide modulators, potassium channel inhibitors, PPAR alpha agonists, PPAR delta agonists, PPAR gamma agonists, protein fimH inhibitors, P-selectin glycoprotein ligand-1 inhibitors, RNA polymerase inhibitors, sphingosine 1 phosphate phosphatase 1 stimulators, sphingosine 1 phosphate phosphatase modulators, sphingosine-1-phosphate receptor-1 agonists, sphingosine-1-phosphate receptor-1 antagonists, sphingosine-1-phosphate receptor-1 modulators, sphingosine-1-phosphate receptor-5 modulators, STAT3 gene inhibitors, stem cell antigen-1 inhibitors, superoxide dismutase modulators, superoxide dismutase stimulators, SYK inhibitors, TGF beta 1 ligand inhibitors, thymulin agonists, TLR antagonists, TLR agonists, TNF alpha ligand inhibitors, TNF antagonists, tumor necrosis factor 14 ligand modulators, type II TNF receptor modulators, Tpl 2 inhibitors, and Zonulin inhibitors.
- Included herein are methods of treatment in which a compound described herein is administered in combination with an agent for treatment of IBD. Examples of agents for treatment of IBD that can be used in combination with a compound described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, include those provided herein for the treatment of an inflammatory disease or condition, and ABX-464, adalimumab; alicaforsen, ALLO-ASC-CD, AMG-966, anakinra, apremilast; Alequel; AMG-139; amiselimod, ASD-003, ASP-3291, AX-1505, BBT-401, balsalazide; beclomethasone dipropionate; BI-655130, BMS-986184; budesonide; CEQ-508; certolizumab; ChAdOx2-HAV, dexamethasone sodium phosphate, DNVX-078, etanercept; cibinetide; Clostridium butyricum; ETX-201, golimumab; GS-4997, GS-9876, GS-4875, GS-4059, infliximab; mesalazine, HLD-400, LYC-30937 EC; IONIS-JB11-2.5Rx, JNJ-64304500, JNJ-4447, naltrexone; natalizumab; neihulizumab, olsalazine; PH-46-A, propionyl-L-carnitine; PTG-100; remestemcel-L; tacrolimus; teduglutide; tofacitinib; ASP-1002; ustekinumab; vedolizumab; AVX-470; INN-108; SGM-1019; PF-06480605; PF-06651600; PF-06687234; RBX-8225, SER-287; Thetanix; TOP-1288; VBY-129; 99mTc-annexin V-128; bertilimumab; DLX-105; dolcanatide; FFP-104; filgotinib; foralumab; GED-0507-34-Levo; givinostat; GLPG-0974; iberogast; JNJ-40346527; K(D)PT; KAG-308; KHK-4083; KRP-203; larazotide acetate; LY-3074828, midismase; olokizumab; OvaSave; P-28-GST; PF-547659; prednisolone; QBECO; RBX-2660, RG-7835; JKB-122; SB-012; STNM-01; Debio-0512; TRK-170; zucapsaicin; ABT-494; Ampion; BI-655066; carotegast methyl; cobitolimod; elafibranor; etrolizumab; GS-5745; HMPL-004; LP-02, ozanimod; peficitinib; quetmolimab (E-6011); RHB-104; rifaximin; tildrakizumab; tralokinumab; brodalumab; laquinimod; plecanatide; vidofludimus; and AZD-058.
- Included herein are methods of treatment in which a compound described herein is administered in combination with an agent for treatment of graft versus host disease. Examples of agents for treatment of graft versus host disease that can be used in combination with a compound described herein include those provided herein for the treatment of an inflammatory disease or condition, and [18F]F-AraG, AM-01, Alpha 1 antitrypsin stimulator: AAT-IV and CSL-964; Allocetra, efavaleukin alfa (AMG-592), arsenic trioxide, ATIR-101, belatacept, belimumab, beta lactamase modulator: ribaxamase, bortezomib, brentuximab vedotin, brimonidine, brimonidine tartrate, cannabidiol, ciclosporin, CYP-001, um, dilanubicel, dornase alfa, DSM-9843, eculizumab, EDP-1066, everolimus, Furestem, GL-101, ibrutinib, IMSUT-CORD, IRX-4204, itolizumab, KD-025, MaaT-013, milatuzumab, mizoribine, mycophenolate mofetil, MSCTC-0010, nalotimagene carmaleucel, MET-2, nilotinib, narsoplimab (OMS-721), pacritinib, PF-05285401, ProTmune, QPI-1002, remestemcel-L, RGI-2001, saratin, SCM-CGH, sirolimus, T-allo10, telmisartan, TOP-1288, TZ-101, voclosporin; CCR5 chemokine antagonist: leronlimab (PRO-140); CD40 ligand receptor antagonist: iscalimab; Complement C1s subcomponent inhibitor: CE-1145, sutimlimab, Cinryze, BIVV-009; B-lymphocyte antigen CD20 inhibitor: obinutuzumab, rituximab; CASP9 gene stimulator: rivogenlecleucel; CD3 antagonist or CD7 inhibitor: T-Guard; Complement C5a factor inhibitor: olendalizumab; Dipeptidyl peptidase IV inhibitor: begelomab; JAK1/2 tyrosine kinase inhibitor: ruxolitinib; Jak1 tyrosine kinase inhibitor: itacitinib; Interleukin-2 ligand: aldesleukin; Interleukin 22 ligand: F-652; IL-2 receptor alpha subunit inhibitor: basiliximab and inolimomab; IL-6 receptor agonist: PLX-1; IL-6 receptor antagonist: clazakizumab; OX40 ligand inhibitor: KY-1005; An example of such OX40 inhibitor is a compound disclosed in U.S. Pat. No. 8,450,460, the entire contents of which are incorporated herein by reference; Signal transducer CD24 modulator: CD24-IgFc; Somatostatin receptor agonist: Thymoglobulin; and sphingosine-1-phosphate receptor-1 agonist: ponesimod.
- Included herein are methods of treatment in which a compound described herein is administered in combination with an agent for treatment of primary sclerosing cholangitis. Examples of agents for treatment of primary sclerosing cholangitis that can be used in combination with compounds described herein include those provided herein for the treatment of an inflammatory disease or condition, and BTT-1023, CM-101, Doconexent, GRI-0124, HTD-1801, HTD-2802, hymecromone, IDN-7314, NGM-282, norursodeoxycholic acid, ORBCEL-C, integrin alpha-V/beta-1 and beta-6 antagonist: PLN-74809; PPAR delta agonist: seladelpar lysine; SCT-5-27, PTGS2 gene and TGF beta 1 gene inhibitor: SCT-5-27, and STP-705; Farnesoid X receptor (FXR, NR1H4) agonists or modulators: AGN-242266, cilofexor tromethamine (GS-9674), EDP-305, EYP-001, GNF-5120, MET-409, nidufexor (LMB-763), obeticholic acid, TERN-101, tropifexor; liver X receptor antagonist: DUR-928; and CCR5/CCR2 chemokine antagonist: cenicriviroc.
- In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of: combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, or a pharmaceutically acceptable salt of any of the foregoing, or any combinations thereof.
- In some embodiments, the one or more additional therapeutic agents is selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, or a pharmaceutically acceptable salt of any of the foregoing, or any combinations thereof.
- In some embodiments, the one or more additional therapeutic agent is an immune modulating agent, e.g., an immunostimulant or an immunosuppressant. In certain other embodiments, an immune modulating agent is an agent capable of altering the function of immune checkpoints, including the CTLA-4, LAG-3, B7-H3, B7-H4, Tim3, BTLA, KIR, A2aR, CD200 and/or PD-1 pathways. In other embodiments, the immune modulating agent is immune checkpoint modulating agents. Exemplary immune checkpoint modulating agents include anti-CTLA-4 antibody (e.g., ipilimumab), anti-LAG-3 antibody, anti-B7-H3 antibody, anti-B7-H4 antibody, anti-Tim3 antibody, anti-BTLA antibody, anti-KIR antibody, anti-A2aR antibody, anti CD200 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-CD28 antibody, anti-CD80 or -CD86 antibody, anti-B7RP1 antibody, anti-B7-H3 antibody, anti-HVEM antibody, anti-CD137 or -CD137L antibody, anti-OX40 or -OX40L antibody, anti-CD40 or -CD40L antibody, anti-GAL9 antibody, anti-IL-10 antibody and A2aR drug. For certain such immune pathway gene products, the use of either antagonists or agonists of such gene products is contemplated, as are small molecule modulators of such gene products. In some embodiments, immune modulating agents include those agents capable of altering the function of mediators in cytokine mediated signaling pathways.
- In some embodiments, a compound as disclosed herein may be combined with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents in any dosage amount of the compound described herein (e.g., from 10 mg to 1000 mg of compound).
- A compound described herein may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 500 mg of compound) the same as if each combination of dosages were specifically and individually listed.
- In some embodiments, provided are kits comprising a pharmaceutical composition comprising a compound described herein or a compound described herein and at least one additional therapeutic agent, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. In some embodiments, kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents are provided. Any pharmaceutical composition provided in the present disclosure may be used in the kits, the same as if each and every composition were specifically and individually listed for use in a kit. In some embodiments, the kit comprises instructions for use in the treatment of an inflammatory disease or condition. In some embodiments, the instructions in the kit are directed to use of the pharmaceutical composition for the treatment of IBD.
- Articles of manufacture comprising a container in which a compound described herein and at least one pharmaceutically acceptable carrier are contained are provided. The article of manufacture may be a bottle, vial, ampoule, single-use disposable applicator, or the like, containing the pharmaceutical composition provided in the present disclosure. The container may be formed from a variety of materials, such as glass or plastic and in one aspect also contains a label on, or associated with, the container which indicates directions for use in the treatment of cancer or inflammatory conditions.
- It should be understood that the active ingredient may be packaged in any material capable of providing reasonable chemical and physical stability, such as an aluminum foil bag.
- Unit dosage forms of the pharmaceutical composition comprising a compound described herein and at least one pharmaceutically acceptable carrier are also provided.
- Any pharmaceutical composition provided in the present disclosure may be used in the articles of manufacture, the same as if each and every composition were specifically and individually listed for use an article of manufacture.
- Also provided is a kit that includes a compound described herein; a label, and/or instructions for use of the compound in the treatment of a disease or condition mediated, at least in part, by α4β7 integrin.
- Also provided is an article of manufacture which includes a compound described herein; and a container. In some embodiments, the container may be a vial, jar, ampoule, preloaded syringe, or an intravenous bag.
- Formulations of compound(s) of the present disclosure, i.e., a compound described herein or the combination of a compound described herein and an additional agent may be accomplished by admixing said compounds or salt thereof with one or more non-toxic, pharmaceutically acceptable vehicles, carriers and/or diluents and/or adjuvants collectively referred to herein as excipients or carrier materials. The compounds of the disclosure may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such route, and in a therapeutically effective dose. The compounds or the combination of compounds for the disclosure may be delivered orally, mucosally, parenterally, including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intranasally in dosage formulations containing conventional pharmaceutical excipients.
- In some embodiments, the combination of a compound described herein, and an additional therapeutic agent may be formulated in a fixed dose or combined dose formulation in a tablet, capsule or premixed IV solution. In another embodiment, the fixed dose combination preferably comprises of a compound described herein, and an additional anti-inflammatory agent. Other fixed dose formulations may include premixed liquids, suspensions, elixirs, aerosolized sprays or patch presentations. As used herein fixed dose or combined dose formulations are synonymous with simultaneous co-administration of the active ingredients of the compound described herein and at least one additional therapeutic agent.
- Also provided herein are methods for treating a subject who is undergoing one or more standard therapies for treatment of an inflammatory disease or condition comprising administering or co-administering a compound described herein to said subject. Accordingly, one or more compounds described herein may be administered before, during, or after administration of another therapeutic agent for treatment of an inflammatory disease or condition, or combination thereof.
- In some embodiments, the subject may be a human who is (i) substantially refractory to at least one treatment of an inflammatory disease or condition, or (ii) in relapse after treatment with treatment of an inflammatory disease or condition, or both (i) and (ii). In some of embodiments, the subject is refractory to at least two, at least three, or at least four treatment of an inflammatory disease or condition (including standard or experimental treatments of an inflammatory disease or condition).
- The above therapeutic agents when employed in combination with a compound(s) disclosed herein, may be used, for example, in those amounts indicated in the referenced manuals, e.g., Physicians' Desk Reference or in amounts generally known to a qualified care giver, i.e., one of ordinary skill in the art. In the methods of the present disclosure, such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the compound described herein. Certain other therapeutic agents may be combined into a single formulation or kit when amenable to such. For example, tablet, capsule or liquid formulations may be combined with other tablet, capsule or liquid formulations into one fixed or combined dose formulation or regimen. Other combinations may be given separately, contemporaneously or otherwise.
- Improvements in any of the foregoing response criteria are specifically provided by the methods of the present disclosure.
- The compounds of the disclosure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds of formula (I), e.g., compounds having structures described by one or more of formula (I), or other formulas or compounds disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, may be accomplished as described in the following examples.
- Typical embodiments of compounds in accordance with the present disclosure may be synthesized using the general reaction schemes and/or examples described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Starting materials are typically obtained from commercial sources or synthesized using published methods for synthesizing compounds which are embodiments of the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. Group labels (e.g., R1, Ra) used in the reaction schemes herein are for illustrative purposes only and unless otherwise specified do not necessarily match by name or function the labels used elsewhere to describe compounds of formula (I), or any formula described herein, or aspects or fragments thereof.
- The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
- Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein.
- Furthermore, the compounds of this disclosure may contain one or more asymmetric (“chiral”) centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
- The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis., USA). Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989) organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- The terms “solvent,” “inert organic solvent” or “inert solvent” refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like). Unless specified to the contrary, the solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
- The term “q.s.” means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
- Compounds as provided herein may be synthesized according to the general schemes provided below. In the Schemes below, it should be appreciated that each of the compounds shown therein may have protecting groups as required present at any step. Standard protecting groups are well within the pervue of one skilled in the art.
- Scheme 1 shows an exemplary synthetic route for the synthesis of compounds provided herein (e.g., compounds of Formula I). The compounds of Formula I, or other formulas or compounds disclosed herein, are typically prepared by first providing the molecular core 503 and then attaching the desired R1 substituents using suitable coupling conditions (e.g., Suzuki coupling) and the desired phenylamide substituents (substituted at the phenyl by R2-R6) using suitable amide coupling conditions. In Scheme 1, p, R1, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, X3, X4, X5, X6, and X7 are as defined herein, R51 is a leaving group (e.g., halo); R52 is C1-6 alkyl; R53 is hydroxy or a leaving group (e.g., halo); R54 is a moiety suitable for undergoing a coupling reaction (e.g., a boronic acid or halo); R55 is O (i.e., oxo) or N, where if R55 is N then R55 is a constituent of optional ring to E1; E1 is a double bonded N-auxiliary that is optionally cyclized at R55, or E1 may be a single bonded N-protecting group and R8; and R56 is a moiety suitable for undergoing a metal-catalyzed coupling reaction (e.g., halo, or a boronic acid or an ester thereof).
- In Scheme 1, compound 501 is reacted with compound 502 under standard nucleophilic displacement conditions (e.g., using a base) in a suitable solvent (e.g., THF etc.), optionally under an inert atmosphere, to provide compound 503. In general, compound 502 is deprotonated using a strong base, such as potassium hydroxide or butyllithium, and then contacted with compound 501. The reaction is carried out in an inert solvent, for example dichloromethane or THF. The reaction is typically conducted at a temperature of about −78 to 0° C., for about 5 minutes to about 1 hour, or at a temperature of about 0 to 50° C., for about 1 hour to about 12 hours. When the reaction is substantially complete, the product compound 503 is isolated by conventional means.
- Compound 508 is reacted under acidic conditions sufficient to remove E1. For example, compound 508 may be contacted with an acid in the presence of water or an alcohol, if E1 is double bonded to N, such as when E1 is a diphenylmethine. For example, compound 508 may be contacted with HCl in a suitable solvent, such as methanol/dioxane. Alternatively, compound 508 may be contacted with an acid (e.g., HCl or trifluoroacetic acid) in an inert solvent (e.g., dioxane or dichloromethane), if E1 is single bonded to N, such as when E1 is a tert-butoxycarbonyl. Following removal of E1, N—H derivative of compound 508 is reacted with compound 505 under standard amide coupling conditions in a suitable solvent (e.g., THE etc.), optionally under an inert atmosphere, to provide compound 510.
- In compound 505, R53 may be leaving group (e.g., halo), or —OH. Where R53 is —OH, compound 505 is activated using a suitable agent, such as HATU, and contacted with compound 508 in the presence of a base (e.g., an organic base such as triethylamine or diisopropylethylamine). The reaction is carried out in an inert solvent, for example dichloromethane, DMF or THF. Where R53 is a leaving group, compound 505 is contacted with compound 508 in the presence of a base (e.g., an organic base such as triethylamine or diisopropylethylamine) in an inert solvent, for example dichloromethane or THF. The reaction is typically conducted at a temperature of about 0 to 30° C., for about 5 minutes to about 12 hours. When the reaction is substantially complete, the product compound 510 is isolated by conventional means.
- Alternatively, in Scheme 1, compound 503 is reacted under acidic conditions sufficient to remove E1. For example, compound 503 may be contacted with an acid in the presence of water or an alcohol, if E1 is double bonded to N, such as when E1 is a diphenylmethine. For example, compound 503 may be contacted with HCl in a suitable solvent, such as methanol/dioxane. Alternatively, compound 503 may be contacted with an acid (e.g., HCl or trifluoroacetic acid) in an inert solvent (e.g., dioxane or dichloromethane), if E1 is single bonded to N, such as when E1 is a tert-butoxycarbonyl. Following removal of E1, N—H derivative of compound 503 is reacted with compound 505 under standard amide coupling conditions in a suitable solvent (e.g., THF etc.), optionally under an inert atmosphere, to provide compound 506. In compound 505, R53 may be a leaving group (e.g., halo), or —OH. Where R53 is —OH, compound 505 is activated using a suitable agent, such as HATU, and contacted with compound 503 in the presence of a base (e.g., an organic base such as triethylamine or diisopropylethylamine). The reaction is carried out in an inert solvent, for example dichloromethane, DMF or THF. Where R53 is a leaving group, compound 505 is contacted with compound 503 in the presence of a base (e.g., an organic base such as triethylamine or diisopropylethylamine) in an inert solvent, for example dichloromethane or THF. The reaction is typically conducted at a temperature of about 0 to 30° C., for about 5 minutes to about 24 hours. When the reaction is substantially complete, the product compound 506 is isolated by conventional means.
- Compound 506 is coupled with compound 507 under standard metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., dioxane, water, etc.), optionally under an inert atmosphere, to provide compound 510. Compound 507 is an appropriate derivative of formula R1-R54. If R54 is a boronic acid —B(OH)2, or an ester thereof, compound 507 is coupled to compound 506 where R56 is a halogen (e.g., Br). If R54 is a halogen, compound 506 may first be coupled with a suitable source of boron, e.g., bis(pinacolato)diboron, to provide a boronic acid, or an ester thereof, at R56. The coupling reaction is carried out in an inert solvent, for example aqueous N,N-dimethylformamide, in the presence of a mild base, for example potassium acetate, potassium carbonate, or sodium bicarbonate. The reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(II) or dichloro 1,1′-bis(diphenylphosphino)ferrocene palladium(II), at a temperature of about 60 to 150° C., for about 10 minutes to about 12 hours. When the reaction is substantially complete, the product compound 510 is isolated by conventional means.
- In general, compound 510 is hydrolyzed at R52 under standard aqueous hydrolysis conditions (e.g., using a base or acid) in a suitable aqueous medium (e.g., THE and water, ethanol and water, etc.), optionally under an inert atmosphere, to provide compound 511. The reaction is typically conducted at a temperature of about 0 to 30° C., for about 10 minutes to about 1 hour or at a higher temperature, i.e., 30 to 100° C. for about 10 minutes to about 1 hour. When the reaction is substantially complete, the product of Formula I is isolated by conventional means.
- It will be appreciated that the R1 substituent can be added either before (as shown in Scheme 1) or after the removal of the E1 moiety. Thus, the R1 moiety may be coupled to the core-E1 compound 503 under coupling reaction conditions with an appropriate reagent of formula R1-R54 as shown in Scheme 1. Alternatively, the R1 moiety may be coupled to the core compound 506 with an appropriate reagent of formula R1-R54, following reaction with compound 505 as shown in Scheme 1.
- In some embodiments, compound 508 may be synthesized by routes illustrated in Scheme 2. For example, an alternative route for the synthesis of compound 508-1 is shown in Scheme 2, wherein the ring Y—Z forms an indazolyl or an isoquinolinyl. In the embodiment of scheme 2, R55 is O, E1 is a protecting group (e.g., tert-butoxycarbonyl), and the optional ring between E1 and R55 is absent. R52 is as defined above. Compound 516 is an appropriate acrylate derivative. Compound 515 is coupled with compound 516 under Heck metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., dioxane, water, etc.), optionally under an inert atmosphere, to provide compound 517. The coupling reaction is carried out in an inert solvent, for example aqueous N,N-dimethylformamide, in the presence of a mild base, for example triethylamine, potassium phosphate or sodium carbonate. The reaction is typically conducted in the presence of a metal catalyst, for example palladium(II) acetate, at a temperature of about 60 to 150° C., for about 10 minutes to about 12 hours. Compound 517 is reduced under suitable conditions including a reducing agent (e.g., sodium borohydride or hydrogen), and a metal catalyst, optionally in an inert solvent. For example, compound 517 is contacted with the reducing agent sodium borohydride and nickel(II) chloride in methanol. Alternatively, compound 517 is contacted with pressurized hydrogen gas (e.g., 20 to 5000 psi) and palladium on carbon (e.g., 10% Pd/C) in an inert solvent (e.g., ethanol). When the reaction is substantially complete, the product compound 508-1 is isolated by conventional means.
- In some embodiments, compound 503 may be synthesized by routes illustrated in Scheme 3. For example, an alternative route for the synthesis of compound 503-1 is shown in Scheme 3, wherein the ring Y—Z forms a 1,6-naphthyridine. In the embodiment of scheme 3, R55 is O, E1 is tert-butoxycarbonyl, and the optional ring between E1 and R55 is absent. The reaction of compound 520 with compound 521 is conducted under Negishi metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., DMF, etc.), optionally under an inert atmosphere, to provide compound 503-1. The coupling reaction is carried out in an inert solvent, for example N,N-dimethylformamide in which compound 520 is contacted with zinc dust, e.g., in the presence of a catalytic activator (e.g., I2). The reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(II), at a temperature of about 20 to 100° C., for about 10 minutes to about 24 hours. When the reaction is substantially complete, the product compound 503-1 is isolated by conventional means.
- In some embodiments, compound 503 may be synthesized by routes illustrated in Scheme 4. For example, an alternative route for the synthesis of compound 503-2 is shown in Scheme 4, wherein the ring Y—Z forms a naphthyl. In Scheme 4, E2 is a double bonded N-auxiliary such as diphenylmethine. R51, R52, and R56 are as described above. The reaction of compound 501 with compound 525 is carried out under standard nucleophilic displacement conditions (e.g., using a base) in a suitable solvent (e.g., THF etc.), optionally under an inert atmosphere, to provide compound 526. Compound 525 is deprotonated using a strong base, such as potassium hydroxide or butyllithium, and then contacted with compound 501. The reaction is carried out in an inert solvent, for example dichloromethane or THF. The reaction is typically conducted at a temperature of about −78 to 0° C., for about 5 minutes to about 1 hour, or at a temperature of about 0 to 50° C., for about 1 hour to about 12 hours. When the reaction is substantially complete, the product compound 526 is isolated by conventional means. Compound 526 is converted to compound 503-2 by standard deprotection and protection steps, where E1 is trityl or tert-butoxycarbonyl, R55 is O, and the optional ring between E1 and R55 is absent. The product compound 503-2 is isolated by conventional means.
- In some embodiments, compound 515 may be synthesized by routes illustrated in Scheme 5. For example, an alternative route for the synthesis of compounds 515-1 and 515-2 is shown in Scheme 5, wherein the ring Y—Z forms an indazolyl. In Scheme 5, R1 and R54 are as described above. The reaction of compound 530 to form compound 531 is carried out by contacting compound 530 with a strong base (e.g., sodium hydride) in an inert solvent (e.g., DMF) and then adding an electrophilic source of an alkylating agent (e.g., methyl iodide). The reaction is typically conducted at a temperature of about 0 to 50° C., for about 10 minutes to about 12 hours. When the reaction is substantially complete, the product compound 531 is isolated by conventional means. Compound 531 is then coupled with compound 507 under standard metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., DMF, water, etc.), optionally under an inert atmosphere, to provide a mixture of compound 515-1 and compound 515-2. Compound 507 is an appropriate derivative of formula R1-R54 in which R54 is a boronic acid —B(OH)2, or an ester thereof. The coupling reaction is carried out in an inert solvent, for example aqueous N,N-dimethylformamide, in the presence of a mild base, for example sodium carbonate. The reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example tetrakis(triphenylphosphine) palladium(O), at a temperature of about 60 to 150° C., for about 10 minutes to about 12 hours. When the reaction is substantially complete, the product compounds 515-1 and 515-2 are isolated by conventional means. Compounds 515-1 and 515-2 may be separated by conventional means, e.g., by chromatography.
- In some embodiments, an alternative route for the synthesis of compound 515 is illustrated in Scheme 6, wherein the ring Y—Z forms an isoquinoline. In Scheme 6, R1 and R54 are as described above. The reaction of compound 535 to form compound 515-3 and compound 515-4 is carried out by coupling with compound 507 under standard metal-catalyzed coupling conditions (e.g., using a palladium catalyst) in a suitable solvent (e.g., dioxane, water, etc.), optionally under an inert atmosphere, to provide a mixture of compound 515-3 and compound 515-4. Compound 507 is an appropriate derivative of formula R1-R54 in which R54 is a boronic acid —B(OH)2, or an ester thereof. The coupling reaction is carried out in an inert solvent, for example aqueous dioxane, in the presence of a mild base, for example sodium carbonate. The reaction is typically conducted in the presence of a metal catalyst with an appropriate ligand, for example dichlorobis(triphenylphosphine) palladium(II), at a temperature of about 60 to 150° C., for about 10 minutes to about 12 hours. When the reaction is substantially complete, the product compounds 515-3 and 515-4 are isolated by conventional means. Compounds 515-3 and 515-4 may be separated by conventional means, e.g., by chromatography.
- Suitably substituted compounds for use in the methods provided herein can be purchased from commercial sources or synthesized by known methods. Resolution of the isomers of compound 511 can be performed as needed using standard chiral separation/resolution conditions (e.g., chromatography, crystallization, etc.).
- Methods for preparing the novel compounds described herein will be apparent to those of skill in the art with suitable procedures being described, for example, in the reaction schemes and examples below.
-
- Methyl (S)-3-(5-bromoquinolin-8-yl)-2-((diphenylmethylene)amino)propanoate (EQ1): To a stirred solution of methyl 2-((diphenylmethylene)amino)acetate (98.0 g, 386.89 mmol) in dichloromethane (2.94 L) was added (−)-cinchonidine (11.38 g, 38.68 mmol) at room temperature. Then the reaction mixture was cooled to 0° C. 50% KOH solution (0.784 L) and 5-bromo-8-(bromomethyl)quinoline (139.82 g, 464.27 mmol) were added and the reaction mixture was allowed to warm to RT and stirred for 6 h. The progress of reaction was monitored by TLC (10% ethyl acetate in pet ether). The reaction mixture was diluted with water and stirred for 15 min, extracted with DCM and the organics were concentrated to provide the title compound.
- Methyl (S)-2-amino-3-(5-bromoquinolin-8-yl)propanoate hydrochloride (EQ2): (i). 4M HCl in 1,4-dioxane (1.26 L) was added to a stirred solution of methyl (S)-3-(5-bromoquinolin-8-yl)-2-((diphenylmethylene)amino)propanoate (EQ1) (180 g, 380.26 mmol) in methanol (0.90 L) at 0° C. and the reaction mixture was allowed to stir at room temperature for 16 h. The progress of reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure, dissolved in water and washed with ethyl acetate. The aqueous layer was separated and basified (pH-8) using Sat. NaHCO3 and extracted with 10% methanol/DCM. The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure and purified by column chromatography by silica gel (100-200 mesh size) at 2% McOH/DCM to obtain methyl (S)-2-amino-3-(5-bromoquinolin-8-yl)propanoate as a mixture of two isomers. (ii). The mixture was suspended in MTBE (400 mL) and heated to reflux for 1 h, cooled to room temperature (25-30° C.), the mixture was filtered, dried over sodium sulfate and concentrated. The above process was repeated twice to afford 19.5 g of methyl (S)-2-amino-3-(5-bromoquinolin-8-yl)propanoate. The material was dissolved in DCM and cooled to 0° C. and 4.0 M HCl in dioxane (60 mL) was added and resulting reaction mixture was evaporated under reduced pressure to obtain the title compound.
- Methyl (S)-3-(5-bromoquinoiin-8-yl)-2-(2,6-difluorobenzamido)propanoate (EQ3): To a stirred solution of EQ2 (230 mg, 0.74 mmol)) in DCM (5 mL) was added 2-fluoro-6-methylbenzoyl chloride (0.18 mL, 1.48 mmol) and TEA (0.31 mL, 2.22 mmol). The reaction mixture was allowed to stir at RT for 2 h, then concentrated. The material was taken up in McOH and crashed out with water. The material was collected via filtration and dried on the high vacuum to afford the title compound.
- Methyl (S)-2-(2,6-difluorobenzamido)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl)propanoate (EQ4): To a stirred solution of EQ3 (750 mg, 1.55 mmol) in toluene (12 mL) was added bis(pinacolato)diboron (435 mg, 1.71 mmol), followed by potassium acetate (458 mg, 4.66 mmol) and dichloro 1,1′-bis(diphenylphosphino)ferrocene palladium (II) dichloromethane (64 mg, 0.08 mmol). The reaction vessel was flushed with nitrogen then heated to 100° C. overnight. It was cooled to RT and filtered. The reaction was concentrated and purified on silica gel eluting with EtOAc in hexanes (5-100%) to give the title compound.
- Methyl (S)-3-(5-bromoquinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoate (EQ5): The title compound was prepared according to the method presented for the synthesis of compound EQ3, starting with EQ2 and 2,6-dichlorobenzoyl chloride.
- Methyl (S)-2-(2,6-dichlorobenzamido)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl)propanoate (EQ6): The title compound was prepared according to the method presented for the synthesis of compound EQ4 starting with EQ5.
- 5-Bromo-8-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)quinolone: To a stirring solution of (R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine in THF (26 mL) at −78° C. was added BuLi (4.37 mL, 7.2 mmol, 1.6M) dropwise over 5 min. After 20 min at −78° C., 5-bromo-8-(bromomethyl)quinoline (1.55 g, 5.15 mmol) was added in THF (21 mL) dropwise over 15 min. After 15 min at −78° C. water and ethyl acetate were added and the mixture was allowed to warm to RT, extracted with ethyl acetate, dried over sodium sulfate, filtered, and concentrated. The residue was purified using ISCO chromatography eluting with ethyl acetate in hexanes to afford the title compound.
- 8-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolone: To a suspension of 5-bromo-8-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)quinoline (600 mg, 1.48 mmol), bis(pinacolato)diboron (754 mg, 2.97 mmol) and potassium acetate (437 mg, 4.45 mmol) in DMA (10 mL) was added cataCXium A Pd-G3 (54 mg, 0.074 mmol) and the reaction vial was degassed with nitrogen, sealed, and heated to 90° C. for 90 min. It was cooled to RT, and water was added and the mixture extracted 3× with EtOAc, dried over sodium sulfate, filtered, and concentrated under vacuum to afford the title compound which was used without further purification.
- 5-(2,6-Dichloro-4-fluorophenyl)-8-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)quinolone: To a solution of 2-bromo-1,3-dichloro-5-fluorobenzene (225 mg, 0.93 mmol), 8-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (278 mg, 0.616 mmol) in DME (4 mL) was added tetrakis(triphenylphosphine)palladium(O) (50 mg, 0.043 mmol) and potassium phosphate (2.1 mL, 2.1 mmol, 1N), and the reaction vial was degassed with nitrogen, sealed, and heated to 85° C. for 4 h. It was diluted with water and extracted with ethyl acetate, dried over sodium sulfate, filtered, concentrated and purified on silica gel eluting with hexanes and ethyl acetate to afford the title compound.
- Methyl (S)-2-amino-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)propanoate (EQ7): 5-(2,6-dichloro-4-fluorophenyl)-8-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)quinoline (436 mg, 0.893 mmol) was dissolved in THE (3.6 mL) and added aqueous HCl (2.7 mL, 5.4 mmol, 2N). The mixture was stirred for 4.5 h and diluted with sat. NaHCO3, then extracted with DCM, dried over sodium sulfate, concentrated under vacuum and the residue was purified by silica gel chromatography eluting with dichloromethane and methanol to afford the title compound.
- Methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl)propanoate (EQ8): To a suspension of methyl (S)-3-(5-bromoquinolin-8-yl)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)propanoate (550 mg, 0.958 mmol), Bis(pinacolato)diboron (292 mg, 1.15 mmol) and potassium acetate (282 mg, 2.87 mmol) in toluene (10 mL) was added [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (39 mg, 0.048 mmol) and the reaction vial was degassed with nitrogen, sealed, and heated to 100° C. for 90 min. It was cooled to RT, and water was added and the mixture extracted 3× with EtOAc, dried over sodium sulfate, filtered, and concentrated under vacuum to afford the title compound which was used without further purification.
- Methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl)propanoate (EQ9): To a suspension of methyl (S)-3-(5-bromoquinolin-8-yl)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)propanoate (550 mg, 0.958 mmol), bis(pinacolato)diboron (292 mg, 1.15 mmol) and potassium acetate (282 mg, 2.87 mmol) in toluene (10 mL) was added [1,1-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (39 mg, 0.048 mmol) and the reaction vial was degassed with nitrogen, sealed, and heated to 100° C. for 90 min. It was cooled to RT, and water was added and the mixture extracted 3× with EtOAc, dried over sodium sulfate, filtered, and concentrated under vacuum to afford the title compound which was used without further purification.
- Methyl (S)-3-(8-bromoquinolin-5-yl)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzamido)propanoate (EQ10): To a stirred solution of EQ2 (670 mg, 2 mmol) and N-ethyl-N-isopropylpropan-2-amine (840 mg, 2 mmol) in DCM (1.5 mL) HATU (0.83 g, 2 mmol) was added 2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzoic acid (0.88 g, 2 mmol). The mixture was stirred overnight, diluted with water, concentrated, and chromatographed on silica gel eluting with methanol in dichloromethane to afford the title compound.
- Methyl (R)-2,6-difluoro-4-(3-(trifluoromethyl)morpholino)benzoate: To methyl 4-bromo-2,6-difluorobenzoate (120 g, 478 mmol), 3-(trifluoromethyl)morpholine hydrochloride (109 g, 573 mmol), cesium carbonate (779 g, 2.39 mol), RuPhos (8.92 g, 19.1 mmol), and tBuBrettPhos-Pd-G3 (8.17 g, 9.56 mmol) was added 840 mL Toluene. The mixture was de gassed by bubbling with N2 for 10 min then heated to 120° C. for 16 h. Water (500 mL) was added and the mixture was filtered. The filtrate was washed with ethyl acetate (2×200 mL) and organics were washed with brine, dried over sodium sulfate, concentrated and chromatographed on silica gel eluting with petroleum ether, ethyl acetate, and methanol. The residue was stirred with 600 mL of a 15/1 mixture of petroleum ether and ethyl acetate for 12 and filtered to afford 78 g of the racemic title compound which was further resolved by SFC chromatography (column: DAICEL CHIRALPAKAS (250 mm*30 mm, 10 um); mobile phase: [Neu-ETOH]; B %: 14%-14%, 4.5 min) to provide the title compound.
- (R)-2,6-difluoro-4-(3-(trifluoromethyl)morpholino)benzoic acid (T1) methyl (R)-2,6-difluoro-4-(3-(trifluoromethyl)morpholino)benzoate (35 g, 107.5 mmol, 1.00 eq) was added to a round bottom flask charged with THE (100.0 mL) and McOH (100.0 mL) and H2O (120.0 mL). Lithium hydroxide (12.9 g, 537 mmol, 5 eq) was added and the mixture heated at 50° C. for 2 h. The mixture was concentrated on a rotary evaporator, extracted with ethyl acetate (3×20 mL) and the combined organic layers were dried over sodium sulfate, concentrated and triturated with petroleum ether/ethyl acetate (5/1, 50 mL×3) for 30 min to afford the title compound.
- tert-Butyl (R)-2,6-difluoro-4-((1,1,1-trifluorobutan-2-yl)amino)benzoate: To a stirred suspension of tert-butyl 4-bromo-2,6-difluorobenzoate (250 mg, 0.55 mmol), (R)-1,1,1-trifluorobutan-2-amine (85 mg, 0.67 mmol), cesium carbonate (904 mg, 2.8 mmol) and toluene (5 mL) was added XPhos Pd G3 (42 mg, 0.06 mmol). The reaction mixture was sparged with nitrogen and then heated to 90° C. for 12 h. The mixture was cooled to RT and diluted with ethyl acetate (50 mL). The resultant suspension was filtered through a pad of Celite®, and the filtrate was evaporated under reduced pressure to afford the title compound. MS (m/z) 284.1 [M+H−C4H8]+.
- (R)-2,6-difluoro-4-((1,1,1-trifluorobutan-2-yl)amino)benzoic acid (T2): To a stirred solution of tert-butyl (R)-2,6-difluoro-4-((1,1,1-trifluorobutan-2-yl)amino)benzoate (188 mg, 0.55 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (1 mL). The reaction mixture was allowed to stir at RT for 20 mins. The reaction mixture was concentrated under reduced pressure to afford crude material. This material was purified by silica gel column chromatography and eluted ethyl acetate in hexanes to afford the title compound. MS (m/z) 338.1 [M+H]+.
- tert-Butyl (R)-2,6-difluoro-4-((2,2,2-trifluoro-1-phenylethyl)amino)benzoate: To a 500 mL pressure vessel was added tert-butyl 4-bromo-2,6-difluorobenzoate (3 g, 6.65 mmol), (R)-2,2,2-trifluoro-1-phenylethan-1-amine (1.39 g, 7.98 mmol), cesium carbonate, (10.84 g, 33.26 mmol), XPhos Pd G3 (0.5 g, 0.67 mmol), toluene (37 mL) and the mixture was sparged with N2 for 15 min, sealed and stirred at 90° C. overnight. The mixture was cooled, filtered through celite, concentrated under vacuum to afford the title compound which was used without further purification.
- (R)-2,6-Difluoro-4-((2,2,2-trifluoro-1-phenylethyl)amino)benzoic acid (T3): tert-butyl (R)-2,6-difluoro-4-((2,2,2-trifluoro-1-phenylethyl)amino)benzoate (3.88 g, 10 mmol), was dissolved in DCM (30 mL), then added TFA (30 mL). The solution was swirled and allowed to stand for 1 h. The mixture was concentrated under vacuum, then chromatographed on silica gel eluting with hexanes and ethyl acetate to afford the title compound.
-
- Synthesis of 1-bromo-4-(bromomethyl)naphthalene (NIA): To a stirred solution of 1-bromo-4-methylnaphthalene (50.0 g, 0.226 mol) in chloroform (1.0 L) was added NBS (39.0 g, 0.226 mol) and AIBN (0.188 g, 1.13 mmol) at RT. The reaction mixture was heated to 70° C. for 16 h. After completion, the reaction was cooled to RT and diluted with DCM. The organic layer was washed with water, brine, and dried over anhydrous Na2SO4 before concentrating under reduced pressure to afford NIA.
- Synthesis of methyl (S)-3-(4-bromonaphthalen-1-yl)-2-((diphenylmethylene) amino)propanoate (NIB): To a stirred solution of methyl 2-((diphenylmethylene)amino)acetate (38.72 g, 0.153 mol) in dichloromethane (1.53 L) was added (−)-cinchonidine (5.0 g, 0.017 mol) at RT. The reaction mixture was cooled to 0° C. and KOH (0.408 L, 50% aq) was added followed by N1A (51.0 g, 0.17 mol). The reaction mixture was allowed to stir at RT for 6 h. The reaction mixture was diluted with water and stirred for 15 min. The aqueous layer was then extracted with DCM. The combined organic layer was washed with saturated NaHCO3, brine, and dried over anhydrous Na2SO4. Volatiles were removed under reduced pressure to afford compound N1B. The crude compound was used without further purification for the next step.
- Synthesis of methyl (S)-2-amino-3-(4-bromonaphthalen-1-yl)propanoate (N1C): To a stirred solution of N1B (35.0 g, 0.138 mol) in methanol (0.175 L) was added HCl in 1,4-dioxane (0.35 L, 4M) at 0° C. The reaction mixture was allowed to stir at RT for 16 h. The reaction mixture was concentrated under reduced pressure, dissolved in water, and washed with ethyl acetate. The aqueous layer was adjusted to ˜pH 8 using saturated NaHCO3 and extracted with ethyl acetate. The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford crude N1C. This material was purified by 100-200 mesh silica gel column chromatography and eluted with 2% methanol in DCM to afford compound N1C (mixture of isomers). The mixture of stereoisomers was then purified by chiral SFC (Chiralpak IC (30×250 mm), 5p; 0.5% isopropyl amine in IPA) to give N1C.
- Synthesis of methyl (S)-2-amino-3-(4-bromonaphthalen-1-yl)propanoate HCl (N1): To a stirred solution of N1C (5.5 g, 16.2 mmol) in dichloromethane (55.0 mL) was added HCl in 1,4-dioxane (16.5 mL, 4M) at 0° C. The reaction mixture was allowed to stir at RT for 30 m. The reaction mixture was concentrated under reduced pressure to obtain N1.
- Methyl (S)-3-(4-bromonaphthalen-1-yl)-2-(2,6-difluorobenzamido)propanoate (N2): To a stirred solution of N1 (172 mg, 0.5 mmol)) in DCM (5 mL) was added 2-fluoro-6-methylbenzoyl chloride (0.07 mL, 0.55 mmol) and TEA (0.35 mL, 2.5 mmol). The reaction mixture was allowed to stir for 1 h, then diluted with DCM and concentrated. The material was purified on silica gel eluting with EtOAc in hexanes (0-80%) to give the title compound.
- Methyl (S)-2-(2,6-difluorobenzamido)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)propanoate (N3): To a stirred solution of N2 (152 mg, 0.34 mmol) in dioxane (3.5 mL) was added bis(pinacolato)diboron (172 mg, 0.68 mmol), followed by potassium acetate (100 mg, 1.0 mmol) and dichloro 1,1′-bis(diphenylphosphino)ferrocene palladium (II) dichloromethane (22.15 mg, 0.03 mmol). The reaction vessel was flushed with nitrogen then heated to 100° C. for 2 h. EtOAc was added then filtered through Celite and concentrated under reduced pressure to afford the title compound that was used without further purification.
- Methyl (S)-3-(4-bromonaphthalen-1-yl)-2-(2,6-dichlorobenzamido)propanoate (N4): The title compound was prepared according to the method presented for the synthesis of compound N2 starting with N1 and 2,6-dichlorobenzoyl chloride.
- Methyl (S)-2-(2,6-dichlorobenzamido)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)propanoate (N5): The title compound was prepared according to the method presented for the synthesis of compound N3 starting with N4.
-
- Synthesis of methyl (S)-3-(4-bromonaphthalen-1-yl)-2-(tritylamino)propanoate (N6A): The title compound was prepared according to the method presented for the synthesis of compound N2 starting with N1 and trityl chloride.
- Synthesis of methyl (S)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)-2-(tritylamino)propanoate (N6): The title compound was prepared according to the method presented for the synthesis of compound N-3 starting with N6A.
-
- Synthesis of methyl (S)-3-(4-bromonaphthalen-1-yl)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)propanoate (N7A): To a stirred solution of N1 (100 mg, 0.29 mmol)) in DCM (1 mL) and DMF (1 mL) was added T1 (90 mg, 0.32 mmol), HATU (121 mg, 0.32 mmol) and DIPEA (0.25 mL, 1.5 mmol). The reaction mixture was allowed to stir for 1 h and concentrated. The material was purified on silica gel eluting with EtOAc in hexanes (0-50%) to give the title compound.
- Synthesis of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)propanoate (N7): To a stirred solution of N7A (149 mg, 0.26 mmol) in dioxane (3 mL) was added bis(pinacolato)diboron (131 mg, 0.52 mmol), followed by potassium acetate (76 mg, 0.78 mmol) and dichloro 1,1′-bis(diphenylphosphino)ferrocene palladium (II) dichloromethane (17 mg, 0.02 mmol). The reaction vessel was flushed with nitrogen then heated to 100° C. overnight. EtOAc was added then filtered through Celite and concentrated under reduced pressure. The crude was purified on silica gel eluting with EtOAc in hexanes (0-60%) to give the title compound.
-
- Synthesis of methyl (S)-3-(4-bromonaphthalen-1-yl)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)propanoate (N8A): The title compound was prepared according to the method presented for the synthesis of compound N7A starting with N1 and T2.
- Synthesis of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)propanoate (N8): The title compound was prepared according to the method presented for the synthesis of compound N3 starting with N8A.
- 2-Bromo-5-fluoro-1-methoxy-3-(trifluoromethyl)benzene (H1): To a stirred solution of 2-bromo-5-fluoro-3-(trifluoromethyl)phenol (0.21 g, 0.64 mmol) in DMF was added K2CO3 (133 mg, 0.96 mmol) and iodomethane (0.105 g, 0.74 mmol). The reaction mixture was allowed to stir ON at RT. EtOAc and water was added to the reaction mixture. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure and purified by silica gel chromatography using hexanes/EtOAc as gradient.
- 3-Bromo-6-fluoro-1,4-dimethylquinolin-2(1H)-one (H2): To a solution of 6-fluoro-1,4-dimethylquinolin-2(1H)-one (210 mg, 1.1 mmol) in CH3CN (11 mL, 0.1 M) was added NBS (489 mg, 2.75 mmol) and the mixture was heated at 100° C. for 1.5 h in a MW reactor, and then filtered. The material was used directly in the next step.
- 3-Chloro-1,4,6-trimethylpyridin-2(1H)-one (H3): 3-chloro-4,6-dimethylpyridin-2(1H)-one (0.950 g, 6 mmol), methyl iodide, (0.375 mL, 6 mmol), potassium carbonate (0.83 g, 6 mmol) and DME were combined and heated to 95° C. for 2 h. The reaction mixture was partitioned between ethyl acetate and water, layers were separated and the organics were dried over sodium sulfate, filtered and concentrated. The material was chromatographed on silica gel eluting with EA in hexanes 0-100% to afford the title compound.
-
-
- a) 7-Fluoro-1,4-dimethylquinolin-2(1H)-one: To a stirred solution of 7-fluoro-4-methylquinolin-2-ol (1.0 g, 5.644 mmol) in DMF (56 mL) at 0° C. was added sodium hydride (0.293 g, 7.337 mmol) and methyl iodide (0.422 mL, 6.773 mmol). The reaction mixture was allowed to stir while warming to room temperature for 12 h. The reaction was quenched with NaOH (2 mL, 1M) then water and EtOAc were added. The organic phase was separated and the aqueous phase was extracted with EtOAc (3×). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The crude mixture was purified via trituration from DCM to afford the title compound.
- b) 3-Bromo-7-fluoro-1,4-dimethylquinolin-2(1H)-one: To a stirred solution of 7-fluoro-1,4-dimethylquinolin-2(1H)-one (414 mg, 2.165 mmol) in DMF (2 mL) was added N-bromosuccinimide (424 mg, 2.382 mmol) and the reaction mixture was allowed to stir under microwave irradiation at 110° C. for 30 min. The mixture was filtered to afford the title compound without further purification.
- 3-Bromo-1,4-dimethylquinolin-2(1H)-one (H5): Prepared as described in Journal of Organic Chemistry (1961), 26, 4949-5.
- 6-Bromo-3-iodo-1,4-dimethylquinolin-2(1H)-one (H6): To a solution of (H5) (160 mg, 0.635 mmol) in DMF (6.00 mL, 0.1 M) was added NBS (124 mg, 0.698 mmol) and the mixture was stirred overnight. The mixture was filtered to afford the title compound.
-
-
- a) N-(4-Bromophenyl)-N-methyl-3-oxobutanamide (H7A): To a stirred solution of 4-bromo-N-methylaniline (1.0 g, 5.375 mmol) in toluene (5 mL) was added 2,2,6-trimethyl-4H-1,3-dioxin-4-one (0.79 ml, 5.91 mmol) and allowed to stir open to the atmosphere at 100° C. for 2 h. Upon completion (monitored with LCMS and TLC 50:50 EtOAc:hexanes), the reaction mixture was concentrated under reduced pressure and the crude product was purified via silica gel chromatography eluting hexanes/EtOAc 0-100% to afford the title compound.
- b) 6-Bromo-1,4-dimethylquinolin-2(1H)-one (H7B): A stirred solution of H7A (1.78 g, 6.59 mmol) in conc. sulfuric acid (7.0 mL) was heated to 95° C. for 2 h. The reaction mixture was poured over ice and filtered to afford the title compound without further purification.
- c) 3-Bromo-6-cyclopropyl-1,4-dimethylquinolin-2(1H)-one (H7C): To a solution of H7B (0.13 g, 0.52 mmol) in degased toluene:water (4:1, 50 mL) was added K3PO4 (657 mg, 3.1 mmol), cyclopropyl boronic acid (133 mg, 1.55 mmol), and
- palladium tetrakistriphenylphosphine (60 mg, 0.052 mmol) in a sealed tube. The mixture was heated at 108° C. overnight. The mixture was diluted with EtOAc, washed with water, dried (Na2SO4), and concentrated under reduced pressure to provide the product. The material was purified using flash chromatography (EtOAc in hexanes 12-100%) to afford the title compound.
- d) 3-Bromo-6-cyclopropyl-1,4-dimethylquinolin-2(1H)-one (H7): To a stirred solution of H7C (453 mg, 2.124 mmol) in DMF (21 mL) was added N-bromosuccinimide (416 mg, 2.336 mmol) and the reaction was allowed to stir at room temperature for 12 h. The crude product was purified via silica gel chromatography eluting hexanes/EtOAc 12-100% to afford the title compound.
- 6-Chloro-3-bromo-1,4-dimethylquinolin-2(1H)-one (H8): Prepared analogously to the method to produce H6 employing 6-chloro-1,4-dimethylquinolin-2(1H)-one in place of 3-bromo-1,4-dimethylquinolin-2(1H)-one.
-
-
- a) Synthesis of N-methyl-N-(4-(trifluoromethyl)phenyl)but-2-ynamide (H9A): To a solution of the N-methylaniline (1.5 g, 8.56 mmol) in CH2Cl2 (0.25 M) was added tetralic acid (0.79 g, 9.42 mmol) and DMAP (0.105 g, 0.856 mmol) at 0° C., followed by a solution of DCC (2.65 g, 12.85 mmol) in CH2Cl2. The reaction mixture was warmed to RT and stirred overnight. The mixture was filtrated, washed with CH2Cl2 and the filtrate was evaporated to provide the crude intermediate, which was purified using silica gel flash chromatography 10-100% EtOAc in hexanes to afford the product.
-
- b) Synthesis of 3-iodo-1,4-dimethyl-6-(trifluoromethyl)quinolin-2(1H)-one (H9): To a solution of H9A (0.234 g, 0.97 mmol) in chlorobenzene (0.1 M) was added a pre-mixed solution of PIFA (0.918 g, 2.134 mmol) and BF3.OEt2 (0.296 g, 0.97 mmol) in chlorobenzene (0.1 M) at RT under a N2 atmosphere. The reaction was then heated at 80° C. overnight.
- Upon completion, the solvent was removed under reduced pressure and the crude residue was dissolved in EtOAc, washed with Satd. NaHCO3, dried (Na2SO4), and concentrated under reduced pressure. The crude was purified using silica gel flash chromatography 10-100% EtOAc in hexanes to afford the title compound.
- b) Synthesis of 3-iodo-1,4-dimethyl-6-(trifluoromethyl)quinolin-2(1H)-one (H9): To a solution of H9A (0.234 g, 0.97 mmol) in chlorobenzene (0.1 M) was added a pre-mixed solution of PIFA (0.918 g, 2.134 mmol) and BF3.OEt2 (0.296 g, 0.97 mmol) in chlorobenzene (0.1 M) at RT under a N2 atmosphere. The reaction was then heated at 80° C. overnight.
-
-
- a) To a stirred solution of 4-(trifluoromethyl)-1,5,6,7-tetrahydro-2H-cyclopenta[b]pyridin-2-one (2.5 g, 12.31 mmol) and potassium carbonate (1.87 g, 0.01 mol) in DMF (20 mL) was added methyl iodide (1.92 g, 14 mmol). After stirring overnight the mixture was diluted with ethyl acetate, washed with brine and the organic layer was concentrated and the residue was purified by silica gel chromatography eluting with ethyl acetate in hexanes to afford 1-methyl-4-(trifluoromethyl)-1,5,6,7-tetrahydro-2H-cyclopenta[b]pyridin-2-one. 1H NMR (400 MHz, DMSO-d6) δ 6.54 (q, J=1.1 Hz, 1H), 3.43 (s, 3H), 3.07-2.91 (m, 2H), 2.79 (t, J=7.2 Hz, 2H), 2.12 (q, J=7.7 Hz, 2H).
- b) To a stirred suspension of 1-methyl-4-(trifluoromethyl)-1,5,6,7-tetrahydro-2H-cyclopenta[b]pyridin-2-one (158 mg, 0.73 mmol) in THF (7 mL) at −78° C. was dropwise added 1 M 2,2,6,6-tetramethylpiperidinylmagnesium chloride, lithium chloride in THF (1.1 ml, 1N, 1.1 mmol). After 30 min solid iodine was added and the reaction mixture was removed from the dry ice bath and continued to stir for 1 h. The reaction mixture was adsorbed onto silica gel and chromatographed eluting with ethyl acetate in hexanes to afford the title compound.
-
-
- a) 1-Methyl-4-(trifluoromethyl)quinolin-2(1H)-one: To a stirred solution of 4-(trifluoromethyl)quinolin-2-ol (3.15 g, 0.015 mol) in DMF (10 mL) was added sodium hydride (0.711 g, 0.018 mol) and the reaction mixture was allowed to stir at room temperature for 20 min. Iodomethane (1.383 mL, 0.022 mol) was added and the reaction mixture was allowed to stir 14 h. The reaction was concentrated under reduced pressure and purified via silica gel chromatography eluting hexanes/EtOAc 0-100% to afford the title compound as a mixture of N-methyl and O-methyl.
- b) 6-Bromo-1-methyl-4-(trifluoromethyl)quinolin-2(1H)-one: To a stirred solution of 1-methyl-4-(trifluoromethyl)quinolin-2(1H)-one (0.60 g, 0.003 mol) in acetonitrile was added N-bromosuccinimide (1.175 g, 0.007 mol) and the reaction was allowed to stir at 125° C. for 3 h. The reaction mixture was concentrated under reduced pressure and purified via silica gel chromatography to afford the title compound.
- c) 6-Bromo-3-iodo-1-methyl-4-(trifluoromethyl)quinolin-2(1H)-one: To a stirred solution of 6-bromo-1-methyl-4-(trifluoromethyl)quinolin-2(1H)-one (641 mg, 2.094 mmol) in THF (15 mL) at −78° C. was added 2,2,6,6-tetramethylpiperidinylmagnesium chloride lithium chloride in THF (1M, 2.51 mL, 2.513 mmol). The reaction mixture was allowed to stir at −78° C. for 30 min then iodine (1.329 g, 0.005 mol) in THF (5 mL) was added dropwise and the reaction was allowed to stir at −78° C. for an additional 10 min. The reaction mixture was purified via direct loading onto silica gel and subsequent normal phase chromatography eluting hexanes/EtOAc 0-60% to afford the title compound.
- 3-Iodo-1-methyl-4-(trifluoromethyl)quinolin-2(1H)-one (H12): To a stirred solution of 1-methyl-4-(trifluoromethyl)quinolin-2(1H)-one (243 mg, 1.07 mmol) in THF (10 mL) was added LiMg-TMP (1.74 mL, 1.74 mmol, 1M) dropwise at −78° C. The reaction mixture was allowed to stir for 30 min, and a solution of iodine (488 mg, 2 mmol) in THF (5 mL) was added at −78° C. The reaction mixture was allowed to warm to RT, concentrated under reduced pressure, and purified by silica gel chromatography eluting with ethyl acetate in hexanes to afford the title compound.
- 1-Bromo-4-fluoro-2-methoxy-5-methylbenzene (H13): To a stirred solution of 5-fluoro-2-bromo-4-methylphenol (300 mg, 0.952 mmol) and K2CO3 (197 mg, 1.428 mmol) in DMF (2 mL) was added iodomethane (0.068 mL, 1.095 mmol) and the reaction mixture was allowed to stir at room temperature for 1 hr. The reaction mixture was diluted with EtOAc, filtered, concentrated under reduced pressure, and purified via silica gel chromatography eluting hexanes/EtOAc 0-50% to afford the title compound.
- 1-Bromo-4,5-difluoro-2-(methoxy-d3)benzene (H14): To a stirred solution of 2-bromo-4,5-difluorophenol (200 mg, 0.766 mmol) and K2CO3 (159 mg, 1.148 mmol) in DMF (1 mL) was added iodomethane-D3 (128 mg, 0.880 mmol) and the reaction mixture was allowed to stir at room temperature for 1 hr. The reaction mixture was diluted with EtOAc, filtered, concentrated under reduced pressure, and purified via silica gel chromatography eluting hexanes/EtOAc 0-50% to afford the title compound.
- 2-Bromo-1-chloro-5-fluoro-3-methoxybenzene (H15): To a stirred solution of 2-bromo-3-chloro-5-fluorophenol (250 mg, 0.887 mmol) and K2CO3 (184 mg, 1.331 mmol) in DMF (1.5 mL) was added iodomethane (0.064 mL, 1.020 mmol) and the reaction mixture was allowed to stir at room temperature for 1 hr. The reaction mixture was diluted with EtOAc, filtered, concentrated under reduced pressure, and purified via silica gel chromatography eluting hexanes/EtOAc 0-50% to afford the title compound.
- 1-Bromo-5-chloro-4-fluoro-2-methoxybenzene (H16): To a stirred solution of 2-bromo-4-chloro-5-fluorophenol (200 mg, 0.710 mmol) and K2CO3 (147 mg, 1.06 mmol) in DMF (1 mL) was added iodomethane (0.051 mL, 0.816 mmol) and the reaction mixture was allowed to stir at room temperature for 1 hr. The reaction mixture was diluted with EtOAc, filtered, concentrated under reduced pressure, and purified via silica gel chromatography eluting hexanes/EtOAc 0-50% to afford the title compound.
- 1-Bromo-2-cyclopropoxy-4,5-difluorobenzene (H17): To a stirred solution of 2-bromo-4,5-difluorophenol (500 mg, 2.4 mmol) in DMF was added KI (397 mg, 2.4 mmol), Cs2CO3 (445 mg, 7 mmol) and bromocyclopropane (0.575 mL, 7 mmol). The reaction mixture was heated at 180° C. for 2 h in a microwave reactor. The reaction mixture was diluted with EtOAc and water. The aqueous layer was adjusted to pH 2 with 2M NaOH, extracted with EtOAc (2×), and the organic layer was washed with brine and concentrated. The crude product was purified via silica gel chromatography eluting hexanes/EtOAc 0-10% to afford the title compound.
- 3-Iodo-1,6-dimethyl-4-(trifluoromethyl)pyridin-2(1H)-one (H18): Prepared according to the procedure for H10 employing 6-methyl-4-(trifluoromethyl)pyridin-2(1H)-one as starting material.
-
-
- a) 7-Chloro-1,4-dimethylquinolin-2(1H)-one: To a stirred solution of N-(3-chlorophenyl)-N-methyl-3-oxobutanamide was added H2SO4 (5 mL) and the mixture was heated to 95° C. for 2 h, poured over ice, filtered and used in the next step without further purification.
- b) 3-Bromo-7-chloro-1,4-dimethylquinolin-2(1H)-one: To a solution of 7-chloro-1,4-dimethylquinolin-2(1H)-one (0.54 g, 2.6 mmol) in DMF (26 mL) was added NBS (0.51 g, 2.86 mmol) and the mixture was stirred at overnight. The reaction was added to silica gel and chromatographed eluting with ethyl acetate in hexanes to afford 0.54 g of the title compound.
-
-
- a) Synthesis of 4-(trifluoromethyl)isoquinolin-3-amine (H20A): To a sealed tube, tris(trimethylsilyl)silyl chloride (0.35 ml, 1.25 mmol), 3-aminoisoquinoline (150 mg, 1.04 mmol), and Togni's reagent (412 mg, 1.25 mmol) were dissolved in ACN and was heated to 80° C. for 1 hour. Then the reaction mixture was concentrated and purified on silica gel eluting with EtOAc/hexanes 0-100%.
- b) Synthesis of 3-bromo-4-(trifluoromethyl)isoquinoline (H20): H20A (221 mg, 1.04 mmol) was added to HBr solution (16.8 mL, 148 mmol) at 0° C. (ice bath), then Br2 (0.32 mL, 6.25 mmol) was added slowly at 0° C., stir for 10 min and NaNO2 (360 mg, 5.21 mmol) in water was added dropwise over 5 min. The reaction mixture was stirred at 0° C. for 30 min then allowed to warm to RT for 60 min. Quench with satd. NaHCO3 and extracted with DCM (3×). Organic layers were combined, concentrated and purified using silica gel eluting with 0-15% EtOAc in hexanes.
-
-
- a) Synthesis of 2-oxo-1,2-dihydro-1,6-naphthyridine-3-carboxylic acid (H21A): To a stirred solution of 4-aminonicotinaldehyde (0.15 g, 1.2 mmol) in EtOH (2 mL) was added Meldrum's acid (0.17 g, 1.2 mmol), piperidine (10 μL, 0.13 mmol), and acetic acid (20 μL, 0.36 mmol). The reaction mixture was stirred at room temperature for 20 min and then heated at 100° C. for 2 h. After cooling to room temperature, the mixture was filtered, washed with EtOH, and dried in vacuum to give the title compounds without further purification.
- b) Synthesis of 3-iodo-1,6-naphthyridin-2(1H)-one (H21B): In a microwave vial (10 mL) that contained a solution of compound H21A (80 mg, 0.42 mmol) in a mixture of DMF/water (9:1, 5 mL) were added NIS (331 mg, 1.47 mmol) and LiOAc (42 mg, 0.63 mmol). The vial was sealed and then heated under microwave heating at 120° C. for 30 min. After cooling, water was added, and the mixture was extracted with DCM. The organic layer was washed with brine, dried with Na2SO4, filtered, and concentrated under reduced pressure to give the title compound which was used without further purification.
- c) Synthesis of 3-iodo-1-methyl-1,6-naphthyridin-2-one (H21): To a stirred solution of compound H21B (114 mg, 0.42 mmol) in DMF (4 mL) at 0° C. was added sodium hydride (60%, 20 mg, 0.5 mmol) and the mixture was stirred for 10 min at 0° C., followed by the addition of Mel (31 μL, 0.5 mmol). Ice bath was removed, and the reaction mixture was stirred at RT for 30 min. EA and water was added to the reaction mixture. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified by silica gel chromatography using McOH in DCM as eluent to afford the title compound.
-
-
- a) Synthesis of N-(4-fluorophenyl)-N-methyl-3-oxobutanamide (H22A): To a solution of N-methylaniline (0.500 g, 4.00 mmol) in toluene (4.0 mL) at 110° C. in an open vial (to evaporate off acetone-byproduct) was added 2,2,6-trimethyl-4H-1,3-dioxin-4-one (0.568 g, 4.00 mmol) and the mixture was heated at 110° C. for 3 h. Upon completion, the solvent was evaporated off under reduced pressure. The material was purified by flash chromatography using EA in hexanes to afford the product (mixture of keto and enol form).
- b) Synthesis of 6-fluoro-1,4-dimethylquinolin-2(1H)-one (H22B): A mixture of H22A (0.250 g, 1.20 mmol) and concentrated H2SO4 (5.53 g, 56.4 mmol) was heated at 95° C. for 2 h. Upon completion, the reaction mixture was poured over ice. The precipitate was filtered off to afford the product that was used without further purification.
- c) Synthesis of 3-bromo-6-fluoro-1,4-dimethylquinolin-2(1H)-one (H22): To a microwave vial was added H22B (0.210 g, 1.10 mmol), NBS (0.489 g, 2.75 mmol) and CH3CN (11 mL), and the mixture was heated at 100° C. for 1 h. The precipitate was filtered off to afford the title compound and used without further purification.
-
- Methyl (S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluoro benzamido)propanoate: To a stirred solution of methyl (S)-2-amino-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)propanoate (EQ7) (75 mg, 0.191 mmol) in DCM (2 mL) was added N,N-diisopropylethylamine (0.066 mL) and 2,6-difluorobenzoyl chloride (0.03 mL, 0.229 mmol) was then added. After stirring for 30 min the mixture was directly loaded onto silica gel and chromatographed on silica gel eluting with hexanes and ethyl acetate (0-100%) to afford the title compound.
- Methyl (S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluorobenzamido)propanoate (100 mg, 0.188 mmol) was dissolved in THE (2 mL) added 2N NaOH (0.75 mL, 2 mmol) and stirred for 90 min. The mixture was acidified with TFA, diluted with DMSO and chromatographed on C18 eluting with acetonitrile and water containing 0.4% TFA to afford the title compound. MS (m/z) 519.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (d, J=8.1 Hz, 1H), 9.00 (dd, J=4.1, 1.7 Hz, 1H), 7.79 (d, J=7.3 Hz, 1H), 7.76 (d, J=8.6 Hz, 2H), 7.71 (dd, J=8.5, 1.7 Hz, 1H), 7.54 (dd, J=8.5, 4.1 Hz, 1H), 7.47 (tt, J=8.4, 6.5 Hz, 1H), 7.43 (d, J=7.3 Hz, 1H), 7.14-7.03 (m, 2H), 5.01 (ddd, J=10.5, 8.1, 4.8 Hz, 1H), 4.01 (dd, J=13.5, 4.8 Hz, 1H), 3.41 (dd, J=13.6, 10.5 Hz, 1H).
-
- (S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2-fluoro-6-methoxybenzamido)propanoic acid: The title compound was prepared according to the method presented for the synthesis of Example 1 replacing 2-fluoro-6-methoxybenzoyl chloride for 2,6-difluorobenzoyl chloride. MS (m/z) 531.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.99 (dd, J=4.2, 1.7 Hz, 1H), 8.89 (d, J=7.9 Hz, 1H), 7.82 (d, J=7.4 Hz, 1H), 7.79-7.75 (m, 2H), 7.72 (dd, J=8.5, 1.7 Hz, 1H), 7.55 (dd, J=8.5, 4.1 Hz, 1H), 7.48 (d, J=7.3 Hz, 1H), 7.35 (td, J=8.4, 6.8 Hz, 1H), 6.85 (dd, J=8.5, 0.8 Hz, 1H), 6.77 (ddd, J=9.1, 8.4, 0.8 Hz, 1H), 4.91 (ddd, J=10.4, 7.8, 4.6 Hz, 1H), 3.92 (dd, J=13.9, 4.6 Hz, 1H), 3.65 (s, 3H), 3.47 (dd, J=14.0, 10.4 Hz, 1H).
-
- Methyl (S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluoro-4-(((R)-2,2,2-trifluoro-1-phenylethyl)amino)benzamido)propanoate: To a stirred solution of methyl (S)-2-amino-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)propanoate (EQ7) (30 mg, 0.076 mmol) in DCM (1 mL) was added N,N-diisopropylethylamine (0.04 mL), 1-[bis (dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (44 mg, 0.11 mmol) and (R)-2,6-difluoro-4-((2,2,2-trifluoro-1-phenylethyl)amino)benzoic acid (T3) (30 mg, 0.09 mmol) was then added. After stirring for 30 min the mixture was directly loaded onto silica gel and chromatographed on silica gel eluting with hexanes and ethyl acetate (0-100%) to afford the title compound.
- (S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluoro-4-(((R)-2,2,2-trifluoro-1-phenylethyl)amino)benzamido)propanoic acid: methyl (S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluoro-4-(((R)-2,2,2-trifluoro-1-phenylethyl)amino) benzamido)propanoate (39 mg, 0.069 mmol) was dissolved in THE (2 mL), added 2N NaOH (0.75 mL, 2 mmol) and stirred for 90 min. The mixture was acidified with TFA, diluted with DMSO and chromatographed on C18 eluting with acetonitrile and water containing 0.4% TFA to afford the title compound. MS (m/z) 692.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.98-8.95 (m, 1H), 8.77 (d, J=7.9 Hz, 1H), 7.78-7.74 (m, 3H), 7.69 (dd, J=8.5, 1.7 Hz, 1H), 7.57 (d, J=7.2 Hz, 2H), 7.54-7.48 (m, 2H), 7.45-7.35 (m, 4H), 6.52 (d, J=11.3 Hz, 2H), 5.70 (p, J=8.4, 7.9 Hz, 1H), 4.92-4.84 (m, 1H), 3.94 (dd, J=13.5, 4.7 Hz, 1H), 3.38 (ddd, J=12.9, 10.2, 1.9 Hz, 1H).
-
- (S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluoro-4-(methylsulfonamido)benzamido)propanoic acid: The title compound was prepared according to the method presented for the synthesis of Example 3 replacing T3 with 2,6-difluoro-4-(methylsulfonamido)benzoic acid. MS (m/z) 612.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.43 (s, 1H), 9.08 (d, J=8.0 Hz, 1H), 9.00 (dd, J=4.1, 1.7 Hz, 1H), 7.77 (d, J=7.4 Hz, 1H), 7.76 (d, J=8.6 Hz, 2H), 7.71 (dd, J=8.5, 1.7 Hz, 1H), 7.54 (dd, J=8.5, 4.2 Hz, 1H), 7.43 (d, J=7.3 Hz, 1H), 6.83-6.77 (m, 2H), 4.96 (ddd, J=10.5, 8.1, 4.8 Hz, 1H), 4.00 (dd, J=13.5, 4.8 Hz, 1H), 3.40 (dd, J=13.5, 10.4 Hz, 1H), 3.13 (s, 3H).
-
- (2S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluoro-4-(3-(trifluoromethyl)morpholino)benzamido)propanoic acid: The title compound was prepared according to the method presented for the synthesis of Example 3 replacing T3 with 2,6-difluoro-4-(3-(trifluoromethyl)morpholino)benzoic acid. Enantiomers were arbitrarily assigned after separation by supercritical fluid chromatography eluting with 20% McOH/DEA co-solvent on an IC SFC column.
- MS (m/z) 672.1 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 8.97 (dd, J=4.2, 1.7 Hz, 1H), 8.90 (d, J=7.8 Hz, 1H), 7.81-7.72 (m, 3H), 7.68 (dd, J=8.5, 1.7 Hz, 1H), 7.52 (dd, J=8.4, 4.1 Hz, 1H), 7.40 (dd, J=7.3, 2.7 Hz, 1H), 6.71 (d, J=11.6 Hz, 2H), 4.90 (s, 2H), 4.13 (d, J=12.9 Hz, 1H), 3.93 (d, J=13.2 Hz, 2H), 3.72 (s, 1H), 3.53 (t, J=11.0 Hz, 1H), 3.39 (d, J=9.8 Hz, 1H), 3.21 (t, J=12.0 Hz, 1H).
- MS (m/z) 672.1 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 12.69 (s, 1H), 8.97 (dd, J=4.2, 1.7 Hz, 1H), 8.91 (d, J=7.9 Hz, 1H), 7.80-7.72 (m, 3H), 7.68 (dd, J=8.5, 1.7 Hz, 1H), 7.52 (dd, J=8.5, 4.2 Hz, 1H), 7.40 (dd, J=7.3, 2.7 Hz, 1H), 6.72 (d, J=11.6 Hz, 2H), 4.89 (d, J=9.3 Hz, 3H), 4.13 (d, J=12.7 Hz, 1H), 4.02-3.86 (m, 2H), 3.71 (d, J=13.2 Hz, 1H), 3.53 (t, J=11.0 Hz, 1H), 3.39 (d, J=9.8 Hz, 1H), 3.21 (t, J=12.0 Hz, 1H).
-
- (S)-3-(5-(2,6-dichloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-dichloro benzamido)propanoic acid: The title compound was prepared according to the method presented for the synthesis of Example 1 replacing 2,6-difluorobenzoyl chloride with 2,6-dichlorobenzoyl chloride. MS (m/z) 550.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.75 (s, 1H), 9.15 (d, J=8.5 Hz, 1H), 9.00 (dd, J=4.1, 1.7 Hz, 1H), 7.85 (d, J=7.4 Hz, 1H), 7.81-7.73 (m, 2H), 7.70 (dd, J=8.4, 1.7 Hz, 1H), 7.54 (dd, J=8.5, 4.1 Hz, 1H), 7.45-7.33 (m, 4H), 5.08 (ddd, J=11.2, 8.5, 3.9 Hz, 1H), 4.04 (dd, J=13.5, 4.0 Hz, 1H), 3.35 (m, 1H).
- Methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(5-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)quinolin-8-yl)propanoate: To a stirred solution of 5-bromo-1,3,6-trimethylpyrimidine-2,4(1H,3H)-dione (51 mg, 0.22 mmol), methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-yl)propanoate (EQ9) (125 mg, 0.20 mmol) in DME (2 mL) was added XPhos Pd G3 (9 mg, 0.012 mmol) and potassium phosphate (0.7 mL, 0.7 mmol, 1N), and the reaction vial was degassed with nitrogen, sealed, and heated to 120° C. in a microwave reactor for 30 min. It was diluted with water and extracted with ethyl acetate dried over sodium sulfate, filtered, concentrated and purified on silica gel eluting with hexanes and ethyl acetate to afford the title compound.
- To a stirred solution of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(5-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)quinolin-8-yl)propanoate (83 mg, 0.128 mmol) in THE (2 mL) and methanol (2 mL) was added lithium hydroxide (0.6 mL, 1.2 mmol, 2 mL) and the mixture as stirred for 4 h. The mixture was acidified with TFA, diluted with DMSO and the more volatile components were removed on a rotary evaporator. The residue was chromatographed on C-18 modified silica gel eluting with acetonitrile in water (0.4% TFA) to afford example 8 and example 9. Example 8 was the first eluting isomer. MS (m/z) 634.72 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.94 (dd, J=4.2, 1.7 Hz, 1H), 8.72 (d, J=8.1 Hz, 1H), 8.12 (dd, J=8.5, 1.7 Hz, 1H), 7.66 (d, J=7.3 Hz, 1H), 7.49 (dd, J=8.5, 4.2 Hz, 1H), 7.28 (d, J=7.3 Hz, 1H), 6.73 (d, J=9.5 Hz, 1H), 6.39 (d, J=11.4 Hz, 2H), 4.87 (ddd, J=10.7, 8.1, 4.5 Hz, 1H), 4.28 (d, J=10.9 Hz, 1H), 4.00 (dd, J=13.2, 4.4 Hz, 1H), 3.43 (d, J=0.5 Hz, 3H), 3.22 (s, 3H), 1.93 (s, 3H), 1.75 (ddd, J=13.6, 7.3, 3.3 Hz, 1H), 1.50 (ddd, J=13.5, 10.4, 7.1 Hz, 1H), 0.95-0.85 (m, 3H).
- Prepared as describe above for example 8, example 9 was the second eluting peak from reversed phase chromatography. MS (m/z) 634.72 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.94 (ddd, J=4.2, 2.7, 1.7 Hz, 1H), 8.78 (d, J=7.5 Hz, 1H), 8.13 (ddd, J=8.5, 4.8, 1.8 Hz, 1H), 7.67 (t, J=7.3 Hz, 1H), 7.53-7.45 (m, 1H), 7.29 (dd, J=10.8, 7.2 Hz, 1H), 6.74 (t, J=10.1 Hz, 1H), 6.42 (d, J=11.5 Hz, 1H), 4.76 (ddd, J=9.8, 7.5, 5.3 Hz, 1H), 4.29 (s, 1H), 3.79 (dd, J=13.6, 5.2 Hz, 1H), 3.50 (dd, J=13.6, 9.7 Hz, 1H), 3.43 (q, J=0.8 Hz, 2H), 3.22 (d, J=1.2 Hz, 3H), 1.92 (d, J=5.8 Hz, 3H), 1.75 (ddd, J=13.7, 7.2, 3.2 Hz, 1H), 1.51 (ddd, J=13.8, 10.4, 7.1 Hz, 1H), 0.95-0.86 (m, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: To a microwave vial were added (EQ6) (266 mg, 0.5 mmol), 3-bromo-6-fluoro-1,4-dimethylquinolin-2(1H)-one H2 (136 mg, 0.504 mmol), potassium phosphate (321 mg, 1.5 mmol), palladium tetrakistriphenylphoshine (29 mg, 0.025 mmol), dioxane (4 mL) and water (1 mL). The vial was purged with nitrogen, sealed and heated in a microwave reactor at 100° C. for 30 min. Sodium hydroxide (2 mL, 2N, 4 mmol) was added and the mixture stirred an additional 10 min. The mixture was acidified with TFA and volatile components were removed via rotary evaporator. The residue was dissolved in DMSO and chromatographed on C-18 modified silica gel eluting with acetonitrile in water (0.4% TFA) to afford the title compound. MS (m/z) 578.10 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.14 (dd, J=8.5, 5.1 Hz, 1H), 8.95 (ddd, J=9.4, 4.1, 1.7 Hz, 1H), 7.86 (dd, J=8.5, 1.7 Hz, 1H), 7.74 (d, J=31.7 Hz, 1H), 7.66 (dd, J=9.4, 4.9 Hz, 1H), 7.58 (dd, J=11.5, 8.7 Hz, 1H), 7.47-7.42 (m, 1H), 7.42-7.35 (m, 2H), 7.31 (t, J=7.3 Hz, 1H), 5.05 (m, 1H), 4.08 (dd, J=13.6, 4.0 Hz, 1H), 3.88 (dd, J=13.5, 4.6 Hz, 1H), 3.66 (d, J=3.8 Hz, 3H), 3.24 (dd, J=13.5, 11.1 Hz, 1H), 2.09 (d, J=7.5 Hz, 3H).
- Example 10 (S)-2-(2,6-dichlorobenzamido)-3-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid was chromatographed on an SFC-ADH column eluting with 30% methanol to afford example 11 as the first eluting isomer. MS (m/z) 578.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.76 (s, 1H), 9.17 (d, J=8.5 Hz, 1H), 8.98 (dd, J=4.1, 1.7 Hz, 1H), 7.88 (dd, J=8.5, 1.6 Hz, 1H), 7.80-7.73 (m, 2H), 7.68 (dd, J=9.4, 4.9 Hz, 1H), 7.60 (td, J=9.4, 8.8, 2.9 Hz, 1H), 7.48-7.36 (m, 4H), 7.32 (d, J=7.2 Hz, 1H), 5.10 (ddd, J=12.0, 8.5, 3.9 Hz, 1H), 4.10 (dd, J=13.5, 4.1 Hz, 1H), 3.68 (s, 3H), 3.26 (dd, J=13.1, 11.3 Hz, 1H), 2.12 (s, 2H).
- Example 10 (S)-2-(2,6-dichlorobenzamido)-3-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid was chromatographed on an SFC-ADH column eluting with 30% methanol to afford example 12 as the second eluting isomer. MS (m/z) 578.10 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.14 (dd, J=8.5, 5.1 Hz, 1H), 8.95 (ddd, J=9.4, 4.1, 1.7 Hz, 1H), 7.86 (dd, J=8.5, 1.7 Hz, 1H), 7.74 (d, J=31.7 Hz, 1H), 7.66 (dd, J=9.4, 4.9 Hz, 1H), 7.58 (dd, J=11.5, 8.7 Hz, 1H), 7.47-7.42 (m, 1H), 7.42-7.35 (m, 2H), 7.31 (t, J=7.3 Hz, 1H), 5.05 (m, 1H), 4.08 (dd, J=13.6, 4.0 Hz, 1H), 3.88 (dd, J=13.5, 4.6 Hz, 1H), 3.66 (d, J=3.8 Hz, 3H), 3.24 (dd, J=13.5, 11.1 Hz, 1H), 2.09 (d, J=7.5 Hz, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(5-fluoro-3-methoxypyridin-2-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 2-chloro-5-fluoro-3-methoxypyridine in place of H2. MS (m/z) 513.967 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.5 Hz, 1H), 8.95 (dd, J=4.1, 1.7 Hz, 1H), 8.32 (dd, J=2.4, 0.4 Hz, 1H), 7.91 (dd, J=8.5, 1.7 Hz, 1H), 7.75 (d, J=7.4 Hz, 1H), 7.70 (dd, J=11.1, 2.4 Hz, 1H), 7.55-7.43 (m, 3H), 7.41-7.32 (m, 3H), 5.08 (ddd, J=10.7, 8.4, 4.5 Hz, 1H), 3.98 (dd, J=13.5, 4.5 Hz, 1H), 3.74 (s, 3H), 3.36 (dd, J=13.6, 10.8 Hz, 1H).
-
- (S)-3-(5-(benzo[d]thiazol-4-yl)quinolin-8-yl)-2-(2,6-dichloro benzamido) propanoic acid: Prepared according to the procedure described for example 10 employing 4-bromobenzo[d]thiazole in place of H2. MS (m/z) 521.936 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.26 (s, 1H), 9.12 (d, J=8.4 Hz, 1H), 8.95 (dd, J=4.2, 1.7 Hz, 1H), 8.30 (dd, J=8.1, 1.2 Hz, 1H), 7.86-7.72 (m, 3H), 7.65 (t, J=7.7 Hz, 1H), 7.53 (d, J=7.3 Hz, 3H), 7.47-7.24 (m, 6H), 5.11 (s, 1H), 4.02 (s, 1H), 3.39 (s, 1H)
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(3-(trifluoromethyl)pyrazin-2-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 2-chloro-3-(trifluoromethyl)pyrazine in place of H2. MS (m/z) 535.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (d, J=2.4 Hz, 1H), 9.00 (dd, J=4.1, 1.7 Hz, 1H), 8.97 (dt, J=2.4, 0.5 Hz, 1H), 7.87 (dd, J=8.5, 1.7 Hz, 1H), 7.80 (d, J=7.4 Hz, 1H), 7.53-7.47 (m, 2H), 7.37 (dt, J=15.5, 8.3 Hz, 3H), 5.09 (s, 1H), 4.10-3.92 (m, 1H), 3.50-3.29 (m, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(6-methyl-4-(trifluoromethyl)pyridazin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-bromo-6-methyl-4-(trifluoromethyl)pyridazine in place of H2. MS (m/z) 549.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.14 (d, J=18.1 Hz, 1H), 9.00 (s, 1H), 8.25 (s, 1H), 8.21 (qd, J=0.8, 0.4 Hz, 1H), 7.82 (d, J=7.4 Hz, 1H), 7.71 (dd, J=8.5, 1.7 Hz, 1H), 7.56-7.47 (m, 2H), 7.38 (d, J=6.5 Hz, 4H), 5.10 (s, 1H), 4.01 (d, J=13.7 Hz, 1H), 3.41 (t, J=12.3 Hz, 1H), 2.86 (s, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 4-bromo-1-methyl-3-(trifluoromethyl)-1H-pyrazole in place of H2. MS (m/z) 536.957 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.5 Hz, 1H), 8.97 (dd, J=4.1, 1.7 Hz, 1H), 8.18-7.97 (m, 2H), 7.73 (d, J=7.3 Hz, 1H), 7.54 (dd, J=8.5, 4.1 Hz, 1H), 7.45-7.28 (m, 4H), 3.97 (dd, J=4.4 Hz, 2H), 3.34 (dd, J=13.7, 10.9 Hz, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(1,5-dimethyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 4-bromo-1,5-dimethyl-3-(trifluoromethyl)-1H-pyrazole in place of H2. MS (m/z) 536.957 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.5 Hz, 1H), 8.97 (dd, J=4.1, 1.7 Hz, 1H), 8.18-7.97 (m, 2H), 7.73 (d, J=7.3 Hz, 1H), 7.54 (dd, J=8.5, 4.1 Hz, 1H), 7.45-7.28 (m, 4H), 3.97 (dd, J=4.4 Hz, 2H), 3.34 (dd, J=13.7, 10.9 Hz, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-bromo-5-fluoro-1-methylpyridin-2(1H)-one in place of H2. MS (m/z) 513.934 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, J=8.3 Hz, 1H), 8.94 (dd, J=4.1, 1.7 Hz, 1H), 8.11 (dd, J=4.7, 3.3 Hz, 1H), 8.01 (dd, J=8.5, 1.7 Hz, 1H), 7.71 (d, J=7.3 Hz, 1H), 7.60 (s, 1H), 7.49 (dd, J=8.5, 4.1 Hz, 1H), 7.44-7.29 (m, 4H), 5.03 (ddd, J=10.2, 8.3, 4.7 Hz, 1H), 3.49 (s, 3H), 3.36 (dd, J=13.7, 10.4 Hz, 1H), 2.65 (t, J=1.9 Hz, 1H), 2.52 (s, 1H), 2.31 (t, J=1.9 Hz, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(isochroman-8-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 8-bromoisochromane in place of H2. MS (m/z) 521.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.07 (dd, J=15.5, 8.5 Hz, 1H), 8.97 (ddd, J=5.9, 4.1, 1.8 Hz, 1H), 7.78-7.69 (m, 2H), 7.49 (ddd, J=8.5, 4.1, 1.9 Hz, 1H), 7.44-7.23 (m, 6H), 7.03-6.93 (m, 1H), 5.11 (ddt, J=11.0, 8.9, 4.6 Hz, 1H), 4.32 (dd, J=15.3, 2.7 Hz, 1H), 4.06-3.77 (m, 4H), 3.34 (ddd, J=28.9, 13.5, 11.1 Hz, 1H), 2.98-2.82 (m, 2H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(1-methyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-bromo-1-methylquinolin-2(1H)-one in place of H2. MS (m/z) 545.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.13 (d, J=8.3 Hz, 1H), 8.96 (dd, J=4.1, 1.7 Hz, 1H), 8.08 (dt, J=8.5, 1.5 Hz, 1H), 7.99 (s, 1H), 7.83 (d, J=7.7 Hz, 1H), 7.79-7.60 (m, 3H), 7.55-7.45 (m, 2H), 7.45-7.29 (m, 4H), 5.13-5.00 (m, 1H), 4.01-3.91 (m, 1H), 3.73 (s, 3H), 3.41 (t, J=12.2 Hz, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(1-ethyl-2-oxo-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-bromo-1-ethylpyridin-2(1H)-one in place of H2. MS (m/z) 510.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.4 Hz, 1H), 8.93 (dd, J=4.2, 1.8 Hz, 1H), 7.96 (dd, J=8.5, 1.8 Hz, 1H), 7.86 (dd, J=6.8, 2.1 Hz, 1H), 7.70 (d, J=7.4 Hz, 1H), 7.49 (dd, J=8.5, 4.2 Hz, 1H), 7.46-7.31 (m, 4H), 6.40 (t, J=6.8 Hz, 1H), 5.11-4.95 (m, 1H), 3.99 (m, 3H), 3.36 (m, 1H), 1.27 (t, J=7.1 Hz, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(1-methyl-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-bromo-1-methyl-5-(trifluoromethyl)pyridin-2(1H)-one in place of H2. MS (m/z) 564.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.4 Hz, 1H), 8.94 (dd, J=4.1, 1.7 Hz, 1H), 8.56 (s, 1H), 8.01 (dd, J=8.5, 1.7 Hz, 1H), 7.72 (d, J=7.4 Hz, 1H), 7.50 (dd, J=8.5, 4.2 Hz, 1H), 7.45-7.31 (m, 4H), 5.10-4.99 (m, 1H), 3.95 (dd, J=13.6, 4.7 Hz, 1H), 3.58 (s, 3H), 3.36 (dd, J=13.6, 10.5 Hz, 1H).
-
- (S)-3-(5-(chroman-8-yl)quinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing 8-bromochromane in place of H2. MS (m/z) 521.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.11-9.02 (m, 1H), 8.92 (dd, J=4.2, 1.7 Hz, 1H), 7.89 (dt, J=8.5, 1.7 Hz, 1H), 7.71 (dd, J=7.3, 3.5 Hz, 1H), 7.65-7.57 (m, 4H), 7.57-7.50 (m, 3H), 7.48 (dd, J=8.5, 4.1 Hz, 1H), 7.44-7.29 (m, 4H), 7.18 (dd, J=6.8, 2.8 Hz, 1H), 7.02-6.90 (m, 2H), 5.08 (dtd, J=11.4, 7.5, 4.5 Hz, 1H), 3.97 (q, J=7.1, 5.4 Hz, 4H), 3.32 (q, J=12.2 Hz, 1H), 2.87 (dd, J=15.4, 8.3 Hz, 2H), 1.93-1.86 (m, 3H).
-
- (S)-3-(5-(4-bromoisoquinolin-3-yl)quinolin-8-yl)-2-(2,6-dichloro benzamido)propanoic acid: Prepared according to the procedure described for example 10 employing 3,4-dibromoisoquinoline in place of H2. MS (m/z) 594.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 9.45 (s, 1H), 9.17 (t, J=11.7 Hz, 1H), 8.97 (s, 1H), 8.36-8.29 (m, 1H), 8.26 (d, J=8.5 Hz, 1H), 8.04 (ddd, J=8.4, 6.9, 1.3 Hz, 1H), 7.89 (ddd, J=8.1, 7.0, 1.1 Hz, 1H), 7.85-7.77 (m, 2H), 7.57 (d, J=7.2 Hz, 1H), 7.50-7.43 (m, 1H), 7.43-7.31 (m, 3H), 5.10 (d, J=9.2 Hz, 1H), 4.02 (d, J=13.4 Hz, 1H), 3.40 (q, J=14.3, 13.1 Hz, 1H).
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(2,5-dimethyl-2H-1,2,3-triazol-4-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 4-bromo-2,5-dimethyl-2H-1,2,3-triazole in place of H2. MS (m/z) 483.880 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.07 (d, J=8.5 Hz, 1H), 8.99 (dd, J=4.1, 1.7 Hz, 1H), 8.39 (d2, J=1.8 Hz, 1H), 7.77 (d, J=7.4 Hz, 1H), 7.61-7.52 (m, 2H), 7.41-7.30 (m, 3H), 5.10 (ddd, J=10.9, 8.6, 4.5 Hz, 1H), 4.19 (s, 3H), 4.06 (s, 1H), 3.99 (dd, J=13.5, 4.5 Hz, 1H), 3.35 (dd, J=13.6, 10.9 Hz, 1H), 2.21 (s, 3H), 2.16 (s, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(4-methyl-3-oxo-3,4-dihydropyrazin-2-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-chloro-1-methylpyrazin-2(1H)-one in place of H2. MS (m/z) 496.898 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, J=8.3 Hz, 1H), 8.95 (dd, J=4.1, 1.7 Hz, 1H), 8.27 (dd, J=8.6, 1.7 Hz, 1H), 7.82 (d, J=4.2 Hz, 1H), 7.74 (d, J=7.4 Hz, 1H), 7.65 (d, J=7.4 Hz, 1H), 7.54-7.47 (m, 2H), 7.43-7.31 (m, 3H), 5.05 (ddd, J=10.4, 8.3, 4.8 Hz, 1H), 3.94 (dd, J=13.5, 4.8 Hz, 1H), 3.53 (s, 3H), 3.52-3.25 (m, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(5-fluoro-2-methoxypyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-bromo-5-fluoro-2-methoxypyridine in place of H2. MS (m/z) 513.883 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.08 (d, J=8.5 Hz, 1H), 8.96 (s, 1H), 8.30 (s, 1H), 7.87 (dd, J=8.5, 1.7 Hz, 1H), 7.74 (t, J=9.5 Hz, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.51 (dd, J=8.5, 4.1 Hz, 1H), 7.41 (dt, J=24.6, 7.3 Hz, 4H), 5.08 (s, 1H), 3.74 (s, 3H), 3.36 (dd, J=51.4, 12.2 Hz, 1H).
-
- (S)-3-(5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)quinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing 3-bromo-5-chloro-1-methylpyridin-2(1H)-one in place of H2. MS (m/z) 529.865 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.3 Hz, 1H), 8.94 (dd, J=4.2, 1.7 Hz, 1H), 8.16 (d, J=2.9 Hz, 1H), 8.05-7.98 (m, 1H), 7.71 (d, J=7.3 Hz, 1H), 7.50 (dd, J=8.5, 4.2 Hz, 1H), 7.45-7.29 (m, 3H), 5.04 (td, J=9.7, 9.1, 4.6 Hz, 1H), 3.94 (dd, J=13.6, 4.7 Hz, 1H), 3.50 (s, 3H), 3.36 (dd, J=13.7, 10.5 Hz, 1H).
-
- 2-(2,6-Dichlorobenzamido)-3-(5-(1,4-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-chloro-1,4-dimethylpyridin-2(1H)-one in place of H2. MS (m/z) 510.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.11 (dd, J=8.3, 6.1 Hz, 1H), 8.93 (ddd, J=10.2, 4.2, 1.8 Hz, 1H), 7.80 (dt, J=8.5, 2.0 Hz, 1H), 7.77-7.67 (m, 2H), 7.47 (ddd, J=8.5, 4.2, 0.8 Hz, 1H), 7.43-7.29 (m, 3H), 7.25 (dd, J=9.2, 7.2 Hz, 1H), 6.33-6.23 (m, 1H), 5.03 (dddd, J=23.3, 10.6, 8.3, 4.3 Hz, 1H), 3.94 (ddd, J=74.2, 13.7, 4.4 Hz, 1H), 3.49 (dd, J=13.9, 10.6 Hz, 1H), 3.44 (d, J=3.4 Hz, 3H), 3.25 (dd, J=13.5, 11.0 Hz, 1H), 1.78 (d, J=7.9 Hz, 3H).
-
- (S)-2-(2,6-Dichlorobenzamido)-3-(5-(1,5-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-chloro-1,5-dimethylpyridin-2(1H)-one in place of H2. MS (m/z) 510.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.3 Hz, 1H), 8.92 (dd, J=4.2, 1.8 Hz, 1H), 7.97 (dd, J=8.5, 1.7 Hz, 1H), 7.69 (d, J=7.3 Hz, 1H), 7.66 (dd, J=2.5, 1.1 Hz, 1H), 7.47 (dd, J=8.5, 4.1 Hz, 1H), 7.43-7.26 (m, 5H), 5.03 (t, J=11.7 Hz, 1H), 3.92 (d, J=13.4 Hz, 1H), 3.48 (s, 3H), 3.38 (d, J=16.4 Hz, 1H), 2.13-2.06 (m, 3H).
-
- 2-(2,6-Dichlorobenzamido)-3-(5-(4-methoxy-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-chloro-4-methoxy-1-methylpyridin-2(1H)-one in place of H2. MS (m/z) 526.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (dd, J=8.4, 1.2 Hz, 1H), 8.91 (ddd, J=6.1, 4.2, 1.8 Hz, 1H), 7.94-7.81 (m, 2H), 7.71 (t, J=6.9 Hz, 1H), 7.46 (ddd, J=8.5, 4.2, 2.6 Hz, 1H), 7.43-7.32 (m, 3H), 7.26 (dd, J=12.7, 7.3 Hz, 1H), 6.44 (dd, J=7.8, 4.8 Hz, 1H), 5.03 (dddd, J=23.9, 10.6, 8.4, 4.5 Hz, 1H), 3.93 (ddd, J=53.0, 13.8, 4.5 Hz, 1H), 3.66 (d, J=9.1 Hz, 3H), 3.44 (d, J=2.3 Hz, 3H), 3.26 (dd, J=13.6, 10.9 Hz, 1H).
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-chloro-1,6-dimethylpyridin-2(1H)-one in place of H2. MS (m/z) 510.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.3 Hz, 1H), 8.93 (dd, J=4.2, 1.8 Hz, 1H), 7.98 (dd, J=8.5, 1.8 Hz, 1H), 7.70 (d, J=7.3 Hz, 1H), 7.48 (dd, J=8.5, 4.2 Hz, 1H), 7.42-7.27 (m, 5H), 6.31 (dd, J=7.0, 0.9 Hz, 1H), 5.04 (td, J=9.5, 8.5, 4.7 Hz, 1H), 3.93 (d, J=13.4 Hz, 1H), 3.51 (s, 3H), 3.43-3.30 (m, 1H), 2.44 (d, J=0.8 Hz, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: Prepared according to the procedure described for example 10 employing H5 in place of H2. MS (m/z) 560.042 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.14 (dd, J=8.4, 5.1 Hz, 1H), 8.95 (ddd, J=8.7, 4.2, 1.7 Hz, 1H), 7.96-7.85 (m, 2H), 7.78 (dd, J=7.2, 5.1 Hz, 1H), 7.70 (ddd, J=8.5, 7.0, 1.4 Hz, 1H), 7.63-7.60 (m, 1H), 7.46 (dd, J=8.5, 4.2 Hz, 1H), 7.43-7.27 (m, 5H), 5.35-4.91 (m, 1H), 4.07 (dd, J=13.4, 4.0 Hz, 1H), 3.88 (dd, J=13.8, 4.7 Hz, 1H), 3.67 (d, J=3.6 Hz, 3H), 3.52 (dd, J=13.8, 10.6 Hz, 1H), 3.27 (dd, J=13.5, 11.1 Hz, 1H), 2.12 (d, J=7.3 Hz, 3H).
-
- (2S)-2-(2,6-dichlorobenzamido)-3-(5-(4-fluoro-2-methoxy-6-(trifluoromethyl) phenyl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing H1 in place of H2. MS (m/z) 581.549 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (t, J=9.0 Hz, 1H), 8.93 (dd, J=4.2, 1.7 Hz, 1H), 7.76 (dd, J=7.3, 5.3 Hz, 1H), 7.60 (ddd, J=8.5, 2.7, 1.7 Hz, 1H), 7.45 (ddd, J=8.5, 4.1, 1.6 Hz, 2H), 7.42-7.31 (m, 4H), 7.31-7.25 (m, 1H), 5.16-4.94 (m, 1H), 3.97 (ddd, J=14.0, 10.3, 3.9 Hz, 1H), 3.61 (d, J=10.8 Hz, 3H), 3.35 (dt, J=14.0, 10.3 Hz, 1H).
-
- (2S)-3-(5-(2-chloro-4-fluoro-6-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichloro benzamido)propanoic acid: Prepared according to the procedure described for example 10 employing H15 in place of H2. MS (m/z) 547.061 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (t, J=8.5 Hz, 1H), 8.94 (dt, J=4.1, 2.0 Hz, 1H), 7.77 (dd, J=7.3, 3.7 Hz, 1H), 7.65 (ddd, J=8.4, 2.9, 1.8 Hz, 1H), 7.47 (ddd, J=8.5, 4.2, 1.7 Hz, 1H), 7.41-7.32 (m, 3H), 7.30 (dd, J=7.2, 1.5 Hz, 1H), 7.17 (dddd, J=21.1, 11.2, 4.1, 2.4 Hz, 2H), 5.16-4.96 (m, 1H), 4.06-3.94 (m, 1H), 3.62 (d, J=10.7 Hz, 3H), 3.40-3.21 (m, 1H).
-
- (2S)-3-(5-(2-chloro-6-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichloro benzamido) propanoic acid: Prepared according to the procedure described for example 10 employing (2-chloro-6-methoxyphenyl)boronic acid in place of EQ6 and EQ5 in place of H2. MS (m/z) 530.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (t, J=8.2 Hz, 1H), 8.94 (ddd, J=4.2, 2.5, 1.8 Hz, 1H), 7.78 (dd, J=7.3, 3.4 Hz, 1H), 7.68-7.44 (m, 6H), 7.42-7.28 (m, 4H), 7.22 (ddd, J=8.1, 4.0, 0.9 Hz, 1H), 7.18 (ddd, J=8.6, 4.1, 0.9 Hz, 1H), 5.16-4.98 (m, 1H), 4.01 (ddd, J=13.6, 6.4, 4.1 Hz, 1H), 3.61 (d, J=10.7 Hz, 3H), 3.32 (ddd, J=13.5, 11.2, 8.2 Hz, 1H).
-
- (S)-2-(8-(2-carboxy-2-(2,6-dichlorobenzamido)ethyl)quinolin-5-yl)pyridine 1-oxide: Prepared according to the procedure described for example 10 employing 2-bromopyridine 1-oxide in place of H2. MS (m/z) 482.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 9.10 (d, J=8.4 Hz, 1H), 9.05-8.91 (m, 1H), 8.47-8.35 (m, 1H), 7.84-7.69 (m, 2H), 7.65-7.46 (m, 4H), 7.46-7.29 (m, 3H), 5.21-4.98 (m, 1H), 3.99 (ddd, J=23.5, 13.6, 4.7 Hz, 1H), 3.49-3.23 (m, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-bromo-1-methylpyridin-2(1H)-one in place of H2. MS (m/z) 496.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J=8.4 Hz, 1H), 8.94 (dd, J=4.2, 1.7 Hz, 1H), 8.00 (dd, J=8.5, 1.8 Hz, 1H), 7.86 (dd, J=6.8, 2.1 Hz, 1H), 7.71 (d, J=7.3 Hz, 1H), 7.50 (dd, J=8.5, 4.2 Hz, 1H), 7.46-7.30 (m, 5H), 6.38 (t, J=6.8 Hz, 1H), 5.13-4.99 (m, 1H), 3.94 (m, J=13.7 Hz, 1H), 3.52 (s, 3H), 3.34 (m, J=13.3 Hz, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(4-methylisoquinolin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 3-chloro-4-methylisoquinoline in place of H2. MS (m/z) 530.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.52 (s, 1H), 9.16 (d, J=8.5 Hz, 1H), 9.01 (s, 1H), 8.37 (d, J=8.1 Hz, 1H), 8.28 (s, 1H), 8.06 (s, 2H), 7.88 (dt, J=15.4, 7.3 Hz, 3H), 7.60 (d, J=7.2 Hz, 1H), 7.50 (dd, J=8.5, 4.1 Hz, 1H), 7.47-7.32 (m, 3H), 5.11 (s, 1H), 4.14-3.91 (m, 1H), 3.61-3.27 (m, 1H), 2.40 (s, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(7-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: Prepared according to the procedure described for example 10 employing H4 in place of H2. MS (m/z) 578 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.20-9.13 (m, 2H), 8.98 (d, J=12.6 Hz, 2H), 8.03-7.94 (m, 2H), 7.91 (d, J=8.5 Hz, 2H), 7.80 (dd, J=7.2, 4.7 Hz, 2H), 7.56-7.31 (m, 12H), 7.36 (d, J=36.1 Hz, 7H), 7.23 (td, J=8.6, 2.4 Hz, 2H), 5.13-5.02 (m, 2H), 4.10 (dd, J=13.9, 4.4 Hz, 1H), 3.90 (dd, J=13.5, 4.7 Hz, 1H), 3.65 (d, J=3.8 Hz, 5H), 3.52 (dd, J=13.7, 10.5 Hz, 2H), 3.27 (dd, J=14.0, 11.7 Hz, 1H), 2.12 (d, J=7.2 Hz, 5H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(3,5-difluoro-2-methoxyphenyl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 1-bromo-3,5-difluoro-2-methoxybenzene in place of H2. MS (m/z) 560.042 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.14 (dd, J=8.4, 5.1 Hz, 1H), 8.95 (ddd, J=8.7, 4.2, 1.7 Hz, 1H), 7.96-7.85 (m, 2H), 7.78 (dd, J=7.2, 5.1 Hz, 1H), 7.70 (ddd, J=8.5, 7.0, 1.4 Hz, 1H), 7.63-7.60 (m, 1H), 7.46 (dd, J=8.5, 4.2 Hz, 1H), 7.43-7.27 (m, 5H), 5.35-4.91 (m, 1H), 4.07 (dd, J=13.4, 4.0 Hz, 1H), 3.88 (dd, J=13.8, 4.7 Hz, 1H), 3.67 (d, J=3.6 Hz, 3H), 3.52 (dd, J=13.8, 10.6 Hz, 1H), 3.27 (dd, J=13.5, 11.1 Hz, 1H), 2.12 (d, J=7.3 Hz, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(3,4-difluoro-2-methoxyphenyl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 1-bromo-3,4-difluoro-2-methoxybenzene in place of H2. MS (m/z) 530.940 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (dd, J=11.5, 8.5 Hz, 1H), 8.97 (dt, J=4.2, 1.7 Hz, 1H), 7.91 (dd, J=8.5, 1.7 Hz, 1H), 7.77 (dd, J=7.3, 3.3 Hz, 1H), 7.52 (dd, J=8.5, 4.2 Hz, 1H), 7.44-7.24 (m, 5H), 7.05 (dddd, J=16.8, 8.4, 6.0, 2.1 Hz, 1H), 5.74 (s, 1H), 5.24-4.99 (m, 1H), 4.12-3.88 (m, 1H), 3.57 (dd, J=12.3, 1.8 Hz, 3H), 3.52-3.23 (m, 1H).
-
- (2S)-3-(5-(2-chloro-6-(trifluoromethyl)phenyl)quinolin-8-yl)-2-(2,6-dichloro benzamido)propanoic acid: Prepared according to the procedure described for example 10 employing 2-bromo-1-chloro-3-(trifluoromethyl)benzene in place of H2. MS (m/z) 536.957 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (dd, J=8.4, 2.6 Hz, 1H), 8.97 (ddd, J=4.1, 1.8, 1.2 Hz, 1H), 8.11-7.90 (m, 2H), 7.82 (d, J=7.3 Hz, 1H), 7.61-7.43 (m, 2H), 7.44-7.20 (m, 4H), 5.04 (dtd, J=11.5, 8.1, 3.9 Hz, 1H), 4.00 (ddd, J=18.3, 13.8, 3.9 Hz, 1H), 3.44-3.23 (m, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(3-fluoro-2-methoxyphenyl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 1-bromo-3-fluoro-2-methoxybenzene in place of H2. MS (m/z) 512.892 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.11 (dd, J=13.6, 8.5 Hz, 1H), 8.98 (dt, J=4.1, 1.7 Hz, 1H), 7.96-7.80 (m, 1H), 7.53 (dd, J=8.5, 4.2 Hz, 1H), 7.51-7.36 (m, 5H), 7.30-7.19 (m, 1H), 7.11-7.02 (m, 1H), 5.76 (s, 1H), 5.11 (s, 1H), 4.17-3.92 (m, 1H), 3.52 (dd, J=11.7, 1.5 Hz, 3H), 3.37 (dd, J=13.6, 11.0 Hz, 1H), 2.57-2.51 (m, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(4,5-difluoro-2-methoxyphenyl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 1-bromo-4,5-difluoro-2-methoxybenzene in place of H2. MS (m/z) 533.6 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.72 (s, 1H), 9.08 (dd, J=8.5, 2.2 Hz, 1H), 8.95 (td, J=4.2, 1.7 Hz, 1H), 7.84 (dd, J=8.5, 1.8 Hz, 1H), 7.74 (d, J=7.3 Hz, 1H), 7.56-7.46 (m, 1H), 7.46-7.29 (m, 6H), 5.10 (qd, J=9.6, 4.4 Hz, 1H), 4.00 (ddd, J=22.8, 13.5, 4.4 Hz, 1H), 3.65 (d, J=4.3 Hz, 4H), 3.39 (dd, J=13.7, 10.7 Hz, 1H).
- Prepared according to the procedure described for example 11 employing H5 in place of H2. The title compound was identified as the first eluting peak from chiral separation. MS (m/z) 561.22 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.13 (d, J=8.3 Hz, 1H), 8.93 (dd, J=4.2, 1.7 Hz, 1H), 7.96-7.83 (m, 2H), 7.78 (d, J=7.3 Hz, 1H), 7.75-7.66 (m, 1H), 7.62 (d, J=7.7 Hz, 1H), 7.48-7.24 (m, 5H), 3.97-3.83 (m, 1H), 3.67 (s, 3H), 2.65 (d, J=1.8 Hz, 1H), 2.11 (s, 3H).
- Prepared according to the procedure described for example 12 employing H5 in place of H2. The title compound was identified as the second eluting peak from chiral separation. MS (m/z) 561.23 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 9.14 (d, J=8.5 Hz, 1H), 8.96 (dd, J=4.2, 1.7 Hz, 1H), 8.00-7.83 (m, 2H), 7.77 (d, J=7.3 Hz, 1H), 7.73-7.67 (m, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.51-7.21 (m, 7H), 5.18-4.97 (m, 1H), 4.08 (dd, J=13.3, 3.9 Hz, 1H), 3.66 (s, 3H), 3.37-3.13 (m, 1H), 2.12 (s, 3H).
-
- Prepared according to the procedure described for example 11 employing H1 in place of H2. The title compound was identified as the first eluting peak. MS (m/z) 581.074 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.39 (s, 1H), 8.19 (d, J=27.8 Hz, 2H), 7.71 (d, J=46.0 Hz, 3H), 7.35 (dtd, J=6.7, 4.8, 2.4 Hz, 7H), 7.05 (s, 1H), 5.22 (s, 1H), 4.20 (s, 1H), 3.80-3.60 (m, 3H), 1.35 (s, 1H).
- Prepared according to the procedure described for example 12 employing H1 in place of H2. The title compound was identified as the second eluting peak. MS (m/z) 581.089 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.39 (s, 1H), 8.15 (d, J=8.7 Hz, 1H), 8.02 (d, J=7.4 Hz, 1H), 7.70 (dd, J=8.5, 4.9 Hz, 1H), 7.54 (d, J=7.4 Hz, 1H), 7.41 (d, J=6.0 Hz, 1H), 7.31-7.26 (m, 3H), 7.20 (dd, J=8.6, 2.3 Hz, 1H), 6.97 (dd, J=9.9, 2.5 Hz, 1H), 5.17 (d, J=5.4 Hz, 1H), 4.23 (dd, J=15.0, 4.1 Hz, 1H), 3.63 (d, J=1.9 Hz, 3H), 3.43 (dd, J=15.0, 7.2 Hz, 1H).
-
- (S)-3-(5-(3-chloro-4-(trifluoromethyl)pyridin-2-yl)quinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing 2-bromo-3-chloro-4-(trifluoromethyl)pyridine in place of H2. MS (m/z) 568.070 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.36 (d, J=4.9 Hz, 1H), 8.87 (d, J=5.0 Hz, 1H), 8.33 (dd, J=8.6, 1.5 Hz, 1H), 8.12 (d, J=7.4 Hz, 1H), 7.85-7.73 (m, 3H), 7.53 (d, J=5.7 Hz, 1H), 7.31-7.26 (m, 2H), 5.12 (q, J=5.9 Hz, 1H), 4.23 (dd, J=15.0, 4.2 Hz, 1H), 3.53 (dd, J=15.0, 6.9 Hz, 1H), 1.25 (s, 1H).
-
- (S)-3-(5-(5-chloro-4-fluoro-2-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichloro benzamido)propanoic acid: Prepared according to the procedure described for example 10 employing 1-bromo-5-chloro-4-fluoro-2-methoxybenzene in place of H2. MS (m/z) 547.327 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.56 (dd, J=39.5, 5.1 Hz, 1H), 8.55-8.46 (m, 1H), 8.12-8.00 (m, 1H), 7.84 (dt, J=9.3, 4.8 Hz, 1H), 7.65 (dd, J=10.3, 7.3 Hz, 1H), 7.44-7.27 (m, 2H), 6.90 (dd, J=10.6, 3.2 Hz, 1H), 5.24 (d, J=5.5 Hz, 1H), 4.23 (ddd, J=28.8, 14.8, 4.3 Hz, 1H), 3.68 (dd, J=2.7, 0.6 Hz, 3H), 3.48 (ddd, J=28.4, 14.9, 8.5 Hz, 1H).
-
- Prepared according to the procedure described for example 10 employing H15 in place of H2. The title compound was identified as the first eluting peak. MS (m/z) 547.535 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.55 (d, J=5.1 Hz, 1H), 8.35 (dd, J=8.5, 1.5 Hz, 1H), 8.07 (d, J=7.4 Hz, 1H), 7.80 (dd, J=8.5, 5.1 Hz, 1H), 7.62 (d, J=7.3 Hz, 1H), 7.33 (d, J=6.3 Hz, 1H), 7.30-7.26 (m, 2H), 7.25-7.21 (m, 1H), 6.96 (dd, J=8.2, 2.4 Hz, 1H), 6.75 (dd, J=10.3, 2.4 Hz, 1H), 5.25 (s, 1H), 4.26 (dd, J=15.0, 4.1 Hz, 1H), 3.65 (s, 3H), 3.44 (dd, J=14.9, 8.4 Hz, 1H).
- Prepared according to the procedure described for example 10 employing H15 in place of H2. The title compound was identified as the second eluting peak. MS (m/z) 547.343 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.55 (d, J=5.1 Hz, 1H), 8.43-8.31 (m, 1H), 8.10 (dd, J=14.2, 7.4 Hz, 1H), 7.86-7.76 (m, 1H), 7.63 (t, J=6.9 Hz, 1H), 7.42-7.32 (m, 1H), 7.29-7.20 (m, 5H), 6.97 (ddd, J=8.4, 6.1, 2.4 Hz, 1H), 6.80-6.68 (m, 1H), 5.27 (d, J=8.9 Hz, 1H), 4.23 (td, J=15.9, 15.1, 4.2 Hz, 1H), 3.65 (d, J=4.2 Hz, 3H), 3.49 (ddd, J=24.1, 14.9, 8.6 Hz, 1H).
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(4,5-difluoro-2-(methoxy-d3)phenyl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing H14 in place of H2. MS (m/z) 534.042 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.07 (dd, J=8.4, 2.1 Hz, 1H), 8.94 (td, J=3.9, 1.7 Hz, 1H), 7.83 (dt, J=8.5, 1.8 Hz, 1H), 7.73 (d, J=7.3 Hz, 1H), 7.64-7.58 (m, 4H), 7.58-7.57 (m, 1H), 7.56-7.52 (m, 2H), 7.51-7.46 (m, 1H), 7.42-7.34 (m, 4H), 5.15-5.00 (m, 1H), 4.04-3.91 (m, 1H), 3.33 (ddd, J=37.9, 13.5, 10.8 Hz, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(4-fluoro-2-methoxy-5-methyl phenyl) quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing H13 in place of H2. MS (m/z) 526.914 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.08 (d, J=3.7 Hz, 1H), 9.06 (s, 1H), 8.92 (ddd, J=4.4, 2.8, 1.7 Hz, 1H), 7.81 (dd, J=8.5, 1.7 Hz, 1H), 7.71 (d, J=7.3 Hz, 1H), 7.47 (dd, J=8.5, 4.1 Hz, 1H), 7.42-7.35 (m, 3H), 7.32 (dd, J=7.3, 2.9 Hz, 1H), 7.12-7.00 (m, 2H), 5.08 (dt, J=5.4, 3.1 Hz, 1H), 4.01-3.91 (m, 1H), 3.61 (d, J=4.4 Hz, 3H), 3.28 (dd, J=7.4, 6.7 Hz, 2H), 2.23-2.19 (m, 3H), 2.18-2.12 (m, 1H), 1.94-1.82 (m, 1H).
-
- (S)-3-(5-(4-chloro-3-(trifluoromethyl)pyridin-2-yl)quinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing 2-bromo-4-chloro-3-(trifluoromethyl)pyridine in place of H2. MS (m/z) 568.071 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.13 (dd, J=23.8, 8.4 Hz, 1H), 8.98 (ddd, J=7.5, 4.1, 1.7 Hz, 1H), 8.87 (ddt, J=6.7, 5.3, 0.6 Hz, 1H), 7.96 (dq, J=5.3, 0.8 Hz, 1H), 7.85 (ddd, J=8.5, 2.7, 1.7 Hz, 1H), 7.76 (dd, J=7.3, 5.4 Hz, 1H), 7.64-7.57 (m, 1H), 7.56-7.54 (m, 1H), 7.51 (ddd, J=8.5, 4.2, 2.8 Hz, 1H), 7.44-7.35 (m, 3H), 5.74 (s, 1H), 5.05 (dddd, J=26.3, 10.7, 8.4, 4.4 Hz, 1H), 3.97 (dd, J=13.6, 4.4 Hz, 1H), 3.39 (ddd, J=15.8, 13.7, 10.7 Hz, 1H).
-
- (S)-3-(6-bromo-1-methyl-2-oxo-4-(trifluoromethyl)-1,2-dihydro-[3,5′-biquinolin]-8′-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing H11 in place of H2. MS (m/z) 694.049 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (dd, J=12.2, 8.3 Hz, 1H), 8.95 (ddd, J=7.7, 4.2, 1.7 Hz, 1H), 8.08-7.92 (m, 1H), 7.92-7.69 (m, 3H), 7.69-7.22 (m, 9H), 5.19-4.85 (m, 1H), 4.03 (dd, J=13.5, 4.0 Hz, 1H), 3.90 (d, J=13.7 Hz, 1H), 3.70 (d, J=5.6 Hz, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(1-methyl-2-oxo-4-(trifluoromethyl)-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: Prepared according to the procedure described for example 10 employing H12 in place of H2. MS (m/z) 614.049 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (dd, J=12.2, 8.3 Hz, 1H), 8.95 (ddd, J=7.7, 4.2, 1.7 Hz, 1H), 8.08-7.92 (m, 1H), 7.92-7.69 (m, 3H), 7.69-7.22 (m, 9H), 5.19-4.85 (m, 1H), 4.03 (dd, J=13.5, 4.0 Hz, 1H), 3.90 (d, J=13.7 Hz, 1H), 3.70 (d, J=5.6 Hz, 3H).
-
- Prepared according to the procedure described for example 10 employing H18 in place of H2. The title compound was identified as the first eluting peak. MS (m/z) 577.8 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.76 (d, J=4.3 Hz, 1H), 8.23-7.94 (m, 5H), 7.81-7.68 (m, 1H), 7.60-7.37 (m, 5H), 7.37-7.16 (m, 7H), 4.85 (d, J=4.6 Hz, 1H), 4.10-3.91 (m, 1H), 3.81 (s, 4H), 3.66 (dd, J=15.0, 4.8 Hz, 1H), 3.49 (s, 1H), 1.21 (d, J=6.1 Hz, 1H).
- Prepared according to the procedure described for example 11 employing H18 in place of H2. The title compound was identified as the second eluting peak. MS (m/z) 578.054 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (dd, J=11.3, 8.5 Hz, 1H), 8.97 (dd, J=4.1, 1.7 Hz, 1H), 7.89 (dt, J=8.5, 1.9 Hz, 1H), 7.82-7.72 (m, 1H), 7.52 (ddd, J=8.5, 4.1, 0.8 Hz, 1H), 7.45-7.28 (m, 4H), 5.21-4.96 (m, 1H), 3.99 (td, J=12.8, 4.1 Hz, 1H), 3.92 (s, 2H), 3.55-3.16 (m, 1H).
-
- Prepared according to the procedure described for example 12 employing H12 in place of H2. The title compound was identified as the first eluting peak. MS (m/z) 614.049 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.88 (dd, J=19.7, 5.0 Hz, 1H), 8.23-7.86 (m, 3H), 7.86-7.14 (m, 13H), 5.03-4.78 (m, 1H), 4.22-3.94 (m, 1H), 3.87-3.64 (m, 4H), 3.64-3.39 (m, 1H), 1.43-1.05 (m, 2H).
- Prepared according to the procedure described for example 11 employing H12 in place of H2. The title compound was identified as the second eluting peak. MS (m/z) 614.049 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.88 (dd, J=19.7, 5.0 Hz, 1H), 8.23-7.86 (m, 3H), 7.86-7.14 (m, 13H), 5.03-4.78 (m, 1H), 4.22-3.94 (m, 1H), 3.87-3.64 (m, 4H), 3.64-3.39 (m, 1H), 1.43-1.05 (m, 2H).
-
- Prepared according to the procedure described for example 12 employing H11 in place of H2. The title compound was identified as the first eluting peak. MS (m/z) 692.049 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 7.93 (d, J=2.2 Hz, 1H), 7.90 (d, J=2.1 Hz, 1H), 7.88-7.84 (m, 2H), 7.65 (s, 1H), 7.63 (s, 1H), 7.29-7.21 (m, 1H), 7.20-7.11 (m, 1H), 4.32 (t, J=5.1 Hz, 1H), 3.72 (s, 7H), 3.42-3.33 (m, 1H), 2.59-2.51 (m, 1H), 2.48 (p, J=1.9 Hz, 11H), 1.65-1.49 (m, 1H), 1.48-1.34 (m, 1H), 1.33-1.21 (m, 1H).
- Prepared according to the procedure described for example 10 employing H11 in place of H2. The title compound was identified as the second eluting peak. MS (m/z) 692.049 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.93 (d, J=2.2 Hz, 1H), 7.90 (d, J=2.1 Hz, 1H), 7.88-7.84 (m, 2H), 7.65 (s, 1H), 7.63 (s, 1H), 7.29-7.21 (m, 1H), 7.20-7.11 (m, 1H), 4.32 (t, J=5.1 Hz, 1H), 3.72 (s, 7H), 3.42-3.33 (m, 1H), 2.59-2.51 (m, 1H), 2.48 (p, J=1.9 Hz, 11H), 1.65-1.49 (m, 1H), 1.48-1.34 (m, 1H), 1.33-1.21 (m, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(1,4-dimethyl-2-oxo-6-(trifluoromethyl)-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: Prepared according to the procedure described for example 10 employing H9 in place of H2. MS (m/z) 628.3 [M+H]+. 1H NMR (400 MHz, CDCl3-d) b 9.17 (d, J=4.9 Hz, 1H), 8.44 (dd, J=8.5, 1.6 Hz, 1H), 8.38 (dd, J=8.6, 1.4 Hz, 2H), 8.17-8.06 (m, 5H), 7.92 (d, J=8.8 Hz, 2H), 7.77 (dd, J=8.4, 5.1 Hz, 1H), 7.73-7.67 (m, 2H), 7.64-7.57 (m, 4H), 5.18-5.09 (m, 2H), 4.32 (dd, J=14.9, 3.6 Hz, 1H), 4.08 (dd, J=14.9, 4.9 Hz, 1H), 3.83 (d, J=1.9 Hz, 6H), 3.72 (dd, J=15.0, 5.9 Hz, 1H), 3.37 (dd, J=14.9, 8.3 Hz, 1H), 2.29 (d, J=7.0 Hz, 6H).
-
- (S)-3-(6-chloro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing H8 in place of H2. MS (m/z) 594.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (dd, J=8.3, 3.0 Hz, 1H), 8.97 (ddd, J=8.2, 4.1, 1.7 Hz, 1H), 7.94 (dd, J=7.9, 2.4 Hz, 1H), 7.89 (dd, J=8.5, 1.8 Hz, 1H), 7.80-7.77 (m, 1H), 7.75 (dd, J=9.0, 2.4 Hz, 1H), 7.66 (d, J=9.1 Hz, 1H), 7.64-7.58 (m, 1H), 7.58-7.53 (m, 1H), 7.48-7.44 (m, 1H), 7.43-7.37 (m, 3H), 7.33 (t, J=7.0 Hz, 1H), 5.07 (m, 2H), 4.09 (dd, J=13.5, 4.8 Hz, 1H), 3.90 (dd, J=13.5, 4.9 Hz, 2H), 3.67 (d, J=3.7 Hz, 6H), 3.25 (d, J=13.0 Hz, 2H), 2.12 (d, J=7.1 Hz, 2H), 1.38 (s, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(1-methyl-2-oxo-4-(trifluoromethyl)-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing H10 in place of H2. MS (m/z) 604.142 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.15 (dd, J=13.0, 8.4 Hz, 1H), 8.93 (ddd, J=8.8, 4.2, 1.8 Hz, 1H), 7.81 (d, J=8.5 Hz, 1H), 7.71 (d, J=7.4 Hz, 1H), 7.46 (dd, J=8.4, 4.2 Hz, 1H), 7.42-7.32 (m, 3H), 7.19 (dd, J=7.2, 5.2 Hz, 1H), 5.08-4.85 (m, 1H), 4.00 (dd, J=13.4, 4.0 Hz, 1H), 3.88 (dd, J=14.0, 4.4 Hz, 1H), 3.53-3.36 (m, 3H), 3.35-3.18 (m, 1H), 3.09 (t, J=7.8 Hz, 2H), 2.13 (q, J=7.9, 7.2 Hz, 2H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(5-methoxy-2-methyl-3-oxo-2,3-dihydro pyridazin-4-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing 4-chloro-5-methoxy-2-methylpyridazin-3(2H)-one in place of H2. MS (m/z) 527.114 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, J=8.5 Hz, 1H), 8.94 (ddd, J=5.1, 4.2, 1.7 Hz, 1H), 8.30 (d, J=6.3 Hz, 1H), 7.92 (ddd, J=8.5, 5.9, 1.7 Hz, 1H), 7.73 (dd, J=7.4, 4.7 Hz, 1H), 7.48 (ddd, J=8.5, 4.2, 1.6 Hz, 1H), 7.44-7.23 (m, 4H), 5.04 (dddd, J=21.4, 10.7, 8.5, 4.4 Hz, 1H), 3.84 (s, 2H), 3.69 (d, J=2.4 Hz, 3H), 3.41 (dd, J=13.8, 10.6 Hz, 1H), 3.25 (dd, J=13.5, 11.0 Hz, 1H).
-
- (S)-3-(6-bromo-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing H6 in place of H2. MS (m/z) 640 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (d, J=8.5 Hz, 1H), 9.01 (dd, J=4.1, 1.6 Hz, 1H), 8.25 (d, J=8.7 Hz, 1H), 7.95 (s, 1H), 7.81-7.75 (m, 3H), 7.60-7.54 (m, 3H), 7.43-7.34 (m, 4H), 5.12 (ddd, J=10.6, 9.2, 5.6 Hz, 2H), 4.02 (dd, J=13.3, 4.5 Hz, 2H), 3.81 (s, 3H), 3.66 (d, J=3.6 Hz, 1H), 3.38 (dd, J=13.6, 10.8 Hz, 2H), 2.73 (s, 3H).
-
- (S)-3-(6-cyclopropyl-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing H7 in place of H2. MS (m/z) 601.1 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 9.23 (s, 1H), 8.92 (d, J=5.5 Hz, 1H), 8.29 (dd, J=28.0, 8.5 Hz, 1H), 8.07 (dd, J=22.7, 8.0 Hz, 1H), 7.89 (d, J=6.1 Hz, 1H), 7.69-7.61 (m, 2H), 7.60-7.52 (m, 4H), 7.52-7.44 (m, 2H), 7.38 (d, J=13.1 Hz, 3H), 7.35-7.27 (m, 3H), 5.07-4.95 (m, 2H), 4.28-4.20 (m, 1H), 4.03 (dd, J=14.9, 5.8 Hz, 1H), 3.78 (s, 3H), 3.71 (dd, J=14.8, 6.9 Hz, 1H), 3.42 (dd, J=16.1, 5.5 Hz, 1H), 2.23 (d, J=22.7 Hz, 3H), 2.09-2.00 (m, 2H), 1.06 (q, J=7.2 Hz, 2H), 0.76 (q, J=5.7, 5.2 Hz, 2H).
-
- Prepared according to the procedure described for example 11 employing 4-chloro-5-methoxy-2-methylpyridazin-3(2H)-one in place of H2. The title compound was identified as the first eluting peak. MS (m/z) 527.082 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, J=8.5 Hz, 1H), 8.93 (ddd, J=5.7, 4.2, 1.8 Hz, 1H), 8.30 (d, J=6.4 Hz, 1H), 7.92-7.85 (m, 1H), 7.72 (dd, J=7.3, 3.5 Hz, 1H), 7.46 (dd, J=8.5, 4.1 Hz, 1H), 7.43-7.26 (m, 3H), 4.10-3.95 (m, 1H), 3.84 (s, 2H), 3.81 (s, 1H), 3.69 (d, J=2.4 Hz, 3H), 3.35-3.18 (m, 1H), 1.22 (s, 1H), 1.14 (t, J=7.2 Hz, 1H).
- Prepared according to the procedure described for example 12 employing 4-chloro-5-methoxy-2-methylpyridazin-3(2H)-one in place of H2. The title compound was identified as the second eluting peak. MS (m/z) 527.082 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, J=8.5 Hz, 1H), 8.93 (ddd, J=5.7, 4.2, 1.8 Hz, 1H), 8.30 (d, J=6.4 Hz, 1H), 7.92-7.85 (m, 1H), 7.72 (dd, J=7.3, 3.5 Hz, 1H), 7.46 (dd, J=8.5, 4.1 Hz, 1H), 7.43-7.26 (m, 3H), 4.10-3.95 (m, 1H), 3.84 (s, 2H), 3.81 (s, 1H), 3.69 (d, J=2.4 Hz, 3H), 3.35-3.18 (m, 1H), 1.22 (s, 1H), 1.14 (t, J=7.2 Hz, 1H).
-
- (S)-3-(7-chloro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 10 employing H19 in place of H2. MS (m/z) 596 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (dd, J=8.3, 6.1 Hz, 1H), 9.00-8.95 (m, 1H), 7.97-7.89 (m, 2H), 7.80 (d, J=11.8 Hz, 1H), 7.72 (d, J=1.9 Hz, 1H), 7.66-7.54 (m, 1H), 7.48 (d, J=12.7 Hz, 1H), 7.44-7.36 (m, 4H), 7.33 (d, J=7.4 Hz, 1H), 5.16-4.99 (m, 3H), 4.10 (dd, J=13.6, 3.8 Hz, 1H), 3.91 (dd, J=14.2, 4.4 Hz, 1H), 3.67 (d, J=3.8 Hz, 3H), 3.52 (dd, J=14.1, 10.8 Hz, 1H), 3.27 (dd, J=13.1, 11.3 Hz, 1H), 2.12 (d, J=6.7 Hz, 3H).
-
- Prepared according to the procedure described for example 11 employing H8 in place of H2. The title compound was identified as the first eluting peak. MS (m/z) 594.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.74 (s, 1H), 9.16 (d, J=8.5 Hz, 1H), 8.98 (dd, J=4.1, 1.6 Hz, 1H), 7.96 (d, J=2.4 Hz, 1H), 7.88 (dd, J=8.5, 1.7 Hz, 1H), 7.78 (d, J=7.3 Hz, 1H), 7.75 (dd, J=9.1, 2.4 Hz, 1H), 7.67 (d, J=9.1 Hz, 1H), 7.49-7.38 (m, 4H), 7.31 (d, J=7.2 Hz, 1H), 5.10 (ddd, J=12.0, 8.5, 4.0 Hz, 1H), 4.10 (dd, J=13.5, 4.1 Hz, 1H), 3.67 (s, 3H), 3.27 (dd, J=13.2, 11.3 Hz, 1H), 2.13 (s, 3H).
- Prepared according to the procedure described for example 12 employing H8 in place of H2. The title compound was identified as the second eluting peak. MS (m/z) 594.10 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.74 (s, 1H), 9.16 (d, J=8.5 Hz, 1H), 8.98 (dd, J=4.1, 1.5 Hz, 1H), 7.95 (d, J=2.3 Hz, 1H), 7.88 (dd, J=8.4, 1.6 Hz, 1H), 7.78 (d, J=7.3 Hz, 1H), 7.75 (dd, J=9.1, 2.2 Hz, 1H), 7.67 (d, J=9.1 Hz, 1H), 7.48-7.37 (m, 4H), 7.31 (d, J=7.2 Hz, 1H), 5.13-5.06 (m, 1H), 4.13-4.06 (m, 2H), 3.67 (s, 3H), 3.30-3.22 (m, 2H), 2.13 (s, 3H).
- (S)-3-(7-chloro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Prepared according to the procedure described for example 11 employing H19 in place of H2. The title compound was identified as the first eluting peak. MS (m/z) 544.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J=8.2 Hz, 1H), 8.89 (s, 1H), 8.79 (s, 1H), 7.98-7.93 (m, 1H), 7.76-7.61 (m, 5H), 7.54 (s, 1H), 7.36 (t, J=7.5 Hz, 1H), 7.16-7.09 (m, 2H), 4.80 (2H), 3.89 (dd, J=14.8, 3.9 Hz, 1H), 3.72 (d, J=12.2 Hz, 1H), 3.64 (s, 3H), 3.56 (dd, J=14.4, 9.8 Hz, 1H), 3.36 (dd, J=14.2, 10.7 Hz, 1H), 3.29 (s, 3H).
-
- (S)-2-(2,6-difluorobenzamido)-3-(5-(4-(ethoxymethyl)-2,6-dimethoxyphenyl) quinolin-8-yl)propanoic acid: To a microwave vial was added EQ-2 (100 mg, 0.223 mmol), potassium phosphate (0.78 mL, 0.78 mmol, 1N), (4-(ethoxymethyl)-2,6-dimethoxyphenyl) boronic acid (59 mg, 0.245 mmol), and DME 2.4 mL. The vial was purged with nitrogen sealed and heated in a microwave reactor to 130° C. The reaction was diluted with DMSO, acidified with TFA and purified by HPLC and lyophilized to afford the title compound. MS (m/z) 551.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J=7.8 Hz, 1H), 8.89 (dd, J=4.2, 1.7 Hz, 1H), 7.80-7.60 (m, 2H), 7.54-7.37 (m, 2H), 7.27 (d, J=7.3 Hz, 1H), 7.18-7.02 (m, 2H), 6.77 (d, J=1.1 Hz, 2H), 4.90 (ddd, J=10.0, 7.7, 4.8 Hz, 1H), 4.53 (s, 2H), 3.91 (dd, J=13.8, 4.8 Hz, 1H), 3.62-3.50 (m, 7H), 3.41 (dd, J=13.7, 10.0 Hz, 1H), 1.20 (t, J=7.0 Hz, 3H).
- (S)-3-(5-(4,5-difluoro-2-methoxyphenyl)quinolin-8-yl)-2-(2,6-difluorobenzamido) propanoic acid: Prepared according to the procedure described for example 78 employing (4,5-difluoro-2-methoxyphenyl)boronic acid in place of (4-(ethoxymethyl)-2,6-dimethoxyphenyl) boronic acid. MS (m/z) 499.048 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.22 (dd, J=12.8, 8.0 Hz, 1H), 8.94 (ddd, J=4.2, 1.8, 0.7 Hz, 1H), 7.86 (ddd, J=8.5, 3.9, 1.8 Hz, 1H), 7.69 (dd, J=7.3, 5.7 Hz, 1H), 7.54-7.42 (m, 2H), 7.41-7.27 (m, 3H), 7.11 (ddd, J=8.6, 7.6, 1.6 Hz, 2H), 4.90 (dtd, J=10.0, 7.4, 4.8 Hz, 1H), 3.96 (ddd, J=19.0, 13.6, 4.9 Hz, 1H), 3.63 (d, J=4.4 Hz, 3H), 3.37 (ddd, J=18.4, 13.6, 10.1 Hz, 1H).
-
- (S)-2-(2,6-difluorobenzamido)-3-(5-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 78 employing EQ-4 in place of (4-(ethoxymethyl)-2,6-dimethoxyphenyl) boronic acid and 5-bromo-1,3-dimethylpyrimidine-2,4(1H,3H)-dione in place of EQ-3. MS (m/z) 495.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J=7.9 Hz, 1H), 8.94 (dd, J=4.2, 1.7 Hz, 1H), 8.22 (dd, J=8.5, 1.7 Hz, 1H), 7.88 (s, 1H), 7.66 (d, J=7.3 Hz, 1H), 7.52 (dd, J=8.5, 4.2 Hz, 1H), 7.50-7.43 (m, 1H), 7.40 (d, J=7.3 Hz, 1H), 7.16-7.06 (m, 2H), 4.87 (td, J=8.9, 8.0, 4.9 Hz, 1H), 3.93 (d, J=13.4 Hz, 1H), 3.38 (m, 4H), 3.24 (s, 3H).
- Prepared according to the procedure described for example 78 employing EQ-4 in place of (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid and 5-bromo-1,3,6-trimethylpyrimidine-2,4(1H,3H)-dione in place of EQ-3. The first eluting isomer provided example 81. MS (m/z) 509.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.13 (d, J=8.4 Hz, 1H), 8.95 (dd, J=4.2, 1.7 Hz, 1H), 8.13 (dd, J=8.5, 1.8 Hz, 1H), 7.66 (d, J=7.3 Hz, 1H), 7.52-7.40 (m, 2H), 7.29 (d, J=7.2 Hz, 1H), 7.06 (dd, J=8.5, 7.5 Hz, 2H), 5.00 (ddd, J=10.9, 8.4, 4.4 Hz, 1H), 4.07 (dd, J=13.3, 4.4 Hz, 1H), 3.43 (s, 3H), 3.22 (s, 4H), 1.94 (s, 3H); 1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J=7.7 Hz, 1H), 8.93 (dd, J=4.2, 1.8 Hz, 1H), 8.14 (dd, J=8.5, 1.8 Hz, 1H), 7.68 (d, J=7.3 Hz, 1H), 7.55-7.40 (m, 2H), 7.32 (d, J=7.3 Hz, 1H), 7.10 (dd, J=8.4, 7.5 Hz, 2H), 4.87 (ddd, J=9.8, 7.7, 5.3 Hz, 1H), 3.83 (dd, J=13.7, 5.3 Hz, 1H), 3.52 (dd, J=13.7, 9.8 Hz, 1H), 3.43 (s, 3H), 3.22 (s, 3H), 1.92 (s, 3H).
- Prepared according to the procedure described for example 78 employing EQ-4 in place of (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid and 5-bromo-1,3,6-trimethylpyrimidine-2,4(1H,3H)-dione in place of EQ-3. The second eluting isomer provided example 82. MS (m/z) 509.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.13 (d, J=8.4 Hz, 1H), 8.95 (dd, J=4.2, 1.7 Hz, 1H), 8.13 (dd, J=8.5, 1.8 Hz, 1H), 7.66 (d, J=7.3 Hz, 1H), 7.52-7.40 (m, 2H), 7.29 (d, J=7.2 Hz, 1H), 7.06 (dd, J=8.5, 7.5 Hz, 2H), 5.00 (ddd, J=10.9, 8.4, 4.4 Hz, 1H), 4.07 (dd, J=13.3, 4.4 Hz, 1H), 3.43 (s, 3H), 3.22 (s, 4H), 1.94 (s, 3H); 1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J=7.7 Hz, 1H), 8.93 (dd, J=4.2, 1.8 Hz, 1H), 8.14 (dd, J=8.5, 1.8 Hz, 1H), 7.68 (d, J=7.3 Hz, 1H), 7.55-7.40 (m, 2H), 7.32 (d, J=7.3 Hz, 1H), 7.10 (dd, J=8.4, 7.5 Hz, 2H), 4.87 (ddd, J=9.8, 7.7, 5.3 Hz, 1H), 3.83 (dd, J=13.7, 5.3 Hz, 1H), 3.52 (dd, J=13.7, 9.8 Hz, 1H), 3.43 (s, 3H), 3.22 (s, 3H), 1.92 (s, 3H).
-
- Prepared according to the procedure described for example 78 employing EQ-4 in place of (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid and H17 in place of EQ-3. MS (m/z) 525.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.18 (d, J=8.0 Hz, 1H), 8.93 (dt, J=3.9, 1.8 Hz, 1H), 7.83 (td, J=8.2, 1.7 Hz, 1H), 7.67 (d, J=7.3 Hz, 1H), 7.57-7.40 (m, 3H), 7.40-7.26 (m, 2H), 7.15-7.02 (m, 2H), 4.90 (ddd, J=12.7, 9.9, 4.9 Hz, 1H), 3.95 (ddd, J=24.7, 13.6, 4.8 Hz, 1H), 3.80 (tt, J=6.1, 2.9 Hz, 1H), 3.37 (ddd, J=17.0, 13.6, 10.2 Hz, 1H), 0.80-0.56 (m, 2H), 0.49 (dd, J=11.8, 3.1 Hz, 1H), 0.29 (ddd, J=17.8, 7.3, 4.3 Hz, 1H).
-
- (S)-2-(2,6-difluorobenzamido)-3-(1-methyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: Prepared according to the procedure described for example 78 employing EQ-4 in place of (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid and 3-bromo-1-methylquinolin-2(1H)-one in place of EQ-3. MS (m/z) 514.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.22 (d, J=7.8 Hz, 1H), 8.95 (dd, J=4.1, 1.7 Hz, 1H), 8.07 (dd, J=8.5, 1.7 Hz, 1H), 8.02 (s, 1H), 7.86-7.78 (m, 1H), 7.73-7.65 (m, 2H), 7.65-7.59 (m, 1H), 7.55-7.43 (m, 3H), 7.32 (ddd, J=7.7, 7.0, 1.1 Hz, 1H), 7.11 (dd, J=8.4, 7.5 Hz, 2H), 4.91 (s, 1H), 3.93 (d, J=35.0 Hz, 1H), 3.71 (s, 3H), 3.46 (d, J=54.5 Hz, 1H).
- Methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(5-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoate: To a solution of H18 (103 mg, 0.325 mmol), EQ8 (192 mg, 0.296 mmol) in DME (6 mL) was added XPhos Pd G3 (13 mg, 0.018 mmol) and potassium phosphate (1 mL, 1 mmol, 1N), and the reaction vial was degassed with nitrogen, sealed, and heated to 90° C. for 20 min. It was diluted with water and extracted with ethyl acetate dried over sodium sulfate, filtered, concentrated and purified on silica gel eluting with hexanes and ethyl acetate to afford the title compound.
- Methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(5-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoate: (Atropisomers 1 & 2) were isolated on a chiral SFC AD-H column eluting with 30% methanol and carried individually into the ensuing hydrolysis reactions.
- To a stirred solution of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl) morpholino)benzamido)-3-(5-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)quinolin-8-yl)propanoate (Atropisomer 1, first eluting peak) (24 mg, 0.034 mmol) in THE (2 mL) and methanol (2 mL) was added sodium hydroxide (0.071 mL, 0.071 mmol, 1 N) and the mixture as stirred for 4 h, acidified with TFA, diluted with DMSO and the more volatile components were removed on a rotary evaporator. The residue was chromatographed on C-18 modified silica gel eluting with acetonitrile in water (0.4% TFA) to afford example 85. MS (m/z) 699.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.95 (dd, J=11.7, 5.7 Hz, 2H), 7.83 (d, J=8.5 Hz, 1H), 7.70 (d, J=7.3 Hz, 1H), 7.49 (dd, J=8.6, 4.2 Hz, 1H), 7.26 (d, J=7.3 Hz, 1H), 6.75 (d, J=11.8 Hz, 2H), 6.64 (s, 1H), 4.91 (d, J=9.1 Hz, 1H), 4.81 (d, J=11.4 Hz, 1H), 4.16 (d, J=12.7 Hz, 1H), 3.95 (d, J=10.1 Hz, 1H), 3.88 (dd, J=13.9, 4.8 Hz, 1H), 3.74 (d, J=12.7 Hz, 1H), 3.57 (d, J=12.3 Hz, 1H), 3.52 (s, 3H), 3.48-3.36 (m, 2H), 3.24 (t, J=12.4 Hz, 1H), 2.55 (s, 3H).
- To a stirred solution of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl) morpholino)benzamido)-3-(5-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl) quinolin-8-yl)propanoate (Atropisomer 2, second eluting peak) (26 mg, 0.035 mmol) in THE (2 mL) and Methanol (2 mL) was added sodium hydroxide (0.071 mL, 0.071 mmol, 1 N) and the mixture as stirred for 4 h, acidified with TFA, diluted with DMSO and the more volatile components were removed on a rotary evaporator. The residue was chromatographed on C-18 modified silica gel eluting with acetonitrile in water (0.4% TFA) to afford example 86. MS (m/z) 699.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.99-8.81 (m, 2H), 7.82 (d, J=8.4 Hz, 1H), 7.69 (d, J=7.3 Hz, 1H), 7.48 (dd, J=8.6, 4.2 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H), 6.73 (d, J=11.7 Hz, 2H), 6.64 (s, 1H), 4.97-4.81 (m, 2H), 4.15 (d, J=12.7 Hz, 1H), 3.94 (dd, J=11.5, 6.9 Hz, 2H), 3.74 (d, J=12.7 Hz, 1H), 3.57 (d, J=11.8 Hz, 1H), 3.51 (s, 3H), 3.47-3.33 (m, 2H), 3.24 (t, J=12.5 Hz, 1H), 2.55 (s, 3H).
-
- (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: Prepared according to the procedure described for example 85 employing H2 in place of H18. The title compound was identified as the first eluting peak. MS (m/z) 699.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.96 (t, J=6.0 Hz, 2H), 7.91 (d, J=8.5 Hz, 1H), 7.78-7.65 (m, 3H), 7.64-7.56 (m, 1H), 7.47 (dd, J=8.6, 4.2 Hz, 1H), 7.34 (d, J=7.2 Hz, 1H), 6.76 (d, J=11.9 Hz, 2H), 4.98-4.79 (m, 2H), 4.16 (d, J=12.7 Hz, 1H), 3.95 (d, J=11.5 Hz, 1H), 3.84 (dd, J=13.5, 5.3 Hz, 1H), 3.74 (d, J=12.7 Hz, 1H), 3.69 (s, 3H), 3.57 (q, J=12.7 Hz, 2H), 3.43 (d, J=12.8 Hz, 1H), 3.24 (t, J=12.4 Hz, 1H), 2.09 (s, 3H).
-
- (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: Prepared according to the procedure described for example 86 employing H2 in place of H18. The title compound was identified as the second eluting peak. MS (m/z) 699.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.96 (d, J=4.1 Hz, 1H), 8.90 (d, J=8.1 Hz, 1H), 7.89 (d, J=8.4 Hz, 1H), 7.79-7.64 (m, 3H), 7.60 (dd, J=10.4, 7.7 Hz, 1H), 7.46 (dd, J=8.5, 4.2 Hz, 1H), 7.31 (d, J=7.1 Hz, 1H), 6.73 (d, J=11.7 Hz, 2H), 5.01-4.84 (m, 2H), 4.16 (d, J=12.7 Hz, 1H), 4.07 (dd, J=13.3, 4.4 Hz, 1H), 3.95 (d, J=9.2 Hz, 1H), 3.73 (d, J=13.1 Hz, 1H), 3.68 (s, 3H), 3.55 (t, J=11.5 Hz, 1H), 3.42 (d, J=12.6 Hz, 1H), 3.27 (dt, J=26.4, 12.3 Hz, 2H), 2.10 (s, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-((dimethylcarbamoyl)oxy)quinolin-8-yl)propanoic acid: a) methyl (S)-2-(2,6-dichlorobenzamido)-3-(5-hydroxyquinolin-8-yl) propanoate: To a vial were added EQ-5 (200 mg, 0.415 mmol) cesium hydroxide (62 mg, 0.415 mmol) and TBuBrett Phos Pd G3 (354 mg, 0.415 mmol), dioxane (4 mL) and water (1 mL) and the vial was sealed and heated at 70° C. overnight. 1N HCl in methanol was added and the mixture was stirred an additional 24 h. The mixture was neutralized with NaHCO3 and chromatographed on silica eluting with methanol in dichloromethane to afford the title compound. b) (S)-2-(2,6-dichlorobenzamido)-3-(5-((dimethylcarbamoyl)oxy)quinolin-8-yl)propanoic acid: To a stirred solution of methyl (S)-2-(2,6-dichlorobenzamido)-3-(5-hydroxyquinolin-8-yl)propanoate (25 mg, 0.059 mmol), trimethylamine (15 mg, 0.18 mmol), in dichloromethane (1 mL) was added dimethylcarbamic chloride (13 mg, 0.12 mmol) and let stir for 30 min. THE (1 mL) and lithium hydroxide (0.5 mL, 0.5 mmol, 1N) was then added the reaction stirred for an additional 2 h. The mixture was diluted with DMSO and neutralized with TFA, volatile components were removed on a rotary evaporator and the residue was chromatographed on C-18 functionalized silica gel eluting with acetonitrile in water (0.4% TFA) to afford the title compound after lyophilizing. MS (m/z) 475.967 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.06 (d, J=8.4 Hz, 1H), 8.98 (dd, J=4.2, 1.7 Hz, 1H), 8.29 (dd, J=8.5, 1.8 Hz, 1H), 7.67 (d, J=7.9 Hz, 1H), 7.59 (dd, J=8.5, 4.2 Hz, 1H), 7.42-7.31 (m, 3H), 7.28 (d, J=7.8 Hz, 1H), 5.08-4.81 (m, 1H), 3.88 (dd, J=13.6, 4.6 Hz, 1H), 3.30 (dd, J=13.7, 10.6 Hz, 1H), 3.19 (s, 3H), 2.95 (s, 3H).
-
- 5-(((5-Bromo-2-methylphenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (CL-A): To a stirred mixture of 5-bromo-2-methylaniline (3.70 g, 20 mmol) and triethyl orthoformate (16.5 mL, 99 mmol) at RT was added 2,2-dimethyl-1,3-dioxane-4,6-dione (3.15 g, 21.9 mmol). The reaction mixture was heated to 100° C. and allowed to stir for 3 h. The reaction was then cooled to RT and McOH (˜5 mL) was added. After stirring for 5 min the solid was filtered and rinsed with McOH. The solid was dried under reduced pressure and the resulting crude material of CL-A was used with no further purification.
- 5-Bromo-8-methylquinolin-4-ol (CL-B): A stirred suspension of compound CL-A (1.04 g, 3.07 mmol) in diphenyl ether (8.8 mL) was heated at 200° C. After 20 min, the reaction was cooled to RT and Et2O was added. The solid was filtered, rinsed with Et2O and dried under reduced pressure. The resulting crude material of CL-B was used with no further purification.
- 5-Bromo-4-chloro-8-methylquinoline (CL-C): To a stirred solution of CL-B (1.0 g, 4.2 mmol) in toluene (21 mL) at RT was added PCl5 (1.06 mL, 8.4 mmol). The reaction mixture was heated to 80° C. for 1 hr. The reaction mixture was then cooled to RT and water was carefully added. After stirring for 5 min, EtOAc was added to the reaction mixture. The aqueous layer was separated and extracted with EtOAc (2×). The combined organics were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with EtOAc in Hex (0-10%) to give the title compound.
- 5-Bromo-8-(bromomethyl)-4-chloroquinoline (CL-D): To a stirred solution of CL-C (640 mg, 2.5 mmol) in benzene (7.1 mL) was added NBS (488 mg, 2.7 mmol) at RT. The reaction mixture was heated to reflux under tungsten light for 45 min. The reaction was cooled to RT, water added and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford crude material. The material was purified on silica gel eluting with EtOAc in Hex (0-10%) to give the title compound.
- Methyl 5-bromo-4-chloro-8-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-7,8-quinoline (CL-E): To a stirred solution of (R)-2,5-Dihydro-3,6-dimethoxy-2-isopropylpyrazine in 2-MeTHF (9.5 mL) was added nBuLi (1.6 mL, 1.6 M solution in hexanes) dropwise at −78° C. After stirring for 25 min, a solution of CL-D (640 mg, 1.9 mmol) in 2-MeTHF (11 mL) was added over a 3 min time frame. The reaction mixture was allowed to stir at −78° C. for 15 min. H2O was added to the reaction mixture while allowing to warm to RT. The aqueous layer was separated and extracted with EtOAc (2×). The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified by silica gel chromatography using 0-30% EtOAc in hexanes to afford the title compound.
- Methyl (S)-2-amino-3-(5-bromo-4-chloroquinolin-8-yl)propanoate (CL-F): To a stirred solution of CL-E (726 mg, 1.7 mmol) in MeCN (17 mL) at RT was added aq HCl (4.1 mL, 2M). The reaction mixture was allowed to stir for 1 h and then carefully poured into sat aq NaHCO3. EtOAc was then added to the mixture. The aqueous layer was separated and extracted with EtOAc (2×, ˜10 mL) and 2-MeTHF (1×, ˜10 mL). The organic layers were combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The resulting crude material of the title compound was used with no further purification.
- Methyl (S)-3-(5-bromo-4-chloroquinolin-8-yl)-2-(2,6-difluorobenzamido) propanoate (CL-G): To a stirred solution of CL-F (2.0 g, 5.8 mmol) in DCM (57 mL) at RT was added 2-6-difluorobenzoyl chloride (0.82 mL, 5.8 mmol) and DI EA (5.0 mL, 129 mmol). The reaction mixture was allowed to stir for 10 min. DCM and water was added to the reaction mixture. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with EtOAc in hexanes (0-70%) to afford the title compound.
- Methyl (S)-3-(4-chloro-5-(2-chloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluorobenzamido)propanoate (CL-H) and methyl (S)-3-(4,5-bis(2-chloro-4-fluorophenyl)quinolin-8-yl)-2-(2,6-difluorobenzamido)propanoate (CL-I): To a pressure tube was added CL-G (149 mg, 0.29 mmol), 4,5-difluoro-2-methoxyphenylboronic acid (92 mg, 0.49 mmol), Pd(PPh3)4 (17 mg, 0.014 mmol), and aq Na2CO3 (0.87 mL, 1M) in DME (5.2 mL). The reaction mixture was allowed to stir at 100° C. for 20 min. EtOAc and water was added to the reaction mixture. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified by silica gel chromatography using 0-50% EtOAc in hexanes to afford both the title compounds.
- To a stirred solution of CL-H and CL-I (2:1 mixture, 60 mg, 0.11 mmol) in THE (1.1 mL) and H2O (1.1 mL) was added LiOH.H2O (24 mg, 0.56 mmol). The reaction mixture was allowed to stir for 30 min then concentrated under reduced pressure. The material was purified via reverse phase HPLC to afford the title compound. MS (m/z) 520.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.13 (d, J=8.3 Hz, 1H), 8.90 (dd, J=4.7, 2.1 Hz, 1H), 7.78 (dd, J=7.4, 2.3 Hz, 1H), 7.71 (dd, J=4.7, 1.0 Hz, 1H), 7.58-7.51 (m, 1H), 7.51-7.27 (m, 3H), 7.17-7.04 (m, 2H), 4.99 (dt, J=8.3, 5.1 Hz, 1H), 4.02 (ddd, J=40.7, 13.4, 4.9 Hz, 1H), 3.46-3.28 (m, 1H).
- Prepared as mixture with example 90 and separated on reversed phase chromatography to afford the title compound. MS (m/z) 614.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.18 (dd, J=8.1, 3.4 Hz, 1H), 9.04 (dd, J=4.3, 0.9 Hz, 1H), 7.76 (dd, J=7.4, 4.7 Hz, 1H), 7.54-7.33 (m, 2H), 7.30 (dd, J=4.3, 1.4 Hz, 1H), 7.24 (d, J=7.3 Hz, 1H), 7.15-6.97 (m, 5H), 5.10-4.96 (m, 1H), 4.05 (d, J=13.4 Hz, 1H), 3.45 (dt, J=13.6, 9.7 Hz, 1H).
-
- (S)-3-(4-chloro-5-(4,5-difluoro-2-methoxyphenyl)quinolin-8-yl)-2-(2,6-difluoro benzamido)propanoic acid: The title compound was prepared according to the method presented for the synthesis of Example 90 replacing (2-chloro-4-fluorophenyl) boronic acid with (4,5-difluoro-2-methoxyphenyl)boronic acid. MS (m/z) 533.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (dd, J=15.4, 8.1 Hz, 1H), 8.87 (dd, J=4.6, 0.6 Hz, 1H), 7.74 (dd, J=7.4, 6.0 Hz, 1H), 7.68 (d, J=4.6 Hz, 1H), 7.54-7.42 (m, 1H), 7.37 (dd, J=7.4, 1.4 Hz, 1H), 7.34-7.24 (m, 1H), 7.23-7.15 (m, 1H), 7.12 (ddd, J=8.5, 7.6, 1.9 Hz, 2H), 4.94 (ddd, J=10.6, 8.0, 4.7 Hz, 1H), 3.98 (ddd, J=41.4, 13.6, 4.9 Hz, 1H), 3.60 (d, J=3.2 Hz, 3H), 3.50-3.27 (m, 1H).
-
- (S)-3-(4-chloro-5-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)quinolin-8-yl)-2-(2,6-difluorobenzamido)propanoic acid: The title compound was prepared according to the method presented for the synthesis of Example 90 replacing (2-chloro-4-fluorophenyl) boronic acid with (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid. MS (m/z) 585.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.18 (d, J=7.9 Hz, 1H), 8.81 (d, J=4.6 Hz, 1H), 7.72 (d, J=7.5 Hz, 1H), 7.59 (d, J=4.6 Hz, 1H), 7.55-7.42 (m, 1H), 7.24 (d, J=7.4 Hz, 1H), 7.12 (dd, J=8.4, 7.5 Hz, 2H), 6.68 (d, J=5.3 Hz, 2H), 4.94 (dd, J=8.0, 4.9 Hz, 1H), 4.52 (s, 2H), 3.94 (dd, J=13.6, 5.0 Hz, 1H), 3.64-3.50 (m, 8H), 3.41 (dd, J=13.7, 10.1 Hz, 1H), 1.21 (t, J=7.0 Hz, 3H).
-
- (S)-3-(4-chloro-5-(4,5-difluoro-2-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoic acid: The title compound was prepared according to the method presented for the synthesis of Example 90 replacing (2-chloro-4-fluorophenyl)boronic acid with (4,5-difluoro-2-methoxyphenyl)boronic acid. MS (m/z) 566.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.06 (t, J=8.3 Hz, 1H), 8.93-8.82 (m, 1H), 7.79 (dd, J=7.4, 2.4 Hz, 1H), 7.67 (dd, J=4.7, 0.8 Hz, 1H), 7.49-7.25 (m, 4H), 7.20 (dd, J=12.5, 7.3 Hz, 1H), 5.20-4.99 (m, 1H), 4.00 (td, J=13.5, 4.4 Hz, 1H), 3.61 (d, J=5.0 Hz, 3H), 3.45-3.21 (m, 1H).
-
- (S)-3-(4-chloro-5-(4,5-difluoro-2-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoic acid: Atropisomers obtained in Example 94 were arbitrarily assigned after separation by supercritical fluid chromatography eluting with 20% McOH/DEA co-solvent on an IC SFC column to give Example 95 and Example 96. The title compound was identified as the second eluting peak. MS (m/z) 565.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.06 (t, J=8.3 Hz, 1H), 8.94-8.83 (m, 1H), 7.79 (dd, J=7.4, 2.4 Hz, 1H), 7.67 (dd, J=4.6, 0.8 Hz, 1H), 7.48-7.10 (m, 6H), 5.20-5.03 (m, 1H), 4.00 (td, J=13.5, 4.4 Hz, 1H), 3.61 (d, J=5.0 Hz, 3H), 3.43-3.22 (m, 1H).
-
- (S)-3-(4-chloro-5-(4,5-difluoro-2-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoic acid: The title compound was identified as the third eluting peak. MS (m/z) 565.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.06 (t, J=8.3 Hz, 1H), 8.87 (dd, J=5.3, 4.6 Hz, 1H), 7.79 (dd, J=7.4, 2.4 Hz, 1H), 7.67 (dd, J=4.7, 0.8 Hz, 1H), 7.51-7.10 (m, 5H), 5.21-4.99 (m, 1H), 4.00 (td, J=13.5, 4.4 Hz, 1H), 3.61 (d, J=5.0 Hz, 3H), 3.33 (ddd, J=34.2, 13.6, 11.0 Hz, 1H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(5-(4,5-difluoro-2-methoxyphenyl)-4-methylquinolin-8-yl)propanoic acid: To a microwave vial was added methyl (S)-3-(4-chloro-5-(4,5-difluoro-2-methoxyphenyl)quinolin-8-yl)-2-(2,6-dichlorobenzamido)propanoate (104 mg, 0.18 mmol) (prepared according to the procedure described for CL-H replacing 2,6-difluoro benzoyl chloride with 2,6-dichlorobenzoyl chloride, and (2-chloro-4-fluorophenyl)boronic acid with (4,5-difluoro-2-methoxyphenyl)boronic acid). Trimethylboroxine (45 mg, 0.359 mmol), Tetrakis (triphenylphosphine) palladium(O) (10 mg, 0.01 mmol), sodium carbonate (0.9 mL, 1N, 0.9 mmol) and 1,2-dimethoxyethane were added to a microwave vial and heated to 130 C for 30 min. Trimethylboroxine (68 mg, 0.538 mmol) was added to the vial and the mixture was heated to 140° C. for 40 min. The mixture was diluted with ethyl acetate and water, the pH was adjusted to pH 4 and the organic layer was decanted, volatile components were removed on a rotary evaporator and the residue was loaded onto silica gel and chromatographed eluting with methanol in dichlormethane and diethyl ether to afford the title compound. MS (m/z) 546.7 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.70 (s, 1H), 9.07 (dd, J=8.5, 2.3 Hz, 1H), 8.99-8.91 (m, 1H), 8.86 (s, 1H), 8.78 (dd, J=5.3, 4.3 Hz, 1H), 7.68 (d, J=7.3 Hz, 1H), 7.46-7.32 (m, 4H), 7.32-7.08 (m, 5H), 5.19-4.99 (m, 1H), 3.99 (td, J=12.6, 4.3 Hz, 1H), 3.64 (d, J=4.3 Hz, 4H), 2.06 (d, J=18.9 Hz, 5H).
-
- Atropisomers were arbitrarily assigned after separation by supercritical fluid chromatography eluting with 20% McOH/DEA co-solvent on an IC SFC column.
- The title compound was identified as the first eluting isomer: MS (m/z) 546.7 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.74 (t, J=4.8 Hz, 1H), 8.56 (s, 1H), 7.83-7.73 (m, 1H), 7.70 (d, J=7.3 Hz, 1H), 7.46 (s, 1H), 7.41-7.05 (m, 6H), 4.83 (s, 1H), 4.03-3.87 (m, 1H), 3.62 (t, J=4.3 Hz, 3H), 3.39 (d, J=14.3 Hz, 1H), 2.01 (s, 3H).
- The title compound was identified as the second eluting isomer: MS (m/z) 546.4 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.75 (dd, J=5.3, 4.3 Hz, 1H), 8.52 (d, J=28.5 Hz, 1H), 7.72 (d, J=7.3 Hz, 1H), 7.45-7.07 (m, 7H), 4.82 (d, J=13.6 Hz, 1H), 4.07-3.86 (m, 1H), 3.64 (d, J=4.8 Hz, 3H), 3.46-3.34 (m, 1H), 2.03 (s, 3H).
-
- (S)-2-(2,6-dichlorobenzamido)-3-(1,4′-dimethyl-2-oxo-1,2-dihydro-[3,5′-biquinolin]-8′-yl)propanoic acid: The title compound was prepared according to the method presented for the synthesis of Example 97 replacing (4,5-difl uoro-2-methoxyphenyl)boronic acid with 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-2(1H)-one. MS (m/z) 561.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (d, J=8.4 Hz, 1H), 8.80 (d, J=4.3 Hz, 1H), 7.90 (d, J=27.6 Hz, 1H), 7.80 (ddd, J=9.5, 7.8, 1.5 Hz, 1H), 7.73-7.60 (m, 3H), 7.46-7.28 (m, 5H), 5.14-4.98 (m, 1H), 3.96 (ddd, J=34.5, 13.6, 4.8 Hz, 1H), 3.71 (d, J=0.9 Hz, 3H), 3.38 (ddd, J=29.5, 13.6, 10.3 Hz, 1H), 2.33 (d, J=2.5 Hz, 3H).
-
- (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzamido)-3-(5-(2,6-dimethoxyphenyl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing EQ10 in place of EQ6, and (2,6-dimethoxyphenyl) boronic acid in place of H2. MS (m/z) 743.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.20 (s, 1H), 9.10 (d, J=7.8 Hz, 1H), 8.85 (dd, J=4.2, 1.8 Hz, 1H), 8.33 (dt, J=5.4, 0.6 Hz, 1H), 8.11-8.02 (m, 2H), 8.02-7.91 (m, 2H), 7.76-7.70 (m, 1H), 7.67 (dd, J=8.4, 1.8 Hz, 1H), 7.64-7.50 (m, 3H), 7.46-7.38 (m, 2H), 7.25 (d, J=7.3 Hz, 1H), 6.80 (dd, J=8.8, 3.8 Hz, 4H), 4.84 (ddd, J=10.1, 7.8, 4.9 Hz, 1H), 3.92-3.81 (m, 1H), 3.54 (d, J=2.4 Hz, 6H), 3.35 (dd, J=13.8, 10.1 Hz, 1H).
- (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzamido)-3-(5-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)quinolin-8-yl)propanoic acid: Prepared according to the procedure described for example 10 employing EQ10 in place of EQ6, and (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid in place of H2. MS (m/z) 801.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.20 (s, 1H), 9.10 (d, J=7.8 Hz, 1H), 8.85 (dd, J=4.2, 1.8 Hz, 1H), 8.33 (dt, J=5.3, 0.6 Hz, 1H), 8.12-8.01 (m, 2H), 8.01-7.91 (m, 2H), 7.77-7.48 (m, 5H), 7.41 (dd, J=8.5, 4.2 Hz, 1H), 7.24 (d, J=7.3 Hz, 1H), 6.91-6.70 (m, 4H), 6.45 (dt, J=2.4, 0.6 Hz, 1H), 4.84 (ddd, J=10.1, 7.8, 4.9 Hz, 1H), 4.53 (s, 2H), 3.86 (dd, J=13.7, 4.7 Hz, 1H), 3.62-3.50 (m, 8H), 3.35 (dd, J=13.9, 10.0 Hz, 1H), 1.20 (t, J=7.0 Hz, 3H).
-
- Synthesis of methyl (S)-3-(8-bromoquinolin-5-yl)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzamido)propanoate (103A): The title compound was prepared according to the method presented for the synthesis of compound N7A starting with 2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzoic acid and N1.
- Synthesis of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(4-(2,6-dimethoxyphenyl)naphthalen-1-yl)propanoic acid (103): To a microwave vial was added 103A (170 mg, 0.25 mmol), (2,6-dimethoxyphenyl)boronic acid (54 mg, 0.29 mmol), Pd(PPh3)4 (28 mg, 0.02 mmol), and aq Na2CO3 (0.37 mL, 2M) in DME (2 mL). The reaction mixture was allowed to stir at 135° C. for 30 min. EtOAc and water was added to the reaction mixture. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified via reverse phase HPLC to afford the title compound. MS (m/z) 742.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.20 (s, 1H), 9.13 (d, J=7.9 Hz, 1H), 8.33 (d, J=5.3 Hz, 1H), 8.16-8.01 (m, 3H), 8.03-7.93 (m, 2H), 7.72 (dt, J=5.3, 1.8 Hz, 1H), 7.59 (d, J=1.3 Hz, 1H), 7.52 (ddd, J=8.4, 6.5, 1.6 Hz, 1H), 7.46-7.27 (m, 4H), 7.12 (d, J=7.2 Hz, 1H), 6.88-6.68 (m, 4H), 4.68 (ddd, J=9.9, 7.9, 4.3 Hz, 1H), 3.65 (dd, J=14.6, 4.3 Hz, 1H), 3.53 (d, J=1.8 Hz, 6H), 3.28 (dd, J=14.7, 9.9 Hz, 1H).
-
- Synthesis methyl (S)-2-(4-((4-(1H-1,2,4-triazol-1-yl)phenyl)sulfonamido)-2,6-difluoro benzamido)-3-(4-bromonaphthalen-1-yl)propanoate (104A): The title compound was prepared according to the method presented for the synthesis of compound N7A starting with 4-((4-(1H-1,2,4-triazol-1-yl)phenyl)sulfonamido)-2,6-difluorobenzoic acid and N1.
- Synthesis of methyl (S)-2-(4-((4-(1H-1,2,4-triazol-1-yl)phenyl)sulfonamido)-2,6-difluorobenzamido)-3-(4-(2,6-dimethoxyphenyl)naphthalen-1-yl)propanoate (104B): The title compound was prepared according to the method presented for the synthesis of compound 103 in example 103 starting with 104A and (2,6-dimethoxyphenyl)boronic acid.
- Synthesis of (S)-2-(4-((4-(1H-1,2,4-triazol-1-yl)phenyl)sulfonamido)-2,6-difluoro benzamido)-3-(4-(2,6-dimethoxyphenyl)naphthalen-1-yl)propanoic acid (104): To a stirred solution of 104B (50 mg, 0.07 mmol) in THF (1 mL) was added LiOH (0.21 mL, 1M). The reaction mixture was allowed to stir for 1 hour then concentrated under reduced pressure. The material was purified via reverse phase HPLC to afford the title compound. MS (m/z) 714.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.15 (s, 1H), 9.38 (s, 1H), 9.12 (d, J=7.9 Hz, 1H), 8.28 (s, 1H), 8.14-8.06 (m, 3H), 8.05-7.96 (m, 2H), 7.59-7.47 (m, 1H), 7.43-7.26 (m, 4H), 7.12 (d, J=7.2 Hz, 1H), 6.79 (dd, J=8.7, 6.2 Hz, 4H), 4.68 (ddd, J=9.9, 7.9, 4.2 Hz, 1H), 3.65 (dd, J=14.6, 4.3 Hz, 1H), 3.53 (d, J=1.3 Hz, 6H), 3.28 (dd, J=14.6, 9.8 Hz, 1H).
-
- Synthesis of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)naphthalen-1-yl)propanoic acid (105): To a microwave vial was added 103A (64 mg, 0.09 mmol), (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid (26 mg, 0.11 mmol), Pd(PPh3)4 (11 mg, 0.01 mmol), and aq Na2CO3 (0.14 mL, 2 M) in DME (1 mL). The reaction mixture was allowed to stir at 135° C. for 30 min. Then cool to RT and LiOH (0.25 mL, 1M) was added. The reaction mixture was allowed to stir for 1 hour then concentrated under reduced pressure. The material was purified via reverse phase HPLC to afford the title compound. MS (m/z) 800.45 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.22 (s, 1H), 9.15 (d, J=7.8 Hz, 1H), 8.33 (d, J=5.3 Hz, 1H), 8.13-8.01 (m, 3H), 8.02-7.93 (m, 2H), 7.73 (dt, J=5.3, 1.8 Hz, 1H), 7.59 (s, 1H), 7.56-7.48 (m, 1H), 7.43-7.26 (m, 3H), 7.11 (d, J=7.2 Hz, 1H), 6.81 (d, J=9.1 Hz, 2H), 6.74 (s, 2H), 4.74-4.59 (m, 1H), 4.53 (s, 2H), 3.63 (s, 1H), 3.60-3.54 (m, 2H), 3.53 (d, J=1.9 Hz, 6H), 3.31-3.20 (m, 1H), 1.20 (t, J=7.0 Hz, 3H).
-
- Synthesis of (S)-3-(4-(2,6-dichloro-4-fluorophenyl)naphthalen-1-yl)-2-(2,6-difluoro benzamido)propanoic acid (106): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N2 and (2,6-dichloro-4-fluorophenyl)boronic acid. MS (m/z) 519.5 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 9.27 (d, J=8.1 Hz, 1H), 8.22 (d, J=8.5 Hz, 1H), 7.72 (d, J=8.6 Hz, 2H), 7.64 (ddd, J=8.4, 6.8, 1.3 Hz, 1H), 7.56 (s, 1H), 7.53-7.41 (m, 2H), 7.32-7.21 (m, 2H), 7.10 (dd, J=8.5, 7.4 Hz, 2H), 4.79 (ddd, J=10.3, 8.0, 4.2 Hz, 1H), 3.76 (dd, J=14.5, 4.2 Hz, 1H), 3.32 (s, 1H).
-
- Synthesis of (S)-3-(4-(2,6-dichloro-4-fluorophenyl)naphthalen-1-yl)-2-(2,6-dichloro benzamido)propanoic acid (107): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N4 and (2,6-dichloro-4-fluorophenyl)boronic acid. MS (m/z) 551.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J=8.4 Hz, 1H), 8.24 (d, J=8.5 Hz, 1H), 7.76-7.68 (m, 2H), 7.66 (ddd, J=8.4, 6.8, 1.3 Hz, 1H), 7.61 (d, J=7.3 Hz, 1H), 7.50 (ddd, J=8.1, 6.8, 1.1 Hz, 1H), 7.44-7.33 (m, 3H), 7.30-7.20 (m, 2H), 4.83 (ddd, J=10.7, 8.3, 3.5 Hz, 1H), 3.78 (dd, J=14.3, 3.5 Hz, 1H), 3.32 (dd, J=14.4, 10.8 Hz, 1H).
- Synthesis of (S)-2-(2,6-dichlorobenzamido)-3-(4-(1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)naphthalen-1-yl)propanoic acid (108): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N5 and 3-bromo-1-methylquinolin-2(1H)-one. MS (m/z) 546.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J=8.2 Hz, 1H), 8.25-8.17 (m, 1H), 7.93 (d, J=16.9 Hz, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.71-7.57 (m, 4H), 7.51 (d, J=7.3 Hz, 1H), 7.48-7.37 (m, 5H), 7.36-7.26 (m, 2H), 4.83 (td, J=8.8, 4.7 Hz, 1H), 3.71 (s, 3H), 3.37 (s, 1H).
-
- Synthesis of (S)-2-(2,6-dichlorobenzamido)-3-(4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)naphthalen-1-yl)propanoic acid Atropisomer 1 (109): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N5 and 5-bromo-1,3,6-trimethylpyrimidine-2,4(1H,3H)-dione. The acid product 109B was separated into its 2 diastereomeric atropisomers by reverse phase HPLC. The title compound was identified as the first eluting peak. MS (m/z) 541.6 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.23 (dd, J=12.0, 8.3 Hz, 1H), 8.19 (dd, J=8.6, 3.8 Hz, 1H), 7.71 (d, J=8.7 Hz, 1H), 7.68-7.54 (m, 1H), 7.49 (t, J=7.9 Hz, 2H), 7.46-7.33 (m, 4H), 7.25-7.10 (m, 1H), 4.90-4.73 (m, 1H), 3.81-3.59 (m, 1H), 3.48 (s, 3H), 3.22 (d, J=2.8 Hz, 3H), 1.91 (d, J=1.8 Hz, 3H).
- Synthesis of (S)-2-(2,6-dichlorobenzamido)-3-(4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)naphthalen-1-yl)propanoic acid Atropisomer 2 (110): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N5 and 5-bromo-1,3,6-trimethylpyrimidine-2,4(1H,3H)-dione. The acid product 109B was separated into its 2 diastereomeric atropisomers by reverse phase HPLC. The title compound was identified as the second eluting peak. MS (m/z) 541.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J=8.3 Hz, 1H), 8.21 (d, J=8.5 Hz, 1H), 8.07-7.96 (m, 1H), 7.66 (ddd, J=8.4, 6.8, 1.2 Hz, 1H), 7.58 (ddd, J=8.2, 6.8, 1.2 Hz, 1H), 7.50-7.33 (m, 4H), 7.28 (d, J=7.3 Hz, 1H), 4.83 (s, 1H), 4.82-4.73 (m, 1H), 4.39 (d, J=4.6 Hz, 2H), 3.68 (dd, J=14.4, 4.2 Hz, 1H), 3.42 (s, 3H), 3.31-3.25 (m, 1H), 3.13 (s, 3H).
-
- Synthesis of (S)-3-(4-(chroman-8-yl)naphthalen-1-yl)-2-(2,6-dichlorobenzamido) propanoic acid (111): The title compound was prepared according to the method presented for the synthesis of compound 105 in example 105 starting with N4 and chroman-8-ylboronic acid heating at 120° C. for 20 min in a microwave reactor. MS (m/z) 520.1 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 9.24 (d, J=8.3 Hz, 1H), 8.17 (d, J=8.5 Hz, 1H), 7.58 (ddd, J=8.2, 6.5, 1.4 Hz, 1H), 7.54-7.44 (m, 3H), 7.44-7.35 (m, 3H), 7.20 (dd, J=7.2, 2.8 Hz, 1H), 7.15 (dt, J=7.0, 2.2 Hz, 1H), 6.97-6.88 (m, 2H), 4.92-4.75 (m, 1H), 3.94 (q, J=4.8, 4.3 Hz, 2H), 3.71 (ddd, J=14.7, 10.8, 4.3 Hz, 1H), 3.30 (d, J=10.0 Hz, 1H), 2.92-2.75 (m, 2H), 1.89 (p, J=5.3, 4.8 Hz, 2H).
-
- Synthesis of (S)-3-(4-(chroman-8-yl)naphthalen-1-yl)-2-(2,6-difluorobenzamido) propanoic acid (112): The title compound was prepared according to the method presented for the synthesis of compound 105 in example 105 starting with N2 and chroman-8-ylboronic acid heat at 120° C. for 20 min in microwave. MS (m/z) 488.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (dd, J=10.5, 8.0 Hz, 1H), 8.25-8.05 (m, 1H), 7.65-7.34 (m, 5H), 7.23 (t, J=7.3 Hz, 1H), 7.18-7.07 (m, 3H), 6.99-6.88 (m, 2H), 4.73 (ddd, J=9.9, 8.0, 4.2 Hz, 1H), 4.18-3.86 (m, 2H), 3.71 (ddd, J=26.0, 14.4, 4.3 Hz, 1H), 3.33 (ddd, J=28.2, 14.5, 9.9 Hz, 1H), 2.95-2.76 (m, 2H), 1.89 (d, J=7.3 Hz, 2H).
- Synthesis of (S)-3-(4-(4-bromoisoquinolin-3-yl)naphthalen-1-yl)-2-(2,6-dichlorobenzamido) propanoic acid (113): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N5 and 3,4-dibromoisoquinoline heating at 120° C. for 20 min in microwave. MS (m/z) 595.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.50-9.42 (m, 1H), 9.31 (dd, J=16.4, 8.3 Hz, 1H), 8.32 (d, J=8.2 Hz, 1H), 8.29-8.21 (m, 2H), 8.03 (ddt, J=8.6, 7.0, 1.6 Hz, 1H), 7.88 (ddt, J=8.0, 7.1, 1.0 Hz, 1H), 7.71-7.57 (m, 2H), 7.48-7.41 (m, 4H), 7.41-7.31 (m, 2H), 4.95-4.77 (m, 1H), 3.77 (ddd, J=14.1, 7.4, 4.2 Hz, 1H), 3.40-3.33 (m, 1H).
- Synthesis of (S)-3-(4-(4-bromoisoquinolin-3-yl)naphthalen-1-yl)-2-(2,6-difluoro benzamido)propanoic acid (114): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N3 and 3,4-dibromoisoquinoline heating at 120° C. for 20 min in microwave. MS (m/z) 563.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.45 (dd, J=2.7, 0.8 Hz, 1H), 9.32 (dd, J=8.0, 3.2 Hz, 1H), 8.33 (d, J=8.2 Hz, 1H), 8.29-8.22 (m, 2H), 8.03 (ddd, J=8.4, 7.0, 1.3 Hz, 1H), 7.88 (ddd, J=8.1, 7.0, 1.1 Hz, 1H), 7.68-7.60 (m, 1H), 7.60-7.52 (m, 1H), 7.47 (dddd, J=15.0, 7.9, 6.6, 3.7 Hz, 3H), 7.38-7.32 (m, 1H), 7.17-7.06 (m, 2H), 4.79 (ddd, J=18.7, 9.7, 4.0 Hz, 1H), 3.73 (dd, J=14.4, 4.8 Hz, 1H), 3.40 (ddd, J=41.1, 14.4, 10.0 Hz, 1H).
-
- Synthesis of (S)-2-(2,6-dichlorobenzamido)-3-(4-(4-(trifluoromethyl)isoquinolin-3-yl)naphthalen-1-yl)propanoic acid (115): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N5 and 3-bromo-4-(trifluoromethyl)isoquinoline heating at 120° C. for 30 min in microwave. MS (m/z) 584.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.66 (d, J=5.0 Hz, 1H), 9.32 (dd, J=21.4, 8.3 Hz, 1H), 8.47-8.39 (m, 1H), 8.33-8.19 (m, 2H), 8.14-8.04 (m, 1H), 7.99-7.90 (m, 1H), 7.72-7.61 (m, 1H), 7.58 (dd, J=7.3, 2.1 Hz, 1H), 7.52-7.34 (m, 5H), 7.32 (d, J=7.2 Hz, 1H), 4.87 (dddd, J=26.8, 10.1, 8.3, 4.2 Hz, 1H), 3.77 (dt, J=14.2, 3.8 Hz, 1H), 3.40 (dt, J=14.3, 9.9 Hz, 1H).
-
- Synthesis of (S)-3-(4-(2-cyclopropoxy-4,5-difluorophenyl)naphthalen-1-yl)-2-(2,6-dichlorobenzamido)propanoic acid (116): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N5 and H17 heating at 130° C. for 30 min in microwave. MS (m/z) 556.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.27-9.14 (m, 1H), 8.18 (dd, J=8.6, 3.6 Hz, 1H), 7.60 (dddd, J=8.3, 6.1, 4.2, 1.6 Hz, 1H), 7.55-7.46 (m, 2H), 7.46-7.34 (m, 5H), 7.30-7.15 (m, 2H), 4.82 (ddq, J=8.1, 6.1, 2.2 Hz, 1H), 3.80 (dq, J=6.0, 3.0 Hz, 1H), 3.70 (ddd, J=14.2, 7.1, 4.3 Hz, 1H), 3.30 (d, J=14.5 Hz, 1H), 0.73-0.58 (m, 2H), 0.53-0.38 (m, 1H), 0.29 (dddd, J=9.8, 7.6, 4.8, 2.6 Hz, 1H).
- Synthesis of (S)-2-(2,6-dichlorobenzamido)-3-(4-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)naphthalen-1-yl)propanoic acid atropisomer 1 (117): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N5 and H5 heating at 130° C. for 35 min in microwave. The acid product 117B was then separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an OJ-H 4.6×100 mm column. The title compound was identified as the first eluting peak. MS (m/z) 561.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (dd, J=14.6, 8.3 Hz, 1H), 8.22 (dd, J=8.6, 4.0 Hz, 1H), 7.90 (ddd, J=7.9, 6.2, 1.5 Hz, 1H), 7.73-7.66 (m, 1H), 7.66-7.55 (m, 2H), 7.54 (d, J=7.3 Hz, 1H), 7.52-7.25 (m, 6H), 7.20 (t, J=7.1 Hz, 1H), 4.92-4.75 (m, 1H), 3.85-3.68 (m, 1H), 3.67 (d, J=2.4 Hz, 3H), 3.39-3.22 (m, 1H), 2.08 (d, J=0.7 Hz, 3H).
- Preparation of (S)-2-(2,6-dichlorobenzamido)-3-(4-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)naphthalen-1-yl)propanoic acid Atropisomer 2 (118): 117B was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% McOH a co-solvent, at a flow rate of 3.0 mL/min, using an OJ-H 4.6×100 mm column. The title compound was identified as the second eluting peak. MS (m/z) 561.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J=8.3 Hz, 1H), 8.22 (dd, J=8.7, 1.1 Hz, 1H), 7.91 (dd, J=8.1, 1.4 Hz, 1H), 7.69 (ddd, J=8.5, 7.0, 1.4 Hz, 1H), 7.63 (ddd, J=8.4, 6.8, 1.4 Hz, 2H), 7.55 (d, J=7.2 Hz, 1H), 7.51-7.30 (m, 6H), 7.20 (d, J=7.2 Hz, 1H), 4.82 (ddd, J=10.6, 8.3, 3.6 Hz, 1H), 3.79 (dd, J=14.2, 3.6 Hz, 1H), 3.67 (s, 3H), 3.28 (dd, J=14.3, 10.6 Hz, 1H), 2.08 (s, 3H).
-
- Synthesis of (S)-2-(2,6-difluorobenzamido)-3-(4-(1,4-dimethyl-2-oxo-1,2-dihydro quinolin-3-yl)naphthalen-1-yl)propanoic acid Atropisomer 1 (119): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N3 and H5 heating at 130° C. for 35 min in microwave. The acid product 119B was then separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an OJ-H 4.6×100 mm column. The title compound was identified as the first eluting peak. MS (m/z) 527.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.23 (d, J=8.5 Hz, 1H), 7.90 (ddd, J=8.0, 4.5, 1.4 Hz, 1H), 7.69 (ddd, J=8.5, 7.0, 1.4 Hz, 1H), 7.64-7.55 (m, 2H), 7.54-7.43 (m, 3H), 7.43-7.37 (m, 1H), 7.34 (ddd, J=8.1, 7.0, 1.2 Hz, 1H), 7.20 (dd, J=10.7, 7.2 Hz, 1H), 7.15-7.06 (m, 2H), 4.72 (s, 1H), 3.88-3.70 (m, 1H), 3.67 (d, J=1.3 Hz, 3H), 3.43 (dd, J=14.5, 9.3 Hz, 1H), 2.08 (d, J=7.4 Hz, 3H).
- Preparation of (S)-2-(2,6-difluorobenzamido)-3-(4-(1,4-dimethyl-2-oxo-1,2-dihydro quinolin-3-yl)naphthalen-1-yl)propanoic acid Atropisomer 2 (120): 119B was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% McOH a co-solvent, at a flow rate of 3.0 mL/min, using an OJ-H 4.6×100 mm column. The title compound was identified as the second eluting peak. MS (m/z) 527.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ9.24 (d, J=8.2 Hz, 1H), 8.20 (d, J=8.5 Hz, 1H), 8.01-7.84 (m, 1H), 7.69 (ddd, J=8.5, 7.0, 1.4 Hz, 1H), 7.64-7.57 (m, 2H), 7.52-7.44 (m, 3H), 7.44-7.39 (m, 1H), 7.35 (ddd, J=8.1, 7.0, 1.2 Hz, 1H), 7.20 (d, J=7.2 Hz, 1H), 7.10 (dd, J=8.4, 7.5 Hz, 2H), 4.86-4.72 (m, 1H), 3.82 (dd, J=14.2, 3.9 Hz, 1H), 3.67 (s, 3H), 3.30-3.23 (m, 1H), 2.09 (s, 3H).
-
- Preparation of (S)-2-(2,6-dichlorobenzamido)-3-(4-(1-methyl-2-oxo-4-(trifluoromethyl)-1,2-dihydroquinolin-3-yl)naphthalen-1-yl)propanoic acid (121): The title compound was prepared according to the method presented for the synthesis of compound 104 in example 104 starting with N5 and H12 heating at 135° C. for 30 min in microwave. MS (m/z) 614.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.31 (dd, J=18.1, 8.3 Hz, 1H), 8.23 (t, J=7.8 Hz, 1H), 7.94 (d, J=8.1 Hz, 1H), 7.87-7.73 (m, 2H), 7.70-7.59 (m, 1H), 7.59-7.50 (m, 2H), 7.52-7.36 (m, 5H), 7.22 (dd, J=7.2, 5.2 Hz, 1H), 4.92-4.74 (m, 1H), 3.77 (dd, J=14.0, 3.5 Hz, 1H), 3.72 (d, J=4.4 Hz, 3H), 3.32 (dd, J=14.4, 10.3 Hz, 1H).
- Preparation of methyl (S)-3-(4-(4-methyl-3-(trifluoromethyl)pyridin-2-yl)naphthalen-1-yl)-2-(tritylamino)propanoate (122A): To a solution of N6 (609.0 mg, 0.561 mmol) and 2-chloro-4-methyl-3-(trifluoromethyl)pyridine (132.0 mg, 0.673 mmol) in 1,2-dimethoxyethane (6.0 mL) was added XPhos Pd G3 (23.7 mg, 0.028 mmol) and a 1.0 M aqueous solution of K3PO4 (1.96 mL, 1.96 mmol). The reaction mixture was heated to 90° C. for 1 hr before concentrating under reduced pressure and purifying the crude product by silica gel chromatography eluting with EtOAc in hexanes (0-100%) to give 122A.
- Preparation of methyl (S)-2-amino-3-(4-(4-methyl-3-(trifluoromethyl)pyridin-2-yl)naphthalen-1-yl)propanoate (122B): To a stirring solution of 122A (243.0 mg, 0.385 mmol) in DCM (4.0 mL) was added TFA (0.072 mL, 0.963 mmol). The reaction mixture was allowed to stir for 1 hr before concentrating under reduced pressure and purifying the crude product by silica gel chromatography eluting with McOH in DCM (0-20%) to afford 122B.
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(4-methyl-3-(trifluoromethyl)pyridin-2-yl)naphthalen-1-yl)propanoate (122C): To a stirring solution of 122B (24.0 mg, 0.062 mmol), T2 (21.2 mg, 0.068 mmol) and HATU (25.8 mg, 0.068 mmol) in THE (1.50 mL) and DMF (0.40 mL) was added DIPEA (0.043 mL, 0.25 mmol). The reaction mixture was stirred for 1 hr before concentrating under reduced pressure. The crude product was purified by silica gel chromatography eluting with EtOAc in hexanes (0-80%) to afford 122C.
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(4-methyl-3-(trifluoromethyl)pyridin-2-yl)naphthalen-1-yl)propanoic acid (122): To a stirring solution of 122C (33.0 mg, 0.048 mmol) in THF (1.5 mL) was added an aqueous 1.0 M solution of LiOH (0.24 mL, 0.24 mmol). The reaction mixture was stirred for 1 hr before concentrating under reduced pressure. The material was purified via reverse phase HPLC to afford the title compound. MS (m/z) 668.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.98 (dd, J=8.0, 4.7 Hz, 1H), 8.76 (d, J=5.0 Hz, 1H), 8.23 (d, J=8.6 Hz, 1H), 7.68-7.58 (m, 2H), 7.55-7.42 (m, 2H), 7.28 (dd, J=8.4, 1.1 Hz, 1H), 7.23 (dd, J=7.2, 2.3 Hz, 1H), 6.76 (dd, J=11.5, 3.8 Hz, 2H), 4.98-4.85 (m, 1H), 4.80-4.65 (m, 1H), 4.16 (d, J=12.7 Hz, 1H), 3.95 (dd, J=11.5, 3.8 Hz, 1H), 3.83-3.66 (m, 2H), 3.55 (td, J=11.8, 3.3 Hz, 1H), 3.48-3.30 (m, 2H), 3.23 (t, J=12.7 Hz, 1H), 2.61 (q, J=2.6 Hz, 3H).
-
- Preparation of methyl (S)-3-(4-(4-methyl-3-(trifluoromethyl)pyridin-2-yl)naphthalen-1-yl)-2-(tritylamino)propanoate (122A): The title compound was prepared according to the method described in Example 122.
- Preparation of methyl (S)-2-amino-3-(4-(4-methyl-3-(trifluoromethyl)pyridin-2-yl)naphthalen-1-yl)propanoate (122B): The title compound was prepared according to the method described in Example 122.
- Preparation of methyl (S)-3-(4-(4-methyl-3-(trifluoromethyl)pyridin-2-yl)naphthalen-1-yl)-2-(tritylamino)propanoate (123A): The title compound was prepared according to the method presented for the synthesis of compound 122C starting with T1 and 122B.
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(4-methyl-3-(trifluoromethyl)pyridin-2-yl)naphthalen-1-yl)propanoic acid (123): The title compound was prepared according to the method presented for the synthesis of compound 122 starting with 123A. MS (m/z) 640.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.82 (dd, J=7.9, 5.7 Hz, 1H), 8.75 (d, J=5.0 Hz, 1H), 8.22 (d, J=8.6 Hz, 1H), 7.67-7.58 (m, 2H), 7.54-7.41 (m, 2H), 7.28 (d, J=8.4 Hz, 1H), 7.23 (dd, J=7.2, 3.1 Hz, 1H), 6.77 (dd, J=9.4, 6.1 Hz, 1H), 6.49-6.41 (m, 2H), 4.77-4.62 (m, 1H), 4.31 (d, J=11.2 Hz, 1H), 3.73 (ddd, J=25.2, 14.3, 4.3 Hz, 1H), 3.36 (ddd, J=19.5, 14.3, 10.0 Hz, 1H), 2.61 (q, J=2.6 Hz, 3H), 1.84-1.70 (m, 1H), 1.61-1.44 (m, 1H), 0.93 (t, J=7.5, 1.6 Hz, 3H).
- Preparation of methyl (S)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)-2-(tritylamino)propanoate (124A): The title compound was prepared according to the method presented for the synthesis of compound 122A starting with N6 and 3-bromo-4-methoxy-1,6-dimethylpyridin-2(1H)-one.
- Preparation of methyl (S)-2-amino-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate (124B): The title compound was prepared according to the method presented for the synthesis of compound 122B starting with 124A.
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate (124C): The title compound was prepared according to the method presented for the synthesis of compound 122C starting with 124B.
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate Atropisomer 1 (124D): Ester 124C was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 40% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an OD-H 4.6×100 mm column. The title compound was identified as the first eluting peak.
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (124): The title compound was prepared according to the method presented for the synthesis of compound 122 starting with 124D. MS (m/z) 660.3 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 8.97 (d, J=7.7 Hz, 1H), 8.14 (d, J=8.5 Hz, 1H), 7.55 (t, J=7.6 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.45-7.36 (m, 2H), 7.13 (d, J=7.2 Hz, 1H), 6.78 (d, J=11.8 Hz, 2H), 6.39 (s, 1H), 4.97-4.84 (m, 1H), 4.67 (td, J=8.7, 4.4 Hz, 1H), 4.16 (d, J=12.7 Hz, 1H), 3.97-3.93 (m, 1H), 3.75 (d, J=14.6 Hz, 2H), 3.63 (s, 3H), 3.59-3.52 (m, 1H), 3.45 (s, 4H), 3.39-3.31 (m, 1H), 3.24 (t, J=12.5 Hz, 1H), 2.48 (s, 3H).
-
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid Atropisomer 2 (125): Ester 124C was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 40% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an OD-H 4.6×100 mm column. 125A was identified as the second eluting peak. The title compound was prepared according to the method presented for the synthesis of compound 122 starting with 125A. MS (m/z) 660.29 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 8.96 (d, J=7.8 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.58 (ddd, J=8.4, 5.3, 2.9 Hz, 1H), 7.48 (d, J=7.3 Hz, 1H), 7.47-7.39 (m, 2H), 7.13 (d, J=7.2 Hz, 1H), 6.77 (d, J=11.6 Hz, 2H), 6.21 (s, 1H), 4.91 (dd, J=8.6, 3.6 Hz, 1H), 4.69 (td, J=8.7, 4.5 Hz, 1H), 4.16 (d, J=12.7 Hz, 1H), 3.99-3.91 (m, 1H), 3.79-3.69 (m, 2H), 3.68 (d, J=4.7 Hz, 1H), 3.45 (s, 5H), 3.28-3.18 (m, 1H), 2.41 (s, 3H), 1.71 (s, 3H).
- Preparation of methyl (S)-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl) naphthalen-1-yl)-2-(tritylamino)propanoate (126A): The title compound was prepared according to the method presented for the synthesis of compound 122A starting with N6 and 3-bromo-1,4,6-trimethylpyridin-2(1H)-one.
- Preparation of methyl (S)-2-amino-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl) naphthalene 1-yl)propanoate (126B): The title compound was prepared according to the method presented for the synthesis of compound 122B starting with 126A.
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl) morpholino)benzamido)-3-(4-(1,4,6-tri methyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate (126C): The title compound was prepared according to the method presented for the synthesis of compound 122C starting with 126B.
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl) morpholino)benzamido)-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate Atropisomer 1 (126D): Ester 126C was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 40% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an IC 4.6×100 mm 5 mic column. The title compound was identified as the first eluting peak.
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (126): The title compound was prepared according to the method presented for the synthesis of compound 122 starting with 126D. MS (m/z) 644.2 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 8.96 (d, J=7.8 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.58 (ddd, J=8.4, 5.3, 2.9 Hz, 1H), 7.48 (d, J=7.3 Hz, 1H), 7.47-7.39 (m, 2H), 7.13 (d, J=7.2 Hz, 1H), 6.77 (d, J=11.6 Hz, 2H), 6.21 (s, 1H), 4.91 (dd, J=8.6, 3.6 Hz, 1H), 4.69 (td, J=8.7, 4.5 Hz, 1H), 4.16 (d, J=12.7 Hz, 1H), 3.99-3.91 (m, 1H), 3.79-3.69 (m, 2H), 3.68 (d, J=4.7 Hz, 1H), 3.45 (s, 5H), 3.28-3.18 (m, 1H), 2.41 (s, 3H), 1.71 (s, 3H).
-
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (127): Ester 126C was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 40% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an IC 4.6×100 mm 5 mic column. 127A was identified as the second eluting peak. The title compound was prepared according to the method presented for the synthesis of compound 122 starting with 127A. MS (m/z) 646.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.93 (d, J=8.1 Hz, 1H), 8.17 (d, J=8.5 Hz, 1H), 7.59 (ddd, J=8.4, 5.4, 2.7 Hz, 1H), 7.50-7.39 (m, 3H), 7.10 (d, J=7.1 Hz, 1H), 6.75 (d, J=11.6 Hz, 2H), 6.21 (s, 1H), 4.89 (dt, J=12.3, 6.1 Hz, 1H), 4.79-4.68 (m, 1H), 4.16 (d, J=12.7 Hz, 1H), 3.94 (d, J=3.9 Hz, 1H), 3.80-3.69 (m, 2H), 3.59-3.49 (m, 1H), 3.45 (s, 4H), 3.26 (ddd, J=24.2, 13.7, 10.0 Hz, 2H), 2.41 (s, 3H), 1.72 (s, 3H).
-
- Preparation of methyl (S)-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydro pyridin-3-yl)naphthalen-1-yl)-2-(tritylamino)propanoate (128A): The title compound was prepared according to the method presented for the synthesis of compound 122A starting with N6 and H18.
- Preparation of methyl (S)-2-amino-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate (128B): The title compound was prepared according to the method presented for the synthesis of compound 122B starting with 128A.
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate (128C): The title compound was prepared according to the method presented for the synthesis of compound 122C starting with 128B.
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate Atropisomer 1 (128D): Ester 128C was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an OD-H 4.6×100 mm 5 mic column. The title compound was identified as the first eluting peak.
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (128): The title compound was prepared according to the method presented for the synthesis of compound 122 starting with 128D. MS (m/z) 698.2 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 8.95 (d, J=7.9 Hz, 1H), 8.16 (d, J=8.5 Hz, 1H), 7.58 (ddd, J=8.4, 6.6, 1.5 Hz, 1H), 7.47-7.31 (m, 3H), 7.11 (d, J=7.3 Hz, 1H), 6.73 (d, J=11.6 Hz, 2H), 6.60 (d, J=0.8 Hz, 1H), 4.90 (dd, J=8.7, 3.6 Hz, 1H), 4.70 (ddd, J=10.1, 7.9, 4.3 Hz, 1H), 4.14 (d, J=12.7 Hz, 1H), 3.93 (dd, J=11.5, 3.8 Hz, 1H), 3.75-3.70 (m, 1H), 3.68 (d, J=4.3 Hz, 1H), 3.52 (m, 1H), 3.49 (s, 3H), 3.44-3.16 (m, 3H), 2.55-2.51 (m, 3H).
-
- Preparation of (129): Ester 128C was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an OD-H 4.6×100 mm 5 mic column. 129A was identified as the second eluting peak. The title compound was prepared according to the method presented for the synthesis of compound 122 starting with 129A. MS (m/z) 698.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.97 (d, J=7.8 Hz, 1H), 8.16 (d, J=8.5 Hz, 1H), 7.58 (ddd, J=8.4, 6.5, 1.5 Hz, 1H), 7.49-7.34 (m, 3H), 7.12 (d, J=7.3 Hz, 1H), 6.75 (d, J=11.6 Hz, 2H), 6.59 (s, 1H), 4.89 (dt, J=8.8, 4.4 Hz, 1H), 4.68 (ddd, J=9.9, 7.8, 4.2 Hz, 1H), 4.14 (d, J=12.7 Hz, 1H), 3.93 (dd, J=11.5, 3.8 Hz, 1H), 3.75-3.64 (m, 2H), 3.49 (s, 3H), 3.43-3.35 (m, 2H), 3.34 (s, 1H), 3.28-3.14 (m, 1H), 2.52 (s, 3H).
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl) propanoate (130A): The title compound was prepared according to the method presented for the synthesis of compound 123A starting with 124B.
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl) propanoate Atropisomer 1 (130B): Ester 130A was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 40% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an IC 4.6×100 mm 5 mic column. The title compound was identified as the first eluting peak.
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (130): The title compound was prepared according to the method presented for the synthesis of compound 123 starting with 130B. MS (m/z) 632.2 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 8.81 (d, J=7.5 Hz, 1H), 8.14 (d, J=8.5 Hz, 1H), 7.55 (t, J=7.6 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.42 (dd, J=10.1, 7.3 Hz, 2H), 7.13 (d, J=7.2 Hz, 1H), 6.77 (d, J=9.4 Hz, 1H), 6.47 (d, J=11.6 Hz, 2H), 6.39 (s, 1H), 4.65 (td, J=8.6, 4.4 Hz, 1H), 4.31 (d, J=8.7 Hz, 1H), 3.66 (d, J=4.7 Hz, 1H), 3.63 (d, J=4.8 Hz, 3H), 3.45 (s, 3H), 3.35 (dd, J=14.6, 9.3 Hz, 1H), 2.48 (s, 3H), 1.78 (ddd, J=14.1, 7.3, 3.3 Hz, 1H), 1.53 (ddt, J=17.7, 14.4, 7.5 Hz, 1H), 0.93 (t, J=7.3 Hz, 3H).
-
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(4-methoxy-1,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (131): Ester 130A was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 40% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an IC 4.6×100 mm 5 mic column. 131A was identified as the second eluting peak. The title compound was prepared according to the method presented for the synthesis of compound 123 starting with 131A. MS (m/z) 632.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.83 (d, J=7.6 Hz, 1H), 8.14 (d, J=8.5 Hz, 1H), 7.55 (t, J=7.7 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.46-7.35 (m, 2H), 7.13 (d, J=7.2 Hz, 1H), 6.77 (d, J=9.4 Hz, 1H), 6.47 (d, J=11.7 Hz, 2H), 6.40 (s, 1H), 4.66 (td, J=8.7, 4.2 Hz, 1H), 4.31 (d, J=10.0 Hz, 1H), 3.68 (d, J=4.3 Hz, 1H), 3.63 (d, J=4.9 Hz, 3H), 3.44 (s, 3H), 3.33 (dd, J=14.5, 9.4 Hz, 1H), 2.48 (s, 3H), 1.78 (ddt, J=13.2, 9.0, 6.6 Hz, 1H), 1.53 (ddd, J=13.5, 10.2, 6.9 Hz, 1H), 0.93 (t, J=7.3 Hz, 3H).
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate (132A): The title compound was prepared according to the method presented for the synthesis of compound 123A starting with 126B.
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate Atropisomer 1 (132B): Ester 132A was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an AZ-H 4.6×100 mm 5 mic column. The title compound was identified as the first eluting peak.
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (132): The title compound was prepared according to the method presented for the synthesis of compound 123 starting with 132B. MS (m/z) 616.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.80 (d, J=7.7 Hz, 1H), 8.17 (d, J=8.5 Hz, 1H), 7.58 (ddd, J=8.4, 5.3, 2.8 Hz, 1H), 7.50-7.38 (m, 3H), 7.13 (d, J=7.2 Hz, 1H), 6.77 (d, J=9.4 Hz, 1H), 6.46 (d, J=11.6 Hz, 2H), 6.21 (s, 1H), 4.67 (td, J=8.8, 4.7 Hz, 1H), 4.31 (d, J=10.2 Hz, 1H), 3.65 (dd, J=14.4, 4.5 Hz, 1H), 3.45 (s, 3H), 3.39 (dd, J=14.5, 9.7 Hz, 1H), 2.41 (s, 3H), 1.78 (ddd, J=13.7, 7.1, 3.1 Hz, 1H), 1.71 (s, 3H), 1.53 (ddt, J=17.8, 14.6, 7.5 Hz, 1H), 0.93 (t, J=7.3 Hz, 3H).
-
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(1,4,6-trimethyl-2-oxo-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (133): Ester 132A was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% McOH as co-solvent, at a flow rate of 3.0 mL/min, using an AZ-H 4.6×100 mm 5 mic column. 133A was identified as the second eluting peak. The title compound was prepared according to the method presented for the synthesis of compound 123 starting with 133A. MS (m/z) 616.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.78 (d, J=8.0 Hz, 1H), 8.17 (d, J=8.5 Hz, 1H), 7.59 (ddd, J=8.3, 5.4, 2.7 Hz, 1H), 7.51-7.37 (m, 3H), 7.11 (d, J=7.1 Hz, 1H), 6.74 (d, J=9.4 Hz, 1H), 6.43 (d, J=11.6 Hz, 2H), 6.21 (s, 1H), 4.70 (td, J=9.4, 8.4, 4.1 Hz, 1H), 4.30 (d, J=9.5 Hz, 2H), 3.74 (dd, J=14.2, 4.2 Hz, 2H), 3.45 (s, 3H), 3.28 (dd, J=14.3, 10.2 Hz, 1H), 2.41 (s, 3H), 1.81-1.74 (m, 1H), 1.74 (s, 1H), 1.53 (ddd, J=13.7, 10.1, 6.9 Hz, 1H), 0.93 (t, J=7.3 Hz, 3H).
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoate (134A): The title compound was prepared according to the method presented for the synthesis of compound 123A starting with 128B.
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoatee Atropisomer 1 (134B): Ester 134A was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% iPrOH as co-solvent, at a flow rate of 3.0 mL/min, using an OD-H 4.6×100 mm 5 mic column. The title compound was identified as the first eluting peak.
- (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (134): The title compound was prepared according to the method presented for the synthesis of compound 123 starting with 134B. MS (m/z) 670.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.81 (d, J=7.8 Hz, 1H), 8.15 (d, J=8.5 Hz, 1H), 7.58 (ddd, J=8.4, 6.6, 1.5 Hz, 1H), 7.50-7.31 (m, 3H), 7.12 (d, J=7.3 Hz, 1H), 6.76 (d, J=9.4 Hz, 1H), 6.59 (d, J=0.8 Hz, 1H), 6.44 (d, J=11.4 Hz, 2H), 4.65 (ddd, J=9.9, 7.8, 4.2 Hz, 1H), 4.38-4.19 (m, 1H), 3.66 (dd, J=14.6, 4.1 Hz, 1H), 3.50 (s, 3H), 3.35 (dd, J=14.7, 10.0 Hz, 1H), 2.52 (d, J=0.9 Hz, 3H), 1.75 (ddd, J=13.6, 7.3, 3.2 Hz, 1H), 1.51 (ddd, J=13.7, 10.4, 7.2 Hz, 1H), 0.91 (t, J=7.3 Hz, 3H).
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)naphthalen-1-yl)propanoic acid (135): Ester 134A was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% iPrOH as co-solvent, at a flow rate of 3.0 mL/min, using an OD-H 4.6×100 mm 5 mic column. 135A was identified as the second eluting peak. The title compound was prepared according to the method presented for the synthesis of compound 123 starting with 135A. MS (m/z) 670.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.80 (d, J=7.9 Hz, 1H), 8.23-8.05 (m, 1H), 7.58 (ddd, J=8.4, 6.6, 1.5 Hz, 1H), 7.49-7.32 (m, 3H), 7.11 (d, J=7.3 Hz, 1H), 6.74 (d, J=9.4 Hz, 1H), 6.60 (d, J=0.8 Hz, 1H), 6.42 (d, J=11.3 Hz, 2H), 4.68 (ddd, J=10.1, 7.9, 4.3 Hz, 1H), 4.31 (m, 1H), 3.68 (dd, J=14.4, 4.2 Hz, 1H), 3.49 (s, 3H), 3.31 (dd, J=14.4, 10.1 Hz, 1H), 2.56-2.50 (m, 3H), 1.75 (ddd, J=13.7, 7.3, 3.3 Hz, 1H), 1.51 (ddd, J=13.7, 10.4, 7.2 Hz, 1H), 0.91 (t, J=7.3 Hz, 3H).
- Preparation of methyl (S)-3-(4-(5-methoxy-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)naphthalen-1-yl)-2-(tritylamino)propanoate (136A): The title compound was prepared according to the method described in Example 129 starting with N6 and 4-chloro-5-methoxy-2-methylpyridazin-3(2H)-one.
- Preparation of methyl (S)-3-(4-(5-methoxy-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)naphthalen-1-yl)-2-(tritylamino)propanoate (136B): The title compound was prepared according to the method described in Example 122 starting with 136A.
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(5-methoxy-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)naphthalen-1-yl)propanoate (136C): The title compound was prepared according to the method presented for the synthesis of compound 123A starting with 136B.
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(5-methoxy-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)naphthalen-1-yl)propanoate Atropisomer 1 (136D): Ester 136C was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% EtOH/TFA as co-solvent, at a flow rate of 3.0 mL/min, using an IG-H-5 μm-4.6×100 mm column. The title compound was identified as the first eluting peak.
- (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(5-methoxy-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)naphthalen-1-yl)propanoic acid (136): The title compound was prepared according to the method presented for the synthesis of compound 123 starting with 136D. MS (m/z) 619.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.89 (s, 1H), 8.83 (dd, J=8.0, 3.7 Hz, 1H), 8.29 (s, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.60 (t, 1H), 7.55-7.41 (m, 3H), 7.24 (d, J=7.1 Hz, 1H), 6.77 (d, J=9.3 Hz, 1H), 6.46 (d, J=11.8 Hz, 2H), 4.72-4.60 (m, 1H), 4.38-4.24 (m, 1H), 3.80 (s, 3H), 3.74-3.68 (m, 3H), 3.43-3.28 (m, 1H), 1.85-1.71 (m, 1H), 1.62-1.45 (m, 1H), 0.93 (t, J=7.3 Hz, 3H).
-
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(5-methoxy-2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)naphthalen-1-yl)propanoic acid (137): Ester 136C was separated into its 2 diastereomeric atropisomers by supercritical fluid chromatography using 30% EtOH/TFA as co-solvent, at a flow rate of 3.0 mL/min, using an IG-H-5 μm-4.6×100 mm column. 137A was identified as the second eluting peak. The title compound was prepared according to the method presented for the synthesis of compound 123 starting with 137A. MS (m/z) 619.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.87-8.78 (m, 1H), 8.29 (s, 1H), 8.18 (d, J=8.6 Hz, 1H), 7.60 (t, J=7.7 Hz, 1H), 7.54-7.41 (m, 3H), 7.24 (d, J=7.3 Hz, 1H), 6.77 (d, J=9.2 Hz, 1H), 6.46 (d, J=11.9 Hz, 2H), 4.73-4.63 (m, 1H), 4.34-4.27 (m, 1H), 3.80 (s, 3H), 3.72-3.69 (m, 4H), 3.35 (q, J=12.9 Hz, 1H), 1.83-1.73 (m, 1H), 1.60-1.47 (m, 1H), 0.93 (t, J=7.4 Hz, 3H).
-
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)naphthalen-1-yl)propanoate (138A): To a microwave vial was added N8 (186.0 mg, 0.287 mmol), 5-bromo-1,3,6-trimethylpyrimidine-2,4(1H,3H)-dione (80.2 mg, 0.344 mmol), Pd(PPh3)4 (33.2 mg, 0.029 mmol), and aq Na2CO3 (0.43 mL, 2M) in DME (3.0 mL). The reaction mixture was allowed to stir at 130° C. for 30 min. The reaction mixture was then filtered over a pad of Celite, washing with McOH. Volatiles were removed under reduced pressure and the crude product was used as is, without further purification.
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)naphthalen-1-yl)propanoic acid (138): To a stirring solution of the crude product 138A in THF (3.0 mL) was added an aqueous 1.0 M solution of LiOH (0.86 mL, 0.86 mmol). The reaction mixture was allowed to stir for 1 hr before concentrating under reduced pressure. The material was then purified via reverse phase HPLC to afford the title compound. MS (m/z) 661.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.99-8.89 (m, 1H), 8.16 (dd, J=8.5, 3.1 Hz, 1H), 7.70 (dd, J=8.3, 2.9 Hz, 1H), 7.64-7.54 (m, 1H), 7.46 (t, J=7.2 Hz, 2H), 7.18 (dd, J=10.7, 7.2 Hz, 1H), 6.74 (t, J=11.4 Hz, 2H), 4.96-4.82 (m, 1H), 4.77-4.64 (m, 1H), 4.14 (d, J=12.7 Hz, 1H), 3.93 (dd, J=11.4, 3.9 Hz, 2H), 3.76-3.67 (m, 1H), 3.69-3.59 (m, 1H), 3.53 (t, J=11.7 Hz, 1H), 3.47-3.32 (m, 4H), 3.22 (s, 4H), 1.90 (d, J=7.1 Hz, 3H).
-
- Preparation of methyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)naphthalen-1-yl)propanoate (139A): The title compound was prepared according to the method described in Example 145 starting with N-7 and 5-bromo-1,3,6-trimethylpyrimidine-2,4(1H,3H)-dione.
- Preparation of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)naphthalen-1-yl)propanoic acid (139): The title compound was prepared according to the method presented for the synthesis of compound 138 starting with 139A. MS (m/z) 633.2 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 8.78 (q, J=10.1, 9.4 Hz, 1H), 8.18-8.12 (m, 1H), 7.70 (dd, J=8.5, 3.2 Hz, 1H), 7.65-7.51 (m, 2H), 7.48-7.42 (m, 1H), 7.18 (dd, J=9.7, 7.2 Hz, 1H), 6.75 (t, J=9.3 Hz, 1H), 6.42 (t, J=11.2 Hz, 2H), 4.75-4.59 (m, 1H), 4.29 (s, 1H), 3.74 (dd, J=14.3, 3.9 Hz, 1H), 3.46-3.32 (m, 3H), 3.26 (dd, J=14.4, 4.0 Hz, 1H), 3.22 (d, J=1.6 Hz, 3H), 1.90 (d, J=6.5 Hz, 3H), 1.74 (d, J=6.9 Hz, 1H), 1.59-1.42 (m, 1H), 0.91 (t, J=7.3 Hz, 3H).
-
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(4-(1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)naphthalen-1-yl)propanoate (140A): To a solution of N8 (394.0 mg, 0.273 mmol) and 3-iodo-1-methyl-1,6-naphthyridin-2(1H)-one (H21, 93.9 mg, 0.328 mmol) in 1,4-dioxane (4.0 mL) was added XPhos Pd G3 (11.6 mg, 0.014 mmol) and a 1.0 M aqueous solution of K3PO4 (0.96 mL, 0.96 mmol). The reaction mixture was degassed with N2 before heating at 90° C. for 1 hr. Volatiles were then removed under reduced pressure and the crude product was purified by silica gel chromatography eluting with EtOAc in hexanes (0-100%) followed by McOH in DCM (0-50%).
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)naphthalen-1-yl)propanoic acid (140): To a stirring solution of the 140A (58.0 mg, 0.060 mmol) in THE (1.0 mL) was added an aqueous 1.0 M solution of LiOH (0.24 mL, 0.24 mmol). The reaction mixture was allowed to stir for 1 hr before concentrating under reduced pressure. The material was then purified via reverse phase HPLC to afford the title compound. MS (m/z) 667.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (s, 1H), 8.99 (d, J=8.0 Hz, 1H), 8.77 (s, 1H), 8.23 (d, J=8.5 Hz, 1H), 8.18 (s, 1H), 7.83 (d, J=6.3 Hz, 1H), 7.71 (d, J=8.5 Hz, 1H), 7.65 (t, J=7.7 Hz, 1H), 7.56-7.45 (m, 2H), 7.39 (d, J=7.2 Hz, 1H), 6.78 (d, J=11.9 Hz, 2H), 4.97-4.85 (m, 1H), 4.71 (ddd, J=11.8, 8.7, 4.0 Hz, 1H), 4.17 (d, J=12.7 Hz, 1H), 3.96 (dd, J=11.4, 3.6 Hz, 1H), 3.73 (s, 5H), 3.63 (m, 2H), 3.25 (t, J=12.3 Hz, 2H).
-
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(4-(4,5-dimethylpyrimidin-2-yl)naphthalen-1-yl)propanoate (141A): The title compound was prepared according to the method described in Example 148 for the synthesis of 140A starting with N8 and 2-chloro-4,5-dimethylpyrimidine.
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(4,5-dimethylpyrimidin-2-yl)naphthalen-1-yl)propanoic acid (141): The title compound was prepared according to the method described in Example 148 for the synthesis of 140 starting with 141A. MS (m/z) 615.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.95 (d, J=8.0 Hz, 1H), 8.68 (s, 1H), 8.59 (d, J=8.6 Hz, 1H), 8.24 (d, J=8.5 Hz, 1H), 7.83 (d, J=7.3 Hz, 1H), 7.65 (t, J=7.7 Hz, 1H), 7.56 (t, J=7.0 Hz, 2H), 6.77 (d, J=11.8 Hz, 2H), 4.90 (dt, J=11.4, 8.0 Hz, 1H), 4.71 (td, J=9.1, 4.1 Hz, 1H), 4.16 (d, J=12.8 Hz, 1H), 3.95 (dd, J=11.6, 3.7 Hz, 1H), 3.80-3.70 (m, 2H), 3.39 (d, J=10.3 Hz, 2H), 3.20 (d, J=25.9 Hz, 2H), 2.54 (s, 3H), 2.33 (s, 3H).
-
- Preparation of methyl (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino) benzamido)-3-(4-(1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)naphthalen-1-yl)propanoate (142A): The title compound was prepared according to the method described in Example 148 for the synthesis of 140A starting with N7 and 3-iodo-1-methyl-1,6-naphthyridin-2(1H)-one (H21).
- Preparation of (S)-2-(2,6-difluoro-4-((R)-3-(trifluoromethyl)morpholino)benzamido)-3-(4-(1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)naphthalen-1-yl)propanoic acid (142): The title compound was prepared according to the method described in Example 148 for the synthesis of 140 starting with 142A. MS (m/z) 639.2 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 9.13 (s, 1H), 8.83 (d, J=7.9 Hz, 1H), 8.77 (d, J=6.4 Hz, 1H), 8.26-8.14 (m, 2H), 7.84 (d, J=6.6 Hz, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.65 (t, J=7.7 Hz, 1H), 7.57-7.46 (m, 2H), 7.39 (d, J=7.2 Hz, 1H), 6.78 (d, J=9.3 Hz, 1H), 6.47 (d, J=11.8 Hz, 2H), 4.68 (t, J=9.2 Hz, 1H), 4.31 (d, J=10.7 Hz, 1H), 3.79 (m, 1H), 3.73 (d, J=1.4 Hz, 3H), 3.36 (m, 1H), 1.77 (d, J=10.5 Hz, 1H), 1.54 (dt, J=19.8, 9.3 Hz, 1H), 0.93 (t, J=7.3 Hz, 3H).
-
- Synthesis of 4,7-dibromo-1-methyl-1H-indazole (143A): To a solution containing 4,7-dibromo-1H-indazole (600 mg, 2.29 mmol) in DMF (16 mL), sodium hydride was added in one portion at 0° C., and stir for 30 min. Then iodomethane (0.21 mL, 3.44 mmol) was added and the reaction mixture was stirred at RT for 30 min. Quench with water and extract with EtOAc (3×). Organic layers were combined, dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified on silica gel eluting with EtOAc in hexanes (0-30%-60%) to give the title compound.
- Synthesis of 7-bromo-4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazole (143B): To a microwave vial was added 60A (890 mg, 3.07 mmol), (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid (774 mg, 3.22 mmol), Pd(PPh3)4 (355 mg, 0.31 mmol), and aq Na2CO3 (4.6 mL, 2M) in DME (30 mL). The reaction mixture was allowed to stir at 135° C. for 30 min. EtOAc and water was added to the reaction mixture. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified by silica gel chromatography using 0-20%-40%-60% EtOAc in hexanes to afford the title compounds 60B as peak 1 and 60C as peak 2.
- Synthesis of methyl (Z)-2-((tert-butoxycarbonyl)amino)-3-(4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-7-yl)acrylate (143D): To a sealed tube was added 60B (127 mg, 0.31 mmol) and DMF (3 mL). This solution was degassed with nitrogen for 30 min. To this, methyl 2-((tert-butoxycarbonyl)amino)acrylate (189 mg, 0.94 mmol), tetrabutylammonium chloride (TBACI, 105 mg, 0.38 mmol), TEA (0.05 mL, 0.36 mmol) and palladium acetate (35 mg, 0.16 mmol) were added. The tube was sealed and heated to 90° C. for 6 h. Reaction mixture was cooled to RT and purified by silica gel chromatography using 0-100% EtOAc in hexanes to afford the title compound.
- Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-3-(4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-7-yl)propanoate (143E): To a Parr shaker bottle was added 60D (94 mg, 0.18 mmol) and EtOH (30 mL). Pd on carbon (10% wt, 94 mg, 0.89 mmol) was added and the bottle was put on Parr shaker, shake under 45 psi Hydrogen gas for 12 h. Reaction mixture was filtered through Celite and concentrated to give the title compound that was used without further purification.
- Synthesis of methyl 2-amino-3-(4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-7-yl)propanoate TFA salt (143F): To a solution of 60E (94 mg, 0.18 mmol) in DCM (2 mL), TFA (0.34 mL, 4.5 mmol) was added and the reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated to give the title compound that was used without further purification.
- Synthesis of methyl 2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-7-yl)propanoate (143G): To a stirred solution of 60E (94 mg, 0.18 mmol) in DMF (1 mL) was added 2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzoic acid (80 mg, 0.19 mmol), HATU (75 mg, 0.19 mmol) and DIPEA (0.09 mL, 0.53 mmol). The reaction mixture was allowed to stir for 2 hr at RT. The reaction mixture was concentrated under reduced pressure and purified by silica gel chromatography using 0-100% EtOAc in hexanes to afford the title compound.
- Synthesis of 2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-7-yl)propanoic acid (143): To a stirred solution of 60G (145 mg, 0.18 mmol) in THE (2 mL) was added LiOH (0.53 mL, 0.53 mmol). The reaction mixture was allowed to stir for 1 hour then concentrated under reduced pressure. The material was purified via reverse phase HPLC to afford the title compound. MS (m/z) 804.5 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.22 (s, 1H), 9.15 (d, J=8.0 Hz, 1H), 8.33 (d, J=5.3 Hz, 1H), 8.12-8.03 (m, 2H), 8.02-7.93 (m, 2H), 7.72 (dt, J=5.3, 1.8 Hz, 1H), 7.59 (d, J=1.6 Hz, 1H), 7.40 (s, 1H), 7.14 (d, J=7.4 Hz, 1H), 6.79 (dd, J=14.8, 8.2 Hz, 3H), 6.70 (s, 2H), 4.66 (ddd, J=10.2, 8.0, 4.3 Hz, 1H), 4.49 (s, 2H), 4.26 (s, 3H), 3.75 (dd, J=15.0, 4.3 Hz, 1H), 3.57 (d, J=1.2 Hz, 6H), 3.53 (t, J=7.0 Hz, 2H), 3.29-3.21 (m, 1H), 1.19 (t, J=7.0 Hz, 3H).
-
- Preparation of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-7-yl)propanoic acid (144): 143 was separated into its 2 enantiomers by supercritical fluid chromatography using 30% McOH co-solvent, at a flow rate of 55 mL/min, using an AD-H 5 μm 21×250 mm column. The title compound was identified as the first eluting peak. MS (m/z) 804.5 [M+H]+.
- Preparation of (R)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(4-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-7-yl)propanoic acid (145): 143 was separated into its 2 enantiomers by supercritical fluid chromatography using 30% McOH co-solvent, at a flow rate of 55 mL/min, using an AD-H 5 μm 21×250 mm column. The title compound was identified as the second eluting peak. MS (m/z) 804.5 [M+H]+.
- Synthesis of methyl (Z)-2-((tert-butoxycarbonyl)amino)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-4-yl)acrylate (146A): The title compound was prepared according to the method presented for the synthesis of compound 143D in example 143 starting with 143C.
- Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-4-yl)propanoate (146B): The title compound was prepared according to the method presented for the synthesis of compound 143E in example 143 starting with 146A.
- Synthesis of methyl 2-amino-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-4-yl)propanoate TFA salt (146C): The title compound was prepared according to the method presented for the synthesis of compound 143F in example 143 starting with 146B.
- Synthesis of methyl 2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-4-yl)propanoate (146D): The title compound was prepared according to the method presented for the synthesis of compound 143G in example 143 starting with 146C.
- Synthesis of 2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-4-yl)propanoic acid (146): The title compound was prepared according to the method presented for the synthesis of compound 143 in example 143 starting with 146D. MS (m/z) 804.4 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.21 (s, 1H), 9.08 (d, J=7.8 Hz, 1H), 8.33 (d, J=5.3 Hz, 1H), 8.09-8.01 (m, 3H), 8.02-7.90 (m, 2H), 7.72 (dt, J=5.4, 1.8 Hz, 1H), 7.59 (d, J=1.5 Hz, 1H), 6.98-6.85 (m, 2H), 6.80 (d, J=9.1 Hz, 2H), 6.72 (s, 2H), 4.69 (ddd, J=9.5, 7.8, 4.7 Hz, 1H), 4.51 (s, 2H), 3.60 (d, J=1.6 Hz, 6H), 3.54 (m, 2H), 3.44 (s, 3H), 3.43-3.35 (m, 1H), 3.21 (dd, J=14.6, 9.4 Hz, 1H), 1.19 (t, J=7.0 Hz, 3H).
-
- Preparation of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-4-yl)propanoic acid (147): 146 was separated into its 2 enantiomers by supercritical fluid chromatography using 30% McOH co-solvent, at a flow rate of 55 mL/min, using an AD-H 5 μm 21×250 mm column. The title compound was identified as the first eluting peak. MS (m/z) 804.5 [M+H]+.
- Preparation of (R)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1-methyl-1H-indazol-4-yl)propanoic acid (148): 146 was separated into its 2 enantiomers by supercritical fluid chromatography using 30% McOH co-solvent, at a flow rate of 55 mL/min, using an AD-H 5 μm 21×250 mm column. The title compound was identified as the second eluting peak. MS (m/z) 804.5 [M+H]+.
-
- Synthesis of 4-bromo-7-(bromomethyl)benzo[c][1,2,5]thiadiazole (149A): To a stirred solution of 4-bromo-7-methylbenzo[c][1,2,5]thiadiazole (1.00 g, 4.37 mmol) in benzene (11 mL) was added NBS (0.932 g, 5.24 mmol) at RT. The reaction mixture was heated to reflux under tungsten light for 16 h. The reaction was cooled to RT, filtered, and concentrated to yield 149A.
- Synthesis of 4-bromo-7-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)benzo[c][1,2,5]thiadiazole (149B): n-Butyllithium (1.6 M in hexanes, 0.93 mL, 1.5 mmol) was added dropwise to a stirred solution of (R)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (250 mg, 1.36 mmol) in THE (14 mL) at −78° C. and the resulting reaction mixture was stirred for 30 min. Next, 149A (543 mg, 1.76 mmol) was added. The reaction mixture was stirred for 1 h, and then it was allowed to warm to room temperature over 1 h. The reaction mixture was quenched by the addition of a saturated ammonium chloride solution, the layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organics were washed with water and saturated sodium chloride, dried over sodium sulfate, and concentrated under reduced pressure to obtain crude compound. The crude compound was purified by flash chromatography on silica gel (eluent 1-30% EtOAc/hexanes linear gradient) to obtain 149B.
- Synthesis of methyl (S)-2-amino-3-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)propanoate (149C): To a stirred solution of 149B (158 mg, 0.384 mmol) in acetonitrile (7.6 mL) was added 3M hydrochloric acid (0.77 mL, 2.3 mmol), and the reaction was allowed to stir for 4 h at room temperature. It was concentrated, diluted with dimethylsulfoxide, and purified by preparatory HPLC (C18 column, water/MeCN with 0.1% TFA eluent). The fractions containing product were concentrated, treated with 2M aqueous sodium carbonate until a pH of 12 was reached, and were extracted twice with dichloromethane. The combined organics were dried over anhydrous sodium sulfate, filtered, and concentrated to yield 149C.
- Synthesis of methyl (S)-3-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzamido)propanoate (149D): To a stirred solution of 149C (31 mg, 0.098 mmol) and 2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzoic acid (40 mg, 0.098 mmol) in dichloromethane (1 mL) was added diisopropylethylamine (38 mg, 0.29 mmol) and HATU (37 mg, 0.098 mmol), and the reaction was stirred for 16 h at RT. It was diluted with ethyl acetate and washed with 10% citric acid, sodium bicarbonate, and brine. It was dried over anhydrous sodium sulfate, filtered, and concentrated. It was purified on the by flash chromatography on silica gel (eluent: 5-100% EtOAc/hexanes linear gradient) to yield 149D.
- Synthesis of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)benzo[c]-[1,2,5]thiadiazol-4-yl)propanoic acid (149): A microwave vial was charged with 149D (47 mg, 0.067 mmol), (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid (18 mg, 0.073 mmol), and tetrakis(triphenylphosphine)palladium(O) (4 mg, 0.003 mmol). Next, 1,2-dimethoxyethane (1 mL) and 2M aqueous sodium carbonate (0.12 mL, 0.24 mmol) were added, and the reaction was degassed with nitrogen and sealed. It was heated to 130° C. for 30 min by microwave irradiation, and then was cooled to room temperature. It was diluted with DMSO, acidified with trifluoroacetic acid, and purified by preparatory HPLC to yield 149. MS (m/z) 808.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.88 (s, 1H), 11.19 (s, 1H), 9.06 (d, J=8.1 Hz, 1H), 8.35 (d, J=5.3 Hz, 1H), 8.07 (d, J=8.3 Hz, 2H), 7.98 (d, J=8.3 Hz, 2H), 7.74 (dd, J=5.6, 1.9 Hz, 1H), 7.60 (s, 1H), 7.50 (d, J=7.1 Hz, 1H), 7.36 (d, J=7.0 Hz, 1H), 6.80 (d, J=9.0 Hz, 2H), 6.74 (s, 2H), 4.94 (td, J=9.1, 8.1, 4.8 Hz, 1H), 4.52 (s, 2H), 3.81-3.65 (m, 1H), 3.61-3.52 (m, 8H), 3.33 (dd, J=14.4, 10.3 Hz, 1H), 1.21 (t, J=7.0 Hz, 3H).
-
- Synthesis of methyl (S)-3-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)-2-(2,6-difluoro benzamido)propanoate (150A): The title compound was prepared according to the method presented for the synthesis of compound N2 starting with 149C and 2,6-difluorobenzoyl chloride.
- Synthesis of (S)-3-(7-(2,6-dichloro-4-fluorophenyl)benzo[c][1,2,5]thiadiazol-4-yl)-2-(2,6-difluorobenzamido)propanoic acid (150): To a sealed vial was added 150A (88 mg, 0.19 mmol), (2,6-dimethoxyphenyl)boronic acid (81 mg, 0.38 mmol), SPhos Pd G4 (34 mg, 0.04 mmol), and K3PO4 (127 mg, 0.6 mmol) in toluene. The reaction mixture was allowed to stir at 120° C. for 1 h. EtOAc and water was added to the reaction mixture. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with EtOAc in hexanes (0-100%) to give the ester product, which was then hydrolyzed to the acid using 1M LiOH and purified with prep HPLC to give the desired product. MS (m/z) 526.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.96 (s, 1H), 9.18 (d, J=8.3 Hz, 1H), 7.72 (d, J=8.6 Hz, 2H), 7.65 (d, J=7.1 Hz, 1H), 7.60 (d, J=7.0 Hz, 1H), 7.45 (tt, J=8.4, 6.5 Hz, 1H), 7.07 (dd, J=8.5, 7.5 Hz, 2H), 5.07 (ddd, J=10.8, 8.3, 4.8 Hz, 1H), 3.80 (dd, J=14.2, 4.7 Hz, 1H), 3.45-3.35 (m, 1H).
-
- Synthesis of methyl 4-bromo-3-hydroxy-2-nitrobenzoate (151A): SOCl2 (23 mL, 314.00 mmol) was added slowly to the solution of 3-hydroxy-2-nitrobenzoic acid (23.00 g, 125.60 mmol) in McOH (250 mL) at 0° C., and the resulting mixture was heated to reflux for overnight. TLC showed the SM was consumed, and the reaction mixture was concentrated. Then to the solution of this crude product in HOAc (500 mL) was added Br2 (42.15 g, 263.76 mmol) drop wise, and the resulting suspension was stirred at 60° C. for overnight. The reaction mixture was quenched with sat. Na2SO3 (1.0 L), and the mixture was extracted with EtOAc (500 mL×2). The combined organic layer was washed with sat. NaHCO3 (1.0 L), followed with brine (1.0 L), dried over Na2SO4, filtered and concentrated to give the crude product.
- Synthesis of methyl 2-amino-4-bromo-3-hydroxybenzoate (151B): To a solution of compound 151A (31 g, 112.3 mmol) in THF (300 mL) was added a solution of Na2S2O4 (97.8 g, 561.51 mmol) in water (300 mL) drop wise, and the resulting mixture was stirred at RT for 0.5 h. TLC showed the SM was consumed. The reaction was diluted with 1 N HCl (500 mL), extracted with EtOAc (500 mL×2). The combined organic layer was washed with brine (500 mL), dried over Na2SO4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (PE:EA=15:1) to afford the desired product.
- Synthesis of methyl 7-bromo-2-methylbenzo[d]oxazole-4-carboxylate (151C): A mixture of compound 151B (6.0 g, 24.38 mmol), acetyl chloride (2.1 g, 26.82 mmol), TEA (2.7 g, 26.82 mmol), PPTS (1.84 g, 7.31 mmol) in toluene (600 mL) was heated to reflux for overnight. TLC showed the most of SM was consumed. The reaction mixture was cooled to 0° C., washed with 1 N HCl (300 mL), and the organic layer was washed with brine (300 mL), dried over Na2SO4, filtered and concentrated to give the crude product which was triturated with MTBE to afford the crude product.
- Synthesis of (7-bromo-2-methylbenzo[d]oxazol-4-yl)methanol (151D): To a solution of compound 151C (5.0 g, 18.51 mmol) in THF (200 mL) was added DIBAL-H (1 M, 46 mmol) drop wise at −5˜0° C., and the resulting mixture was stirred at 0° C. for 0.5 h. TLC showed the SM was consumed. The reaction was quenched with 5 mL H2O slowly, and then diluted with sat. NaHCO3 (300 mL). The mixture was extracted with EtOAc (200 mL×2), and the combined organic layer was washed with brine (300 mL), dried over Na2SO4, filtered and concentrated to give the crude product which was purified by column chromatography on Al2O3 to afford the product.
- Synthesis of 7-bromo-4-(bromomethyl)-2-methylbenzo[d]oxazole (151E): To a solution of compound 151 D (2.5 g, 10.33 mmol) in DCM (100 mL) was added PPh3 (5.42 g, 20.66 mmol), followed with CBr4 (6.85 g, 20.66 mmol) at 0° C., and the resulting suspension was stirred at 0° C. RT for 1 h. TLC showed the SM was consumed. The reaction mixture was diluted with DCM (200 mL), washed with sat. Na2SO3 (200 mL), followed with brine (200 mL), dried over Na2SO4, filtered and concentrated to give the crude product which was purified by column chromatography on Al2O3 (PE:EA=30:1) to afford the mixed product.
- Synthesis of 7-bromo-4-(((2S,5S)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-2-methyl-3a,7a-dihydrobenzo[d]oxazole (151 F): The title compound was prepared according to the method presented for the synthesis of compound 149B in Example 149 using 151D. MS (m/z) 410.1 [M+H]+.
- Synthesis of methyl (S)-3-(7-bromo-2-methylbenzo[d]oxazol-4-yl)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzamido)propanoate (151G): The title compound was prepared according to the method presented for the synthesis of compound 149C Example 149 starting with 151F. MS (m/z) 703.1 [M+H]+.
- Synthesis of methyl (S)-3-(7-bromo-2-methylbenzo[d]oxazol-4-yl)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzamido)propanoate (151H): The title compound was prepared according to the method presented for the synthesis of compound 149D Example 149 starting with 2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzoic acid and 151G. MS (m/z) 703.1 [M+H]+.
- Synthesis of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-2-methyl benzo[d]oxazol-4-yl) propanoic acid (151): The title compound was prepared according to the method presented for the synthesis of compound 149 of Example 149 starting with 151H. MS (m/z) 805.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.19 (s, 1H), 9.04 (d, J=7.9 Hz, 1H), 8.35-8.30 (m, 1H), 8.11-8.02 (m, 2H), 8.00-7.94 (m, 2H), 7.72 (dt, J=5.3, 1.8 Hz, 1H), 7.59 (d, J=1.6 Hz, 1H), 7.46 (dt, J=8.1, 0.9 Hz, 1H), 7.36 (ddd, J=8.2, 7.1, 1.2 Hz, 1H), 7.14-7.09 (m, 1H), 7.01 (d, J=7.7 Hz, 1H), 6.80 (d, J=9.1 Hz, 1H), 6.71 (s, 2H), 4.73 (ddd, J=10.0, 7.8, 5.1 Hz, 1H), 4.49 (s, 2H), 3.62 (s, 6H), 3.54 (q, J=7.0 Hz, 2H), 3.45 (dd, J=14.2, 5.0 Hz, 1H), 3.13 (dd, J=14.1, 9.8 Hz, 1H),), 2.47 (s, 2H), 1.19 (t, J=7.0 Hz, 3H).
- Synthesis of 7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-4-(((2S,5S)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-2-methyl benzo[d]oxazole (152A): To a microwave vial was added 151F (350 mg, 0.853 mmol), (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid (225 mg, 0.938 mmol), XPhos PD G2 (34 mg, 0.043 mmol), and aq Na2CO3 (1.5 mL, 2M) in DME (5 mL). The reaction mixture was allowed to stir at 130° C. for 30 min. Concentrated and DCM (50 mL) was added. The organic layer was washed with water (50 mL×2), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude material was used for the next step.
- Synthesis of methyl (S)-2-amino-3-(7-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-2-methylbenzo[d]oxazol-4-yl)propanoate (152B): The title compound was prepared according to the method presented for the synthesis of compound 149C in Example 149 starting with 152A.
- Synthesis of (S)-2-(2,6-difluorobenzamido)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxy phenyl)-2-methylbenzo[d]oxazol-4-yl)propanoic acid (152): The title compound was prepared according to the method presented for the synthesis of compound N2 starting with 152B and 2,6-difluorobenzoyl chloride to give the methyl ester product, then saponification according to the method for the synthesis of compound 104 in example 104. MS (m/z) 555.2 [M+H]+. 1H NM R (400 MHz, DMSO-d6) δ 9.20 (d, J=7.8 Hz, 1H), 7.49 (tt, J=8.5, 6.6 Hz, 1H), 7.18 (d, J=7.8 Hz, 1H), 7.12 (dd, J=8.4, 7.6 Hz, 2H), 7.04 (d, J=7.7 Hz, 1H), 6.72 (s, 2H), 4.80 (ddd, J=9.8, 7.8, 5.1 Hz, 1H), 4.49 (s, 2H), 3.64 (d, J=2.8 Hz, 6H), 3.54 (q, J=7.0 Hz, 2H), 3.19 (dd, J=14.1, 9.7 Hz, 1H), 2.52 (s, 3H), 1.19 (t, J=7.0 Hz, 3H).
-
- Synthesis of (S)-2-(2,6-dichlorobenzamido)-3-(7-(4-(ethoxymethyl)-2,6-dimethoxy phenyl)-2-methylbenzo[d]oxazol-4-yl)propanoic acid (153): The title compound was prepared according to the method presented for the synthesis of compound N2 starting with 152B and 2,6-dichlorobenzoyl chloride to give the methyl ester product, then saponification according to the method for the synthesis of compound 104 in example 104. MS (m/z) 587.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.07 (d, J=8.3 Hz, 1H), 7.43-7.33 (m, 3H), 7.21 (d, J=7.8 Hz, 1H), 7.00 (d, J=7.7 Hz, 1H), 6.72 (s, 2H), 4.95 (ddd, J=10.7, 8.3, 4.6 Hz, 1H), 4.50 (s, 2H), 3.65 (d, J=5.2 Hz, 6H), 3.58-3.48 (m, 3H), 3.14 (dd, J=14.1, 10.7 Hz, 1H), 2.53 (s, 3H), 1.19 (t, J=7.0 Hz, 3H).
-
- Synthesis of 5-bromo-8-(((2S,5S)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)quinoxaline (154A): The title compound was prepared according to the method presented for the synthesis of compound 149B in Example 149 starting with 5-bromo-8-(bromomethyl)quinoxaline.
- Synthesis of methyl (S)-2-amino-3-(8-bromoquinoxalin-5-yl)propanoate (154B): The title compound was prepared according to the method presented for the synthesis of compound 149C in Example 149 starting with 154A.
- Synthesis of methyl (S)-3-(8-bromoquinoxalin-5-yl)-2-(2,6-difluoro-4-((4-(2-fluoro pyridin-4-yl)phenyl)sulfonamido)benzamido)propanoate (154C): The title compound was prepared according to the method presented for the synthesis of compound 149D in Example 149 starting with 154B.
- Synthesis of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(8-(2,6-dimethoxyphenyl)quinoxalin-5-yl)propanoic acid (154): The title compound was prepared according to the method presented for the synthesis of compound 149 in Example 66 starting with 154C and (2,6-dimethoxyphenyl)boronic acid. MS (m/z) 744.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.20 (s, 1H), 9.04 (d, J=8.0 Hz, 1H), 8.89 (d, J=1.8 Hz, 1H), 8.79 (d, J=1.8 Hz, 1H), 8.33 (d, J=5.3 Hz, 1H), 8.10-8.00 (m, 2H), 8.00-7.91 (m, 2H), 7.72 (dt, J=5.4, 1.8 Hz, 1H), 7.68 (d, J=7.4 Hz, 1H), 7.59 (d, J=1.5 Hz, 1H), 7.47 (d, J=7.3 Hz, 1H), 7.34 (t, J=8.4 Hz, 1H), 6.78 (d, J=9.1 Hz, 2H), 6.73 (d, J=8.5 Hz, 2H), 4.84 (ddd, J=10.2, 8.0, 5.0 Hz, 1H), 3.88 (dd, J=13.8, 4.9 Hz, 1H), 3.50 (d, J=1.1 Hz, 6H), 3.36-3.28 (m, 1H).
-
- Synthesis of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)quinoxalin-5-yl)propanoic acid (155): The title compound was prepared according to the method presented for the synthesis of compound 149 in Example 149 starting with 154C and (4-(ethoxymethyl)-2,6-dimethoxyphenyl) boronic acid. MS (m/z) 802.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.19 (s, 1H), 9.04 (d, J=8.1 Hz, 1H), 8.89 (d, J=1.8 Hz, 1H), 8.79 (d, J=1.8 Hz, 1H), 8.33 (d, J=5.3 Hz, 1H), 8.11-8.00 (m, 2H), 8.02-7.92 (m, 2H), 7.72 (dt, J=5.4, 1.8 Hz, 1H), 7.67 (d, J=7.4 Hz, 1H), 7.59 (d, J=1.5 Hz, 1H), 7.47 (d, J=7.3 Hz, 1H), 6.78 (d, J=9.1 Hz, 2H), 6.69 (s, 2H), 4.84 (ddd, J=10.4, 8.1, 5.1 Hz, 1H), 4.50 (s, 2H), 3.88 (dd, J=13.7, 5.0 Hz, 1H), 3.59-3.51 (m, 2H), 3.50 (d, J=1.5 Hz, 6H), 3.34 (dd, J=13.8, 10.3 Hz, 1H), 1.20 (t, J=7.0 Hz, 3H).
-
- Synthesis of methyl (S)-3-(8-bromoquinoxalin-5-yl)-2-(2,6-difluorobenzamido) propanoate (156A): The title compound was prepared according to the method presented for the synthesis of compound N2 starting with 154B and 2,6-difluorobenzoyl chloride.
- Synthesis of (S)-3-(8-(2,6-dichloro-4-fluorophenyl)quinoxalin-5-yl)-2-(2,6-difluorobenzamido)propanoic acid (156): The title compound was prepared according to the method presented for the synthesis of compound 150 in Example 150 starting with 156A and (2,6-dichloro-4-fluorophenyl)boronic acid. MS (m/z) 521.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.17 (d, J=8.3 Hz, 1H), 9.03 (d, J=1.8 Hz, 1H), 8.90 (d, J=1.8 Hz, 1H), 7.85 (d, J=7.4 Hz, 1H), 7.73-7.62 (m, 3H), 7.45 (tt, J=8.4, 6.5 Hz, 1H), 7.07 (dd, J=8.5, 7.5 Hz, 2H), 4.99 (ddd, J=10.7, 8.3, 4.9 Hz, 1H), 4.00 (dd, J=13.6, 4.9 Hz, 1H), 3.40 (dd, J=13.7, 10.7 Hz, 1H).
-
- Synthesis of methyl (S)-3-(8-bromoquinoxalin-5-yl)-2-(2,6-dichlorobenzamido) propanoate (157A): The title compound was prepared according to the method presented for the synthesis of compound N2 starting with 154B and 2,6-dichlorobenzoyl chloride.
- Synthesis of (S)-3-(8-(2,6-dichloro-4-fluorophenyl)quinoxalin-5-yl)-2-(2,6-dichloro benzamido)propanoic acid (157): The title compound was prepared according to the method presented for the synthesis of compound 150 in Example 150 starting with 157A and (2,6-dichloro-4-fluorophenyl)boronic acid. MS (m/z) 553.5 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.17 (d, J=8.7 Hz, 1H), 9.04 (d, J=1.8 Hz, 1H), 8.90 (d, J=1.8 Hz, 1H), 7.91 (d, J=7.4 Hz, 1H), 7.72-7.62 (m, 3H), 7.44-7.31 (m, 3H), 5.06 (ddd, J=11.4, 8.7, 4.0 Hz, 1H), 4.01 (dd, J=13.6, 4.0 Hz, 1H), 3.36 (dd, J=13.7, 11.4 Hz, 1H).
- Synthesis of tert-butyl (S)-3-(8-bromoquinoxalin-5-yl)-2-((diphenylmethylene)amino) propanoate (158A): To a stirred solution of 5-bromo-8-(bromomethyl)quinoxaline (180 mg, 0.6 mmol), tert-butyl 2-((diphenylmethylene)amino)acetate (233 mg, 0.8 mmol) and (11bS)-(+)-4,4-dibutyl-4,5-dihydro-2,6-bis(3,4,5-trifluorophenyl)-3H-dinaphth[2,1-c:1′,2′-e]azepinium bromide (33 mg, 0.04 mmol) in toluene (6 mL) at 0° C. was added 50% aq KOH solution (1.8 mL). The reaction mixture was allowed to stir for 6 h while warming to RT. EtOAc and water was added to the reaction mixture. The aqueous layer was separated and extracted with EtOAc (2×). The combined organics were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with EtOAc in Hex (0-20%) to give the title compound.
- Synthesis of tert-butyl (S)-2-((diphenylmethylene)amino)-3-(8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-5-yl)propanoate (158B): To a stirred solution of 158A (718 mg, 1.4 mmol) in DMA (9.3 mL) was added bis(pinacolato)diboron (706 mg, 2.8 mmol), followed by KOAc (409 mg, 4.2 mmol) and cataCXium A Pd G3 (51 mg, 0.07 mmol). The reaction vessel was flushed with nitrogen then heated to 90° C. for 1 hr. EtOAc and water were added to the reaction mixture. The aqueous layer was separated and extracted with EtOAc (2×). The organic layer was washed with water (4×s) and brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with EtOAc in Hex (0-50%) to give the title compound.
- Synthesis of tert-butyl (S)-2-((diphenylmethylene)amino)-3-(8-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)quinoxalin-5-yl)propanoate (158C): To a stirred solution of 158B (783 mg, 1.4 mmol), 3-bromo-6-fluoro-1,4-dimethyl-4a,8a-dihydroquinolin-2(1H)-one (H22, 375 mg, 1.4 mmol), K3PO4 (1032 mg, 4.86 mmol), SPhos Pd G3 (108 mg, 0.14 mmol) were dissolved in toluene (11.6 mL) and heated to 100° C. for 2 h. After cooling to RT, EtOAc and water was added to the reaction mixture. The aqueous layer was separated and extracted with EtOAc (2×). The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to give the title compound.
- Synthesis of tert-butyl (S)-2-amino-3-(8-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydro quinolin-3-yl)quinoxalin-5-yl)propanoate (158D): To a stirred solution of 158C (1.1 g, 1.7 mmol) in THE (10 mL) was added aq. HCl (2.5 mL, 2N). The reaction mixture was allowed to stir at RT for 30 min. The reaction mixture was diluted with EtOAc and sat. aq. NaHCO3 and then extracted with ethyl acetate. The combined organic layer was dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford the crude material. The material was purified using 230-400 mesh silica gel column chromatography and eluted with 10% methanol in DCM to afford the title compound.
- Synthesis of tert-butyl (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino) benzamido)-3-(8-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)quinoxalin-5-yl) propanoate (158E): To a stirred solution of 158D (77 mg, 0.17 mmol), (R)-2,6-difluoro-4-((1,1,1-trifluorobutan-2-yl)amino)benzoic acid (47 mg, 0.17 mmol), DI PEA (0.2 mL, 1.17 mmol) in DCM (1.7 mL) and DMF (1.7 mL) was added HATU (70 mg, 0.18 mmol). The reaction mixture was allowed to stir for 45 min and then concentrated. DCM and water was added and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified by silica gel chromatography eluting with EtOAc in hexanes (0-100%) to give the title compound.
- Synthesis of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(8-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)quinoxalin-5-yl)propanoic acid (158): To a stirred solution of 158E (95 mg, 0.13 mmol) in DCM (0.5 mL) was added TFA (0.1 mL, 1.3 mmol). After stirring for 1 h additional TFA (0.1 mL, 1.3 mmol) was added. This was repeated two more times after 2 h and 3 h. After stirring for 5 h, the reaction mixture was concentrated under reduced pressure. The material was purified via reverse phase HPLC to afford the title compound. MS (m/z) 672.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.99 (t, J=2.1 Hz, 1H), 8.85 (d, J=1.9 Hz, 1H), 8.75 (dd, J=18.7, 8.1 Hz, 1H), 7.82 (dd, J=14.4, 7.4 Hz, 1H), 7.74-7.52 (m, 5H), 6.76 (t, J=9.4 Hz, 1H), 6.43 (t, J=11.6 Hz, 2H), 4.92 (ddd, J=12.6, 8.3, 4.5 Hz, 0.5H), 4.86-4.76 (m, 0.5H), 4.30 (s, 1H), 4.08 (dd, J=13.3, 4.5 Hz, 0.5H), 3.85 (dd, J=13.7, 5.3 Hz, 0.5H), 3.66 (d, J=1.4 Hz, 3H), 3.61-3.50 (m, 0.5H), 3.35-3.19 (m, 0.5H), 2.07 (d, J=7.1 Hz, 3H), 1.77 (s, 1H), 1.53 (d, J=10.3 Hz, 1H), 0.93 (t, J=7.3 Hz, 3H).
-
- Synthesis of tert-butyl (S)-2-(2,6-difluorobenzamido)-3-(8-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)quinoxalin-5-yl)propanoate (159A): The title compound was prepared according to the method presented for the synthesis of compound N2 starting with 158D and 2,6-difluorobenzoyl chloride.
- (S)-2-(2,6-difluorobenzamido)-3-(8-(6-fluoro-1,4-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)quinoxalin-5-yl)propanoic acid (159): The title compound was prepared according to the method presented for the synthesis of compound 158 in Example 158 starting with 159A. MS (m/z) 547.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.24 (d, J=8.0 Hz, 1H), 9.17 (d, J=8.5 Hz, 1H), 9.00 (dd, J=4.6, 1.8 Hz, 1H), 8.86 (t, J=1.3 Hz, 1H), 7.82 (dd, J=18.6, 7.4 Hz, 1H), 7.72 (dt, J=10.1, 3.0 Hz, 1H), 7.69-7.54 (m, 3H), 7.47 (p, J=7.6 Hz, 1H), 7.11 (dt, J=12.0, 8.0 Hz, 2H), 5.10-4.97 (m, 1H), 4.98-4.87 (m, 1H), 4.13 (dd, J=13.3, 4.5 Hz, 1H), 3.88 (dd, J=13.7, 5.4 Hz, 1H), 3.66 (d, J=1.4 Hz, 3H), 3.59 (dd, J=13.8, 9.9 Hz, 1H), 3.35-3.20 (m, 1H), 2.08 (d, J=9.7 Hz, 3H).
-
- Synthesis of 5-bromo-8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinoline (160B): A microwave vial equipped with a magnetic stir bar was charged with (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid (800 mg, 3.33 mmol), 5,8-dibromoisoquinoline (3.83 g, 13.3 mmol), and bis(triphenylphosphine)palladium dichloride (234 mg, 333 umol), followed by 1,4-dioxane (16 mL) and aqueous 2.0 M sodium carbonate solution (3.89 mL, 7.78 mmol). The mixture was flashed with Ar for 1 min, then quickly sealed. The reaction mixture was stirred at 120° C. under microwave irradiation for 3 h, then cooled to room temperature, diluted with water, and extracted three times with DCM. The organic layer was combined, and the resulting solution was adsorbed onto silica gel for purification by silica gel chromatography using 20-40% EtOAc in hexanes. The second eluting peak was the title compound. MS (m/z) 402.1 [M+H]+.
- Synthesis of methyl (Z)-2-((tert-butoxycarbonyl)amino)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-5-yl)acrylate (160C): To a solution of 5-bromo-8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinoline (160B, 401 mg, 997 μmol) in DMF (10 mL) was added palladium acetate (11 mg, 50 μmol), and the mixture was flushed with N2 for 30 min. To the resulting mixture were added methyl 2-((tert-butoxycarbonyl)amino)acrylate (501 mg, 2.49 mmol), tetrabutylammonium chloride (332 mg, 1.20 mmol), and triethylamine (161 uL, 1.16 mmol), and the mixture was flushed with N2 for an additional 2 min. The reaction vial was then sealed and stirred at 90° C. overnight. The reaction mixture was then cooled to room temperature, diluted with EtOAc, and washed with 10% aqueous citric acid solution, sat. NaHCO3, and brine. The organic layer was concentrated under reduced pressure. The resulting material was purified by silica gel chromatography using 0-100% EtOAc in hexanes to afford the title compound. MS (m/z) 523.3 [M+H]+.
- Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-5-yl)propanoate (160D): A solution of methyl (Z)-2-((tert-butoxycarbonyl)amino)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-5-yl)acrylate (160° C., 176 mg, 337 μmol) and nickel(II) chloride (32 mg, 340 μmol) in McOH (17 mL) was cooled in an ice bath with stirring, then treated a single portion of sodium borohydride (64 mg, 1.7 mmol). After 15 min, the reaction mixture was quenched with sat. aqueous ammonium chloride and extracted three times with DCM. The combined organic layers were concentrated under vacuum, and purified by silica gel chromatography using 0-100% EtOAc in hexanes to afford the title compound. MS (m/z) 525.3 [M+H]+.
- Synthesis of methyl 2-amino-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl) isoquinolin-5-yl)propanoate TFA Salt (160E): A solution of methyl 2-((tert-butoxycarbonyl)amino)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-5-yl)propanoate (160D, 140 mg, 267 μmol) in DCM (3 mL) was treated with trifluoroacetic acid (1 mL). The reaction mixture was allowed to stand for 90 min, then was concentrated under vacuum, and co-evaporated with DCM and PhMe to remove residual trifluoroacetic acid, affording the title compound, which was advanced without further purification. MS (m/z) 425.2 [M+H]+.
- Synthesis of 2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-5-yl)propanoic acid (160): The title compound was prepared according to the method presented for the synthesis of compound 143 in Example 143 starting with 160E and 2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzoic acid. MS (m/z) 801.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.23 (s, 1H), 9.16 (d, J=8.1 Hz, 1H), 8.85 (s, 1H), 8.59 (d, J=6.3 Hz, 1H), 8.35 (d, J=5.3 Hz, 1H), 8.26 (d, J=6.2 Hz, 1H), 8.10-8.05 (m, 2H), 8.01-7.96 (m, 2H), 7.84 (d, J=7.4 Hz, 1H), 7.74 (dt, J=5.4, 1.8 Hz, 1H), 7.61 (s, 1H), 7.49 (d, J=7.4 Hz, 1H), 6.82 (s, 3H), 6.80 (s, 1H), 4.77-4.69 (m, 1H), 4.56 (s, 2H), 3.72 (dd, J=14.6, 4.5 Hz, 1H), 3.63-3.55 (m, 8H), 3.37 (dd, J=14.8, 10.3 Hz, 1H), 1.23 (t, J=7.0 Hz, 3H).
-
- Synthesis of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-5-yl)propanoic acid (161): 160 was separated into its 2 enantiomers by supercritical fluid chromatography using 30% McOH co-solvent, at a flow rate of 55 mL/min, using an AD-H 5 μm 21×250 mm column. The title compound was identified as the first eluting peak. MS (m/z) 801.2 [M+H]+.
- Synthesis of (R)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-5-yl)propanoic acid (162): 160 was separated into its 2 enantiomers by supercritical fluid chromatography using 30% McOH co-solvent, at a flow rate of 55 mL/min, using an AD-H 5 μm 21×250 mm column. The title compound was identified as the second eluting peak. MS (m/z) 801.2 [M+H]+.
-
- Synthesis of 8-bromo-5-(2,6-dimethoxyphenyl)isoquinoline (163A): The title compound was prepared according to the method presented for the synthesis of compound 160B in Example 160 starting with 5,8-dibromoisoquinoline and (2,6-dimethoxyphenyl)boronic acid. The first eluting peak was the title compound.
- Synthesis of methyl (Z)-2-((tert-butoxycarbonyl)amino)-3-(5-(2,6-dimethoxyphenyl) isoquinolin-8-yl)acrylate (163C): The title compound was prepared according to the method presented for the synthesis of compound 160C in Example 160 starting with 160B and methyl 2-((tert-butoxycarbonyl)amino)acrylate.
- Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-3-(5-(2,6-dimethoxyphenyl) isoquinolin-8-yl)propanoate (163D): The title compound was prepared according to the method presented for the synthesis of compound 146B in Example 146 starting with 163C.
- Synthesis of methyl 2-amino-3-(5-(2,6-dimethoxyphenyl)isoquinolin-8-yl)propanoate TFA Salt (163E): The title compound was prepared according to the method presented for the synthesis of compound 160E in Example 160 starting with 80D.
- Synthesis of 2-(4-((4-(1H-1,2,4-triazol-1-yl)phenyl)sulfonamido)-2,6-difluoro benzamido)-3-(5-(2,6-dimethoxyphenyl)isoquinolin-8-yl)propanoic acid (163): The title compound was prepared according to the method presented for the synthesis of compound 160 in Example 160 starting with 163E and 4-((4-(1H-1,2,4-triazol-1-yl)phenyl)sulfonamido)-2,6-difluorobenzoic acid. MS (m/z) 715.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.18 (s, 1H), 9.81 (s, 1H), 9.39 (s, 1H), 9.13 (d, J=8.2 Hz, 1H), 8.47 (s, 1H), 8.29 (s, 1H), 8.13-7.97 (m, 4H), 7.77 (s, 2H), 7.56 (d, J=6.2 Hz, 1H), 7.48 (t, J=8.4 Hz, 1H), 6.94-6.69 (m, 4H), 4.90-4.80 (m, 1H), 3.85 (dd, J=14.8, 4.6 Hz, 1H), 3.55 (d, J=0.9 Hz, 6H).
-
- Synthesis of (S)-2-(4-((4-(1H-1,2,4-triazol-1-yl)phenyl)sulfonamido)-2,6-difluoro benzamido)-3-(8-(2,6-dimethoxyphenyl)isoquinolin-5-yl)propanoic acid (164): 163 was separated into its 2 enantiomers by supercritical fluid chromatography using heptane:ethanol 8:2/0.1% IPA-TFA, using an AD-H 5 μm 21×250 mm column. The title compound was identified as the first eluting peak. MS (m/z) 715.2 [M+H]+.
- Synthesis of (R)-2-(4-((4-(1H-1,2,4-triazol-1-yl)phenyl)sulfonamido)-2,6-difluoro benzamido)-3-(8-(2,6-dimethoxyphenyl)isoquinolin-5-yl)propanoic acid (165): 163 was separated into its 2 enantiomers by supercritical fluid chromatography using heptane:ethanol 8:2/0.1% IPA-TFA, using an AD-H 5 μm 21×250 mm column. The title compound was identified as the second eluting peak. MS (m/z) 715.2 [M+H]+.
- Synthesis of methyl (S)-3-(8-bromo-1,6-naphthyridin-5-yl)-2-((tert-butoxycarbonyl) amino)propanoate (166A): A vial equipped with a magnetic stir bar was charged with Zn dust (376 mg, 5.75 mmol) and the head space was purged with N2 for 10 min. DMF (2.6 mL, previously degassed by sparging with N2 for 15 min) was added, followed by solid I2 (21 mg, 82 μmol), and the reaction vial was quickly sealed. The mixture was stirred vigorously for 5 min, then cooled in an ice bath with stirring. Methyl (R)-2-((tert-butoxycarbonyl)amino)-3-iodopropanoate (1.49 g, 4.52 mmol) was added as a solution in degassed DMF (2.6 mL). After 30 min, the ice bath was removed and the reaction mixture was allowed to warm to room temperature. The vial was quickly opened and 8-bromo-5-chloro-1,6-naphthyridine (1.00 g, 4.11 mmol) and trans-dichlorobis(triphenylphosphine)palladium (130 mg, 205 μmol) were added. The vial was then sealed, and the reaction mixture stirred at 50° C. overnight. The reaction mixture was then cooled to room temperature, diluted with water and 10% aqueous citric acid solution, and extracted three times with EtOAc. The combined organics were concentrated under vacuum and purified by silica gel chromatography using 0-100% EtOAc in hexanes to afford the title compound. MS (m/z) 410.1 [M+H]+.
- Synthesis of methyl (S)-2-amino-3-(8-bromo-1,6-naphthyridin-5-yl)propanoate tri hydrochloride (166B): A suspension of methyl (S)-3-(8-bromo-1,6-naphthyridin-5-yl)-2-((tert-butoxycarbonyl)amino)propanoate (166 A, 691 mg, 1.68 mmol) in EtOAc (11 mL) was treated with 4.0 M hydrogen chloride in 1,4-dioxane (4.21 mL, 16.8 mmol), and the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with EtOAc and then filtered. The material was thus dissolved in methanol and filtered. The resulting filtrate was concentrated under vacuum, co-evaporated with EtOAc to remove residual McOH, and dried under vacuum to afford the title compound. MS (m/z) 310.0 [M+H]+.
- Synthesis of methyl (S)-3-(8-bromo-1,6-naphthyridin-5-yl)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzamido)propanoate (166C): The title compound was prepared according to the method presented for the synthesis of compound 149D in Example 149 starting with 166B and 2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido)benzoic acid.
- Synthesis of (S)-2-(2,6-difluoro-4-((4-(2-fluoropyridin-4-yl)phenyl)sulfonamido) benzamido)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)-1,6-naphthyridin-5-yl)propanoic acid (166): The title compound was prepared according to the method presented for the synthesis of compound 149 in Example 149 starting with 166C and (4-(ethoxymethyl)-2,6-dimethoxyphenyl) boronic acid. MS (m/z) 802.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.20 (s, 1H), 9.02 (d, J=7.8 Hz, 1H), 8.98 (dd, J=4.2, 1.7 Hz, 1H), 8.70 (dd, J=8.6, 1.7 Hz, 1H), 8.37 (s, 1H), 8.36-8.33 (m, 1H), 8.09-8.03 (m, 2H), 8.00-7.94 (m, 2H), 7.76-7.71 (m, 1H), 7.64 (dd, J=8.6, 4.2 Hz, 1H), 7.60 (t, J=1.0 Hz, 1H), 6.82-6.75 (m, 2H), 6.73 (s, 2H), 5.21-5.13 (m, 1H), 4.53 (s, 2H), 3.78 (d, J=6.8 Hz, 2H), 3.61-3.52 (m, 8H), 1.21 (t, J=7.0 Hz, 3H).
-
- Synthesis of methyl (S)-3-(8-bromo-1,6-naphthyridin-5-yl)-2-(2,6-difluoro benzamido)propanoate (167A): The title compound was prepared according to the method presented for the synthesis of compound 149D in Example 149 starting with 166B and 2,6-difluorobenzoic acid.
- Synthesis of (S)-2-(2,6-difluorobenzamido)-3-(8-(4-(ethoxymethyl)-2,6-dimethoxy phenyl)-1,6-naphthyridin-5-yl)propanoic acid (167): The title compound was prepared according to the method presented for the synthesis of compound 149 in Example 149 starting with 167A and (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid. MS (m/z) 552.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.19 (d, J=7.8 Hz, 1H), 9.01 (dd, J=4.2, 1.6 Hz, 1H), 8.76 (dd, J=8.6, 1.7 Hz, 1H), 8.43 (s, 1H), 7.69 (dd, J=8.5, 4.2 Hz, 1H), 7.48 (tt, J=8.4, 6.5 Hz, 1H), 7.14-7.05 (m, 2H), 6.74 (s, 2H), 5.30-5.20 (m, 1H), 4.53 (s, 2H), 3.84 (d, J=6.9 Hz, 2H), 3.61-3.54 (m, 8H), 1.22 (t, J=7.0 Hz, 3H).
-
- Synthesis of 1-bromo-4-(bromomethyl)isoquinoline (168A): The title compound was prepared according to the method presented for the synthesis of compound 149A in Example 149 starting with 1-bromo-4-methylisoquinoline and NBS.
- Synthesis of 1-bromo-4-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)isoquinoline (168B): The title compound was prepared according to the method presented for the synthesis of compound 149B in Example 149 starting with 168A and (R)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine.
- Synthesis of methyl (S)-3-(1-bromoisoquinolin-4-yl)-2-(tritylamino)propanoate (168C): To a stirred solution of 168B (675 mg, 2 mmol) in acetonitrile was added 2 M hydrochloric acid (10 mL, 20 mmol), and the reaction was allowed to stir for 4 h at room temperature. It was concentrated, and the crude material was dissolved in DCM, trityl chloride (0.47 g, 2 mmol) was added. The reaction mixture was stirred at RT for 1 h, then purified with by silica gel chromatography using 0-100% EtOAc in hexanes to afford the title compound.
- Synthesis of (S)-3-(1-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-4-yl)-2-(tritylamino)propanoic acid (168D): The title compound was prepared according to the method presented for the synthesis of compound 143B in Example 143 starting with 168D and (4-(ethoxymethyl)-2,6-dimethoxyphenyl)boronic acid.
- Synthesis of (S)-2-(2,6-difluoro-4-(((R)-1,1,1-trifluorobutan-2-yl)amino)benzamido)-3-(1-(4-(ethoxymethyl)-2,6-dimethoxyphenyl)isoquinolin-4-yl)propanoic acid (168): The title compound was prepared according to the method presented for the synthesis of compound 160 in Example 160 starting with 168D and T1. MS (m/z) 676.4 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.84 (d, J=8.1 Hz, 1H), 8.50 (s, 1H), 8.38 (s, 1H), 8.10 (s, 1H), 7.77 (s, 2H), 6.88 (d, J=3.1 Hz, 2H), 6.78 (d, J=9.4 Hz, 1H), 6.44 (d, J=11.7 Hz, 2H), 4.81 (s, 1H), 4.60 (s, 2H), 4.31 (d, J=9.3 Hz, 1H), 3.78 (s, 1H), 3.63 (s, 3H), 3.60 (d, J=7.0 Hz, 2H), 3.46 (d, J=12.3 Hz, 1H), 3.11 (ddd, J=12.1, 7.0, 4.2 Hz, 1H), 1.77 (ddd, J=13.8, 7.8, 3.4 Hz, 1H), 1.52 (ddd, J=13.7, 10.2, 7.0 Hz, 1H), 1.25 (dt, J=10.6, 6.6 Hz, 6H), 1.18 (t, J=7.3 Hz, 1H), 0.92 (t, J=7.3 Hz, 3H).
- Synthesis of 2-bromo-5-(((tert-butyldimethylsilyl)oxy)methyl)phenol (169A): To a stirred solution of 2-bromo-5-(hydroxymethyl)phenol (4.9 g, 24 mmol) and imidazole (1.8 g, 27 mmol) in DCM (30 mL) and THF (10 mL) was added a solution of TBSCI (4.0 g, 27 mmol) in THF (5 mL) dropwise over 30 min at 0° C. The reaction mixture was stirred for 3 hrs. EtOAc and water was added to the reaction mixture. The aqueous layer was separated and extracted with EtOAc (2×). The combined organics were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with EtOAc in Hex (0-100%) to give the title compound.
- Synthesis of ((4-bromo-3-(prop-2-yn-1-yloxy)benzyl)oxy)(tert-butyl)dimethylsilane (169B): To a stirred solution of 169A (200.2 mg, 0.63 mmol) in acetone (2.10 mL) was added potassium carbonate (174.4 mg, 1.26 mmol), followed by propargyl bromide (69 μL, 0.92 mmol). The reaction vessel was sealed and heated to 65° C. for 3 hours. After cooling to room temperature, the reaction was diluted with water and EtOAc. The aqueous layer was extracted and the organic layer was dried over anhydrous MgSO4 and concentrated under reduced pressure. The material was purified by silica gel chromatography using 0-10% EtOAc in hexanes to afford the title compound.
- Synthesis of ((8-bromo-2H-chromen-5-yl)methoxy)(tert-butyl)dimethylsilane (169C): A reaction vessel containing a solution of 169B (192.6 mg, 0.54 mmol) in dichloromethane (5.4 mL) was wrapped in aluminum foil to avoid decomposition from light. To this solution was added (acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I) hexafluoroantimonate (20.9 mg, 0.027 mmol) and the reaction was stirred at room temperature for 16 hours. The reaction was concentrated under reduced pressure and the resulting residue was purified by silica gel chromatography using 0-10% EtOAc in hexanes to afford the title compound.
- Synthesis of (8-bromo-2H-chromen-5-yl)methanol (169D): To a stirred solution of 169C (132.6 mg, 0.37 mmol) in THF (1.87 mL) was added tetrabutylammonium fluoride (1.0M in THF, 0.45 mL, 0.45 mmol) dropwise. The reaction was stirred at room temperature for 15 min and then quenched with water. The reaction was concentrated under reduced pressure and then diluted with water and EtOAc. The aqueous layer was extracted and the organic layer was dried over anhydrous MgSO4 and concentrated under reduced pressure. The material was purified by silica gel chromatography using 0-50% EtOAc in hexanes to afford the title compound.
- Synthesis of 8-bromo-5-(bromomethyl)-2H-chromene (169E): To a solution of compound 169D (20.0 g, 87.30 mmol) in DCM (0.180 L) were added triphenylphosphine (34.31 g, 130.9 mmol) and carbon tetrabromide (43.4 g, 130.9 mmol) at room temperature. The reaction mixture was allowed to stir at RT for 1 hr. The reaction mixture was concentrated under reduced pressure and purified via 100-200 mesh silica gel chromatography eluting 2-6% EA in hexanes to afford the title compound.
- Synthesis of (2S,5R)-2-((8-bromo-2H-chromen-5-yl)methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (169F): To a stirred solution of (R)-2,5-Dihydro-3,6-dimethoxy-2-isopropylpyrazine (0.44 mL, 184 mmol) in 2-MeTHF (8.1 mL) was added nBuLi (1.6 mL, 1.6M solution in hexanes) dropwise at −78° C. After stirring for 25 min, a solution of 169E (500 mg, 1.6 mmol) in 2-MeTHF (13 mL) was added dropwise. The reaction mixture was allowed to stir at −78° C. for 45 min. H2O was added and the reaction mixture was warmed to RT. The aqueous layer was separated and extracted with EtOAc (2×). The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified by silica gel chromatography using 0-40% EtOAc in hexanes to give the title compound.
- Synthesis of (2S,5R)-2-((8-(2,6-dichloro-4-fluorophenyl)-2H-chromen-5-yl)methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (169G): To a stirred solution of 169F (303 mg, 0.74 mmol), (2,6-dichloro-4-fluorophenyl)boronic acid (308 mg, 1.47 mmol), K3PO4 (547 mg, 2.58 mmol), SPhos Pd G3 (575 mg, 0.74 mmol) were dissolved in toluene (5.8 mL) and heated to 100° C. for 2 hours. After cooling to RT, EtOAc and water were added to the reaction mixture. The aqueous layer was separated and extracted with EtOAc (2×). The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with EtOAc in Hex (0-50%) to give the title compound.
- Synthesis of methyl (S)-2-amino-3-(8-(2,6-dichloro-4-fluorophenyl)-2H-chromen-5-yl)propanoate (169H): To a stirred solution of 169G (100 mg, 0.2 mmol) in MeCN (2 mL) at RT was added aq. HCl (0.5 mL, 2M). The reaction mixture was allowed to stir for 2 h and then carefully poured into sat aq. NaHCO3. EtOAc was then added to the mixture. The aqueous layer was separated and extracted with EtOAc (2×, ˜10 mL) and 2-MeTHF (1×, ˜10 mL). The organic layers were combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with DCM in McOH (0-5%) to give the title compound.
- Synthesis of methyl (S)-3-(8-(2,6-dichloro-4-fluorophenyl)-2H-chromen-5-yl)-2-(2,6-dichlorobenzamido)propanoate (1691): To a stirred solution of 169H (0.37 mmol) in DCM (3.7 mL) was added 2,6-dichlorobenzoyl chloride (0.44 mmol) and DI PEA (0.32 mL, 1.8 mmol). The reaction mixture was allowed to stir for 10 min, then DCM and water were added to the reaction mixture. The aqueous layer was separated and extracted with DCM (2×). The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The material was purified on silica gel eluting with EtOAc in Hex (0-50%) to give the title compound.
- Synthesis of (S)-3-(8-(2,6-dichloro-4-fluorophenyl)-2H-chromen-5-yl)-2-(2,6-dichlorobenzamido)propanoic acid (169): The title compound was prepared according to the method presented for the synthesis of compound 1 of Example 1 starting with 1691. MS (m/z) 554.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.90 (s, 1H), 9.17 (d, J=8.3 Hz, 1H), 7.60 (d, J=8.6 Hz, 2H), 7.47-7.36 (m, 3H), 6.98 (d, J=7.9 Hz, 1H), 6.87 (d, J=7.9 Hz, 1H), 6.82 (dt, J=10.1, 1.8 Hz, 1H), 6.03 (dt, J=10.1, 3.7 Hz, 1H), 4.66 (dt, J=4.0, 2.0 Hz, 2H), 4.61 (ddd, J=10.5, 8.3, 4.1 Hz, 1H), 3.25 (dd, J=14.3, 4.1 Hz, 1H), 2.95 (dd, J=14.3, 10.5 Hz, 1H).
- Synthesis of methyl 4-bromo-3-((2-methylbut-3-yn-2-yl)oxy)benzoate (170A): To a flame dried flask containing methyl 4-bromo-3-hydroxybenzoate (2.3 g, 10 mmol) and ACN (100 mL) at 0° C. was added 1,8-Diazabicyclo[5.4.0]undec-7-ene (1.94 mL, 13 mmol) and copper(II) chloride (13 mg, 0.1 mmol). 3-Chloro-3-methylbut-1-yne (1.33 g, 13 mmol) was then added and the mixture was stirred for 16 h, concentrated and chromatographed on silica gel eluting with EtOAc in hexanes to afford the title compound.
- Synthesis of methyl 8-bromo-2,2-dimethyl-2H-chromene-5-carboxylate (170B): To a stirring solution of methyl 4-bromo-3-((2-methylbut-3-yn-2-yl)oxy)benzoate (3 g, 10.1 mmol) in DCM (50 mL) was added (Acetonitrile)[(2-biphenyl)di-tert-butylphosphine]gold(I) hexafluoro antimonate (0.39 g, 0.5 mmol). After 2 hours the mixture was concentrated and chromatographed on silica gel eluting with EtOAc in hexanes (0-40%) to afford the title compound.
- Synthesis of (8-bromo-2,2-dimethyl-2H-chromen-5-yl)methanol (170C): To a stirring solution of methyl 8-bromo-2,2-dimethyl-2H-chromene-5-carboxylate (600 mg, 2 mmol) and THF (5 mL) at 0° C. was added lithium borohydride (5 mL, 5 mmol, 1N) and the mixture was stirred ON. 1 mL of a concentrated Rochelle's salt solution was added and the mixture was stirred for an additional 1 h. The mixture was filtered washed with EtOAc and the eluent was concentrated and the residue was chromatographed on silica gel eluting with EtOAc in hexanes (0-60%) to afford the title compound.
- Synthesis of 8-bromo-5-(bromomethyl)-2,2-dimethyl-2H-chromene (170D): To a stirring solution of (8-bromo-2,2-dimethyl-2H-chromen-5-yl)methanol (527 mg, 1.96 mmol) in DCM (3 mL) was added phosphorous tribromide (1N in DCM, 1.96 mL, 1.96 mmol) and the mixture was stirred ON, loaded directly onto silica gel and chromatographed eluting with EtOAc in hexanes (0-20%) to afford the title compound.
- Synthesis of (2S,5R)-2-((8-bromo-2,2-dimethyl-2H-chromen-5-yl)methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (170E): To a flame dried vial containing (R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (1.01 ml, 5.66 mmol) and THF (28 mL) at −78° C. was added n-butyllithium 2.5 M in hexanes (2.26 ml, 5.66 mmol) dropwise. The reaction was stirred for 20 minutes when 8-bromo-5-(bromomethyl)-2,2-dimethyl-2H-chromene was added (1.044 g, 3.1 mmol) and the mixture was stirred for 1 h at −78° C. and ammonium chloride (sat) was added and the mixture was extracted with EtOAc, concentrated, and the residue was chromatographed on silica gel eluting with EtOAc in hexanes (0-10%) to afford the title compound.
- Synthesis of methyl (S)-2-amino-3-(8-bromo-2,2-dimethyl-2H-chromen-5-yl) propanoate (170F): To a stirred solution of (2S,5R)-2-((8-bromo-2,2-dimethyl-2H-chromen-5-yl)methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine and THF (20 mL) was added 2N HCl (11.5 mL, 23 mmol) and the mixture was stirred for 2 h, diluted with EtOAc and treated with sodium bicarbonate (sat) until basic. The organic layer was concentrated and chromatographed on silica gel eluting with McOH in dichloromethane (0-30%) to afford the title compound.
- Synthesis of methyl (S)-3-(8-bromo-2,2-dimethyl-2H-chromen-5-yl)-2-(2,6-dichloro benzamido)propanoate (170G): To a stirred solution methyl (S)-2-amino-3-(8-bromo-2,2-dimethyl-2H-chromen-5-yl)propanoate (360 mg, 1.06 mmol) and DCM (5 mL) at 0° C. was added N-ethyl-N-isopropylpropan-2-amine (0.37 mL, 2.12 mmol), and 2,6-dichlorobenzoyl chloride (0.15 mL, 1.06 mmol) dropwise. The mixture was stirred for 4 h and sodium bicarbonate (sat, 1 mL) was added and the organic layer was concentrated and chromatographed on silica gel eluting with EtOAc in hexanes (0-100%) to afford the title compound.
- Synthesis of (S)-3-(8-(2,6-dichloro-4-fluorophenyl)-2,2-dimethyl-2H-chromen-5-yl)-2-(2,6-dichlorobenzamido)propanoic acid (170): To a stirred solution of methyl (S)-3-(8-(2,6-dichloro-4-fluorophenyl)-2,2-dimethyl-2H-chromen-5-yl)-2-(2,6-dichlorobenzamido)propanoate (38 mg, 0.06 mmol) and THE (2 mL) was added lithium hydroxide (1N, 0.5 mL, 0.5 mmol) and stirred for 2 h. The mixture was concentrated, TFA was added and the mixture was again concentrated under reduced pressure and chromatographed on reversed phase eluting with ACN and water containing 0.4% TFA to afford the title compound. MS (m/z) 583.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 1H NMR (400 MHz, DMSO-d6) δ 9.13 (d, J=8.4 Hz, 1H), 7.62-7.52 (m, 2H), 7.49-7.28 (m, 3H), 6.90 (d, J=7.9 Hz, 1H), 6.80 (d, J=7.8 Hz, 1H), 6.69 (d, J=10.0 Hz, 1H), 5.87 (d, J=10.0 Hz, 1H), 4.66-4.53 (m, 1H), 3.26 (dd, J=14.2, 4.2 Hz, 1H), 2.92 (dd, J=14.3, 10.6 Hz, 1H), 1.23 (d, J=7.7 Hz, 7H).
- The compounds in Table 1 were prepared by processes described herein.
-
TABLE 1 M/Z Example Structure 1H-NMR [M + H]+ 171 1H NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 7.1 Hz, 1H), 8.95 (dd, J = 4.2, 1.7 Hz, 1H), 7.82 (dd, J = 8.5, 1.7 Hz, 1H), 7.63 (d, J = 7.3 Hz, 1H), 7.49 (dd, J = 8.5, 4.2 Hz, 1H), 7.25 (d, J = 7.3 Hz, 1H), 6.78 (d, J = 11.7 Hz, 2H), 6.69-6.59 (m, 1H), 4.90 (ddd, J = 15.7, 11.1, 5.5 Hz, 2H), 4.17 (d, J = 12.7 Hz, 1H), 3.96 (dd, J = 11.4, 3.8 Hz, 2H), 3.80-3.66 (m, 2H), 3.52 (s, 3H), 3.49 (s, 3H), 3.44 (d, J = 13.2 Hz, 2H), 3.25 (t, J = 12.2 Hz, 1H), 2.55 (s, 3H). 713.2 172 1H NMR (400 MHz, DMSO-d6) δ 9.19- 9.02 (m, 2H), 8.75 (d, J = 6.4 Hz, 1H), 8.26- 8.11 (m, 2H), 7.80 (d, J = 6.5 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 7.50 (dt, J = 11.2, 5.6 Hz, 2H), 7.39 (d, J = 7.2 Hz, 1H), 6.79 (d, J = 11.8 Hz, 2H), 4.99-4.85 (m, 1H), 4.77 (q, J = 7.7, 7.0 Hz, 1H), 4.17 (d, J = 12.7 Hz, 1H), 3.96 (dd, J = 11.4, 3.6 Hz, 1H), 3.72 (s, 5H), 3.68 (s, 3H), 3.57 (d, J = 12.2 Hz, 2H), 3.27 (d, J = 14.6 Hz, 2H). 681.4 173 1H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 7.6 Hz, 1H), 9.25 (s, 1H), 8.97 (dd, J = 4.1, 1.7 Hz, 1H), 7.77 (dd, J = 8.0, 3.9 Hz, 3H), 7.71 (dd, J = 8.5, 1.7 Hz, 1H), 7.54 (dd, J = 8.5, 4.1 Hz, 1H), 7.52-7.46 (m, 1H), 7.44 (d, J = 7.3 Hz, 1H), 7.11 (dd, J = 8.5, 7.6 Hz, 2H), 5.13 (ddd, J = 10.0, 7.6, 5.3 Hz, 1H), 4.49-4.39 (m, 1H), 4.39- 4.27 (m, 1H), 4.00 (dd, J = 13.5, 5.3 Hz, 1H), 3.49 (dd, J = 13.6, 10.0 Hz, 1H), 3.39 (d, J = 13.4 Hz, 2H), 3.25-3.14 (m, 4H), 1.18 (td, J = 7.3, 1.3 Hz, 6H). 618.1 174 1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 7.7 Hz, 1H), 8.68 (s, 1H), 8.59 (d, J = 8.6 Hz, 1H), 8.20 (d, J =8.5 Hz, 1H), 7.84 (d, J = 7.4 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.56 (dd, J = 13.5, 7.4 Hz, 2H), 6.78 (d, J = 11.8 Hz, 2H), 4.91 (dd, J = 9.3, 3.2 Hz, 1H), 4.77 (td, J = 8.5, 4.7 Hz, 1H), 4.16 (d, J = 12.7 Hz, 1H), 3.95 (dd, J = 11.8, 3.7 Hz, 1H), 3.73 (dd, J = 14.3, 4.9 Hz, 2H), 3.68 (s, 3H), 3.56 (d, J = 12.5 Hz, 2H), 3.29-3.16 (m, 2H), 2.54 (s, 3H), 2.33 (s, 3H). 629.2 175 1H NMR (400 MHz, DMSO-d6) δ 9.03 (d, J = 7.8 Hz, 1H), 8.96 (dd, J = 4.1, 1.7 Hz, 1H), 7.88 (dd, J = 8.5, 1.7 Hz, 1H), 7.78- 7.65 (m, 3H), 7.60 (td, J = 9.2, 8.6, 2.8 Hz, 1H), 7.46 (dd, J = 8.5, 4.1 Hz, 1H), 7.31 (d, J = 7.2 Hz, 1H), 6.75 (d, J = 11.7 Hz, 2H), 5.10-4.98 (m, 1H), 4.91 (s, 1H), 4.16 (d, J = 12.8 Hz, 1H), 4.02 (dd, J = 13.0, 5.1 Hz, 1H), 3.96 (dd, J = 11.5, 3.7 Hz, 1H), 3.74 (d, J = 12.6 Hz, 1H), 3.68 (s, 3H), 3.65 (s, 3H), 3.61-3.50 (m, 1H), 3.45-3.30 (m, 1H), 3.33-3.18 (m, 2H), 2.10 (s, 3H). 713.2 176 1H NMR (400 MHz, DMSO-d6) δ 9.05 (d, J = 7.4 Hz, 1H), 8.94 (dd, J = 4.2, 1.7 Hz, 1H), 7.81 (dd, J = 8.5, 1.7 Hz, 1H), 7.66 (d, J = 7.3 Hz, 1H), 7.48 (dd, J = 8.5, 4.1 Hz, 1H), 7.24 (d, J = 7.2 Hz, 1H), 6.75 (d, J = 11.6 Hz, 2H), 6.64 (s, 1H), 5.01-4.87 (m, 2H), 4.16 (d, J = 12.7 Hz, 1H), 3.95 (dd, J = 11.5, 3.8 Hz, 1H), 3.89 (dd, J = 13.2, 5.7 Hz, 1H), 3.74 (d, J = 12.9 Hz, 2H), 3.57 (s, 3H), 3.51 (s, 3H), 3.43 (m, 2H), 3.24 (t, J = 12.4 Hz, 1H), 2.55 (s, 3H). 713.2 177 1H NMR (400 MHz, DMSO-d6) δ 8.96 (d, J = 7.9 Hz, 1H), 8.20 (d, J = 8.6 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.52-7.40 (m, 3H), 6.78 (d, J = 11.9 Hz, 2H), 4.91 (p, J = 8.6, 8.2 Hz, 1H), 4.68 (td, J = 8.8, 4.2 Hz, 1H), 4.16 (d, J = 12.7 Hz, 1H), 3.96 (dd, J = 11.8, 3.6 Hz, 1H), 3.73 (t, J = 13.4 Hz, 2H), 3.56 (s, 3H), 3.36 (d, J = 13.5 Hz, 2H), 3.24 (t, J = 12.8 Hz, 2H), 2.42 (s, 3H), 2.34 (s, 3H). 645.2 178 1H NMR (400 MHz, DMSO-d6) δ 9.00 (d, J = 1.8 Hz, 1H), 8.86 (d, J = 1.8 Hz, 1H), 8.74 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 7.4 Hz, 1H), 7.52 (d, J = 7.3 Hz, 1H), 6.71- 6.53 (m, 4H), 5.01-4.89 (m, 1H), 4.88- 4.78 (m, 1H), 4.14 (d, J = 12.6 Hz, 1H), 4.05-3.91 (m, 2H), 3.72 (d, J = 12.7 Hz, 1H), 3.49 (s, 4H), 3.40-3.19 (m, 2H), 2.53 (s, 4H), 1.95 (s, 3H). 696.2 179 1H NMR (400 MHz, DMSO-d6) δ 8.98 (d, J = 1.8 Hz, 1H), 8.90-8.81 (m, 2H), 7.77 (d, J = 7.4 Hz, 1H), 7.51 (d, J = 7.3 Hz, 1H), 6.72 (d, J = 11.5 Hz, 2H), 6.57 (s, 1H), 4.89 (td, J = 9.3, 4.5 Hz, 2H), 4.15 (d, J = 12.7 Hz, 1H), 4.02-3.90 (m, 2H), 3.73 (d, J = 12.3 Hz, 1H), 3.54 (s, 0H), 3.49 (s, 3H), 3.46-3.15 (m, 2H), 2.53 (s, 3H). 700.2 180 1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 1H), 8.83 (d, J = 8.1 Hz, 1H), 8.63 (d, J = 4.9 Hz, 1H), 7.94 (dd, J = 5.0, 2.5 Hz, 2H), 7.26 (d, J = 7.3 Hz, 1H), 7.11 (d, J = 7.3 Hz, 1H), 6.86 (d, J = 2.3 Hz, 1H), 6.80- 6.61 (m, 4H), 4.87 (ddt, J = 12.1, 8.6, 3.7 Hz, 3H), 4.15 (dd, J = 12.7, 6.2 Hz, 2H), 3.95 (dt, J = 11.4, 4.4 Hz, 2H), 3.66 (d, J = 1.4 Hz, 3H), 3.55 (tt, J = 11.5, 3.8 Hz, 1H), 3.44 (dd, J = 14.8, 3.9 Hz, 2H), 3.35 (d, J = 11.4 Hz, 1H), 3.32-3.20 (m, 3H), 2.04 (d, J = 2.2 Hz, 3H). 670.2 - The potency of inhibitors in preventing α4β7 integrin interaction with MadCAM-1 was measured by monitoring the capture of α4β7 integrin expressing cells on a recombinant MadCAM-1 extracellular domain-coated plate.
- 384-Well plates (Corning 3702) were coated with MadCAM-1 extracellular domain by dispensing 20 μL of MAdCAM-1 at 1.0 μg/mL per well and incubating overnight at 4° C. The plates were then washed with PBS and blocked with 3% BSA for 2 hours before being washed again.
- RPMI8866 cells were spun down and re-suspended in assay medium (DMEM+0.5% FBS+0.5 mM MnCl2) at a density of 0.5×106 cells/mL. The cells were then dispensed (60 μL/well) to a 384-well plate (Greiner 781280) that was previously spotted with 60 nL of test compound per well. The plates were incubated at 37° C. for 1 hour. 50 μL of cells were transferred to the blocked, MadCAM-1-coated plates and incubated for 30 minutes at 37° C. 10 μL of 12% glutaraldehyde containing Hoechst 33342 (0.06 mg/mL) was added to the cells (2% glutaraldehyde and 0.01 mg/mL final concentrations). The plates were incubated for 90 minutes at room temperature. The plates were then washed 3 times with 70 μL of PBS per well and imaged on a Cellomics ArrayScan instrument. The cells that were bound to the plate were counted and plotted against the compound concentration to determine the EC50 of the test compounds. Results are presented in Table 2.
-
TABLE 2 α4β7 Integrin Cell Capture Assay Results EC50 EC50 EC50 EC50 Example α4β7 Example α4β7 Example α4β7 Example α4β7 # (nM) # (nM) # (nM) # (nM) 1 210.3 46 32.2 91 686.0 136 0.8 2 416.7 47 28.6 92 89.4 137 0.9 3 392.6 48 2.1 93 26.8 138 0.3 4 26.0 49 46.2 94 110.8 139 0.4 5 702.0 50 151.7 95 15.2 140 0.1 6 139.0 51 45.1 96 571.5 141 3.6 7 522.2 52 43.8 97 97.2 142 0.5 8 0.8 53 149.6 98 469.5 143 30.2 9 4.1 54 38.8 99 50.4 144 4.9 10 1.1 55 63.1 100 22.2 145 34.9 11 0.5 56 68.5 101 1.7 146 0.6 12 19.5 57 23.6 102 1.0 147 0.4 13 66.9 58 19.2 103 1.9 148 3.6 14 57.7 59 10.7 104 0.8 149 0.3 15 85.0 60 2.7 105 0.8 150 180.6 16 144.0 61 15.1 106 195.7 151 5.8 17 356.2 62 3.2 107 138.6 152 57.8 18 416.5 63 33.8 108 3.4 153 28.4 19 26.3 64 4.4 109 2.1 154 2.6 20 373.7 65 26.8 110 14.2 155 1.6 21 5.8 66 6.2 111 76.6 156 135.4 22 123.2 67 2.5 112 53.3 157 160.7 23 18.5 68 2.7 113 12.3 158 0.4 24 49.5 69 9.2 114 29.9 159 1.9 25 20.0 70 55.1 115 21.7 160 0.6 26 290.5 71 15.4 116 72.6 161 0.5 27 57.7 72 11.2 117 82.0 162 1.7 28 193.6 73 8.4 118 2.5 163 0.9 29 16.7 74 130.8 119 82.9 164 1.3 30 46.4 75 23.0 120 1.5 165 37.8 31 23.2 76 55.7 121 3.9 166 24.4 32 6.0 77 60.4 122 1.1 167 835.8 33 12.2 78 12.4 123 10.2 168 26.6 34 4.0 79 45.7 124 0.2 169 142.1 35 53.5 80 17.0 125 0.5 170 206.34 36 115.3 81 6.6 126 6.4 171 N/A 37 65.6 82 39.0 127 0.4 172 N/A 38 211.8 83 109.3 128 1.7 173 N/A 39 74.0 84 10.9 129 0.1 174 N/A 40 32.7 85 3.0 130 0.6 175 N/A 41 7.5 86 0.3 131 0.5 176 N/A 42 152.5 87 2.9 132 13.7 177 0.22 43 160.5 88 0.1 133 0.5 178 0.08 44 538.3 89 172.7 134 8.3 179 0.10 45 243.0 90 4280.7 135 1.0 180 0.09
Claims (6)
1-53. (canceled)
54. A method for treating an inflammatory disease or condition associated with α4β7 integrin, comprising administrating to a subject in need thereof an effective amount of a pharmaceutical composition comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X1 and X2 are each independently selected from C, and N; wherein the bond between X1 and X2 is a single or a double bond;
X3 and X4 are each independently selected from CR10, and N;
X6 and X7 are each independently selected from CR10R10, CR10, S, S(O), S(O)2, N, NR11, C(O), and O;
each X6 is independently selected from CR10R10, CR10, S, S(O), S(O)2, N, NR11, C(O), and O;
wherein the bond between X5 and X6, X6 and X6, or X6 and X7 is a single or a double, provided that at least one is a double bond;
R1 is selected from -L-A1, -L-A2, -L-A3, and -L-A4;
L is selected from a bond, —O—, —O—C(O)—*, —NH—, —C(O)—N(H)—*, and —N(H)—C(O)—*;
wherein * indicates a point of attachment of L to A1, A2, A3, or A4;
A1 is C6-10aryl optionally substituted with one to six Ra;
A2 is 5-10 membered heteroaryl containing one to five heteroatoms independently selected from S, N, and O, and optionally one or two C(O); wherein A2 is optionally substituted with one to six Ra;
A3 is 5-10 membered cycloalkyl or 5-14 membered heterocyclyl; wherein A3 is optionally substituted with one to six Ra; and
A4 is —NRa1Ra2;
wherein each Ra is independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, —S(O)m—C1-6alkyl, C3-8cycloalkyl, 3-6 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C1-4alkylene-C3-8cycloalkyl, —O-phenyl, and —O—C3-8cycloalkyl;
each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-6haloalkyl, C1-6haloalkoxyl, and —S(O)m—C1-6alkyl of Ra are optionally substituted with one to three Ra3; wherein each Ra3 is independently selected from hydroxyl, cyano, —NRa1Ra2, C1-6alkoxyl, C3-8cycloalkyl, phenyl, and 3-6 membered heterocyclyl; wherein each C3-8cycloalkyl, phenyl, and 3-6 membered heterocyclyl of Ra3 is independently optionally substituted with one to three Ra4;
wherein each Ra4 is independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, C1-6haloalkoxyl, C3-8cycloalkyl, and 3-6 membered heterocyclyl; and
each C3-8cycloalkyl, 3-6 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C1-4alkylene-C3-8cycloalkyl, —O-phenyl, and —O—C3-8cycloalkyl of Ra is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-6haloalkyl, C1-6alkoxyl, and C1-6haloalkoxyl;
each R2, R3, R4, R5, and R6 is independently selected from H, halo, cyano, hydroxyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-8haloalkyl, C1-8haloalkoxyl, —NRb1Rb2, —Rb3S(O)mRb4, —S(O)mRb4, —NRb1S(O)yRb4, —COORb1, —CONRb1Rb2, —NRb1COORb2, —NRb1CORb4, —Rb3NRb1Rb2, —S(O)yNRb1Rb2, C3-12cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 3-12 membered heterocyclyl;
each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxyl, C1-8haloalkyl, and C1-8haloalkoxyl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to two Rc; wherein each Rc is independently selected from azido, oxo, cyano, halo, hydroxyl, —NRa1Ra2, C1-4alkoxyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rc is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-6haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl;
each C6-10aryl and 5-6 membered heteroaryl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to five Rb; and
each C3-12cycloalkyl and 3-12 membered heterocyclyl of R2, R3, R4, R5, and R6 is independently optionally substituted with one to six groups independently selected from ═CRb1Rb2, and Rb;
wherein each Rb is independently selected from azido, cyano, halo, hydroxyl, —NRa1Ra2, C1-6alkyl, C1-8haloalkyl, C1-6alkoxyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl;
wherein each C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rb is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl;
each Rb1 and Rb2 is independently selected from H, C1-8alkyl, C1-8haloalkyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl;
each C1-8alkyl and C1-6haloalkyl of Rb1 and Rb2 is optionally substituted with one to two Rb5; and
each C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl of Rb1 and Rb2 is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-8alkyl, C1-8haloalkyl, C1-6alkoxyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl;
Rb3 is C1-4alkylene;
Rb4 is selected from C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C1-4alkyl, C1-4haloalkyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and the 4-6 membered heterocyclyl of Rb4 is optionally substituted with one to three Rb6;
each Rb5 is independently selected from cyano, hydroxyl, C1-4alkoxyl, C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C3-8cycloalkyl, C6-10aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of Rb5 is optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and phenyl; and
each Rb6 is independently selected from halo, cyano, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, C3-6cycloalkyl, phenyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl; wherein each C3-6cycloalkyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl of Rb6 is independently optionally substituted with one to three groups independently selected from halo, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, and C1-4alkoxyl; or
R2 and R3, R3 and R4, or R5 and R6 together with the atoms to which they are attached may form a C6-10aryl, 5-6 membered heteroaryl, C3-6cycloalkyl, or 5-6 membered heterocyclyl; wherein each C6-10aryl, 5-6 membered heteroaryl, C3-6cycloalkyl, or 5-6 membered heterocyclyl is optionally substituted with one to three groups independently selected from halo, cyano, —NRa1Ra2, C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, C3-8cycloalkyl, 3-6 membered heterocyclyl, C6-10aryl, 5-6 membered heteroaryl, C1-4alkylene-C3-8cycloalkyl, C1-4alkylene-C6-10aryl, and C1-4alkylene-(5-6 membered heteroaryl);
R7 is selected from H, C1-4alkyl, and C1-4haloalkyl;
R8 is selected from H, C1-4alkyl, and C1-4haloalkyl;
R9 is selected from H, C1-6alkyl, —C1-4alkylene-NRa1Ra2, —C1-4alkylene-C(O)NRa1Ra2, —C1-4alkylene-O—C(O)—C1-4alkyl, —C1-4alkylene-O—C(O)—O—C1-4alkyl, —C1-4alkylene-O—C(O)—C1-4alkylene-NRa1Ra2, —C1-4alkylene-O—C1-4alkyl, C3-8cycloalkyl, —C1-4alkylene-C3-8cycloalkyl, 4-6 membered heterocyclyl, and —C1-4alkylene-(4-6 membered heterocyclyl);
wherein each C3-8cycloalkyl, —C1-4alkylene-C3-8cycloalkyl, and 4-6 membered heterocyclyl of R9 is optionally substituted with one to three groups independently selected from halo, C1-4alkyl, C1-4alkoxyl, and C1-4haloalkyl; or
R9 together with the N that attaches to R8 forms a 5 membered heterocyclyl; wherein the 5 membered heterocyclyl is optionally substituted with one to two groups independently selected from halo, C1-6alkyl, C1-6alkoxyl, C1-6haloalkyl, and C6-10aryl; wherein C6-10aryl is optionally substituted with one to three groups independently selected from halo, C1-6alkyl, C1-6alkoxyl, and C1-6haloalkyl;
each R10 is independently selected from H, halo, cyano, hydroxyl, —C(O)Rb1, —NRa1Ra2, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-10cycloalkyl, 3-8 membered heterocyclyl, C6-10aryl, and 5-6 membered heteroaryl; wherein each C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, C1-4haloalkoxyl, C3-10cycloalkyl, 3-8-membered heterocyclyl, C6-10aryl, and 5-6 membered heteroaryl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl; or
two R10 either attached to the same or adjacent atoms form C3-12cycloalkyl or 3-10 membered heterocyclyl; wherein each C3-12cycloalkyl and 3-10 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl;
each R11 is independently selected from H, C1-4alkyl, and C1-4haloalkyl; wherein each C1-4alkyl, —C(O)Rb1, and C1-4haloalkyl of R11 is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NRa1Ra2, C1-4alkyl, C1-4haloalkyl, C1-4alkoxyl, and C3-6cycloalkyl; or
R10 and R11, or two R11 together with the atoms to which they are attached to form 3-12 membered heterocyclyl; wherein 3-12 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C1-4alkyl, C1-4alkoxyl, C1-4haloalkyl, and C1-4haloalkoxyl;
each Ra1 and Ra2 is independently selected from H, C1-6alkyl, and C1-6haloalkyl;
p is selected from 1, 2, and 3;
m is selected from 0, 1, and 2;
v is selected from 1 and 2;
provided that the ring formed by Y and Z is not one of
wherein * indicates a point of attachment to R1; and
at least one pharmaceutically acceptable carrier.
55. The method of claim 54 , wherein the inflammatory disease or condition is selected from inflammatory bowel disease (IBD), Ulcerative colitis (UC), Crohn's disease, graft-versus-host disease (GVHD), and primary sclerosing cholangitis (PSC).
56. The method of claim 54 , further comprising at least one or more additional therapeutic agents.
57. The method of claim 56 , wherein the at least one or more therapeutic agents are independently selected from JAK tyrosine kinase inhibitors, Tumor Progression Locus 2 (TPL2) inhibitors, Toll-like receptor 8 (TLR8) inhibitors, and IRAK4 inhibitors.
58. The method of claim 57 , wherein the at least one or more additional therapeutic agent is a JAK tyrosine kinase inhibitor and wherein the JAK tyrosine kinase inhibitor is fligotinib.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/508,267 US20220152014A1 (en) | 2018-10-30 | 2021-10-22 | Compounds for inhibition of alpha 4 beta 7 integrin |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752854P | 2018-10-30 | 2018-10-30 | |
US16/667,572 US11179383B2 (en) | 2018-10-30 | 2019-10-29 | Compounds for inhibition of α4β7 integrin |
US17/508,267 US20220152014A1 (en) | 2018-10-30 | 2021-10-22 | Compounds for inhibition of alpha 4 beta 7 integrin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/667,572 Continuation US11179383B2 (en) | 2018-10-30 | 2019-10-29 | Compounds for inhibition of α4β7 integrin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220152014A1 true US20220152014A1 (en) | 2022-05-19 |
Family
ID=68536918
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/667,572 Active US11179383B2 (en) | 2018-10-30 | 2019-10-29 | Compounds for inhibition of α4β7 integrin |
US17/508,267 Abandoned US20220152014A1 (en) | 2018-10-30 | 2021-10-22 | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/667,572 Active US11179383B2 (en) | 2018-10-30 | 2019-10-29 | Compounds for inhibition of α4β7 integrin |
Country Status (9)
Country | Link |
---|---|
US (2) | US11179383B2 (en) |
EP (1) | EP3873605A1 (en) |
JP (2) | JP7189369B2 (en) |
KR (1) | KR102659859B1 (en) |
CN (1) | CN112969504B (en) |
AU (1) | AU2019373245C1 (en) |
CA (1) | CA3115830C (en) |
TW (2) | TWI777100B (en) |
WO (1) | WO2020092401A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114489A1 (en) | 2018-04-12 | 2020-09-09 | Morphic Therapeutic Inc | ANTAGONISTS OF THE HUMAN a4b7 INTEGRINE |
KR102641718B1 (en) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
AU2019373242B2 (en) * | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CN112969504B (en) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | Compounds for inhibiting alpha 4 beta 7 integrin |
EP4045039A4 (en) * | 2019-10-16 | 2023-12-13 | Morphic Therapeutic, Inc. | Inhibiting human integrin alpha4beta7 |
EP4355729A1 (en) | 2021-06-16 | 2024-04-24 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
US20230145835A1 (en) * | 2021-10-06 | 2023-05-11 | 48Hd Biopharma Inc. | Modulators of Alpha-4-beta-7 Integrin and MAdCAM |
WO2023134698A1 (en) * | 2022-01-11 | 2023-07-20 | 深圳信立泰药业股份有限公司 | Pyridazine-1(6h)-6-oxo compound, preparation method therefor, and application thereof |
WO2023220741A1 (en) * | 2022-05-13 | 2023-11-16 | Dice Molecules Sv, Inc. | Alpha 4 beta 7 integrin modulators and uses thereof |
WO2024051819A1 (en) * | 2022-09-09 | 2024-03-14 | 西藏海思科制药有限公司 | Propionic acid derivative and use thereof in medicine |
Family Cites Families (232)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2150550A1 (en) | 1992-12-01 | 1994-06-09 | Melissa S. Egbertson | Fibrinogen receptor antagonists |
AU2958195A (en) | 1994-06-29 | 1996-01-25 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
EP0845987A4 (en) | 1995-08-08 | 2000-05-24 | Fibrogen Inc | C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen |
KR100504449B1 (en) | 1996-07-25 | 2005-07-29 | 바이오겐 아이덱 엠에이 인코포레이티드 | Cell adhesion inhibitors |
WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
CA2291708A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
JP2002512625A (en) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | Heterocyclic amide compounds as cell adhesion inhibitors |
DE69833654T2 (en) | 1997-05-29 | 2006-12-14 | Merck & Co., Inc. (A New Jersey Corp.) | BIARYL ALKANIC ACIDS IN USE AS CELL ADHESION INHIBITORS |
PT991619E (en) | 1997-06-23 | 2004-02-27 | Upjohn Co | INHIBITORS OF THE CELLULAR ADHESION MEDIATED BY ALFA4BETA1 |
CN1265672A (en) | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
AR014903A1 (en) | 1997-07-31 | 2001-04-11 | Athena Neurosciences Inc | COMPOUNDS OF TYPE 4-AMINO-PHENYLALANINE INHIBITORS OF THE ADHESION OF LEUCOCITS INTERMEDIATED BY VLA-4, COMPOUND THAT ARE DRUGS OF SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHOD TO ADHER VLA-4 IN A BIOLOGICAL METHOD |
KR20010022413A (en) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
CN1133648C (en) | 1997-07-31 | 2004-01-07 | 伊兰药品公司 | Subtsituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
WO1999013898A1 (en) | 1997-08-15 | 1999-03-25 | Stefan Niewiarowski | EC-3, AN INHIBITOR OF α4β1 AND α4β7 INTEGRINS |
DK1005445T3 (en) | 1997-08-22 | 2004-10-04 | Hoffmann La Roche | N-alkanoylphenylanine derivatives |
PT1005446E (en) | 1997-08-22 | 2004-06-30 | Hoffmann La Roche | N-AROYLPHENYLALANINE DERIVATIVES |
WO1999025731A1 (en) | 1997-11-13 | 1999-05-27 | Toray Industries, Inc. | Cyclic peptides and medicinal use thereof |
EP1033983A1 (en) | 1997-11-24 | 2000-09-13 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
ES2221227T3 (en) | 1997-11-24 | 2004-12-16 | MERCK & CO., INC. | SUBSTITUTED DERIVATIVES OF BETA-ALANINA AS INHIBITORS OF CELLULAR ADHESION. |
US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
DE69830806T2 (en) | 1997-12-17 | 2006-04-27 | Merck & Co., Inc. | INTEGRIN RECEPTOR ANTAGONISTS |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
WO1999052493A2 (en) | 1998-04-16 | 1999-10-21 | Texas Biotechnology Corporation | Compounds that inhibit the binding of integrins to their receptors |
IL139967A (en) | 1998-05-28 | 2005-11-20 | Biogen Idec Inc | Beta-alanine derivatives and pharmaceutical compositions containing the same |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
AU8059598A (en) | 1998-06-11 | 1999-12-30 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
TW591026B (en) | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
WO2000002903A1 (en) | 1998-07-10 | 2000-01-20 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
JP2002521375A (en) | 1998-07-23 | 2002-07-16 | アストラゼネカ アクチエボラーク | Compound |
PL346248A1 (en) | 1998-08-26 | 2002-01-28 | Aventis Pharma Ltd | Aza-bicycles which modulate the inhibition of cell adhesion |
CA2351464A1 (en) | 1998-12-14 | 2000-06-22 | Joan E. Sabalski | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4 |
GB9828074D0 (en) | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
IL143928A0 (en) | 1999-01-22 | 2002-04-21 | Elan Pharm Inc | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
ATE299490T1 (en) | 1999-01-22 | 2005-07-15 | Elan Pharm Inc | MULTICYCLIC COMPOUNDS FOR INHIBITING VLA-4-MEDIATED LEUKOCYTE ADHESION |
WO2000043372A1 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Acyl derivatives which treat vla-4 related disorders |
WO2000043413A2 (en) | 1999-01-26 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
PT1154993E (en) | 1999-02-18 | 2005-01-31 | Hoffmann La Roche | THIOAMIDE DERIVATIVES |
EP1161416B1 (en) | 1999-03-01 | 2004-04-14 | Elan Pharmaceuticals, Inc. | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists |
US6265572B1 (en) | 1999-04-20 | 2001-07-24 | Hoffmann-La Roche Inc. | Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents |
GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
CZ303312B6 (en) | 1999-05-07 | 2012-07-25 | Texas Biotechnology Corporation | Carboxylic acid derivatives inhibiting integrin bond to receptors thereof |
TWI283240B (en) | 1999-06-30 | 2007-07-01 | Daiichi Seiyaku Co | VLA-4 inhibitor compounds |
JP3795305B2 (en) * | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | Pharmaceutical composition |
AU6314200A (en) | 1999-07-26 | 2001-02-13 | Toray Industries, Inc. | Carboxylic acid derivatives and adhesion molecule inhibitors containing the sameas the active ingredient |
CN1377268A (en) | 1999-08-13 | 2002-10-30 | 比奥根公司 | Cell adhesion inhibitors |
AU6903200A (en) | 1999-08-16 | 2001-03-13 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
AU6909300A (en) | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
IL148544A0 (en) | 1999-09-24 | 2002-09-12 | Genentech Inc | Tyrosine derivatives |
WO2001032610A1 (en) | 1999-10-29 | 2001-05-10 | Kaken Pharmaceutical Co., Ltd. | Urea derivative, process for producing the same, and medicine containing the urea derivative |
JP4788939B2 (en) | 1999-11-18 | 2011-10-05 | 味の素株式会社 | New phenylalanine derivatives |
NZ518888A (en) | 1999-12-06 | 2004-02-27 | F | 4-pyridinyl-N-acyl-L-phenylalanines |
ATE357433T1 (en) | 1999-12-06 | 2007-04-15 | Hoffmann La Roche | 4-PYRIMIDINYL-N-ACYL-L-PHENYLANINE |
CA2394431C (en) | 1999-12-16 | 2015-06-30 | Jane Relton | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
DE19962936A1 (en) | 1999-12-24 | 2001-06-28 | Bayer Ag | New beta-aminoacid amide derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological disorders e.g. asthma, diabetes or rheumatoid arthritis |
JP4784803B2 (en) | 1999-12-28 | 2011-10-05 | 味の素株式会社 | New phenylalanine derivatives |
GB0001348D0 (en) | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
GB0001346D0 (en) | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
AU2882801A (en) | 2000-01-28 | 2001-08-07 | Kaken Pharmaceutical Co., Ltd. | Azepine derivatives |
JP4039856B2 (en) | 2000-02-03 | 2008-01-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Integrin expression inhibitor |
WO2001056994A1 (en) | 2000-02-04 | 2001-08-09 | Biogen, Inc. | Integrin antagonists |
AU2001262089A1 (en) | 2000-03-14 | 2001-09-24 | Novartis Ag | Alpha4beta1 and alpha4beta7 integrin inhibitors |
AU2001242743A1 (en) | 2000-03-23 | 2001-10-03 | Ajinomoto Co. Inc. | Novel phenylalanine derivative |
US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
PE20020384A1 (en) | 2000-07-21 | 2002-05-28 | Schering Corp | PEPTIDES AS INHIBITORS OF THE HEPATITIS C VIRUS SERINE NS3 / NS4a PROTEASE |
WO2002008206A1 (en) | 2000-07-21 | 2002-01-31 | Elan Pharmaceuticals, Inc. | 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors |
US6794506B2 (en) | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
EP1325903A4 (en) | 2000-08-11 | 2005-07-27 | Kaken Pharma Co Ltd | 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
AU2001286542A1 (en) | 2000-08-18 | 2002-03-04 | Genentech, Inc. | Integrin receptor inhibitors |
AU7874001A (en) | 2000-08-18 | 2002-03-04 | Ajinomoto Kk | Novel phenylalanine derivatives |
MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
CA2422135A1 (en) | 2000-09-14 | 2003-03-13 | Toray Industries, Inc. | Urea derivatives and adhesion molecule inhibitors containing the same as effective ingredients |
US6919349B2 (en) | 2000-09-25 | 2005-07-19 | Toray Industries, Inc. | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
DE60124573T2 (en) | 2000-09-29 | 2007-06-21 | Ajinomoto Co., Inc. | NEW PHENYLALANINE DERIVATIVES |
US7157487B2 (en) | 2000-12-28 | 2007-01-02 | Daiichi Pharmaceutical Co., Ltd. | Vla-4 inhibitors |
ES2200617B1 (en) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | DERIVATIVES OF UREA AS ANTAGONISTS OF INTEGRINAS ALPHA 4. |
CA2438427C (en) | 2001-02-21 | 2011-04-12 | Eisai Co., Ltd. | Method for testing effect of angiogenesis inhibitor via integrin expression inhibition |
CZ20032259A3 (en) | 2001-02-22 | 2004-01-14 | Celltech R&D Limited | Phenylalanine amide derivatives containing cyclobutane group and their use as integrin inhibitors |
CN1176985C (en) | 2001-06-20 | 2004-11-24 | 旭化成株式会社 | Thermoplastic resin compsn. |
JP2005022976A (en) | 2001-07-18 | 2005-01-27 | Ajinomoto Co Inc | Carboxylic acid derivative |
JP4164871B2 (en) | 2001-07-26 | 2008-10-15 | 味の素株式会社 | Novel phenylpropionic acid derivatives |
US7557130B2 (en) | 2001-07-26 | 2009-07-07 | Ucb Pharma, S.A. | Bicyclic heteroaromatic alanines |
JP2003048889A (en) | 2001-08-01 | 2003-02-21 | Ajinomoto Co Inc | Novel nucleic acid-based compound |
JPWO2003016907A1 (en) | 2001-08-17 | 2004-12-02 | エーザイ株式会社 | Reagent and method for measuring laminin 5 antigen in biological sample |
CA2460149A1 (en) | 2001-09-12 | 2003-03-27 | Kaken Pharmaceutical Co., Ltd. | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same |
GB0127423D0 (en) | 2001-11-15 | 2002-01-09 | Glaxo Group Ltd | Process |
EP1454898A4 (en) | 2001-12-13 | 2006-12-13 | Ajinomoto Kk | Novel phenylalanine derivative |
AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
JP4233353B2 (en) | 2002-02-27 | 2009-03-04 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
MY140707A (en) | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
EP1489081A4 (en) | 2002-03-22 | 2007-06-20 | Toray Industries | Spiro derivatives and adhesion molecule inhibitors comprising the same as the active ingredient |
JP2003277340A (en) | 2002-03-22 | 2003-10-02 | Toray Ind Inc | Adhesive molecule inhibitor and new amino acid derivative |
JPWO2003089410A1 (en) | 2002-04-19 | 2005-08-25 | 協和醗酵工業株式会社 | Phenylalanine derivative |
EP1870402A1 (en) | 2002-04-30 | 2007-12-26 | UCB Pharma, S.A. | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
GB0216568D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
GB0216571D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
GB0216574D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
CN1703395A (en) | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | Aryl and heteroaryl compounds and methods to modulate coagulation |
GB0218630D0 (en) | 2002-08-10 | 2002-09-18 | Tanabe Seiyaku Co | Novel compounds |
MXPA05007394A (en) | 2003-01-08 | 2005-09-12 | Chiron Corp | Antibacterial agents. |
CA2514125A1 (en) | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
CN100436429C (en) | 2003-02-20 | 2008-11-26 | 味之素株式会社 | Methods for producing phenylalanine derivatives having a quinazolinedione skeleton and intermediates for production thereof |
JP2004277338A (en) | 2003-03-14 | 2004-10-07 | Nippon Soda Co Ltd | Method for producing n-acylamino acid |
ES2219177B1 (en) | 2003-05-05 | 2006-02-16 | Almirall Prodesfarma, S.A. | DERIVATIVES OF N- (2-PHENILETIL) SULFAMIDE AS ANTAGONISTS OF INTEGRIN ALFA4. |
CA2525934A1 (en) | 2003-05-20 | 2004-12-02 | Genentech, Inc. | Thiocarbamate inhibitors of alpha-4 integrins |
NZ544367A (en) | 2003-06-25 | 2009-12-24 | Elan Pharm Inc | Combination therapy involving methotrexate for treating rheumatoid arthritis |
JP4676884B2 (en) | 2003-07-24 | 2011-04-27 | 第一三共株式会社 | Cyclohexanecarboxylic acids |
WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
EP1679309A4 (en) | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | Antistress drug and medical use thereof |
US20050176755A1 (en) * | 2003-10-31 | 2005-08-11 | Dyatkin Alexey B. | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
PL1682537T3 (en) | 2003-11-05 | 2012-09-28 | Sarcode Bioscience Inc | Modulators of cellular adhesion |
JP4947482B2 (en) | 2003-11-14 | 2012-06-06 | 味の素株式会社 | Sustained release oral administration of phenylalanine derivatives |
WO2005046696A1 (en) | 2003-11-14 | 2005-05-26 | Ajinomoto Co., Inc. | Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative |
WO2005051925A1 (en) | 2003-11-27 | 2005-06-09 | Ajinomoto Co., Inc. | Crystal of phenylalanine derivative and process for producing the same |
GB0329584D0 (en) | 2003-12-20 | 2004-01-28 | Tanabe Seiyaku Co | Novel compounds |
EP2615087A3 (en) | 2003-12-22 | 2013-08-07 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
MY140489A (en) | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
US7595318B2 (en) | 2004-01-23 | 2009-09-29 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
WO2005077915A1 (en) | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Pyridazinones as antagonists of a4 integrins |
BRPI0506676A (en) | 2004-02-10 | 2007-05-15 | Janssen Phamaceutica N V | urea pyridazinone as alpha4 integrin antagonists |
CA2558893A1 (en) | 2004-03-10 | 2005-09-22 | Merck & Co., Inc. | Vla-4 antagonists |
CA2561164A1 (en) | 2004-04-01 | 2005-10-20 | Elan Pharmaceuticals, Inc. | Steroid sparing agents and their use |
US20050276803A1 (en) | 2004-04-16 | 2005-12-15 | Genentech, Inc. | Method for augmenting B cell depletion |
US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
TW200610754A (en) | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
EP1765412A2 (en) | 2004-07-08 | 2007-03-28 | Elan Pharmaceuticals, Inc. | Multivalent vla-4 antagonists comprising polyethylene glycol moieties |
US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
RU2007109601A (en) | 2004-08-16 | 2008-09-27 | Мерк энд Ко., Инк. (US) | VLA-4 ANTAGONISTS |
EP1805210A4 (en) | 2004-09-09 | 2007-10-24 | Auckland Uniservices Ltd | Novel peptides and methods for the treatment of inflammatory disease |
WO2006052962A2 (en) | 2004-11-10 | 2006-05-18 | Janssen Pharmaceutica, N.V. | Bicyclic triazole a4 integrin inhibitors |
US7910734B2 (en) | 2004-12-20 | 2011-03-22 | Eisai R&D Management Co., Ltd. | Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine |
WO2006066780A1 (en) | 2004-12-22 | 2006-06-29 | F. Hoffmann-La Roche Ag | Combinations of valategrast and montelukast for treating asthma |
ES2390281T3 (en) | 2004-12-24 | 2012-11-08 | Toray Industries, Inc. | Glycine derivative and use thereof |
WO2006081986A1 (en) | 2005-02-07 | 2006-08-10 | F.Hoffmann-La Roche Ag | Bambuterol and integrin inhibitor combination |
WO2006090234A1 (en) | 2005-02-22 | 2006-08-31 | Ranbaxy Laboratories Limited | Heterocyclic derivatives as cell adhesion inhibitors |
WO2006096807A1 (en) | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
CA2603835A1 (en) | 2005-04-14 | 2006-10-26 | Merck & Co., Inc. | Vla-4 antagonists |
WO2006112738A1 (en) | 2005-04-19 | 2006-10-26 | Auckland Uniservices Limited | Novel peptides and methods for the treatment of inflammatory disorders |
JP2008538563A (en) | 2005-04-21 | 2008-10-30 | メルク エンド カムパニー インコーポレーテッド | VLA-4 antagonist |
WO2006127584A1 (en) | 2005-05-20 | 2006-11-30 | Elan Pharmaceuticals, Inc. | Imidazolone phenylalanine derivatives as vla-4 antagonists |
CA2609255A1 (en) | 2005-05-25 | 2006-11-30 | Eisai R&D Management Co., Ltd. | Intermediate in production of [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine compound |
JP4997106B2 (en) | 2005-05-25 | 2012-08-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Production intermediate of [2- (3,3,5,5-tetramethylcyclohexyl) phenyl] piperazine compound |
ATE496041T1 (en) * | 2005-06-09 | 2011-02-15 | Ucb Pharma Sa | 2,6-QUINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICINAL PRODUCTS |
JP2007023029A (en) | 2005-06-17 | 2007-02-01 | Tanabe Seiyaku Co Ltd | Pharmaceutical composition |
JP5046188B2 (en) | 2005-06-21 | 2012-10-10 | 味の素株式会社 | Crystal of phenylalanine derivative, its production method and use thereof |
TW200726767A (en) | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
WO2007069635A1 (en) | 2005-12-13 | 2007-06-21 | Daiichi Sankyo Company, Limited | Vla-4 inhibitory drug |
CA2637240C (en) | 2006-01-18 | 2015-03-24 | F. Hoffmann-La Roche Ag | Pharmaceutical valatograst compositions and process for manufacturing same |
CA2643838A1 (en) | 2006-02-27 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 |
JP2009531304A (en) | 2006-02-28 | 2009-09-03 | エラン ファーマシューティカルズ,インコーポレイテッド | Methods for treating inflammatory and autoimmune diseases using alpha-4 inhibitor compounds |
ES2380135T3 (en) | 2006-11-22 | 2012-05-08 | Ajinomoto Co., Inc. | Method of preparation of phenylalanine derivatives having quinazolinadione skeleton and intermediates for their preparation |
WO2008064830A1 (en) | 2006-11-27 | 2008-06-05 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses |
CN104030990B (en) | 2007-03-12 | 2017-01-04 | Ym生物科学澳大利亚私人有限公司 | Phenyl amino pyrimidine compounds and application thereof |
WO2008125210A1 (en) | 2007-04-12 | 2008-10-23 | Ucb Pharma, S.A. | Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases |
JP5539864B2 (en) | 2007-06-12 | 2014-07-02 | アカオゲン,インコーポレーテッド | Antibacterial agent |
EP2231185A4 (en) | 2007-12-07 | 2012-06-27 | Elan Pharm Inc | Methods and compositions for treating liquid tumors |
WO2009124755A1 (en) | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Compounds with novel medical uses and method of identifying such compounds |
CN102088973A (en) | 2008-05-15 | 2011-06-08 | 杜克大学 | Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
PL2310509T3 (en) | 2008-07-21 | 2015-08-31 | Apogenix Ag | Tnfsf single chain molecules |
KR20100101054A (en) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | Composition for treating or preventing nuclear export of gsk3- mediated disease including compound for inhibiting nuclear export of gsk3 |
WO2010105363A1 (en) | 2009-03-16 | 2010-09-23 | Andrei Yudin | Cyclic amino acid molecules and methods of preparing the same |
GB0905641D0 (en) | 2009-04-01 | 2009-05-13 | Serodus As | Compounds |
BRPI1015259A2 (en) | 2009-04-27 | 2016-05-03 | Elan Pharm Inc | alpha-4 integrin pyridinone antagonists |
EP2491006A1 (en) | 2009-10-21 | 2012-08-29 | Glaxo Group Limited | Process for preparing a phenylalanine derivative |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
WO2011122619A1 (en) | 2010-03-29 | 2011-10-06 | 味の素株式会社 | Phenylalanine derivative salt crystal |
CN106963741A (en) | 2010-03-29 | 2017-07-21 | Ea制药株式会社 | Pharmaceutical preparation containing Phenylalamine derivatives |
EP2569331A1 (en) | 2010-05-10 | 2013-03-20 | Perseid Therapeutics LLC | Polypeptide inhibitors of vla4 |
WO2011150499A1 (en) | 2010-05-31 | 2011-12-08 | The Governing Council Of The University Of Toronto | A method to insert molecular fragments into cyclic molecules |
WO2011159781A2 (en) | 2010-06-17 | 2011-12-22 | Senomyx, Inc. | Bitter taste modulators |
NZ604835A (en) | 2010-07-20 | 2014-05-30 | Council Scient Ind Res | Pyridin- 2 - yl sulfanyl acid esters and process for the preparation thereof |
NZ746603A (en) | 2010-11-16 | 2020-05-29 | Texas Heart Inst | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
US9249087B2 (en) | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
WO2013070842A1 (en) | 2011-11-09 | 2013-05-16 | Aestus Therapeutics, Inc. | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF α4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP |
JP6230199B2 (en) | 2012-01-27 | 2017-11-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Chitosan covalently linked to small molecule integrin antagonists for targeted delivery |
DK2806898T3 (en) | 2012-01-27 | 2018-10-01 | Hoffmann La Roche | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED SUPPLY TO VLA-4 EXPRESSING CELLS |
WO2013148978A1 (en) | 2012-03-30 | 2013-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for the treatment of necrotizing enterocolitis |
DK2842945T3 (en) | 2012-04-24 | 2017-01-30 | Ea Pharma Co Ltd | Sulfonamide derivative and medical use thereof |
US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
WO2014052605A1 (en) | 2012-09-26 | 2014-04-03 | Kflp Biotech, Llc | Compounds for the treatment and prevention of retroviral infections |
JPWO2014051056A1 (en) | 2012-09-28 | 2016-08-22 | 東レ株式会社 | Crystal of glycine derivative and pharmaceutical use thereof |
US20150045435A1 (en) | 2013-08-06 | 2015-02-12 | Indiana University Research And Technology Corporation | Compounds and methods for treating diabetes |
JP6399874B2 (en) | 2013-09-20 | 2018-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Methods for predicting anti-inflammatory or immunosuppressive effects of compounds |
ES2778200T3 (en) | 2013-10-29 | 2020-08-10 | Ea Pharma Co Ltd | Sulfonamide derivative and its medicinal use |
US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
WO2015172196A1 (en) | 2014-05-13 | 2015-11-19 | Monash University | Heterocyclic compounds and use of same |
JP2016037468A (en) | 2014-08-07 | 2016-03-22 | 味の素株式会社 | Sulfonamide derivatives and pharmaceutical applications thereof |
JP2016037467A (en) | 2014-08-07 | 2016-03-22 | 味の素株式会社 | Sulfonamide derivatives and pharmaceutical applications thereof |
US10266526B2 (en) | 2014-09-10 | 2019-04-23 | Epizyme, Inc. | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer |
WO2016051828A1 (en) | 2014-09-29 | 2016-04-07 | 味の素株式会社 | Pharmaceutical composition for treating ulcerative colitis |
US10383842B2 (en) | 2015-02-13 | 2019-08-20 | Global Biolife Inc. | Method and composition for preventing and treating viral infections |
JP2018515424A (en) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Anti-alpha V beta 1 integrin inhibitors and methods of use |
MY187552A (en) | 2015-07-08 | 2021-09-29 | Axerovision Inc | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions |
SI3364958T1 (en) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
CN105483206B (en) | 2016-01-06 | 2019-09-13 | 北京汉氏联合生物技术股份有限公司 | A method of promoting endothelial cell proliferation ability with VCAM-1 detection MSC |
JP6809713B2 (en) | 2016-01-20 | 2021-01-06 | 国立大学法人 岡山大学 | Inflammatory bowel disease suppressant |
CN106995439B (en) | 2016-01-26 | 2019-09-20 | 镇江圣安医药有限公司 | Deuterium replaces 3- (mesyl)-L-phenylalanine derivative and its pharmaceutical composition, pharmaceutical preparation and purposes |
WO2017132620A1 (en) | 2016-01-29 | 2017-08-03 | La Jolla Institute For Allergy And Immunology | Methods and compositions using integrin-based therapeutics |
AU2017214589B2 (en) | 2016-02-05 | 2020-09-03 | Ea Pharma Co., Ltd. | Sulfonamide derivative and pharmaceutical composition containing same |
WO2017135471A1 (en) | 2016-02-05 | 2017-08-10 | Eaファーマ株式会社 | INTEGRIN α4β7 INHIBITOR |
CN109996541A (en) * | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N- acyl amino acid compounds and its application method |
CN110023304A (en) | 2016-09-28 | 2019-07-16 | 布莱德治疗公司 | Calpain regulator and its therapeutical uses |
WO2018085574A2 (en) | 2016-11-02 | 2018-05-11 | Washington University | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof |
WO2018085552A1 (en) | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin antagonists |
CA3042693A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Pyrrole amides as .alpha.v integrin inhibitors |
WO2018089355A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
EA038164B1 (en) | 2016-11-08 | 2021-07-16 | Бристол-Маерс Сквибб Компани | 3-substituted propionic acids as v integrin inhibitors |
WO2018089358A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Azole amides and amines as alpha v integrin inhibitors |
CA3042714A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Indazole derivatives as a .alpha.v integrin antagonists |
EP4147698A1 (en) | 2017-02-28 | 2023-03-15 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
JP7092784B2 (en) | 2017-02-28 | 2022-06-28 | モーフィック セラピューティック,インコーポレイテッド | αvβ6 integrin inhibitor |
US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
CN116370448A (en) | 2017-04-26 | 2023-07-04 | 纳维托制药有限公司 | Modulators of SESTRIN-GATOR2 interactions and uses thereof |
US10875875B2 (en) | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
JP2019031449A (en) | 2017-08-04 | 2019-02-28 | Eaファーマ株式会社 | Sulfonamide derivative and pharmaceutical composition containing the same |
CN109721605B (en) | 2017-10-31 | 2022-03-11 | 维眸生物科技(上海)有限公司 | Immune cell migration inhibitor |
SG11202004077WA (en) | 2017-11-07 | 2020-05-28 | Bristol Myers Squibb Co | Pyrrolopyrazine derivatives as alpha v integrin inhibitors |
CA3093225A1 (en) | 2018-03-07 | 2019-09-12 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
AU2019234836A1 (en) | 2018-03-13 | 2020-09-17 | The Regents Of The University Of California | Inhibitors of integrin alpha 2 beta 1 and methods of use |
AR114489A1 (en) | 2018-04-12 | 2020-09-09 | Morphic Therapeutic Inc | ANTAGONISTS OF THE HUMAN a4b7 INTEGRINE |
AU2019318538A1 (en) | 2018-08-08 | 2021-03-25 | The General Hospital Corporation | Polypeptide integrin antagonists |
HUE051802T2 (en) | 2018-08-17 | 2021-03-29 | Oxurion NV | Integrin antagonists |
WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
JP2021535141A (en) | 2018-08-29 | 2021-12-16 | モーフィック セラピューティック,インコーポレイテッド | Inhibition of αvβ6 integrin |
WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
KR102641718B1 (en) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CN112969504B (en) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | Compounds for inhibiting alpha 4 beta 7 integrin |
WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
-
2019
- 2019-10-29 CN CN201980072089.3A patent/CN112969504B/en active Active
- 2019-10-29 AU AU2019373245A patent/AU2019373245C1/en active Active
- 2019-10-29 US US16/667,572 patent/US11179383B2/en active Active
- 2019-10-29 CA CA3115830A patent/CA3115830C/en active Active
- 2019-10-29 KR KR1020217016019A patent/KR102659859B1/en active IP Right Grant
- 2019-10-29 WO PCT/US2019/058610 patent/WO2020092401A1/en unknown
- 2019-10-29 EP EP19802020.8A patent/EP3873605A1/en active Pending
- 2019-10-29 JP JP2021548535A patent/JP7189369B2/en active Active
- 2019-10-30 TW TW108139336A patent/TWI777100B/en active
- 2019-10-30 TW TW111129761A patent/TW202323238A/en unknown
-
2021
- 2021-10-22 US US17/508,267 patent/US20220152014A1/en not_active Abandoned
-
2022
- 2022-08-03 JP JP2022124131A patent/JP2022140725A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
Also Published As
Publication number | Publication date |
---|---|
KR102659859B1 (en) | 2024-04-25 |
KR20210087960A (en) | 2021-07-13 |
TW202033491A (en) | 2020-09-16 |
AU2019373245C1 (en) | 2022-10-27 |
JP2022513401A (en) | 2022-02-07 |
JP2022140725A (en) | 2022-09-27 |
CA3115830A1 (en) | 2020-05-07 |
WO2020092401A1 (en) | 2020-05-07 |
AU2019373245B2 (en) | 2022-02-24 |
AU2019373245A1 (en) | 2021-05-13 |
CA3115830C (en) | 2023-09-12 |
CN112969504B (en) | 2024-04-09 |
TW202323238A (en) | 2023-06-16 |
US11179383B2 (en) | 2021-11-23 |
TWI777100B (en) | 2022-09-11 |
CN112969504A (en) | 2021-06-15 |
EP3873605A1 (en) | 2021-09-08 |
JP7189369B2 (en) | 2022-12-13 |
US20200163953A1 (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11179383B2 (en) | Compounds for inhibition of α4β7 integrin | |
US11174256B2 (en) | Imidazopyridine derivatives | |
US11116760B2 (en) | Quinoline derivatives | |
US11224600B2 (en) | Compounds for inhibition of alpha 4 beta 7 integrin | |
US11578069B2 (en) | Compounds for inhibition of α4 β7 integrin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: GILEAD SCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLOMGREN, PETER A.;CAMPBELL, TARYN;CHANDRASEKHAR, JAYARAMAN;AND OTHERS;SIGNING DATES FROM 20190925 TO 20191010;REEL/FRAME:060533/0318 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |